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Abstract 
The cell membrane, made up of a complex arrangement of proteins and lipids, is an integral 
component of cells and functions as a protective barrier around cells. Interactions with cell 
membranes can impact the membrane dynamics, integrity and morphology and therefore 
have biological consequences. The study of these interactions allows a deeper 
understanding of fundamental biological processes, particularly the vast number of 
membrane related proteins whose physiological function is still currently unknown. This 
information may also allow us to determine the pathogenesis of diseases associated with 
these membrane related proteins. It can be utilised in the development of effective 
therapeutic agents against these diseases, such as bacterial infections, due to the 
significance of membranes in cell survival.  
Thus, this project is focused on understanding the interactions between biotechnological and 
therapeutic molecules with cell membranes through the use of synthetic liposomes, and a 
range of membrane binding assays. In the first part of this project, the antimicrobial activity of 
a series of membrane binding supramolecular self-associating amphiphiles (SSAs) was 
determined. Stepwise modifications were made to these molecules to ascertain their 
structure-activity relationships which were then utilised to produce second generation 
antimicrobials with improved E. coli activity. The anionic geometry of SSAs heavily influenced 
the acidity of the molecules and subsequent intermolecular interactions, which in turn 
impacted the antimicrobial activity observed. Lipid binding of SSAs was confirmed through 
the use of a competitive binding microscopy assay and fluorescence anisotropy experiments. 
The second-generation antimicrobials were found to gelate in salt solutions; thus, 
fluorescence microscopy was employed to characterise the gelation properties of these 
SSAs. 
In the second part of this study, the lipid binding properties of the membrane related protein 
alpha synuclein (α-Syn), which has been implicated in Parkinson’s Disease (PD) was 
investigated. In addition, the impact of the post-translational modifications acetylation and 
phosphorylation was also explored. Unacetylated and Nt-acetylated α-Syn exhibited high 
affinities to CL and PE lipids in the thermal shift assays conducted. Further, fluorescence 
anisotropy binding experiments revealed binding of acetylated and unacetylated α-Syn to 
POPA, a key signalling lipid. Additionally, unacetylated α-Syn exhibited increased lipid 
binding activities in comparison to acetylated α-Syn, suggesting negative regulation of α-Syn 
by Nt-acetylation. The final part of this project was concerned with the lipid binding 
interactions of the C-elegans myosin 1 homolog, Hum-1, specifically its TH1 domain. Hum-1 
TH1 was found to predominantly interact with anionic lipids, and phosphorylation of Hum-1 
TH1 increased binding to PA lipids. This project demonstrated the value of investigating 
1 
membrane lipid interactions in order to further understand the native roles and regulation of 
membrane proteins and improve the activity of membrane binding therapeutic molecules.  
 
Title image: Widefield fluorescence microscopy image showing the gel strands formed by 
SSA 85 (5mg/mL) in NaNO3 (0.505 M). Scale = 15 µm. 
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Chapter 1: Introduction 
6.1. Cells and growth 
Over 10 million species are estimated to exist on earth, yet despite their differences, they all 
share the same fundamental life processes.1–3 All are made up of fundamental building 
blocks called cells which contain all the genetic information defining the species. Some 
organisms are made up entirely of a single cell, whilst others are made up of intricate 
systems of specialised cells linked by complex communication. Regardless, the construction 
of a new organism begins with cells, which universally possess three distinct features: the 
cytoplasm, which is the solution inside of a cell, genetic material, and a cell membrane.2  
6.1.1. Cell membranes 
All cells contain a barrier, called a membrane, that defines the cell contents and allows 
regulated movement of substances between the external and internal environment of the 
cell.3–5 The fluid mosaic model, introduced in 1972 by Singer and Nicolson, explains the 
structure of the membrane. While this model has evolved over time, the fundamental 
principles still hold true. This model describes the plasma membrane as a dynamic fluid 
combination of molecules, which allows controlled exchange of substances between the cells 
and the environment.6 Membranes are an integral feature of the cell, responsible for 
maintaining the cell structure, function, and survival, and they comprise of phospholipids and 
membrane related proteins, that allow the cells to carry out specialised functions.7 
6.1.2. Phospholipids 
Phospholipids are amphiphilic molecules that make up a large proportion of the cell 
membranes. Amphiphiles are molecules containing hydrophobic components, with greater 
affinity to non-polar solvents, and hydrophilic components, with greater affinity to polar 
solvents.8 Classification of amphiphiles is dependent on the nature of the polar head group. 
Cationic amphiphiles contain a positively charged head group, anionic amphiphiles contain a 
negatively charged head group, non-ionic amphiphiles contain a head group with no net 
charge and zwitterionic amphiphiles contain both a positive and negative charge in the head 
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group (Figure 1).8 Low molecular weight amphiphiles can also be called ‘surfactants’, owing 
to their surface-active properties. 
 
Figure 1. Types of amphiphiles. 
Example amphiphiles categorised by the head group. 1 – cationic amphiphile 
tetrabutylammonium chloride, 2 – anionic surfactant SDS, 3 – nonionic emulsifier 
ethoxylated nonylphenol, and 4 – zwitterionic phospholipid POPC (1-palmitoyl-2-
oleoyl-glycero-3-phosphocholine).9–12 
At concentrations below the critical micelle concentration (CMC), amphiphiles in an aqueous 
environment, orient themselves at the air-water interface, so that the hydrophilic region is in 
contact with water and the hydrophobic portion is in contact with the air.8,13 This lowers the 
surface tension, which can be manipulated for a range of uses such as detergents, 
adhesives, emulsifiers, and drug delivery vehicles.14 As the concentration increases, the 
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surface becomes saturated, and eventually, the molecules begin to form self-associated 
structures, and the point the formation of these structures begins is the CMC.8,13 The CMC 
therefore, as defined by Holmberg et al 2002, is the concentration of molecule above which 





Figure 2. Schematic illustrations of the critical micelle concentration. 
(A) graphical representation and (B) pictorial representations of the CMC.15 
The solvent environment surrounding amphiphilic molecules drives their nanostructure 
formation through solvophobic interactions. In aqueous environments, hydrophilic regions 
interact with the water molecules, while the hydrophobic groups migrate to the center of the 
self-associated structure, away from the water molecules, forming a range of aggregates. 
The geometry and packing properties of the monomeric units also impact the resulting 
aggregate formation. The ratio of the area occupied by the hydrophilic and hydrophobic 
regions, termed the packing parameter or shape factor (p), is often used to predict the 
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Spherical micelle formation is more probably where p < 1/3, which is the case for molecules 
with strong polar or ionic head groups as well as non-ionic molecules with comparatively 
larger head groups (Figure 4a). Cylinder or rod formation occurs when 1/3 < p < ½, which is 
characteristic of single-chain ionic monomers with either strongly bound counterions or 
added electrolytes, and with non-ionic molecules with either intermediately sized head 
groups or a head group similar in size to the tail region (Figure 4b). Double-chain 
amphiphiles, such as phospholipids, and non-ionic amphiphiles with shorter head groups 
tend to form lamellar structures, and their p values fall in the range of ½ - 1 (Figure 4c and 
4d). If p >1, reversed structures are formed, as observed with the continued addition of 
electrolytes to ionic amphiphiles or with amphiphiles in microemulsions (Figure 4e).8,13,16–18   
Surprisingly, cell membranes are not solely comprised of bilayer forming lipids. Non-bilayer 
lipids such as phosphatidylethanolamine (PE) and diaglycerol (DAG) are vital membrane 
constituents, with roles such as mediating proteolipid interactions within the bilayer and 
increasing membrane plasticity.19,20 In fact, bilayers in cell membranes typically exhibit lateral 






Figure 3. Packing parameter (p) equation. 
The packing parameter equation and schematic diagram for determining amphiphile 
assembly morphologies: where v = volume of the hydrophobic segment, a0 = contact 

















Figure 4. Amphiphile geometries 
Example amphiphile geometries and the resultant aggregates that can be predicted 
using the packing parameter (p). (A) spherical micelle formation, (B) cylindrical or rod 
structure formation, (C) bilayer formation, (D) planar bilayer formation, and (E) inverted 
or reversed structure formation.8,13,16–18 
Each individual lipid constituting the membrane plays an essential role that is regulated by 
proteins, contributing to a stable membrane. Functions of these lipids include their use in 
protein recruitment, signaling, and aiding in membrane structure and curvature.21 These roles 
are dependent on the individual lipid structures, which impact the physicochemical 
properties.21 Therefore, it is nearly impossible to understand the membrane and its related 
interactions without first understanding the lipids that constitute it.22 Membrane lipids can be 
classified into three categories: sphingolipids, sterols, and glycerophospholipids (GPLs). 
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Sphingolipids are a subgroup of lipids containing a hydrophilic head group and a hydrophobic 
region, within which is a sphingosine backbone (Figure 5).22,23  
Sterols are a subgroup of lipids that contain a steroidal tetracyclic region, hydrophobic alkyl 
chains, and a hydrophilic alcohol group (Figure 5B).25,26 While sphingolipids and sterols tend 
to constitute a smaller proportion of membranes, in comparison to glycerophospholipids, they 
perform a variety of essential biological functions including regulation of membrane structure, 
cytoskeletal reorganisation, and cell signalling.22,23,25  
Glycerophospholipids (GPLs), on the other hand, are the most abundant membrane lipids. 





Figure 5. Sphingolipid and Sterol structures.  
(A) An example of a sphingolipid comprising of a hydrophilic region (blue) and a 
hydrophobic region (red) made up of a sphingosine backbone (yellow) and a fatty acid 
chain; (B) an example sterol, comprising of a hydrophobic region made up of tetracyclic 
steroid core and hydrocarbon side chains, and a hydrophilic alcohol group.22,24,25 
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and hydrophilic chains, however, GPLs are built on a glycerol backbone as opposed to 











Figure 6. Chemical diversity of glycerophospholipids.  
(A) The general structure of glycerophospholipids. Regions of variation include the sn-1 
and sn-2 fatty acid chains (purple), fatty acid linker (green), and head group substituent 
(blue). Structures of (B) head group substituents, (C) fatty acid linkers, and (D) example 
fatty acid chains.21,27–29 
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Diversity in GPLs arises from variations within the head group, the fatty acid chains, and the 
fatty acid linker (Figure 6A).21,27–29  
Typically, the fatty acids are attached to the first two carbons of the glycerol backbone 
through various fatty acid linkers. While fatty acids can vary in chain length, double bond 
number, and position, the sn-1 fatty acid is usually a saturated or monounsaturated acyl 
chain, such as a stearoyl chain, and sn-2 fatty acid tends to be an unsaturated or 
polyunsaturated chain such as an arachidonoyl chain (Figure 6D).27 Variation in the fatty acid 
chain is thought to influence membrane fluidity. Long saturated chains tend to reduce fluidity 
due to tighter packing and stronger lipid-lipid interactions, whereas unsaturated chains 
prevent tighter packing and reduce lipid-lipid interactions thereby increasing fluidity.27 
GPL head group variation allows for a wide range of functions, as the headgroup present can 
determine the interactions and behaviour of the lipid (Figure 6B).30,31 Variation in the head 
group can influence the overall charge of the lipid, which in turn impacts membrane rigidity, 
lipid orientation, and determine lipid interactions.32–34 For example, negatively charged 
headgroups such as PA or PS may induce membrane curvature in the presence of excess 
ions due to charge repulsion, and more lamellar structures in the absence of ions.35 
As previously discussed, the ratio between the sizes of the head and tail groups can drive 
the resulting bilayer formation. This has multiple implications in cell membrane structures and 
processes, one of these being membrane curvature.19,27 When lipids with similar shapes 
cluster together, known as phase separation, the monolayer will adopt the spontaneous 
curvature of the lipids. Consequently, the bilayer adopts a curvature equal to the difference 
between the curvatures of its inner and outer monolayers. Phosphatidylcholine (PC) and 
phosphatidylserine (PS) are cylindrical lipids, thus tend to form flat layers, whereas lipids 
such as PE, cardiolipin (CA), and phosphatidic acid (PA) impose negative curvature on 
membranes, owing to their smaller comparative head size that results in a conical shape.20,27  
Conversely, lipids with larger headgroups such as those containing the lysophosphatidic acid 
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(LPA) head group or phosphoinositides (PI) tend to bend the membrane into a positive 
curvature, due to their inverted conical shape.27  Specific proteins regulate the migration and 
distribution of lipids in the membrane at various stages. For example, during membrane 
remodeling or processes such as cell fission, non-bilayer forming lipids may migrate to the 
required site and impose membrane curvature to aid membrane deformation (Figure 7).21,36  
 
Figure 7. Prosed lipid migration during cell fission.  
Imposed membrane curvature by asymmetrical lipids allows cells to bend during cell 
fission.21,36  
1.1.3. Diffusion and osmosis 
The internal homeostasis of the cell can be maintained by controlling the movement of 
molecules across the membrane.  The transportation of molecules in and out of cells occurs 
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Figure 8. Routes for cytosolic entry. 
Small, uncharged, polar or water molecules, in the case of osmosis, can passively 
diffuse across the membrane along a concentration gradient; some molecules are 
assisted by proteins to diffuse along a concentration gradient; larger molecules are 
transported by active transport and require energy (typically ATP hydrolysis) to do so. 
Adapted from G.M. Cooper (2002).7  
Passive transport can involve the diffusion of molecules along a concentration gradient. 
Energy is not required for this process, as small, uncharged molecules can freely diffuse 
across the membrane.5,7 Osmosis is a form of passive transport that involves the movement 
of water molecules along a concentration gradient, which is utilised when the membrane is 
not permeable to the solute.5,7 Facilitated diffusion involves the movement of molecules 
along a concentration gradient through the use of carrier proteins or pores in the membranes 
which aid their transportation.5,7 Larger molecules and charged molecules cannot freely 
diffuse across membranes and require additional mechanisms to enable transportation, one 
of these being active transport.2,5 Active transport involves the movement of molecules 
against a concentration or electrochemical gradient through the use of chemical reactions, 
such as ATP hydrolysis. To carry out active transport, the cell utilises a variety of proteins 
that act as controlled passages between the intracellular and extracellular environments.26   
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1.1.4. Membrane Proteins  
While the basic structure of cells is mainly provided by the phospholipid bilayer, associated 
with the membrane are a range of proteins that carry out the majority of membrane functions 
and provide membranes with characteristic functional properties.2,5,7 The complement of 
proteins associated with the membrane varies depending on cell type, function, and 
localisation, and the way a protein is associated with the membrane can indicate its function 
(Figure 9).2,7 
 
Figure 9. Types of membrane proteins. 
The ways membrane proteins can associate with the lipid bilayer; transmembrane proteins 
span across the bilayer; inner membrane proteins are covalently linked to the inner 
membrane leaflet; surface membrane proteins covalently linked to the outer membrane 
leaflet; peripheral proteins are not directly linked to the membrane but associate with the 
membrane through interactions with other proteins or non-covalent interactions with 
phospholipid headgroups. Adapted from Alberts et al., 2002.2 
Peripheral proteins, for example, are proteins that are not directly associated with the 
membrane but interact with the membrane through covalent or non-covalent interactions with 
other membrane proteins and phospholipid head groups. These proteins do not directly 
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interact with the hydrophobic core of the bilayer and tend to be hydrophilic enabling their role 
in cell signalling processes and cell interactions.2,5,7  
Conversely, integral proteins contain several sections that are directly embedded in the 
bilayer. Integral proteins tend to be amphiphilic, to enable anchoring within the hydrophobic 
core of the bilayer.2,5,7 Some integral proteins, however, can be completely hydrophobic and 
provide additional structural support to the membrane by embedding in the hydrophobic core 
only. Integral proteins on the external cell surface can interact with peripheral proteins, acting 
as cell surface receptors and can aid in cell signalling and interaction processes.2,5,7   
Transmembrane proteins are integral proteins that span across the lipid bilayer, with both 
ends exposed on the cytoplasmic side and the external surface.2,5,7 Similar to surface 
proteins, transmembrane proteins are amphipathic, anchoring them to the membrane and 
enabling interactions with both the intracellular and extracellular environments.2,5,7 This is 
particularly useful in active transport, as it allows the passage of molecules that would 
otherwise be impermeable to the membrane. An example of a transmembrane transportation 
protein is the sodium-potassium ion pump in neuronal cells.5,37 The sodium-potassium pump 
channels Na+ ions out of the cell and K+ ions into the cell, against the concentration 
gradients, which allows the cells to maintain a higher concentration of K+ within the cell and a 
high concentration of Na+ outside the cell.5,37 An example of this is seen with neurons, which 
utilise sodium-potassium pumps to maintain a negative resting membrane potential and 
osmotic equilibrium.5,37 Transportation proteins involved in transportation do not remain 
permanently open. Instead, they can exist in closed or open states which can be triggered by 
external or internal signals in a heavily regulated process.5,37  
Inner membrane proteins are integral proteins that associate with the inner membrane leaflet 
of the bilayer. Proteins linked to a monolayer of the membrane are often involved in 
intracellular signalling roles and in anchoring the eukaryotic cytoskeleton.5,7 Cytosolic 
membrane proteins are soluble and not covalently linked to the membrane at all, however, 
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these proteins are recruited to the membrane by specific signalling lipids such as 
phosphatidic acid (PA) or by inner membrane proteins.5,7 The recruitment of cytosolic 
membrane proteins is seen in cell movement and deformation processes like cytokinesis and 
endocytosis. These proteins can function by aiding actin polymerisation and disassembly, 
signalling cell division sites, or facilitating membrane deformation. 5,7,38,39  
Membrane proteins are not always free to move within the membrane. Cells can confine 
proteins to specific locations, thereby creating protein and lipid domains in the membrane.2 
Membrane lipids and proteins influence a range of processes within the cell. The specific 
types of protein associated with the membrane and the lipid composition are largely 
dependent on the type of organism the cells belong to, and all the cells that make up these 
organisms can be classified into two groups; prokaryotic cells and eukaryotic cells.2,5,26 
1.2. Prokaryotes 
Prokaryotes represent the simplest form of life that share many similar characteristics. As 
their name suggests, (pro meaning before, karyon meaning nucleus), they do not contain 
membrane-bound genetic information.4,5,40 Their genetic material instead is typically a single 
molecule of double-stranded DNA within the cytoplasm.41 Prokaryotic cells are also defined 
by their simplified internal structure in comparison to eukaryotic cells; they lack internal 
organelles, and their smaller sizes (1 - 5µm).3,41 Despite the simplicity of prokaryotes, 
exposure to a far harsher environment has led to the development of additional protective 
measures. Furthermore, functional specialisation and optimisation have diversified 
prokaryotes and resulting in a further subdivision.4,40 The most recognizable and well 
classified unicellular prokaryotes are bacteria.42 As their classification suggests, bacteria lack 
membrane bound organelles and a membrane defined nucleus, genetic material in bacteria 
is stored in a singular large circular chromosome instead. Variation only occurs through the 
number of copies of this nucleoid, which changes depending on the life cycle stage of the 
cell.4,42 
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1.2.1. Bacterial life cycle  
Bacterial reproduction is exclusively asexual and only limited by nutrient availability in the 
environment, allowing bacteria to reproduce faster than multicellular organisms.40,41,43 
Bacterial growth in liquid media can be described by a well-characterised four-phase pattern 
(Figure 10).  
 
Figure 10. Graphical representation of the bacterial four-phase growth pattern.  
Lag phase – cells acclimatise and prepare for division; exponential phase – rapid 
division through binary fission; stationary phase – cell death equals replication resulting 
in a plateau; death phase – cell death exceeds replication resulting in population 
decline. 
Initially, cells begin in lag phase where they acclimatise to the new environment.44,45 During 
lag phase, cells begin to prepare for replication by increasing their size, replicating DNA 
replication, and assembling division-related molecules such as the bacterial cytoskeletal 
protein FtsZ. Accumulation of FtsZ triggers cell division due to the protein self-assembling 
into a contractile ring structure at mid cell under the membrane – the site of division.42,44,45 
The FtsZ ring constricts at the leading edge of the invaginating membrane simultaneously 


























|Chapter 1: Introduction 
binary fission.4,44 When cells start replicating, they enter the log or exponential phase of 
growth. During log phase, cells rapidly divide through binary fission, and the cell culture 
reaches its maximal growth rate.45 If nutrient depletion occurs, bacterial growth plateaus as 
the number of cells diving is equal to those dying. This is called the stationary phase. The 
death phase occurs when bacteria lose the ability to divide and the number of dying cells 
exceeds that of living cells. Bacterial growth in this four-phase pattern is typically depicted in 
a growth curve.45 While growth in a controlled culture tends to follow this four-phase growth 
pattern, bacterial growth in the environment can differ significantly due to environmental 
conditions, and availability of nutrients. Additionally, the bacterial cell cycle does not have 
distinct stages in the same way eukaryotes do, the various processes can overlap with one 
another. Thus, cells can alter the length of their cycle stages in response to the 
environmental and nutrient conditions. It is this adaptability that gives rise to a multitude of 
bacterial infections.4 
1.2.2. Bacterial Pathogenesis 
Bacterial infections occur through the invasion of a host organism by bacterial cells, leading 
to various illnesses ranging in severity. The capacity for bacteria to cause diseases (their 
pathogenesis) provides a basis for their organisation into three main groups. Primary 
pathogens are organisms that are the primary cause of infection e.g., salmonella spp., 
opportunistic infections infect hosts with compromised defenses e.g., Serratia marcescens, 
and non-pathogens rarely or never cause infections e.g., Lactobacillus acidophilus.42 The 
pathogenicity of an organism can be measured by virulence, which is affected by multiple 
factors including route of entry, host defenses, and the number of infecting bacteria. Bacterial 
growth is favoured in most cases due to their faster growth rate, high mutation rate, short 
generation time, and faster adaptability in comparison to eukaryotes.42 Bacteria have 
adopted a host of defense mechanisms to evade the host’s defense systems. Some bacteria 
have adapted to acquire the necessary nutrients without too much damage to the host, as 
the death of the host tends to result in the death of the organism. While the host immune 
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system can be sufficient in defending the host against the infection, where the defense 
systems fail, other methods are required to treat the infection.42  
In 1928 Alexander Fleming discovered the first of a class of molecules capable of killing 
bacteria, through a mould contaminated agar plate.46,47 Since then, a multitude of drugs have 
been developed to aid in the treatment of bacterial infections, called antibiotics. Fleming’s 
discovery of Penicillin in 1928 kickstarted what is now termed as the golden era of antibiotic 
discovery.48 An antimicrobial or antibiotic is a drug or molecule that inhibits the growth or kills 
microorganisms, specifically bacteria.49 Antimicrobials can target bacteria through the 
inhibition of specific pathways or enzymes which then results in deficits in the targeted cell 
and may lead to cell death. An example is seen with beta-lactam antibiotics, such as 
penicillin, and glycopeptides such as vancomycin, which inhibit peptidoglycan synthesis, 
resulting in a compromised cell wall and ultimately cell death.49–51 Upon receiving his Nobel 
prize in 1945, Fleming warned that the overuse of these drugs may lead to resistant bacterial 
forms. His concerns were justified, as over 70 years later, antimicrobial resistance (AMR) 
now threatens the prevention and treatment of bacterial infections and is projected to 
overtake the deaths attributed to cancer by 2050.52–54  
1.2.3. Antimicrobial Resistance 
Drug resistance is a natural phenomenon that occurs when a bacterial population is exposed 
to an antibacterial drug.50,55 If a few members within the population already possess intrinsic 
resistance to this drug, selective pressures allow resistant bacteria to survive and susceptible 
bacteria to die.56 If the bacterial population is exposed to the drug at sublethal 
concentrations, bacteria may be able to rapidly adapt due to the high mutation rate and 
relatively short life cycle and survive any toxic effects the drug may have had. While naturally 
occurring, the overuse and misuse of antibiotics have resulted in the acceleration of this 
process, resulting in multiple drug-resistant strains of bacteria.50,56 Consequently, infections 
that have previously been relatively simple to treat now require last antibiotics. Furthermore, 
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the majority of antibiotics in use today were discovered during the golden era of antibiotics. 
Since then, few antimicrobials have been successful in overcoming drug-resistant bacteria. 
Thus, a combination of novel antimicrobial discovery, effective diagnostic procedure 
development, and better stewardship of current antimicrobials are required to overcome 
resistance.57 
1.2.4. Advances in antimicrobial development 
In 2017, the WHO published a priority list of pathogens that have developed resistance to the 
majority of current antimicrobials, including some last-line antimicrobials, to focus drug 
discovery efforts on those pathogens. Since then, a multitude of approaches have been 
employed to tackle AMR.57 Paul Ehrlich by 1990 had conducted extensive systematic 
screenings of potentially antimicrobial compounds in his search for therapeutic agents with 
high affinities for pathogens and low host toxicity, describing them as ‘magic bullets’.58 This 
ideology and the systematic method of screening are still used as a basis for antimicrobial 
drug discovery, albeit with newer technology. Molecules used in these systematic screenings 
tend to be isolated from natural sources, such as marine environments or plants, as many 
organisms produce highly effective toxins to outcompete bacteria that are less likely to 
exhibit mammalian toxicity.48,59 Advances in technology have allowed for more effective 
systematic screenings to be conducted, as the potential for a molecule to be antimicrobial 
can be more accurately predicted. Furthermore, as bacterial genomes continue to be further 
understood, molecules to accurately target specific processes or pathways can be developed 
more efficiently. More recently, supramolecular chemistry has been utilised in the 
development of novel antimicrobials.  
1.2.5. Supramolecular Chemistry and antimicrobial research 
Supramolecular chemistry is a multidisciplinary field concerned with intermolecular 
interactions and self-assembly processes.60,61 The design of self-associated molecules in 
drug design has become a focus due to their capacity for a range of applications, such as 
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drug delivery systems, medicinal gels, and therapeutic agents.62–64 Supramolecular chemistry 
has also been utilised in extending the shelf life of established antimicrobials and for 
combination therapies.48,65,66  
Molecular self-assembly is the spontaneous ordered aggregate formation through the use of 
non-covalent interactions, such as hydrogen bonding or electrostatic interactions. These self-
association events are dependent on a multitude of factors including molecular geometries, 
intermolecular interactions, hydrophobic/hydrophilic interactions with solvent environments.61 
Self-association is at the heart of a range of essential life processes including protein folding, 
membrane bilayer formation, and DNA structure.2,5,7 This is an attractive property for 
antimicrobial molecules as self-association may allow for active and specific targeting, 
alleviates many bioavailability barriers and can achieve high local concentrations of drug to a 
specific region.62,64 The use of small self-associating molecules may also enable 
customisable architectures and simpler optimisation through stepwise molecular changes.64  
One of the hindrances in antimicrobial discovery is the identification of new targets in 
bacteria. The majority of current antibiotics target similar cell processes, such as components 
of cell wall synthesis and DNA/RNA metabolism, and targeting these processes decreases 
the likelihood of effective antimicrobial activity.67,68 Thus, bacterial membranes have become 
attractive targets, as there is a lower propensity for bacteria to gain resistance and may 
provide ways to target bacterial species with high specificity. In order to effectively target 
bacterial membranes, an understanding of the components of bacterial membranes is 
required.    
1.2.6. Bacterial Membranes 
The application of a gram stain allows for bacteria to be subdivided into two groups; gram-
positive bacteria that retain the dye, and gram-negative bacteria that do not.4,41 This 
distinction highlights a significant difference in the cell wall architecture between the two 
groups .4 Bacterial cell walls functions to protect the integrity of the cell and allow bacteria to 
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interact with the environment in a heavily regulated manner.4 In gram-positive bacteria, a 
thick layer of peptidoglycan and other wall polymers such as teichoic acids constitute a large 
proportion of the membrane, which surrounds the cytoplasmic membrane (Figure 11).4,41  
 
Figure 11. Gram positive vs Gram negative cell walls 
A pictorial representation of bacterial cell wall structures, highlighting the differences 
between gram-positive and gram-negative bacteria. Gram-positive bacteria contain a thicker 
peptidoglycan layer, and gram-negative bacteria contain an additional outer membrane. 
Wall teichoic acids are charged anionic polyol phosphates, which give the gram-positive cell 
wall a net negative charge.4 Conversely, the gram-negative bacterial envelope is comprised 
of 3 layers. A cytoplasmic membrane, a thinner peptidoglycan layer in the periplasm, and an 
additional outer membrane.4,41 Gram-negative bacteria also contain a range of periplasmic 
proteins that aid in a variety of processes such as toxin removal, transportation of molecules, 
and intracellular signalling.4,69 The outer membrane of gram-negative bacteria is integral, as 
it acts as a selectively permeable barrier. 
Bacterial plasma membranes carry out some of the functions that organelles in eukaryotes 
would carry out. For example, DNA replication and subsequent protein synthesis can occur 
almost simultaneously at the membrane, as a continual connection exists between DNA and 
membranes. To facilitate their multifunctional properties, proteins, and lipids within bacterial 






|Chapter 1: Introduction 
1.2.7. Bacterial Membrane lipid composition 
E. coli membranes are well characterised and have previously been used as the model to 
understand bacterial membranes. Within E. coli are three major membrane lipids: PE 
(~75%), and anionic lipids PG and CL (~20%).70,71 The membrane composition in E. coli is 
not representative of the diversity in membrane lipids present in other bacteria, as some 
species have more complex lipid compositions, as illustrated in Table 1. 70 
Lipid composition between species can vary drastically and can occur through the use of 
different lipids as well as lipid derivatives. For example, PE derivatives, such as monomethyl-
PE (MMPE) or dimethyl-PE (DMPE) are common constituents in many bacterial species, 
which can either be intermediates in the synthesis of other lipids such as PC or can 
constitute a large proportion of a membrane.70 Similarly, the PG head group can be modified 
through the addition of the amino acids lysine (in LPG), alanine (in alanyl-PG), or arginine (in 
arginyl-PG) which are present in some gram-positive species such as Staphylococcus 
aureus and Bacillus subtilis.70 Some gram-negative bacteria, such as mycobacterium 
tuberculosis can also synthesise PI, typically a eukaryotic membrane lipid. Phospholipids are 
not the only lipids that can constitute bacterial membranes, as DAG (diacylglycerol) lipids, 
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Table 1: Table highlighting the differences in the membrane lipid compositions of 
different bacterial species.   
PG – phosphatidylglycerol; CL – cardiolipin; PE – phosphatidylethanolamine; PC – 
phosphatidylcholine; OL – ornithine lipid; APG – alanyl-phosphatidylglycerol; PI – 
phosphatidylinositol; PIM – phosphatidylinositol mannoside; LPG – lysyl 
phosphatidylglycerol; GPL – glycophospholipid; GL – glycolipid; MMPE – monomethyl-PE; 
DMPE – dimethyl-PE. Adapted from Sohlenkamp & Geiger 2015.70 
Membrane lipid compositions of different bacteria 
Bacteria Membrane lipid composition 
Escherichia coli PG, CL, PE  
Pseudomonas aeruginosa PG, CL, PE, PC, OL, APG  
Vibrio cholerae PG, CL, PE, OL  
Mycobacterium tuberculosis  PG, CL, PE, PI, PIM, OL  
Bacillus subtilis  PG, CL, PE, LPG, GL, GPL  
Staphylococcus aureus  PG, CL, LPG, GPL  
Streptococcus pneumoniae  PG, CL, GL  
Legionella pneumophila PG, CL, PE, MMPE, DMPE, PC 
1.2.8. Membrane Targeting 
Although bacterial lipids make up a comparatively smaller proportion of bacterial 
membranes, they have a range of vital roles within cells. Membrane lipids can directly or 
indirectly influence certain cell processes such as cell signalling, cell division, and the 
regulation of cell shape and size.7,72 Furthermore, as some membrane lipids and isoforms 
can be species-specific, lipid targeting provides an effective way of targeting bacteria with 
minimal mammalian toxicity. Membrane targeting antibiotics are thought to influence specific 
membrane properties that can result in cell death.50 For example, some membrane 
antibiotics cause changes to the distribution of lipids on a membrane by causing clustering of 
lipids in one region. This prevents those lipids from taking part in essential interactions, which 
could therefore limit vital cell processes.50 Gram-negative bacteria are notoriously more 
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resistant to antimicrobials, as previously mentioned, due to the additional membrane. While 
this membrane may provide additional protection against membrane targeting antimicrobials, 
damage to the outer membrane of gram-negative bacteria can result in significant bacterial 
toxicity, as it allows an influx of other larger molecules into the cell space.50 Furthermore, the 
use of combinatory methods utilising membrane-targeting antibiotics and antimicrobials with 
secondary targets could be promising novel antimicrobial research routes.   
1.3. Eukaryotes 
Eukaryotic cells, as their name suggests (Eu = true or well, karyon meaning nucleus) are 
defined by the presence of a well-defined nucleus. Within this nucleus, eukaryotic DNA is 
arranged in linear chromosomes that vary in number and size depending on the organism.3  
Typically, eukaryotic cells are larger in comparison to prokaryotes and contain extensive 
internal compartments called organelles, all with distinct roles.3 Reproduction of eukaryotic 
cells occurs in a more controlled manner through complex pathways and specific cell signals 
and responses, as defects in these responses lead to uncontrolled growth.73 
1.3.1. The eukaryotic life cycle 
Unlike prokaryotes, the eukaryotic cell cycle has four defined and heavily regulated phases, 
these being gap 1 (G1), gap 2 (G2), synthesis (S) phase, which collectively make up 
interphase, and mitosis (Figure 12).2,74,75  
While the length of time spent in each stage varies between organisms, the fundamental 
processes remain the same. Following cytokinesis, the cell enters G1 phase, where the cell 
is metabolically active and continuously growing.7,75 The initiation of DNA replication marks 
the beginning of S-phase, and once complete the cell then enters G2 phase, where the cell 
continues to grow and prepares for mitosis by synthesizing the relevant proteins, organelles, 
and membrane material for two daughter cells. Once the cell is ready, mitosis begins.7,75  
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Figure 12. The stages of the eukaryotic life cycle.  
Cells start in G1; “S”-phase is where DNA replication occurs; G2 stage where the cell 
prepares for division; Mitosis, which is further divided into distinct stages; prophase, 
metaphase, anaphase, and telophase where cytokinesis occurs. Adapted from Cooper 
(2000).7 
Mitosis can be further divided into four distinct stages: prophase, metaphase, anaphase, and 
telophase. Prophase is defined by the condensing of newly replicated connected 
chromosomes (sister chromatids), nuclear envelope break down, and spindle microtubules 
formation. During metaphase, microtubules connect to the kinetochore of condensed sister 
chromatids and are oriented on opposite sides of the chromosomes, lining them up for cell 
division.7 During anaphase sister chromatids are separated by the spindle microtubules, 
which pull each chromosome to opposite poles. Microtubules that are not attached to 
chromosomes also widen the gap between chromosomes and elongate the cell. Mitosis then 
ends with telophase, where nuclear envelopes re-form and chromosomes decondense, then 
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1.3.2. Cytoskeleton 
The cytoskeleton is an extensive network of protein filaments involved in the maintenance of 
cell shape and polarity.5,39,76 Its main substituent, actin, is one of the most highly conserved 
and abundant eukaryotic proteins.77 The actin monomer (G-actin) is a globular protein, made 
up of 4 subdomains and a nucleotide-binding pocket. At critical concentrations and in the 
presence of specific ions, actin can self-assemble into polymerised helical filaments (F-actin), 
in a reversible process known as actin polymerisation.5 F-actin is a polar filament, with two 
ends known as the barbed and pointed ends and this polarity defines the direction of myosin 
movement.  
During actin polymerisation, G-actin initially aggregates to form an unstable oligomer, which 
acts as the nucleus for the subsequent elongation.5 The actin filament is formed through the 
addition of ATP-bound G-actin at the barbed end of the filament.2,76 The wide range of actin 
structures observed, including the actin cytoskeleton, are formed from this basic filament 
through the use of a plethora of actin-binding proteins (Figure 13).2,7,78  
 
Figure 13. Actin polymerisation.  
G- actin initially oligomerizes to form a nucleus, then the continued addition of G-actin 
results in an F-actin filament. 
The second major component of the cytoskeleton is microtubules.2,7 Microtubules are rigid 
polymers, composed of a dimeric protein called tubulin. Similar to actin, tubulin dimers 
polymerise through GTP (an ATP analogue) binding to form protofilaments, which in turn 
assemble in a head-to-tail arrangement into microtubules around a hollow core. Microtubules 
are also polar structures, with a fast-growing end and a slow-growing end, similar to the 
Nucleus G-actin F-actin Elongation 
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barbed and pointed ends of actin. Disassembly of microtubules occurs through GTP 
hydrolysis which weakens the binding affinity of tubulin.7   
Over 50 different proteins have been identified as constituents of intermediate filaments. 
Despite this diversity, intermediate filaments share the same basic structure; an amino 





Figure 14. Intermediate filaments.  
(A) the basic structure for protein units that make up intermediate filaments (B) intermediate 
filament assembly; proteins dimerise, then dimers assemble to form tetramers, tetramers 
assemble into protofilaments and protofilaments assemble into the final intermediate 
filament. Adapted from Cooper (2002).7 
Filament assembly initially occurs through the alpha-helical rod domains of two proteins 
interacting with each other, resulting in dimers (Figure 14B).7 Following this, dimers 
aggregate to form tetramers, then form protofilaments by assembling in an end-to-end 
arrangement.7 The final intermediate filament, made up of up to eight protofilaments, is a 
rope-like filament of proteins. Intermediate filaments are apolar, and as such are not directly 
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1.3.3. Molecular motor proteins 
The movement of microtubules and pulling apart of sister chromatids during anaphase and 
division of cells to form two daughter cells are driven by a group of molecular motors called 
motor proteins.2 Molecular motor proteins possess the ability to convert chemical energy, 
typically ATP hydrolysis, into movement of some kind. Three main superfamilies of motor 
proteins exist, which are the dynein family, the kinesin family, and perhaps the most 
recognisable, the myosin family.2,80 
1.3.4. Myosin  
Myosins are ATP and actin-binding motor proteins, implicated in numerous cellular 
processes such as muscle contraction, cell adhesion, and cytokinesis.78 All myosins exhibit 
the same basic structure a catalytic head domain, a light chain binding neck region, and a tail 
domain.7,78 Myosins can be categorised into 15 classes (Myosin 1-15), or more loosely 
classified as either conventional myosins, which are two-headed muscle myosins, and 
unconventional myosins. The most abundant and thoroughly studied unconventional myosin 
is Myosin 1 (Figure 15) .81  
 
Figure 15. The basic structure of 
Myosin 1.  
Like other myosins, Myosin 1 contains an 
actin-binding head domain, a light chain 
binding neck region, and a C-terminal tail 
domain with a pleckstrin homology (PH) 
domain within.78,81 
Within the monomeric head domain of Myosin 1 proteins is an ATP binding site, which upon 
binding to actin couples ATP hydrolysis with motion. The actin activation of myosin ensures 
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ATP when actin is absent.5 ATP hydrolysis provides sufficient energy for the transportation of 
cargo along actin filaments and may also be utilised to link actin bundles to plasma 
membranes.5,7 Attached to the head domain is an alpha-helical neck region, thought to 
regulate myosin activity through calmodulin binding in response to Ca2+ signals.78,81 All 
myosins are regulated by Ca2+ in some capacity, however, the responses to the Ca2+ signal 
differs between myosins depending on function. The C-terminal tail domains determine the 
specific function and localisation of myosin, as it contains specific binding sites. 81,82  Myosin 
1 tends to localise to cell membranes, which is thought to be due to the presence of the 
pleckstrin homology (PH) domain, which is known to interact with phospholipids.83–85 While 
the mechanisms behind their localisation and specific interactions are not fully characterised, 
myosin 1 proteins are thought to be involved in many transportation and cell deformation 
processes.86–88 One of the deformation processes myosin 1 proteins are thought to be 
involved in is cell motility, which is also reliant on the dynamic properties of the cytoskeleton.2 
1.3.5. Endocytosis  
While channel proteins exist on cell membranes for the transportation of small molecules, 
eukaryotic cells also have a mechanism for the internalisation of larger molecules, such as 
proteins or signalling molecules. 7 This distinct process, called endocytosis, has a variety of 
functions including the detection of environmental changes, nutrient uptake, elimination of 
pathogens, cell-cell communication.89 Eukaryotes utilise many endocytic pathways for cargo 
uptake, a prime example being clathrin-mediated endocytosis (Figure 16). 7,89 During 
clathrin-mediated endocytosis, the cargo to be internalised arrives at the cell surface and 
binds to cell surface receptors in regions called clathrin-coated pits (Figure 16A). A clathrin 
coat assembles at the membrane, and multiple membrane binding and scaffold proteins are 
recruited to the site (Figure 16 B & C).7 Actin polymerisation then drives the invagination of 
the membrane around the cargo (Figure 16 D), forming a clathrin-coated vesicle which then 
buds off from the membrane (Figure 16 E).7 Clathrin-coated vesicles are internalised through 
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actin polymerisation (Figure 16 E), then the clathrin coat is dissembled (Figure 16 F) and the 
components recycled while cargo is directed to the relevant region of the cell (Figure 16 G). 
 
Figure 16.Clathrin-mediated endocytosis.  
(A) Cargo arrives at membrane surface; (B) Clathrin coat forms and various proteins 
are recruited to the site; (C & D) Actin drives invagination of membrane; (E) vesicle 
buds off and is internalised; (F) clathrin coat disassembles; (G) clathrin coat 
components are recycled. Adapted from Schmidt (2017) and Mettlen et al., (2018).90,91 
Clathrin-mediated endocytosis, like many processes within the cell, is very heavily regulated 
through conformational changes and post-translational modifications on associated 
proteins.91 
1.3.6. Post-translational modifications 
Translation is the process by which protein synthesis occurs and modifications made to the 
protein past this point are termed post-translational modifications.2,5 Post-translational 
modifications can reversibly or irreversibly alter protein structure and function, enabling 
eukaryotic cells to dynamically regulate proteins. Almost all cellular events involve post-
translational modifications to some degree, including cell-cell communication, endocytosis, 
gene expression.2,5,92 Post-translational modifications can occur through protein cleavage 
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protein. Three main chemical group additions are typically utilised in protein regulation: 
methylation, acetylation, and phosphorylation (Figure 17). 2,5,92 
 
Figure 17. Chemical groups added to proteins in 
regulation.  
(A) methyl group in methylation; (B) acetyl group in 
acetylation; (C) phosphate group in phosphorylation. 
While methylation is more frequently seen in the regulation of DNA and gene expression, 
proteins can also be regulated through this mechanism.92–94 Specific methyltransferases add 
methyl groups to protein, thereby regulating key cell processes. One of the most well-known 
cell processes regulated by methylation is transcription, where the addition of methyl groups 
to lysine or arginine residues can modulate RNA-protein interactions.92–94  
The most common post-translational modification is phosphorylation. Phosphorylation is the 
addition of phosphate groups to a polar group, catalysed by protein kinases and 
phosphatases.95,96. In proteins, the polar group can be a serine, threonine, tyrosine, or 
histidine residue. The addition of a phosphate group results in a more hydrophilic protein, 
inducing conformational changes, thereby impacting the structure and subsequent 
interactions. Protein phosphorylation has been implicated in a broad range of cellular 
processes, in particular cell signalling, where phosphorylation status is reversible, and rapidly 
affects protein activity and levels.97   
Protein acetylation is a highly specific post-translational modification that involves the 
addition of acetyl groups to proteins through the use of acetyltransferases.98,99 Acetylation 
can be subdivided into three main types. Nα-acetylation, where the acetyl group is 
irreversibly added to the N-terminus, Nε-acetylation, where the acetyl group is reversibly 
added to a lysine residue and O-acetylation, where the acetyl group is added to a tyrosine, 
serine or threonine hydroxyl group.99 Acetylation is a major regulator of transcription and has 
also been implicated in protein folding, mitochondrial function, and membrane interactions.99  
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As cells rely on proteins for all of their physiological functions, the misregulation of proteins 
can have catastrophic effects. Defects in post-translational regulation have frequently been 
shown to result in dysregulation of genes and abnormal protein structure and function, 
resulting in numerous disease states.2,5 An example of this is seen with alpha synuclein. 
1.3.7. Alpha synuclein 
Alpha synuclein (αSyn) is a presynaptic neuronal protein coded by the SNCA gene, thought 
to contribute to the pathogenesis of Parkinson’s disease (PD).100–102 In aqueous solutions, 
αSyn is known to be natively unfolded, however upon binding to anionic lipids has been 
observed forming alpha-helical structure.100,102 Similar to other members of the synuclein 
family, αSyn is composed of three distinct regions: an amino terminus containing lipid-
binding motifs, a hydrophobic central ‘NAC’ region with a propensity to form beta-sheets, and 
a highly unstructured negatively charged C-terminus (Figure 18).100,102 The central NAC 
region separates αSyn from other members of the synuclein family. αSyn is predominantly 
expressed in neuronal cells, making up 1% of total cytosolic proteins, and is also expressed 
in erythrocytes and platelets.100,102 While its physiological function has not yet been fully 
characterised, it has been implicated in modulating synaptic transmission through 
interactions with synaptic vesicles. 100,102 
 
Figure 18. Structure of alpha synuclein.  
αSyn consists of an amino terminus capable of forming an alpha-helical structure; a 
central NAC region capable of forming β-sheets, and an unstructured negatively 
charged C-terminus.  
αSyn contains sites for post-translational modifications to occur, thus it has been suggested 
that misfolding or misregulation of αSyn may result in the formation of aggregated protein 
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structures called Lewy bodies, the hallmark of PD.103 Understanding the roles of these post-
translational modifications and may provide an insight into the function of αSyn and its 
involvement in PD pathogenesis. 
1.3.8. The project 
The function and interactions of individual membrane components has been the focus for a 
large amount of research for several decades.104 While a great deal of information has been 
uncovered, much information surrounding membranes remains undiscovered and further 
research is required to fully understand their complexity. Membrane interactions influence a 
wide range of cell functions, thus once properly understood may provide a way of 
understanding and treating diseases. Additionally, these interactions may be manipulated for 
the creation of new therapeutics. This thesis seeks to investigate membrane lipid interactions 
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Aims of the project 
This project aims to: 
1. Identify and characterise the relationships between the structures of a group of self-
associating amphiphiles and their antimicrobial activity. This information can then be 
utilised in the development of multifunctional antimicrobials with high efficacy against 
gram-negative bacteria in particular.  
2. Understand the membrane binding properties of the molecules through the use of 
synthetic liposomes.  
3. Identify the specific lipid interactions of membrane binding proteins myosin 1 and 
alpha synuclein, to ascertain their physiological functions and localisation. 
4. Explore the impact of phosphorylation and acetylation on these lipid interactions to 
determine their role in protein regulation.
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Table 2. Materials, reagents, and chemicals used in this thesis 
Materials Source Identifier 
DPPE (1, 2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine) 
Avanti Polar lipids 850705 
DSPG (1, 2-distearoyl-sn-glycero-3-phospho-(1'-
rac-glycerol) (sodium salt)) 
Avanti Polar Lipids 840465 
POPA (1-palmitoyl-2-oleoyl-sn-glycero-3-




Avanti Polar Lipids 850457 
POPG (2-Oleoyl-1-palmitoyl-sn-glycero-3-phospho-
rac-(1-glycerol) sodium salt) 
Sigma-Aldrich 63371 
Total lipid extract (E. coli) Sigma-Aldrich 100500P 
Polar lipid extract (E. coli) Sigma-Aldrich 100600P 
Cardiolipin (E. coli) (sodium salt) Sigma-Aldrich 841199P 
Octyl β-D-glucopyranoside (OGP) Sigma-Aldrich O8001 
HisPur™ Ni-NTA Resin Thermo Fisher 88221 
PageRuler™ Unstained Protein Ladder Thermo Fisher 26614 
Coomassie Brilliant blue Thermo Fisher 20278 
QIAprep Spin Miniprep Kit 
Print 
Qiagen 27106 
HisPur™ Ni-NTA Resin Thermo-Fisher 88223 
Invitrogen FM4-64 Thermo-Fisher T13320 
Echelon Biosciences, PIP Strips™ Membranes Thermo Fisher P23750 
Desalting Prepacked Gravity Flow Columns Biorad 7322010 
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Table 3. Plasmids and bacterial strains and used in this thesis 
Lab Stock 
number 
Strain/Plasmid name Antibiotic 
Selection 
2353 E. coli DH10β - 
2757 USA300 MRSA - 
- BL21 DE3 - 
- BL21 NatB Chloramphenicol  
- BL21 Cam 1 Rosetta plysS Chloramphenicol  
V696 Alpha-Synuclein-Cerulean3 
(pDUET-1alpha-Synuclein-Cerulean3)   
Kanamycin 
   
V833 Hum1 TH1 
(pET151/D-TOPO-Nde1-Hum-1-TH1-SalI) 
Ampicillin 
V867 Hum-1-TH1 D-mutant 
(pET151DTOPO_myo1TH1-S782D) 
Ampicillin 




V886 Neon green Hum1 TH1 S734D 
(pET151DTOPO_NcoImNeongreen-Nde1hum1TH1(717-
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2.1. Software 
• Fiji (ImageJ) software. US National Institutes of Health, Bethesda MA USA.105,106 
• Origin (Pro), version 2020. OriginLab Corporation, Northampton MA USA. 
• SkanIt Software version 6.0. Thermo Scientific, Waltham MA USA.  
• MetaMorph Software. Molecular Devices, Sunnyvale, CA, USA. 
• Mars Data Analysis Software. BMG Labtech, Ortenberg Germany. 
• IBM SPSS Statistics for Windows, version 27.0. IBM Corp, Armonk NY: IBM Corp. 
• Compass Data Analysis software version 4.1. Bruker, Billerica MA USA. 
• ShelXT & ShelXS structure solution programs, Olex2 was used as an interface for all 
ShelX programs. G. M. Sheldrick, Universität Göttingen.107–109  
• ACD Labs version 2019. Advanced Chemistry Development Inc., Toronto Canada, 
www.acdlabs.com, 2020. 
• MestReNova version 14.2.0. Mestrelab, Santiago de Compostela, Spain.110  
• Topspin NMR data analysis software version 4.0. Bruker, Billerica MA USA. 
• Kalliope particle analysis software v1.2.0. Anton-Paar, Graz, Austria.  
• IRsolution FTIR software v1.40. Shimadzu, Kyoto Japan. 
• BindFit version 0.5. Supramolecular, OpenDataFit, P. Thordarson, J. Wilmot, and V. 
Efremova, CBNS & UNSW, Sydney Australia.111 
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2.2. Buffers & media recipes 
 
Luria-Bertani (LB) Media 
5 g Yeast Extract 
10 g Tryptone 
10 g Sodium Chloride 
1 L dH2O 
Once prepared, the LB solution was 
autoclaved 
αSyn Binding Buffer 
0.05 M Tris·Cl 
0.5 M NaCl 
1 % Triton x100 
10 mM Imidazole 
pH 7.8 
PMSF to a final concentration of 1 mM 
was then added prior to use 
Ni-NTA Buffer A 
0.05 M NaH2PO4 
0.3 M NaCl 
0.01 M Imidazole 
pH 8.0 
Ni-NTA Buffer B 
0.05 M NaH2PO4 
0.3 M NaCl 
0.02 M Imidazole 
pH 8.0 
 
αSyn Wash Buffer 
0.05 M Tris·Cl 
0.5 M NaCl 
1 % Triton x100 
pH 6.0 
Ni-NTA Buffer C 
0.05 M NaH2PO4 
0.3 M NaCl 
0.5 M Imidazole 
pH 8.0 
αSyn Elution Buffer 
0.05 M Tris·Cl 
0.5 M NaCl 
0.3 M Imidazole 
pH 6.0 
 
Denaturing Lysis Buffer  
7 M Urea 
0.1 M NaH2PO4 
0.1 M Tris·Cl 
pH 8.0 
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Column Storage Buffer 
0.02 M MES 
0.03 M NaCl 
pH 5.0 
Denaturing Wash buffer  
8 M Urea 
0.1 M NaH2PO4 
0.1 M Tris·Cl 
pH 6.3 
 
αSyn Buffer A 
0.02 M Tris·Cl 
0.05 M NaCl 
pH 7.0 
Denaturing Elution buffer  
8 M Urea 
0.1 M NaH2PO4 
0.1 M Tris·Cl 
pH 4.5 
 
αSyn Buffer B 
0.02 M Tris·Cl 
pH 7.0 
Desalting Buffer A 
0.1 M NaH2PO4 
0.1 M Tricl·Cl 
pH 5.0 
Vesicle Buffer A 
0.005 M NaH2PO4  
0.5 M NaCl 
pH 7.2 
Desalting Buffer B 
0.1 M NaH2PO4 
0.1 M Tricl·Cl 
pH 7.2 
Vesicle Buffer B 
0.1 M NaH2PO4 
0.1 M Tris·Cl  
pH 7.2 
High Salt Buffer A 
0.02 M Tris·Cl 
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Vesicle Buffer C 
0.1 M NaH2PO4 
0.1 M Tris·Cl 
0.5 M NaCl 
pH 7.2 
0.1 %Coomassie Brilliant blue 
0.75 g Coomassie R-250 
400 mL Methanol 
100 mL Acetic Acid 
This was stirred for 15 minutes and then 
filtered through filter paper then 500 mL 
dH2O was added 
Tris Running Buffer 
25 mM Tris·Cl 
192 mM Glycine 
3.5 mM SDS 
pH 8.3 
PBS 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.76 mM KH2PO4 
pH 7.4 
PIP Strip Detection Buffer 
Must be made fresh each time 
0.1 M NaCl 
0.1 M Tris·Cl pH 9.6 
5 mM MgCl₂ 
PIP Strip Blocking Buffer 
PBS 
0.1 % v/v Tween 20 
3 % BSA 
 
De-stain 
500 mL Methanol 
140 mL Acetic Acid 
1360 mL dH2O 
PIP Strip Wash Buffer 
PBS  
0.1 % Tween 20 
PIP Strip Protein Buffer 
PBS 
0.1 % Tween 20 
3 % BSA 
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2.3. Biological Techniques 
2.3.1. Preparation of Luria Broth (LB) Agar plates  
Agar (6 g) was added to LB (400 mL) and autoclaved. Once cool, the LB Agar was poured 
into sterile Petri dishes under sterile conditions and allowed to set. LB plates were stored at 4 
ºC until use. 
2.3.2. Preparation of Bacterial Plates  
Sterile LB agar plates were streaked using the desired bacteria (either E. coli or MRSA within 
this thesis), then incubated at 25°C overnight. 
2.3.3. Preparation of Overnight Cultures  
Overnight cultures were created by inoculating LB media (5 mL) with at least 4 single 
colonies of the desired bacteria from a bacterial plate under sterile conditions and incubated 
at 37°C overnight.  
2.3.4. Preparation of Secondary cultures  
Secondary cultures were prepared using LB (5 mL) inoculated with 50 µl from an overnight 
culture, then incubated at 37°C until the culture had reached an optical density of 0.4 at 600 
nm unless otherwise stated.  
2.3.5. Antibiotic Concentrations 
Antibiotics were used to achieve plasmid selection at final concentrations of 50 µg/mL 
(Ampicillin & Kanamycin) or 25 µg/mL (Chloramphenicol). 
2.3.6. DNA Preparation 
Plasmid DNA from E. coli DH10β was extracted using the Qiagen miniprep kit (based on the 
alkaline lysis method) following the manufacturer’s instructions. 
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2.3.7. E. coli Transformation 
Aliquots of competent cells were thawed on ice then 2 µL plasmid DNA was added to the 
cells, mixed gently, and incubated on ice for 30 minutes. Cells were then heat shocked for 90 
seconds at 42°C and returned to the ice for 2 minutes. LB (100 µL) was added to the cells 
and allowed to recover for 1 hour at 37°C before being plated onto an LB plate containing the 
appropriate antibiotic. 
2.3.8. Nickel Column Preparation 
A 10 mL syringe with the plunger removed was fixed onto a clamp stand. Sterile glass wool 
was added to the bottom of the syringe to prevent the nickel beads from pouring through. 
The nickel bead slurry was resuspended and pipetted (2-3 mL) into the column. Once the 
beads had settled the appropriate binding buffer (5 times of the resin volume was used to 
equilibrate the column by gently pipetting along the inside of the column, ensuring beads 
were not disturbed. A cap was used to stop the flow of buffer whenever necessary.  
2.3.9. Nickel Column Protocol 
To run a nickel column, the soluble-cleared cell extract was loaded onto the column, and the 
flow-through was collected to ensure any excess protein was not lost. Once the protein had 
bound to the nickel column, the column was washed using 5x the resin volume of the 
appropriate wash buffer. The protein was then eluted using the appropriate elution buffer, 
collecting 1 mL fractions until all the protein was removed from the column. The presence of 
the protein was then confirmed by SDS PAGE.  
2.3.10. VNp and αS expression98 
VNp or αS plasmids were transformed into calcium competent BL21 DE3 and BL21 NatB98 in 
order to make acetylated and unacetylated versions of this protein. A single colony was used 
in LB (5 mL) and grown overnight at 37 °C. The overnight culture (1 mL) was used to 
inoculate LB (1 L) with the appropriate antibiotics and incubated at 37 °C, with shaking, until 
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an optical density of 0.4-0.6 was reached. IPTG was then added to a final concentration of 
20 ug/mL, to induce the protein under the T7 promoter, and induced for 2-3 hours. Cells were 
then harvested by centrifugation at 1800 rcf for 20 minutes and the resulting pellets were 
frozen at -20°C until purification.  
VNp-mNeongreen = ~ 32.4 kDa 
αS-mNeongreen = ~42.55 kDA 
2.3.11. VNp and αS Nickel Purification98 
Frozen cell pellets were defrosted on ice and then resuspended in αS binding buffer (16 
mL). Cells were then sonicated for 2 minutes; 20 second pulses and a 59 second gap 
between them. The suspension was then centrifuged at 4400 rcf for 30 minutes and the 
supernatant was kept for purification. A nickel column was set up and run as described 
previously, using αS binding buffer for equilibration, αS wash buffer for the wash steps, 
and αS elution buffer for the elution steps.  
2.3.12. Protein Dialysis 
Protein was placed into a cellulose membrane dialysis tubing with a molecular weight cut off 
point of 14,000 Da. The cellulose tubing was securely sealed at both ends and placed into 5 
L αS buffer B which was then placed on a magnetic stirrer at 4 °C. The buffer was changed 
at least 3 times over a 24-48-hour period, divided into aliquots, and flash frozen using liquid 
nitrogen. Aliquots were stored at -80°C until the day of use. 
2.3.13. Protein Concentration Calculation 
Protein concentrations were calculated using absorbance measurements at 280 nm (A280), 
the extinction coefficients and molecular weights listed in Table 4. 
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Table 4. The extinction coefficients and molecular weights of proteins used in this 
thesis.  




VNp-mNeongreen 44350 32546 
VNp-Lz-mNeongreen 45840 36483 
αS-mCerulean 30495 42551 
Hum 1 TH1 15025 27452 
Hum 1 TH1-mNeongreen 57885 51340 
2.3.14. Hum1 TH1 Expression 
Plasmids were transformed into the appropriate calcium competent cells. A single colony 
was used in LB (5 mL) and grown overnight at 37°C. The overnight culture (1 mL) was used 
to inoculate LB (1 L) with the appropriate antibiotics and incubated at 37°C, with shaking, 
until an optical density of 0.4-0.6 was reached. IPTG was then added to a final concentration 
of 20 ug/mL, to induce the protein under the T7 promoter, and induced overnight at 25°C. 
Cells were then harvested by centrifugation at 1800 rcf for 20 minutes and then the resulting 
pellets were frozen at -20°C until purification.  
2.3.15. Hum1 Native Purification 
Frozen cell pellets were defrosted on ice and then resuspended in Ni-NTA buffer A (16 mL). 
Cells were then sonicated for 2 minutes; 20 second pulses and a 59 second gap between 
them. The suspension was then centrifuged at 4400 rcf for 30 minutes and the supernatant 
was kept for purification. A nickel column was prepared and run as described previously, 
using Ni-NTA buffer A for equilibration, Ni-NTA buffer B for the wash steps, and Ni-NTA 
buffer C for the elution steps.  
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2.3.16. Hum1 Denaturing Purification 
Frozen cell pellets were defrosted on ice and then resuspended in denaturing buffer A (16 
mL) and incubated at 25 °C with shaking for 1 hour, then centrifuged at 10,000 rpm for 20-30 
minutes at 25 °C. The supernatant was then kept for purification. A nickel column was 
prepared as described previously, using denaturing buffer A for equilibration, denaturing 
wash buffer for the wash steps, and denaturing elution buffer for the elution steps.    
2.3.17. Hum1 Desalting 
Urea removal from denatured purified protein samples was conducted using the Biorad 
gravity desalting column according to the manufacturer’s instructions using desalting 
buffers A, B & C.  
2.3.18. SDS PAGE 
2.3.18.1. Gel preparation 
The resolving gel was prepared using the volumes in Table 5 and pipetted into the gel 
cassettes, then isopropanol (1 mL) was pipetted to create a level gel interface. Once set, the 
isopropanol was removed and thoroughly washed with water. The stacking gel was then 
prepared using the volumes in Table 5, then pipetted on top of the resolving gel, and a comb 
was gently inserted before being allowed to set in the 37°C incubator.  
Table 5. Volumes of reagents used in 10 % SDS PAGE gel preparation. 
 Resolving Gel Stacking Gel 
dH2O 2.55 mL 7 mL 
1.5 M Tris (pH 8.8) 3.75 mL - 
1 M Tris (pH 6.8) - 1.25 mL 
10 % w/v SDS 100 µL 50 µL 
30 % Acrylamide 3.2 mL 1.7 mL 
10 % w/v APS 100 µL 50 µL 
TEMED 15 µL 15 µL 
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2.3.18.2. Sample preparation 
Loading buffer was added to all protein samples (1/5th of the volume of protein sample) then 
heated to 90°C for 10 minutes before being loaded into wells of the SDS PAGE gel.  
2.3.18.3. SDS PAGE gel protocol 
The PageRuler© unstained ladder was used as the protein standard on all gels. Gels were 
run at 120 V for 90 minutes in Tris running buffer. Then gels were stained with 0.1 % 
Coomassie brilliant blue for at least 1 hour then fully unstained using de-stain. 
2.3.19. PIP Strip Protocol 
PIP strip membranes developed by Echelon Biosciences (Salt Lake, UT) were purchased 
ThermoFisher Scientific (Table 2).  
PIP strip membranes were kept wet throughout all the steps and gentle agitation was used 
where shaking was required. Membranes were placed in a petri dish and covered with PIP 
Strip blocking buffer (5-10 mL) then gently agitated for 1 hour at 25 °C or overnight at 4 °C. 
The PIP Strip blocking buffer was then discarded, and the protein of interest was added (0.5 
µg/mL) in PIP Strip protein buffer (5-10 mL) and incubated for 1 hour at room temperature 
with gentle agitation. The protein solution was discarded, and membranes were washed with 
PIP Strip wash buffer (5 mL) with gentle agitation at 25°C for 10 minutes and repeated three 
times. The desired primary antibody was added (1:2000 in the blocking buffer) and the 
membranes were incubated for 1 hour at 25 °C with gentle agitation. Membranes were then 
washed three times with PIP Strip wash buffer (5 mL) with gentle agitation at 25 °C for 10 
minutes. The wash buffer was discarded, and the desired secondary antibody was added 
(1:2000 in Blocking Buffer), then incubated for 1 hour at 25 °C or overnight at 4 °C with 
gentle agitation. The membranes were washed with the PIP Strip wash buffer three times, 
and the buffer was discarded. PIP Strip detection buffer was added to fully cover the 
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membranes and allowed to rest for 5 minutes. Membranes were removed and placed in an 
empty petri dish and washed over with 1 mL of enzyme substrate until spots could be 
visualised, then rinsed with sterile water. Membranes were then imaged, and results were 
compared to the PIP Strip layout (Figure 19) to determine which phospholipids had bound.  
 
 
Figure 19. PIP Strip layout. 100 picomoles of lipid per spot.112 
2.4. Antimicrobial Assays113 
2.4.1. Preparation of the 0.5 McFarland Standard  
Barium chloride (1 %, 50 µL) was added to sulfuric acid (1 %, 9.95 mL) and mixed. 
The optical density was recorded at 600 nm. 
2.4.2. Preparation of 5 % EtOH 
Unless otherwise stated, 5 % EtOH was prepared in H2O 
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2.4.3. Preparation of Antimicrobial Compounds for Screening  
Stock compound solutions were made on the day of the experiment at 20 mM in 5 % 
ethanol and sterile dH2O.  
2.4.4. Preparation of Antimicrobial Compounds for MIC50 Calculations  
Compound solutions were made on the day of the experiment at eight appropriate 
concentrations, determined by the screening, in 5 % ethanol and sterile dH2O.  
2.4.5. Preparation of Cell Suspension 
A secondary culture was created and grown to an optical density of 0.4 at 600 nm, 
then its density was adjusted using sterile dH2O to equal 0.5 McFarland Standard 
(107 – 108 cfu/mL). McFarland standards are standard solutions used to standardise 
bacterial suspensions so an approximate number of bacteria can be determined. A 
1:10 dilution was carried out using sterile dH2O (900 µL) and the McFarland adjusted 
suspension (100 µL). A final dilution (1:100) was carried using the 1:10 suspension 
(150 µL) and LB (14.85 mL) before use to achieve a final cell concentration of 105 
cfu/mL. 
2.4.6. Preparation of 96 well Microplate for screening 
A 20 mM compound solution was prepared using 5 % ethanol in sterile dH2O. A cell 
suspension prepared as described previously (105 cfu/mL, 150 µL) was pipetted into 
each well of a 96 well sterile plate, then the compound solution (20 mM, 30 µL) was 
added into 6 wells on the plate, to give a final screening concentration of 3.3 mM 
within each well. This was repeated for all compounds to be screened. Absorbance 
values were obtained using the Thermo Scientific Multiscan Go 1510-0318C plate 
reader and recorded using the SkanIt Software 4.0. Values were taken at 600nm, 
every 15 minutes for 25 hours at 37 ºC, then used to generate growth curves. 
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Compounds that showed inhibited growth by 10 % or more were taken forward for 
MIC calculations. 
2.4.7. Preparation of 96 well Microplate for MIC50s 
A cell suspension was created as described previously, then dispensed into individual 
wells of a 96 well sterile plate under sterile conditions (105 cfu/mL, 150 µL). 
Compounds (30 µL) were added to the wells to equal a total volume of 180 µL within 
the wells ensuring that there are six repeats of each concentration of every 
compound on the plate. The plates were sealed using Parafilm, and absorbance 
values were obtained using the Thermo Scientific Multiscan Go 1510-0318C plate 
reader and recorded using the SkanIt Software 4.0. Absorbance values were taken at 
600 nm (OD600), every 15 minutes for 18-25 hours at 37 ºC, then used to generate 
growth curves.  
2.4.8. Growth Curves and MIC50 Calculation 
Growth curves were plotted from OD600 absorbance readings using Microsoft Excel.  
OD600 absorbance readings at 900 minutes for each SSA concentration were plotted 
in Origin. The resultant curve was normalised and fitted using the Boltzmann equation 
to define the MIC50 values for each drug. 
2.4.9. Calculation of Growth rate 
12 consecutive OD600 values were taken from the exponential phase of a plotted 
growth curve and plotted against time. The growth rates were then calculated using 
the equations described by Fattah et al. (2018) and Stensjøen et al. (2015) 
below.114,115 
𝑦 = 𝐴𝑒𝐵𝑥  (where A and B are numbers) 
Equation 1. Exponential phase growth rate equation. 
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𝑦 = 𝐴𝑒𝐵𝑥  → ln
(𝑦 ÷ 𝐴)
𝐵
   
𝑤ℎ𝑒𝑛 𝑦 = 1, 𝑥1 =  
ln(1÷𝐴)
𝐵




𝑇𝑑 = 𝑥2 − 𝑥1 =
[(ln 2 − ln 𝐴) − (ln 1 − ln 𝐴)]
𝐵








Equation 2. Doubling time equation (Td). 




Equation 3. Growth rate (k) 
2.4.10. Compound Co-Drug Studies66 
A cell suspension was created as described previously, then dispensed into individual 
wells of a 96 well sterile plate under sterile conditions (105 cfu/mL, 90 µL).  
Compound 35 - 37 (90 µL) were either added alone or in 1:1 compound mixtures of 
these compounds were added into wells (90 µL). The plates were sealed using 
Parafilm then absorbance values were obtained using the Thermo Scientific 
Multiscan Go 1510-0318C plate reader and recorded using the SkanIt Software 4.0. 
Absorbance values were taken at 600 nm, every 15 minutes for 18-25 hours at 37 ºC, 
then used to generate growth curves. Each experiment was repeated on a different 
day to ensure reproducibility. Growth curves were then plotted and MIC50s were 
calculated as previously described. 
2.4.11. Agar well diffusion assay116 
An overnight culture was prepared as previously described. On the following day, a 
secondary culture was prepared using the overnight culture, then incubated at 37 °C 
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it had reached an optical density of 0.5-0.6 at 600 nm. LB Agar was prepared and 
once autoclaved, the molten agar was placed in a 50 °C water bath and maintained at 
this temperature. The molten agar was then inoculated using the secondary culture 
(15 mL), then swirled to mix. The inoculated agar was added to sterile Petri dishes (6 
mL) and allowed to set under sterile conditions. A sterile cutter was used to remove a 
disk from the inoculated agar, creating a well in the plate, and the bottom was sealed 
using fresh agar (5 µL). Compound gel solutions were prepared and heated, the gel 
solutions were then pipetted (50 µL) into the wells and allowed to set. Sodium 
chloride was pipetted (50 µL) into the wells of the appropriate plates. All the plates 
were then placed into a 37 °C incubator over 18 hours then imaged using the ESPON 
perfection V750 PRO scanner. 
2.4.12. Agar surface diffusion assay116 
An overnight culture was prepared as previously described. On the following day, a 
secondary culture was prepared using the overnight culture, then incubated at 37 °C 
it had reached an optical density of 0.5-0.6 at 600 nm. LB Agar was prepared and 
once autoclaved, the molten agar was placed in a 50°C water bath maintained at this 
temperature. The molten agar was then inoculated using the secondary culture (15 
mL) and swirled to mix. The inoculated agar was added to 60 mm x 15 mm sterile 
Petri dishes (6 mL) then allowed to set under sterile conditions. A compound gel 
solution (50 µL) was pipetted onto a sterile agar plate and allowed to set. Once set, 
the gel domes were carefully lifted using a spatula and placed in the center of the 
agar plate. Sodium chloride was pipetted straight onto the agar plate as a control. All 
the plates were then placed into a 37 °C incubator over 18 hours then imaged using 
the ESPON perfection V750 PRO scanner.   
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2.4.13. Zone of inhibition measurements in ImageJ.106 
Gel plate images were opened in ImageJ,106 and the scale was set based on the 
measurements of the agar plates (d = 60 mm). 4 zones of inhibition measurements 
were subsequently taken using the “measure length” function (Figure 20), and the 
average zone of inhibition was calculated for each plate. The final zone of inhibition 
reported is the average of 3 plates and the standard deviation was used as the error 
value. 
 
Figure 20. Zone of inhibition measurements using the length function in 
ImageJ.106 
Four measurements were taken (red lines) and an average was calculated for each 
plate.  
75 
|Chapter 2: Materials and methods 
2.5. Microscopy 
2.5.1. Competitive Binding Assay 
An overnight culture was prepared as previously described. On the following day, a 
secondary culture was prepared using the overnight culture, then incubated at 37 °C 
it had reached an optical density of 0.4 at 600 nm. The culture (500 µL) and LB (100 
µL) were pipetted into each sterile Eppendorf under sterile conditions. Different 
conditions were set up as follows; solvent alone: 5 % EtOH (100 µL) was added; 
compound alone: the compound (5 mM, 100 µL) was added; FM4-64 alone: 5 % 
EtOH (100 µL) and FM4-64 (0.7 µL) were added and FM4-64 & compound: the 
compound (5 mM, 100 µL) and FM4-64 (0.7 µL) were added. Samples were 
incubated at room temperature for 30 minutes then cells were mounted onto the 
agarose LB pads under coverslips117. Samples were visualised using an Olympus 
IX71 microscope with UAPON 150x 1.45 NA Widefield fluorescence   lens mounted 
on a PIFOC z-axis focus drive (Physik Instrumente, Karlsruhe, Germany), and 
illuminated using LED light sources (Cairn Research Ltd, Faversham, UK) with 
appropriate filters (Chroma, Bellows Falls, VT) using a Zyla 4.2 CMOS camera 
(Andor). The system was controlled with Metamorph software (Molecular Devices). 
Images were subsequently analysed using Metamorph and ImageJ software105. 
2.5.2. Sample Preparation 
Samples were prepared as described by Mulvihill (2017)117. 2 % agarose was placed 
in a 90 °C hot plate until molten. Molten agarose (50 µL) was pipetted into a 
microscope slide and then a pro-former was used to flatten the agarose pads. Once 
set, samples (6-10 µL) were pipetted onto the agarose pads and allowed to almost 
dry under sterile conditions when necessary. A coverslip was then placed onto the 
microscope slide and sealed on two sides. 
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2.5.3. Quantitative Fluorescence analysis 
Images were analysed using ImageJ software105. Line scans were created by drawing 
a line through the width of the cell using the line tool in image J. The same selection 
was made on all the corresponding images and an intensity profile of the line was 
created using the plot profile option. The background fluorescence was determined 
and subtracted from the maximum fluorescence. The fluorescence intensities for ~30 
– 100 cells were measured for each condition and an average fluorescence was used 
to create a bar chart from these data. Error bars show the variation in fluorescence 
within that condition. 
2.5.4. Gel Microscopy 
Samples were visualised using an Olympus IX71 microscope with UAPON 150x 1.45 
NA Widefield fluorescence   lens mounted on a PIFOC z-axis focus drive (Physik 
Instrumente, Karlsruhe, Germany), and illuminated using LED light sources (Cairn 
Research Ltd, Faversham, UK) with appropriate filters (Chroma, Bellows Falls, VT) 
using a Zyla 4.2 CMOS camera (Andor). 
A chamber was created by placing a coverslip on a microscope slide and taping on 
three sides of the coverslip. The appropriate salt solution (1 mL, 0.505 M) was added 
to 5 mg of the compound in a glass vial and heated to 60 °C. The microscope slide 
was placed onto the microscope stage and the gel solutions were pipetted into the 
chamber. The gelation process was then imaged as the gel was setting and analysed 
in imageJ105. 
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2.6. Liposome Studies 
2.6.1. Liposome preparation 
A solution of desired lipids (5 mL, 1 mM) was prepared in chloroform. The chloroform 
was removed on a rotary evaporator to create a thin film of lipid on the flask, then left 
under vacuum overnight to remove trace chloroform. The thin film was then 
rehydrated using buffer B that was at 10 °C above the phase transition temperature of 
each lipid and sonicated to ensure all of the lipid was in solution. For lipid mixes, the 
highest transition temperature was used. Liquid nitrogen and a water bath set 10 °C 
above the phase transition temperature of the desired lipid, were used to conduct 
nine freeze-thaw cycles. Lipids were then extruded before use at 10 °C above the 
Phase transition temperature, then diluted to the concentration required for the assay. 
These liposomes were then used in all assays.  
2.6.2. Co-sedimentation Assay under a density gradient 
Liposomes were prepared as described previously (100 µL, 1 mM) and added to a 
microcentrifuge tube with WT Hum-1 TH1-mNg protein in 30% sucrose (100 µL, 1 
mg/mL). The protein-lipid mixture was incubated at 37°C for 1 hour to allow binding. A 
25% sucrose solution (250 µL) was carefully pipetted over the top of the protein-lipid 
mixture in the microcentrifuge tube, which was then followed by αS buffer B (50 µL). 
Samples underwent centrifugation at 18,0000 xg for 1 hour at 20°C, with a slower 
deceleration. Fractions of 160 µL were carefully extracted and pipetted into separate 
centrifuge tubes. 80 µL from each fraction was pipetted into the wells of a 96 well 
black plate, and FM4-64 (0.8 µL) was added to the wells. These would be the lipid 
detection wells. The remaining 80 µL from each fraction was pipetted into separate 
wells, which would be the protein (mNg) fluorescence detection wells. 3 Fluorescence 
intensity at nm in the FM4-64 wells and nm in the mNg well were measured using the 
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BMG Clariostar microplate reader. The final fluorescence values were an average 
from two independent experiments and the standard deviation was used as the error 
value. Protein in the presence of solvent alone was used as the protein control, and 
FM4-64 in the presence of solvent alone was used as the FM4-64 control. 
2.6.3. Fluorescence Anisotropy (protein) 
Liposomes were prepared as described previously in αS buffer B. Serial dilutions of 
protein from 2.5 mg/mL were prepared in the αS buffer B. Protein solutions (10 µL) 
and the desired vesicle solutions at (50 µL, 1 mM) were pipetted into a 96 well black 
plate, allowed to bind for 30 minutes at room temperature, then anisotropy readings 
were measured using the BMG Clariostar microplate reader with appropriate filters 
and MARS data analysis software. 
2.6.4. Fluorescence Anisotropy (compound) 
Liposomes were prepared as described above in 5 % ethanol in dH2O. Serial 
dilutions of compounds from 5 mM were prepared in the 5 % ethanol in dH2O. The 
desired compound solution (10 µL) and the desired liposome suspension (50 µL, 1 
mM) were pipetted into a 96 well black plate, allowed to bind for 30 minutes at room 
temperature, then anisotropy readings were measured using BMG Clariostar 
microplate reader with appropriate filters and MARS data analysis software.  
2.6.5. Thermal Shift Assay118 
The assay is based on the method developed by Hattori et al., 2012 and Nji et al., 
2018.27,118 PCR tubes comprising of the desired protein (65 µL 3 mg/mL), the desired 
lipid (65 µL, 1 mM), αS Buffer B (5 µL), and OGP (15 µL, 10 %) were prepared. The 
tubes were labeled with the desired temperatures, with three repeats of each 
temperature to be tested. Tubes were heated using a gradient PCR at the chosen 
temperatures for 10 minutes, centrifuged at 18,000 xg, then the supernatant was 
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carefully removed and pipetted into a 96 well black plate. Fluorescence values were 
obtained using the BMG Clariostar microplate reader. Fluorescence values were 
normalised and used to create a melting curve, where the melting temperature (Tm) 
was calculated using Origin labs. The final Tm value reported was an average of the 
three repeats. One-way ANOVA was conducted on the resulting Tm values using IBM 
statistics software.  
2.7. Novel Compound Characterisation 
2.7.1. SSA 82 Synthesis 
Tetrabutylammonium (TBA) hydroxide (1N) in methanol (4 mL, 4 mM) was added to 
2-aminoethane-1-sulfonic acid (0.25 g, 2.0 mM) and taken to dryness. Triphosgene 
(0.309 g, 1 mM) was added to a stirring solution of 4-(6-methylbenzothiazol)aniline 
(0.5 g, 2 mM) in ethyl acetate (30 mL) and the mixture heated at reflux for 4 hours. 
The TBA salt was then dissolved in ethyl acetate (10 mL) and added to the reaction 
mixture and heated at reflux overnight, filtered and the solid washed with ethyl 
acetate (10 mL). Impurities were removed through precipitation in methanol with ethyl 
acetate, the solids filtered, and the filtrate taken to dryness to give the pure product 
as a pale yellow solid. 
2.7.2. SSA 83 Synthesis 
Tetrabutylammonium (TBA) hydroxide (1N) in methanol (4 mL, 4.0 mM) was added to 
3-aminopropane-1-sulfonic acid (0.28 g, 2.0 mM) and taken to dryness. Triphosgene 
(0.309 g, 1 mM) was added to a stirring solution of 4-(6-methylbenzothiazol) aniline 
(0.5 g, 2 mM) in Chloroform (30 mL) and the mixture heated at reflux for 4 hours. The 
TBA salt was then dissolved in Chloroform (10 mL) and added to the reaction mixture 
and heated at reflux overnight, filtered and the solid washed with chloroform (10 mL). 
Impurities were removed by precipitation in methanol with chloroform, the solids 
80 
|Chapter 2: Materials and methods 
filtered, and the filtrate taken to dryness to give the pure product as a pale yellow 
solid. 
2.7.3. Infrared (IR) measurements 
Infrared spectra of SSAs 82 and 83 were obtained using a Shimadzu IR-Affinity-1 
model Infrared spectrometer. The data are analysed in wavenumbers (cm-1) using 
IRsolution software. 
2.7.4. Dynamic Light Scattering (DLS) Studies 
SSAs 82 and 83 to be tested (5.56 mM) were prepared in filtered 5 % ethanol (1 mL) 
then underwent an annealing process in which they were heated at 40 °C before 
being allowed to cool to 25 °C. A series of 10 particle size experiments were carried 
out on the sample using the Anton Paar LitesizerTM 500 at 25 °C then processed 
using KalliopeTM Professional DLS. The sample was removed from the DLS and 
diluted to 0.56 mM, then underwent the annealing process in which it was heated to 
40 °C and cooled to 25 °C. Another series of 10 particle size experiments were 
carried out for these samples. The final hydrodynamic aggregate diameters reported 
is an average of each peak maxima obtained from the average particle size 
distributions from each experiment and the standard error of the mean (SEM) was 
used as the error value. 
2.7.5. Zeta Potential Measurements 
Solvents used were filtered to remove any particulates that may interfere with the 
results. Studies for SSAs 32-81 were conducted by another member of the lab whilst 
compounds 82 and 83 were conducted by me. Compounds (5.56 mM) were dissolved 
in filtered 5 % ethanol (1 mL) and underwent an annealing process in which they 
were heated at 40 °C before being allowed to cool to 25 °C. A series of 10 zeta 
potential measurements were conducted out using the Anton Paar LitesizerTM 500 at 
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25 °C then processed using KalliopeTM Professional DLS. The final zeta potential 
value reported is an average of the experiments conducted and the standard error of 
the mean (SEM) was used as the error value. 
2.7.6. Melting Point Measurements 
The melting points for SSAs 82 and 83 were measured using the Stuart SMP10 
melting point apparatus. 
2.7.7. NMR Spectroscopy 
The NMR spectra of SSAs 82 and 83 were obtained using a Bruker AV2 400 MHz or 
AVNEO 400 MHz spectrometer. The data was processed using ACD Labs, 
MestReNova, or Topspin software. NMR Chemical shift values are reported in parts 
per million (ppm) and calibrated to the center of the residual solvent peak set (s = 
singlet, br = broad, d = doublet, t = triplet, q = quartet, m = multiplet).  
2.7.8. Mass Spectrometry 
Compounds 82 and 83 experiments were conducted by Rebecca Ellaby. High-
resolution mass spectrometry (Electrospray ionization negative -ESI-) was performed 
using a Bruker microTOF-Q mass spectrometer and spectra were recorded and 
processed using Bruker’s Compass Data Analysis software. 
2.7.9. Single crystal X-ray diffraction studies 
Single crystals of SSAs 82 and 83 were prepared from the slow evaporation of 
alcohol: water solutions. Single crystal structures were obtained by Dr. Hiscock.  A 
suitable single crystal of each molecule was selected and mounted on a Rigaku 
Oxford Diffraction Supernova diffractometer. Data were collected using Cu Kα 
radiation at 100 K or 150 K as necessary due to crystal instability at lower 
temperatures. Structures were solved with the ShelXT or ShelXS structure solution 
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programs via Direct Methods and refined with ShelXL by Least Squares 
minimisation.107,108 Olex2 was used as an interface to all ShelX programs.109 
2.7.10. Tensiometry studies 
SSAs 82 and 83 were prepared in an EtOH:H2O (1:19) solution, then underwent an 
annealing process in which they were heated to 40°C before being allowed to cool to 
25°C. Serial dilutions of the SSA solutions were then prepared using the annealed 
sample. Three surface tension measurements for each sample at a given 
concentration were obtained using the pendant drop method. Average values were 
then used to calculate the critical micelle concentration (CMC). 
2.7.11. Inversion test 
SSAs 82 and 83 (5 mg) were dissolved in the appropriate salt solution (1 mL, 0.505 
M) in glass vials. SSA solutions were subsequently heated to ~40°C then allowed to 
cool to 25°C, to allow gel formation. Once cooled, glass vials were upturned and 
imaged. The presence of a stable gel was determined by reproducible n=3 inversion 
tests. 
2.8. Statistical analysis 
Paired-samples t-tests and one-way ANOVA were performed using IBM statistics 
software. 
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relationships of novel antimicrobial compounds 
3.1. Introduction 
The rise of antimicrobial resistance (AMR) within bacterial populations is rapidly 
becoming an increased risk to public health, projected to account for higher deaths per 
year than the combined total of cancer and aids-related diseases by the year 2050.53,119 
Moreover, the increased risk to the global economy due to increased costs of available 
treatments, healthcare, diagnostics tests, and disease surveillance means that new 
methods in the management and treatment of microbial diseases are imperative.52,53,120–
123 This concern has driven a variety of strategies to tackle antimicrobial resistance, 
including increasing global awareness;124 conducting research to improve current 
diagnostic techniques;125 increased development of novel antimicrobial compounds;68 and 
reduced distribution of unnecessary antibiotics in the environment.52,53,68,125,126 
Amphiphiles, such as antimicrobial peptides (AMPs), are versatile molecules composed 
of hydrophilic regions and hydrophobic regions.127,128 These molecules have been at the 
forefront of recent antimicrobial discovery, as AMPs have been shown to interact with 
anionic bacterial membranes, which is desirable as there is a reduced propensity for 
developing resistance and these interactions can lead to broad-spectrum activity.120,121,129 
Amphiphilic molecules have the potential to exhibit bacteriostatic and bactericidal 
activities and their facial amphiphilicity allows for them to effectively insert into bacterial 
membranes through interactions with membrane lipids, which may cause cell death due 
to the loss of membrane integrity.119,120,129 As amphiphilic antimicrobials tend to be based 
on or inspired by naturally occurring molecules,  they tend to have lower toxicity to 
mammalian cells, as observed by Rahman et al.,  whose cholic acid-derived amphiphiles 
exhibited potent activity against gram-negative bacteria and low mammalian cell toxicity 
(Figure 21).120,130 Furthermore, Chrom et al., through the use of AP3 peptide derived 
analogues, linked the ability to bind and permeabilise bacterial membranes to their 
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antimicrobial activity and showed the low cytotoxicity exhibited by their amphiphilic 
analogues.131  
 
Figure 21. Amphiphilic antimicrobials. 
The use of amphiphiles as antimicrobial compounds demonstrated by the work of 
Rahman et al., 2018.120  
As previously discussed, molecular self-association is an essential process that drives a 
variety of regulatory, binding, organisation, and stabilising processes.132–135 These self-
association processes occur through the formation of non-covalent interactions that are 
influenced by solvent interactions and the hydrogen bonding accepting or donating 
(HBA/HBD) groups present within the molecules.136,137 The use of self-associative 
molecules, in particular those that incorporate hydrogen bonding, has increased due to 
their versatility. Specific examples include the work of Supuran et al, whose urea-based 
molecules exhibited activity against M. tuberculosis H37Rv,138 (Figure 22a), Gale et al., 
who incorporated thio(urea) functionalities into their structures to encourage hydrogen-
bonded coordination (Figure 22b).139 This is further explored by Zhou et al., who utilised 
hydrogen-bonded amphiphiles for the development of novel drug delivery systems 
(Figure 22c).140   
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Figure 22. Use of self-associative molecules. 
Example structures of molecules showing the diverse use of self-associative thio(urea) 
derived molecules as demonstrated by (A) Supuran et al.,138 (B) Gale et al.,139 (C) Zhou 
et al.,140 
Understanding the structure-activity relationships of the molecules and their antimicrobial 
activity has proven to be invaluable for the development of novel antimicrobial 
compounds. Stepwise modifications to a generic structure and physicochemical studies 
conducted with the resultant structures can be utilised for accurate optimisation of 
therapeutics and the determination of structure-activity relationships.141,142 Linking the 
chemical structure of an antimicrobial molecule to its biological activity may allow us to 
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Antibiotics with a singular target are far less effective than those with multiple targets, as 
bacteria cannot as easily develop resistance mechanisms with the latter.144–146 
Consequently, coformulations have become more desirable in drug discovery, as they 
provide a way of reviving previously effective molecules, may allow for broad-spectrum 
activity, and improve efficacy.144,147,148 An example of this is the work of Ganewatta et al., 
whose quaternary amine containing compounds not only exhibited biocidal activity but 
were able to form micelles in water which allowed for the encapsulation of ampicillin, 
thereby greatly improving ampicillin activity (Figure 23).149 
3.2. Supramolecular self-associating amphiphiles (SSAs)  
Drawing from the work conducted by Gale et al.,139,150–152, Zhou et al.,140 Supuran et 
al.,138, Rahman et al.,120 and Ganewatta et al.,149  Hiscock et al.,153 created a series of 
supramolecular self-associating amphiphiles (SSAs) with antimicrobial properties, 
hypothesised to interact with membranes.154 These molecules consist of an anionic 
hydrogen accepting group, a thio(urea) hydrogen accepting/donating region, and a 
hydrophobic region as shown in Figure 24. The SSAs contain two hydrogen bond 
 
Figure 23. Use of self-associating molecules in antimicrobial research.  
Example structure of quaternary amine containing compounds developed by 
Ganewatta et al., used in the encapsulation of ampicillin.149 
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accepting sites (the thio(urea) and sulfonate functionalities), and one hydrogen bond 
donating (HBD) site (the amines in the thio(urea) functionality). 
 
Figure 24. General structures of SSAs by developed by Hiscock et al., 2018.154 
A schematic of the regions that made up the SSAs developed by Hiscock et 
al.,66,153,155,156. Green = hydrophobic region, pink = thio(urea) functionality, yellow = 
hydrophilic group, blue = counter cation. 
This allows the molecules to self-associate through the formation of intermolecular 
hydrogen bonds. A combination of 1H NMR dilution studies, DLS, and Zeta potential 
measurements confirmed the presence of self-associated aggregates, ranging from 100 – 
550 nm, with few exceptions.153,154 It is hypothesised that the dimerisation of these 
molecules is directly correlated to their antimicrobial activity, and thus enhancing the 
molecules’ hydrogen bonding capacity will allow for improved self-association, which in 
turn improves antimicrobial activity.  
3.3. Aims and hypothesis 
This chapter will explore the structure-activity relationships of this novel class of 
antimicrobial compounds in relation to their microbial activity. It is hypothesised that the 
antimicrobial activity of these molecules is dependent on the conformation of the self-
associated structures formed. Furthermore, the antimicrobial activity of these molecules 
is attributed to electrostatic interactions with membrane phospholipids, which form pores 
in bacterial membranes leading to a loss of membrane integrity and resulting in cell 
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death119. As such, this chapter will explore the impact of stepwise modifications made to 
SSA 32 on antimicrobial activity, the mode of action and membrane-binding properties of 
these molecules, and this chapter will demonstrate how the compounds can be used in 
combination with other therapeutic agents as adjuvants in response to the decline in 
novel antimicrobial development.119  
The data discussed in this chapter has been published in the following articles: 
Allen, N., White, L.J., Boles, J.E., Williams, G.T., Chu, D.F., Ellaby, R.J., Shepherd, H.J., 
Ng, K.K.L., Blackholly, L.R., Wilson, B., Mulvihill, D.P. and Hiscock, J.R. (2020), Towards 
the Prediction of Antimicrobial Efficacy for Hydrogen-Bonded, Self‐Associating 
Amphiphiles. ChemMedChem, 15, 2193. doi:10.1002/cmdc.202000533 
White, L. J., Wells, N. J., Blackholly, L. R., Shepherd, H. J., Wilson, B., Bustone, G. P., … 
Hiscock, J. R. (2017). Towards quantifying the role of hydrogen bonding within 
amphiphile self-association and resultant aggregate formation. Chemical Science, 8(11), 
7620–7630. https://doi.org/10.1039/c7sc03888g 
Tyuleva, S. N., Allen, N., White, L. J., Pépés, A., Shepherd, H. J., Saines, P. J., … 
Hiscock, J. R. (2019). A symbiotic supramolecular approach to the design of novel 
amphiphiles with antibacterial properties against MSRA. Chemical Communications, 
55(1), 95–98. https://doi.org/10.1039/c8cc08485h 
White, L., Boles, J., Allen, N., Alesbrook, L., Sutton, J., Hind, C., Hilton, K., Blackholly, L., 
Ellaby, R., Williams, G., Mulvihill, D. and Hiscock, J. (2020). Controllable hydrogen 
bonded self-association for the formation of multifunctional antimicrobial materials. 
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3.4. Antimicrobial Activity Assays 
3.4.1. Structures of SSAs 


















































































































Figure 25. Structures of SSAs discussed in this chapter.  
3.4.2. SSA 32 
SSA 32 contains a urea functionality, two NH functionalities, and a sulfonate hydrophilic 
region, which enable the molecule to self-associate through four hydrogen bonds as 
demonstrated in Figure 26.  
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Stepwise modifications made to SSA 32, forming SSAs 33 – 76 (Figure 25), could alter 
hydrogen bonding modes exhibited by the molecules, impacting dimerisation and 
antimicrobial activity. To determine how each modification would alter the antimicrobial 
activity, I carried out antimicrobial activity analysis on SSAs 32 – 81.  
3.4.3. Initial Antimicrobial Screening 
Antimicrobial screenings are often carried out as part of the early drug discovery process 
to provide an initial assessment of activity, allowing for the identification of suitable 
candidates against test organisms and the removal of ineffective molecules.55,157,158 Thus, 
I conducted an initial screening of SSAs 32 – 81 was against E. coli DH10β and MRSA 
USA100. These data was used to compare the effects of the compounds on gram-
negative and gram-positive bacteria, respectively. Antimicrobial screening was carried out 
as described in section 2.4.3 and 2.4.6 of the materials and methods. Briefly, SSAs were 
added to a final concentration of 3.3 mM to mid-log phase cells at a concentration of 105 
cfu/mL in a 96 well plate. OD values were then recorded every 15 minutes over 24 hours.  
3.4.4. Determining Solvent toxicity 
SSAs were dissolved in EtOH: H2O (1:19), (5 % EtOH), to aid their solubility in water, so 
we needed to ensure that the final concentration of ethanol within the experiment would 
 
Figure 26. A representation of the dimerisation of SSA 32.  
Hydrogen bonds formed between the oxygens of the sulfonate group of one molecule 
and the amine groups on the urea group of the other molecule. Purple = monomer 1, blue 
= monomer 2, dashed lines indicate hydrogen bonds. 
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have a minimal impact on growth. As such, bacterial growth in 5 % EtOH was compared 
to growth in LB media, and toxicity was determined by a reduction in bacterial growth, 
determined by the final OD values obtained. If the reduction in growth was ≤ 10%, the 
toxicity was considered minimal. The results of these studies are presented in Figure 27. 
These growth curves revealed a reduction of E. coli growth was by 9% and MRSA growth 
by 10%. As the impact of 5 % EtOH on E. coli and MRSA growth was considered 
minimal, the antimicrobial screening was conducted.  
3.4.5. Analysis of Growth dynamics and kinetics 
As previously described, bacterial growth in closed culture follow a discernible growth 
pattern that has been well characterised in literature.43,45,159 This pattern is made up of 4 
distinct phases: a lag phase, where bacteria acclimatise to the new environment; an 
exponential growth phase, where cells replicate exponentially; a stationary phase, where 
the rates of division and cell death are balanced; and a death phase, where the rate of 





Figure 27. Determining solvent toxicity.  
Growth curves comparing bacterial growth in LB and 5 % EtOH at the same concentration 
as experimental conditions. (A) E. coli; 9% reduction in growth observed in 5 % EtOH (B) 
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Recording OD values at regular intervals throughout the growth process allows for the 
creation of growth curves, which in turn allows for the examination of microbial growth 
dynamics in the presence of these molecules. 49,160   Further, parameters such as growth 
rate (k) can then be calculated, which are essential in providing a full evaluation of the 
activity of these molecules. Initial indications of the mode of action may be evident in the 
growth curves obtained in the presence of each SSA. Consequently, an analysis of the 
growth curves generated using the screening data was performed and the growth rates 
(k) of both MRSA and E. coli in the presence of SSAs 32 – 81 were calculated. These 
were conducted using the exponential phase of the bacterial growth curves in the 
presence of each SSA (Table 6), as described by Fattah et al. (2018) and  Stensjøen et 
al. (2015), [section in 2.4.9 materials and methods].114,115 These rates were compared to 
the growth rate of the bacteria without compound present. 
  
94 
|Chapter 3: Investigating the structure activity of novel antimicrobial compounds      
 
Table 6: Growth rates (k) of MRSA and E. coli in the presence of SSAs 32 – 81 in 
minutes. 
  a - growth rate assumed to be zero due to lack of growth, b – SSAs screened at 3.75 
mM, c– growth control; the growth rate of bacteria in the presence of EtOH: H2O (1:19) 
only. 
Average Growth Rate (k) 
 
 k (mins.)   k (mins.)  
E. coli MRSA   E. coli MRSA 
32 106.38 ± 4.64 NAa 58 90.32 ± 1.12 NAa 
33 95.04 ± 3.36 NAa 
 
60 72.97 ± 3.49 118.71 ± 28.38 
34 89.87 ± 2.15 NAa 
 
61 98.70 ± 2.10 NAa 
35 91.34 ± 4.26 NAa 
 
63 105.06 ± 2.29 NAa 
36 98.70 ± 2.10 NAa 
 
64 84.87 ± 3.99 249.52 ± 90.90 
37 91.54 ± 2.05 NAa 
 
65 97.13 ± 8.61 84.75 ± 5.13 
38 89.16 ± 1.09 79.85 ± 4.60 
 
66b 193.08 ± 41.37 91.82 ± 1.28 
39 84.02 ± 0.59 NAa 
 
67b 331.79 ± 26.01 106.78 ± 4.36 
40 115.57 ± 2.41 83.54 ± 20.79 
 
68b 93.70 ± 2.07 168.49 ± 7.09 
41 113.65 ± 1.67 145.91 ± 1.77 
 
69 90.46 ± 4.33 208.78 ± 9.35 
42 84.04 ± 1.43 NAa 
 
70 85.77 ± 1.55 NAa 
46 82.52 ± 0.80 72.77 ± 0.73 
 
71 90.53 ± 3.53 64.40 ± 1.25 
47 90.03 ± 0.95 87.39 ± 28.83 
 
72 92.45 ± 2.01 363.24 ± 39.40 
48 90.92 ± 1.49 NAa 
 
73 89.45 ± 1.14 738.53 ± 433.59 
49 92.42 ± 0.00 23239.34 ± 
39902.57 
 
74 96.99 ± 2.31 414.1 ± 12.74 
50 123.53 ±16.04 630.13 ± 0 
 
75 114.12 ± 1.79 93.40 ± 2.33 
51 99.91 ± 4.83 NAa 
 
76 102.59 ± 6.19 375.31 ± 82.69 
52 109.19 ± 2.22 201.12 ± 7.53 
 
77 90.69 ± 3.19 168.03 ± 20.89 
53 106.31 ± 3.37 180.85 ± 13.91 
 
78 109.16 ± 0.99 779.79 ± 100.04  
54 89.52 ± 3.01 NAa  79 87.48 ± 1.38 78.99 ± 0.45 
55 100.51 ± 2.66 328.61 ± 114.95  80 88.30 ± 0.65 70.37 ± 0.41 
56 91.83 ± 1.57 130.28 ± 10.55  81 92.83 ± 3.63 163.30 ± 6.66 
57 94.63 ± 0.64 72.21 ± 1.08 Control 
c 
78.57 ± 7.61 65.10 ± 1.12 
 
While the molecules were structurally related, the impact on bacterial growth varied 
significantly, which led to a classification of the type of inhibition exhibited by the SSAs on 
E. coli and MRSA. Screening growth curves were used in this characterisation. The 
categories used in this classification were: minimal inhibition, reversible inhibition, partial 
inhibition, delayed inhibition, and complete inhibition.  
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Minimal inhibition was defined by a reduction in growth that was ≤ 10% and uninterrupted 
bacterial growth stages that mirrored the growth control, as exhibited by SSA 67 in Figure 
28.  
 
Figure 28. Growth curves of E. coli demonstrating compound aggregation.  
Growth curves comparing E. coli growth in the presence of SSA 67 (green) at 3.3 mM 
compared to the 5 % EtOH growth control (black). 
Initially, the growth rate of E. coli in the presence of SSA 67 was calculated to be 830.11 
± 987.14 minutes, which was significantly higher than the growth control. However, the 
large variation prompted further examination of the growth curve produced in the 
presence of SSA 67, which revealed fluctuating OD values. As the fluctuation was 
present from the start of the observation period, this was attributed to compound 
aggregates forming which may be due to low solubility in solution. While SSA 67 may 
have been initially soluble in 5 % EtOH, its stability decreased significantly and resulted in 
the decreased solubility. Further, when compared to the growth control, while growth was 
indeed slower in the presence of this SSA, it was not as significant as the initial 
calculated growth rate suggested and exhibited minimal inhibition to E. coli growth. This 
highlighted the importance of pairing growth rate calculations with growth curve analysis, 
as in this case, this growth rate may have suggested a greater efficacy than the SSA’s 
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growth rate of 331.79 ± 26.01 minutes, which accounts for the compound aggregation. 
Minimal inhibition was further demonstrated by E. coli growth in the presence of SSA 46 
(Figure 29). 
 
Figure 29. Growth curves of E. coli demonstrating minimal inhibition.  
OD600 growth curves of E. coli growth in the presence of SSA 46 at 3.3 mM (green), in 
comparison to the 5 % EtOH growth control (black). 
The growth stages in the presence of SSA 46 appeared to be uninterrupted. Further, the 
growth rate in the presence of 46 was 82.52 minutes, which while higher than the growth 
control (78.57 minutes), the growth curve produced revealed this to not be significant 
(Figure 29). Finally, the culture was able to reach a higher final OD value than the growth 
control, indicating improved E. coli growth. Thus, SSAs 67 and 46, along with any other 
molecule that demonstrated a similar impact on bacterial growth, were classified as 
producing minimal inhibition.  
SSAs that exhibited an elongated lag phase, followed by a recovery, shown by the 
presence of an exponential phase that resulted in the final OD value either being ≥ 10 % 
lower or an OD value that was higher than that of the growth control, were deemed to 
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Figure 30. Growth Curves MRSA demonstrating reversible inhibition.  
OD600 growth curves showing MRSA growth in the presence of SSA 38 (orange) at 3.3 
mM in comparison to the growth control (5 % EtOH) (black). 
While the exponential phase began at ~ 500 minutes, 200 minutes later than the growth 
control, and the growth rate (89.16 minutes) was higher than that of the growth control 
(65.10 minutes), the cells recovered and were able to reach a greater population density 
than the growth control. It has been established that subinhibitory doses of antimicrobials 
allow cells to develop resistance against those SSAs, resulting not only in recovery from 
any initial inhibition that may have taken place but improved growth in the presence of 
that SSA.161 The extended lag phase exhibited in the presence of SSA 38 indicates an 
initial inhibition, and the OD value being higher than the growth control suggests both 
recovery and improved growth, which are indications of resistance. As such, SSA 38 and 
any other SSAs that impacted bacterial growth in this way, were deemed to produce 
reversible inhibition.  
SSAs were classified as exhibiting partial inhibition when an exponential phase was 
observed with the SSA present, however, the final OD value was > 10% lower than the 
growth control. This could involve an extended lag phase, as demonstrated by SSA 69 
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Figure 31. Growth curves of MRSA demonstrating partial inhibition.  
Growth curves showing MRSA growth in the presence of SSA 69 (orange) at 3.3 mM in 
comparison to the growth control (5 % EtOH, black). 
And while cells were able to recover, the growth rate was considerably higher (208.78 
minutes) than the growth control (65.10 minutes) and the final OD value reached was 
significantly lower than that of the growth control. Additional examples of this are shown 
in the MRSA growth curves produced by SSAs 55 and 56 (Figure 32). Growth stages in 
the presence of SSA 55 were severely disrupted. The lag phase was elongated 
marginally, and a brief but rapid exponential phase was observed at ~ 300 minutes. 
However, while the exponential phase continued, it was extended and considerably 
slower, resulting in a growth rate of 328.61 minutes, which was significantly higher than 
that of the growth control. Similarly, SSA 56 exhibited an elongated lag phase, followed 
by a brief exponential phase, which appears to stop between ~400 minutes and 1200 
minutes. Following this, another exponential phase was observed at 1200 minutes 
onward, which obtained a lower growth rate of 130.28 minutes, compared to 55. 
However, the final OD value was still significantly lower than the growth control, hence its 
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Figure 32. Growth curves of MRSA demonstrating partial inhibition.  
Growth curves showing MRSA in the presence of SSAs 55 (brown) and 56 (orange) at 3.3 
mM in comparison to the growth control (5 % EtOH, black). 
This was further demonstrated by MRSA in the presence of SSA 49, shown in Figure 33.  
 
Figure 33. Growth curves of MRSA demonstrating partial inhibition.  
Growth curves showing MRSA growth in the presence of SSA 49 (orange) at 3.3 mM in 
comparison to the growth control (5 % EtOH, black). 
A significantly elongated lag phase was observed, which ended at ~ 500 minutes later 
than that of the growth control. And while cells were able to recover, the growth rate was 
considerably higher, at 92.42 minutes, resulting in a final OD value that was lower than 
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were classified as exhibiting partial inhibition. Partial inhibition was undesirable as this 
increases the propensity for bacteria to develop resistance to the SSAs. SSAs were 
classified as exhibiting delayed inhibition if bacterial death was observed in the later 
stages of growth, such as mid-log phase and stationary phase, shown by a decline in OD 
values. This was the case for SSAs 55 and 66 in the presence of E. coli (Figure 34). A 
decline in absorbance values was observed from ~ 800 minutes, with the decline 
exhibited by SSA 55 being faster than that of SSA 66. This decline in bacterial growth 
was a direct result of the compounds’ presence, as demonstrated by SSA 35 (Figure 34). 
While the final OD value reached in the presence of this compound was lower than that of 
the growth control, a death phase was not observed. Interestingly, while the growth 
pattern of E. coli in the presence of SSAs 66 and 55 was similar, the growth rates differed 
significantly; 66 = 193.08 minutes, 55 = 100.51 minutes.  
 
Figure 34. Example growth curves of E. coli demonstrating delayed inhibition. 
Growth curves showing E. coli growth in the presence of SSAs 35 (purple), 55 (blue) and 
66 (green) at 3.3 mM, in comparison to the 5 % EtOH growth control. 
Further, an elongated lag phase was observed by SSA 66 which was not detected in the 
presence of SSA 55. This observation combined with the more rapid death phase 
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different stages in growth. SSA 66 had a more prominent effect at earlier stages in 
growth, indicated by the later lag phase, whereas SSA 66 impacted the stationary phase 
more prominently, indicated by the more rapid death phase. During bacterial growth, 
multiple changes are made to the phospholipids that make up the membrane during the 
transition from the exponential phase to the stationary phase, which are thought to 
protect against phospholipid degradation and improve stability.162,163 These changes 
include increases in cardiolipin (CL), decreases in phosphatidylglycerol (PG), and 
increases in cyclopropane fatty acids.71,163 As the SSAs are hypothesised to interact with 
bacterial membranes, the  activity observed at different stages of growth may indicate 
specific lipid binding. If the lipids are more prevalent during the stationary phase, then this 
would allow the SSAs to impact the stationary more significantly than the other phases. 
Delayed inhibition is further demonstrated by E. coli in the presence of SSAs 34 and 37 
(Figure 35). A delayed lag phase was observed with compound 34, (Figure 35a), and the 
E. coli growth rate was 89.87 minutes, which was marginally higher than the growth 
control, suggesting a minimal impact on growth in the exponential phase. However, at 
~600 minutes, a rapid death phase was observed followed by fluctuated OD values, and 
the final OD values were close to those observed in the lag phase, suggesting total cell 
death. The growth curve for SSA 37 (Figure 35B) revealed an unhindered lag phase, and 
a marginally impacted exponential phase, indicated by a growth rate of 91.54 minutes 
(Table 6). However, a far more prominent death phase was observed, followed by a 
fluctuation in OD values. The death phase appears to slow down from 1100 minutes, 
which may indicate the cells recovering or adjusting to the presence of this compound, 
which was not detected with SSA 34.  
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This is further confirmed with the growth curves exhibited by SSAs 55 and 56, which 
suggested different compounds impacting different stages of growth. The fluctuation 
observed with SSAs 34 and 37 was only observed either during or after the death phase 





Figure 35: Example growth curves of E. coli demonstrating delayed inhibition. 
Growth curves should E. coli growth in the presence of (A) SSA 34 and (B) SSA 37 at 3.3 
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aggregation was only present within the death phase, decreasing the likelihood of that 
being the case. It was hypothesised that the fluctuation could either be due to bacterial 
aggregation caused by the loss of membrane integrity or due to the compound 
aggregating lipids, as observed with other amphiphilic antimicrobials.164 However, a 
deeper analysis into the membrane-binding properties of the SSAs would allow us to 
determine whether this was the case. 
Lastly, SSAs that resulted in OD values remaining the same as the lag phase OD values 
throughout the growth period were defined as exhibiting complete inhibition. This 
suggested a lack of growth in the presence of those SSAs. SSAs that produced this type 
of inhibition did not have a growth rate calculated, as growth was not detected during the 
growth period.  
E. coli growth rates remained relatively consistent compared to MRSA, which fluctuated 
greatly, as shown in the graphical representations of the growth rates in Figure 36. 
Further, none of the SSAs tested produced complete inhibition against E. coli, whereas ~ 
30% of SSAs tested appeared to completely inhibit MRSA, showing a greater impact on 
MRSA than E. coli. Gram-negative bacteria, like E. coli, have an extra outer lipid 
membrane, which creates an additional obstacle for the SSAs to overcome that isn’t 
present in MRSA, which is gram-positive. As such, a greater impact on MRSA produced 














Figure 36 – Graphical representation of the growth rates presented in Table 6.  
Growth rates (k) of (A) E. coli and (B) in the presence of SSAs 32 – 81 (minutes). Blue 
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Table 7 provides a summary of the types of inhibition exhibited by MRSA and E. coli in 
the presence of the SSAs.  
Table 7: Type of inhibition exhibited by SSAs 32 – 81 against E. coli and MRSA.   
 
E. coli MRSA   E. coli MRSA 
32 Delayed Complete 58 Minimal Partial 
33 Delayed Complete 
 
60 Minimal Reversible 
34 Delayed Complete 
 
61 Partial/Delayed Complete 
35 Partial Complete 
 
63 Minimal Complete 
36 Delayed Complete 
 
64 Partial/Delayed Complete 
37 Delayed Complete 
 
65 Partial/Delayed Partial 
38 Minimal  Reversible 
 
66b Partial Partial 
39 Minimal Complete 
 
67b Minimal Partial 
40 Minimal Partial 
 
68b Minimal Partial 
41 Minimal Partial 
 
69 Partial Partial 
42 Partial Complete 
 
70 Delayed Complete 
46 Minimal Minimal 
 
71 Minimal Minimal 
47 Minimal Reversible 
 
72 Partial/Delayed Partial 
48 Minimal Complete 
 
73 Partial/Delayed Partial 
49 Minimal Partial 
 
74 Partial/Delayed Partial 
50 Minimal Partial 
 
75 Minimal Partial 
51 Minimal Complete 
 
76 Partial/Delayed Partial 
52 Partial/Delayed Partial 
 
77 Partial Partial 
53 Partial Partial 
 
78 Minimal Minimal 
54 Minimal Partial  79 Minimal Minimal 
55 Partial Partial  80 Minimal Minimal 
56 Partial Partial  81 Partial/Delayed Partial 
57 Partial/Delayed Partial    
Following the growth curve analysis, OD values at the end of the growth period were 
taken for each SSA and a percentage change was calculated using the OD values of the 
growth control (5 % EtOH) as a comparison. This would allow us to differentiate between 
effective and ineffective antimicrobial SSAs. Effective SSAs were characterised by a > 10 
% inhibition of bacterial growth, thereby passing the screening, whereas SSAs that 
exhibited a ≤ 10 % inhibition failed the screening process and were not taken forward for 
any further antimicrobial testing. Additionally, as 3.3 mM was a high concentration 
compared to the MICs obtained for commercially available antimicrobials,165,166 SSAs that 
were not soluble in 5 % EtOH at 3.3 mM were considered ineffective molecules, and 
consequently, antimicrobial studies were not conducted. These SSAs are included within 
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this chapter to provide a thorough comparative analysis. The screening results and 
percentage change in growth produced by each SSA are presented in Table 8. 
Table 8. Antimicrobial screening results for SSAs 32 – 81.  
SSAs were screened at 3.3 mM against both E. coli and MRSA. F – failed the screening, 
P – passed the screening. Percentage change calculated using OD values at the end of 
the growth period: + indicates that this value is a percentage increase, all other values 
percentage values were a percentage decrease compared to the 5 % EtOH growth 
control. a – SSA was not soluble under experimental conditions, b – compound 
decomposes over time. 
Antimicrobial Screening for SSAs 32 - 81 









E. coli MRSA E. coli MRSA 
  
E. coli MRSA E. coli MRSA 
32 P P 73.86 100.00 
 
57 P P 28.28 17.31 
33 P P 73.18 99.36 
 
58 F P 7.57 97.63 
34 P P 90.34 100.00 
 
59a - - - - 
35 P P 37.81 99.12 
 
60 F F + 3.71 + 5.74 
36 P P 62.56 99.98 
 
61 P P 88.77 100.00 
37 P P 73.39 100.00 
 
62a - - - - 
38 F F 7.80  + 2.84 
 
63 P P 12.66 99.88 
39 F P 4.18 100.00 
 
64 P P 33.25 87.57 
40 F P 9.20 63.52 
 
65 P P 27.70 22.77 
41 F P 7.32 54.86 
 
66 P P 37.00 100 
42 P P 31.43 100.00 
 
67 F P + 3.04 100 
43a - - - - 
 
68 F P  +2.49 100 
44a - - - - 
 
69 P P 19.44 62.00 
45b - - - - 
 
70 P P 27.12 99.00 
46 F F + 4.50 + 2.70 
 
71 F F + 0.05 + 2.00 
47 F F 4.40 1.91 
 
72 P P 31.76 93.00 
48 F P 7.26 100.00 
 
73 P P 15.38 85.00 
49 F P 4.27 44.20 
 
74 P P 39.26 96.00 
50 F P + 1.52 80.02 
 
75 F P + 1.75 40.00 
51 F P + 1.64 97.61 
 
76 P P 26.36 78.00 
52 P P 46.36 93.00 
 
77 P P 22.83 70.00 
53 P P 54.12 66.23 
 
78 F F 3.01 + 
12.00 
54 F P 5.97 81.73 
 
79 F F 2.04 + 1.00 
55 P P 30.70 85.41 
 
80 F F 1.68 + 2.00 
56 P P 20.49 55.02 
 
81 P P 29.84 78.00 
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3.4.6. MIC50 determination 
The MIC50 represents the concentration of a drug that inhibits 50 % of isolates in a test 
population.167,168 MIC50 values were calculated for the SSAs that passed the screening 
process; those that inhibited bacterial growth > 10 %. Further, as compounds that 
exhibited 100% decreases in growth could not be compared using the screening results, 
their MIC50 values were used for comparison.  
MIC50 values were obtained as described in section 2.4.4, 2.4.7, and 2.4.8 of the 
materials and methods. Briefly, SSA solutions were created in 5 % EtOH, using the 
screening results as a basis for selecting the concentrations tested. The concentrations 
were selected so that the highest concentration would produce total cell death, or as 
close to this as possible, and the lowest concentration would have a minimal impact on 
bacterial growth. The SSA solutions were then added to mid-log cells at a diluted 
concentration of 105 cfu/mL, then incubated at 37 °C in a microplate reader. OD values 
were recorded every 15 minutes for 18 hours, then MIC50 values were calculated using 
the OD values at 900 minutes from each concentration. These values are presented in 
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Table 9. MIC50 values obtained for SSAs 32 – 81.  
MIC50 values calculated for SSAs that passed the screening process, a – compound was 
not soluble under experimental conditions, b – compound breaks down over time, c – 
unable to calculate an MIC50 value due to crystallisation of compound, d – compound 
failed the screening process, * - predicted endpoint used to calculate MIC50 due to 
solubility of the compound under experimental conditions. 
MIC50 values obtained for SSAs 32 – 81. 
 
MIC50 (mM)   MIC50 (mM)  
E. coli MRSA   E. coli MRSA 
32 3.85* 0.46 58 NAd 1.10 
33 3.93* 0.98 
 
61 1.25 1.14 
34 1.48* NAb, c 
 
63 NAa 0.83 
35 NAa 3.03 
 
64 NAd 0.77 
36 NAa 0.25 
 
65 4.30* 2.96 
37 1.85* 1.08 
 
66 NAa 0.46 
39 NAd 0.35 
 





68 NAd 0.71 
41 NAd 2.85 
 
69 3.57* 0.99 
42 5.96* 0.42 
 
70 5.00* 0.93 
48 NAd 0.92 
 
71 NAd 4.41 
49 NAd 5.10 
 
72 5.67* 2.85 
50 NAd 3.00 
 
73 NAa 5.78 
51 NAd 2.18 
 
74 6.03* 3.07 
52 NAa 0.98 
 
75 NAd 2.78 
53 NAa 2.59 
 
76 6.91* 8.99 
54 NAd 1.65 
 
77 6.26* 3.12 
55 8.65* 1.96 
 
81 6.36* 3.18 
56 7.37* 2.24 
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Figure 37. Graphical 
representation of 
the MIC50 values 
presented in Table 
9. 
Antimicrobial efficacy 
of SSAs 32 – 81 
against E. coli and 
MRSA, determined by 
MIC50 values (mM). 
1MIC50 (mM-1) is 
displayed to better 
visualise the MIC50 
values. The larger the 
bar, the smaller the 
MIC value. 
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3.5. Structure-Activity Relationships of SSA 1 – 50 
The data discussed in this section corresponds to the data presented in Tables 6 to 9 and 
Figures 36 and 37. Any physicochemical studies discussed were conducted by Lisa 
White.153,154 
3.5.1. Increased growth of bacteria 
The addition of some of the SSAs to bacteria led to increased bacterial growth in 
comparison to their respective growth controls. These SSAs were 46 (+4.53%),50 
(+0.95%), 51 (+0.97%), 60 (+3.59%), 67 (+0.39%) and 75 (+3.97%) for E. coli and for 38 
(+2.92%), 46 (+2.45%), 60 (+8.81%), 71 (+1.92%), 78 (+7.87%), 79 (+1.55%) and 80 
(+1.31%), for MRSA. Bacteria can rapidly adapt to different environments and utilise their 
environment to improve growth.169,170 As previously mentioned, exposing bacteria to 
sublethal concentrations of antimicrobials can improve growth which may be due to the 
development of resistance and increased nutrient uptake, leading to increased growth. 
Further, the cells may be able to break down and utilise the SSAs to promote growth. 
Therefore, any SSAs that increased bacterial growth were considered ineffective 
antimicrobials. 
3.5.2. Urea and Thiourea functionalities 
Thiourea and urea derived compounds are widely used for a range of purposes, and 
particularly known for their biological activities such as their antiparasitic, anticancer, 
antioxidant, antibacterial, and antifungal properties.171–173 Within these molecules are two 
HBD amine groups,174 which enable self-association events to occur. Whilst structurally 
similar, the change from an oxygen atom to a sulphur atom alters the physicochemical 
properties of the molecule. Polarity exists within the thio(urea) functionality due to the 
electronegativity of the sulphur (S) and oxygen (O) atoms, which results in a partial 
negative charge on the S/O atoms and a partial positive charge on the NH hydrogen 
atoms. However, the sulphur atom is a less electronegative atom so polarises the bond 
less in comparison to the oxygen atom. Thus the NH hydrogens are less acidic in the 
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thiourea functionality than in the urea functionality, allowing the urea to form stronger 
hydrogen-bonded complexes.175–179 However, as the sulphur atom is larger in size than 
the oxygen atom, the partial negative charge is dispersed over a larger area, allowing 
thiourea to be more lipophilic. The thiourea-based molecules were predicted to perform 
better as antimicrobials than urea-based molecules, due to the greater lipophilicity which 
was predicted to allow the molecule to pass through bacterial membranes with greater 
ease than the urea-based molecules. Consequently, the urea functionality was changed 
to a thiourea, giving rise to SSA 35. Rather than increased antimicrobial efficacy, 
however, SSA 35 had considerably less activity than SSA 32. Reduction in bacterial 
growth was 73.86 % for SSA 32 but 37.81% for SSA 35 against E. coli. And although a 
marginal difference between percentage reduction in MRSA growth for SSAs 32 and 35, 
(100.00% and 99.12%, respectively), the MIC50 value for SSA 35 (3.03 mM) was 
considerably higher than that of SSA 32 (0.64 mM). A comparison was made using the 
other molecules containing urea and thiourea functionalities which revealed a decrease in 
efficacy with the thiourea counterparts for the vast majority of molecules. Furthermore, 
the substitution to the thiourea functionality reduced the stability of SSA 45 (compared 
with SSA 38), which we were unable to test as a result of this modification. These 
observations were consistent with the majority of SSAs, where the urea and thiourea 
functionalities were compared, and thus we concluded that the urea functionality played 
an integral role in the antimicrobial action and was more effective than the thiourea 
functionality. This may be due in part to the higher electronegativity of the oxygen atom 
and increased acidity of the urea functionality which may have resulted in stronger 
hydrogen bonded complexes, in comparison to the thiourea functionality. 
3.5.3. Increasing the thio(urea) anion spacer 
Increasing the connective alkyl chain between the sulfonate group and the amine groups 
and the sulfonate group, from n=1 to n=2, resulted in SSAs 33 and its thiourea 
counterpart, SSA 36. Regarding SSA 33, this change decreased antimicrobial efficacy 
drastically against MRSA. Whilst screening results only reveal a minor decrease in 
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activity against MRSA growth, decreasing growth by 99.36% in comparison to the 100% 
reduction in growth by SSA 32, it is with the compound’s MIC50 against MRSA that we 
truly see this. The MIC50 for SSA 33 (0.98 mM) was more than twice the MIC of SSA 32 
(0.46 mM) against MRSA. Antimicrobial activity against E. coli was not as drastically 
different; screening results revealed a 0.68% difference in their effect on growth and while 
slightly lower for SSA 33, the MIC50 for SSAs 32 and 33 against E. coli were similar (3.85 
mM and 3.93 mM) respectively. Solution state studies conducted on SSA 33 revealed a 
lower association constant, in comparison to those obtained for the other SSAs.154 
Further, solid-state studies revealed SSA 33 spent the majority of time forming an 
intramolecular hydrogen bond between the sulfonyl group one of the urea amine groups, 
which is proposed to reduce intermolecular self-association events.  
Increasing the alkyl chain further from n= 2 to n=3 increased antimicrobial activity, 
especially against E. coli. A comparison between SSAs 32 – 34 revealed a reduction in E. 
coli growth of 90.34 % by SSA 34 (n=3), which was higher than that of SSA 32 (n=1), 
(90.34 %) and SSA 33 (n=2), (73.18 %). Further, the MIC50 of SSA 34 (1.48 mM) was 
significantly lower than SSAs 32 (3.85 mM) and 33 (3.93 mM), which was the second 
lowest MIC50 against E. coli. Improved efficacy against MRSA was also observed with 
SSA 34, compared to SSA 33, decreasing growth by 100% in comparison to 33, which 
decreased growth by 99.36%. An MIC50 could not be calculated for SSA 34 against 
MRSA, however, as consistent results could not be obtained. MRSA growth curves 
produced in the presence of SSA 34 varied drastically, which was not observed with E. 
coli (Figure 38).  
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Figure 38. MRSA Growth curves.  
Growth curves showing the variation of MRSA growth in the presence of SSA 34 at 1.67 
mM.  
This was hypothesised to be a result of the SSAs tendency to crystallise, which may have 
had a more pronounced effect at lower concentrations, and given the high efficacy 
against MRSA, this would produce inconsistent results. The thiourea counterparts (SSA 
35 – 37) mirror this increase in efficacy when the alkyl chain was increased n=3, with the 
major difference being the improved stability of SSA 37, in comparison to SSA 34 against 
MRSA.  
An investigation of the structures of SSAs 34 and 37 revealed the molecules did not 
spend as much time forming the intramolecular bond observed with SSA 33.  This may 
allow both the sulfonyl group and both central NH groups to form hydrogen bonds more 
freely, which we hypothesised may be integral to the antimicrobial activity of these 
compounds.  
3.5.4. Exchanging the counter cation 
Hydrogen bond complexation events can be negatively impacted by the presence of 
competitive ion-ion pairs, thus TBA counter cations are more favourable due to low 
coordination. SSAs 38 – 49 were used to investigate how this would impact the 
antimicrobial activity. It was hypothesised that ion-ion pair effects would hinder self-
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antimicrobial activity. The cations selected were tested alone to determine their own 
antimicrobial activity (SSAs 78 – 81). SSAs 78 – 80 had minimal impact on growth, with 
the highest activity being that of 78, which decreased growth by 3.01%. Whilst SSA 81 
had antimicrobial activity on its own, as documented in literature11,180–182, its higher MIC50 
values against E. coli (6.36 mM) and MRSA (3.18 mM) in comparison to those of SSA 32 
(E. coli; 3.85 mM and MRSA; 0.46 mM), as well as the majority of compounds containing 
TBA suggested that the antimicrobial activity could not solely be attributed to TBA.  
Rather, the combination of the anion and the TBA cation produced the antimicrobial 
activity observed. Following this, the compound screening and MIC50 calculations for 
SSAs 38 – 49 were conducted. The sodium counter cation was first selected as it would 
be more strongly co-ordinating to the anion than the TBA cation. Crystal structures of the 
resulting structures formed by SSAs 38 and 45 suggested disrupted dimer formation 
caused by the sulfonate group no longer involved in self-association processes, but urea-




Figure 39. Crystal structures of SSAs 32 and 38.  
Crystal structures showing (A) the dimerisation of SSA 32 in comparison to (B) the urea-
urea stacking observed with SSA 38.183 
Further, in the solution state, dilution studies conducted on 38 revealed ion-ion pair 
effects.154 This was reflected in the activity of these two SSAs, which were compared to 
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SSAs 32 and 35, respectively. SSA 38 revealed a drastic reduction in antimicrobial 
activity during the screening process, only decreasing bacterial growth by 7.80% against 
E. coli and increasing MRSA growth by 2.84%, and thereby failing the screening. Its 
thiourea counterpart, 45, was unstable during the synthesis process so could not be 
taken forward for any antimicrobial activity analysis.  
Charge diffusion and steric hindrance as the cations increased in size would result in 
weaker coordination to the anionic component, in comparison to the sodium ion. The 
pyridinium cation was slightly less coordinated to the anionic component, and the impact 
of this was next examined through the use of SSAs 39 and 46 which were compared to 
SSAs 32 and 35, respectively. While SSA 39 decreased activity against E. coli (4.18% 
decrease was observed for SSA 39, thereby failing the screening process), activity 
against MRSA increased, with a drastically lower MIC50 of 0.35 mM. Its thiourea 
counterpart (46), however, failed the screening process against both bacteria. Next, the 
effect of the TMA cation was observed through SSAs 40 and 47. These molecules 
exhibited improved activity in comparison to SSAs 38 and 45, respectively. While it still 
failed the screening process, SSA 40 decreased E. coli growth by 9.20 %, which was 
higher than that of SSA 38 (7.80 %). MRSA activity significantly increased, shown by 
SSA 40 decreasing growth by 63.52% and producing an MIC50 value of 2.17 mM, in 
comparison to SSA 38 activity, which failed the screening process. The thiourea 
counterpart, SSA 47, failed screening against both bacteria, however, was more stable 
than SSA 45 and able to undergo antimicrobial testing.  
The necessity of maintaining hydrophilicity at the sulfonate portion of the molecule could 
be observed using the TEA cation present in SSAs 41 and 48. TEA was not as strongly 
coordinating in comparison to the sodium, pyridinium, and TMA cations, as shown by the 
solution state studies.154 However, it is hypothesised to not be hydrophilic enough to 
remain at the hydrophilic portion of the molecule (the sulfonate group) and not be 
hydrophobic enough to remain at the hydrophobic (benzene ring) portion of the molecule, 
which could result in a loss of self-associative structures.153,154 This is reflected in the 
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screening results and MIC50 values obtained for SSA 41. SSA 41 exhibited lower 
antimicrobial activity compared to SSAs 38, 40, and 42 against both E. coli and MRSA, 
decreasing E. coli growth by 7.32% and MRSA growth by 58.86%. Further, within this 
urea-based group of compounds (SSAs 38 - 42), SSA 41 had the highest MIC50 value 
against MRSA. This suggested that maintaining hydrophilicity around the sulfonate region 
was essential to the antimicrobial activity, and the counter cation played an integral role in 
this.  
Conversely, the thiourea counterparts did not follow this pattern. A comparison between 
SSAs 47 and 48 revealed SSA 48 had higher antimicrobial activity in comparison to SSA 
47, as the TMA failed the screening process whereas the TEA decreased growth by 
100%. Furthermore, the comparison between SSAs 48 and 49 revealed SSA 48 was 
significantly more effective than 49, as shown by their MIC50 values of 0.92 mM and 5.10 
mM respectively against MRSA. These observations could be a result of multiple factors 
and suggested more complex interactions taking place, which would require further 
analysis for a viable hypothesis to be made.  
The TPA cation present in SSAs 42 and 49, was less coordinated to the anionic 
component than the TEA cation. This was reflected in the drastically improved 
antimicrobial activity exhibited by SSA 42 against both E. coli and MRSA, with MIC50 
values of 5.96 mM and 0.42 mM, respectively, which were the lowest and second lowest 
MIC50 values within this group of compounds. Its thiourea counterpart (49), however, was 
not as effective, as it failed the screening against E. coli and had a higher MIC50 against 
MRSA (5.10 mM) compared to SSAs 47 and 48. The TBA cation was the least 
coordinating cation tested, and this was reflected in the MIC50 for SSA 32 against E. coli 
(3.85 mM) being far lower than those obtained for SSAs 38 – 42. Interestingly, the 
pyridinium cation proved to be the most effective cation against MRSA within this group 
of compounds, as it had the lowest MIC50 of 0.35 mM. The thiourea counterparts (SSAs 
35, 45 – 49) revealed the TEA counter cation was the most effective with respect to 
MRSA activity, as it produced the lowest MIC50 of 0.40 mM against MRSA.   
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Therefore, E. coli activity was improved by the selection of a weakly coordinating cation, 
such as TBA. However, competitive hydrophobicity of the cation impacts the molecule's 
ability to solubilise in an aqueous environment, as observed with SSAs 43 and 44, which 
were not tested due to their insolubility under these experimental conditions. MRSA 
activity, however, appeared to favour the pyridinium cation, as observed with the 
drastically higher activity exhibited by SSAs 39 and 48.  
3.5.5. Altering the sulfonyl group 
Testing the sulfonyl group alone (SSA 77), allowed for the determination of its importance 
to the antimicrobial activity. SSA 77 had an MIC50 of 6.26 mM against E. coli and 3.12 
mM against MRSA. This suggested that the activity of SSA 32 could be attributed in part 
to the presence of this group, due to the significantly higher MIC50 values obtained with 
SSA 77.  
SSAs 59 – 64 demonstrate the impact of changing the sulfonyl group to a neutral 
carboxylic acid group (60 and 63) or to a carboxylate functionality (61 and 64) on the 
antimicrobial activity, which were then compared to SSAs 32 and 35. SSAs 59 and 62 
were both insoluble under experimental conditions, most likely due to their lower 
capability to form hydrogen bonds at the sulfonate end of the molecule. The carboxylic 
acid group exhibited lower activity against E. coli compared to the carboxylate group and 
the sulfonyl group. SSA 60 failed the screening process and SSA 63 decreased growth 
by 12.66%, whereas SSAs 61 and 64 decreased growth by 88.77% and 33.25% 
respectively. Solution state studies, through the use of zeta potential measurements, 
revealed self-associated structures formed by 60 were unstable.154 The modification from 
the sulfonyl (SSA 32) to the carboxylate (SSA 61) increased E. coli activity. SSA 30 
produced the lowest MIC50 against E. coli (1.25 mM) out of all the compounds tested.  
Similarly, when observing MRSA activity, SSA 60, which failed the screening process, 
was far less effective than SSA 61, which not only passed the screening but also had an 
MIC50 of 1.14 mM. However, SSA 32 activity was still higher than that of SSAs 60 and 61, 
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shown by its MIC50 of 0.46 mM. This was further demonstrated by their thiourea 
counterparts, SSAs 63 and 64, which produced MIC50 values of 0.83 mM and 0.77 mM 
respectively, both being lower than SSA 35.  
These data provide evidence of the anion geometry directly impacting antimicrobial 
activity due to the shape of the resultant aggregates formed, demonstrated by the 
carboxylate group improving E. coli efficacy. The sulfonyl group is tetrahedral, whereas 
the carboxylate group is trigonal planar, which impacts the resultant complexes formed. 
The carboxylate forms a planar 6-membered ring system, whereas the angles present in 
the sulfonate group prevents this. Further, solution-state studies on SSA 61 revealed a 
higher association constant, attributed to comparatively increased basicity of the anionic 
component of the molecule. This suggested higher order complex formation, which may 
be beneficial for E. coli activity. However, the sulfonyl group produced far greater MRSA 
activity than the carboxylate and carboxylic acid groups, suggesting differing binding 
modes or targets for MRSA and E. coli activity. 
3.5.6. R groups on the aromatic ring 
As determined previously, maintaining hydrophilicity at the sulfonate end of the molecule 
was essential to the antimicrobial activity of these molecules. Therefore, the next step 
was to determine the importance of maintaining hydrophobicity at the phenyl ring portion 
of the molecules. Attached to the benzene ring of SSA 32 is a CF3 group (Figure 40) 
which is hydrophobic and also electron-withdrawing, thus making the NHs in the 
(thio)urea functionalities more acidic.  
 
Figure 40. Structure of the 
anionic component in SSA 32. 
Structure highlighting the region 
where r-groups were modified. 
Blue = phenyl ring and 
associated R-group, CF3 
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It was hypothesised that maintaining this acidity played a key role in the antimicrobial 
activity of these molecules, due to its impact on the resultant complexes formed, and 
changing the R – group associated with the phenyl ring would impact this. A more 
electron-withdrawing group would make them more acidic, and a more electron-donating 
group would make the NHs less positive. Therefore, to determine this, specific 
functionalities were selected; NH2 (50), MeO (51 and 55), H (52 and 56), NO2 (53 and 57), 
and two CF3 groups in the meta positions on the benzene ring (54 and 58).  
The NH2 functionality present in SSA 50 is a hydrophilic, electron-donating group, 
causing lower lipophilicity at the phenyl ring and less acidity in the NH groups at the urea 
functionality, in comparison to SSA 32, resulting in weaker hydrogen bond formation by 
the urea NHs. This is reflected in the antimicrobial activity of SSA 50, which failed the 
screening process against E. coli, and had a significantly higher MIC50 value against 
MRSA of 3.00 mM. Following this, we examined the impact of the MeO group present in 
SSA 51. This is an electron-donating group that is less hydrophilic than the NH2 group but 
less hydrophobic than the CF3 group. Again, antimicrobial activity against E. coli was 
lower than that of SSA 32, as SSA 51 failed the screening process and had a higher 
MIC50 of 2.18 mM against MRSA. SSA 51 was more effective than SSA 50, however, this 
suggested that increasing hydrophobicity was beneficial to antimicrobial activity. This was 
further explored through the analysis of SSA 52, which has a H atom attached to the 
phenyl ring that is neither electron-withdrawing nor donating but is more hydrophilic than 
SSAs 50 and 51. This may allow for the formation of stronger hydrogen bonds by the 
urea NHs, in comparison to 50 and 51. This could explain the antimicrobial activity of 
SSA 52 being higher in comparison to SSAs 50 and 51. SSA 52 passed the screening 
process, decreasing E. coli growth by 46.36% and the MIC50 values against MRSA was 
significantly lower (0.98 mM) than those of SSAs 50 and 51. The NO2 functionality 
present in SSA 53, revealed a further increase in antimicrobial activity against E. coli, 
which decreased growth by 54.12%, however antimicrobial activity against MRSA 
decreased, with the MIC50 value of 2.59 mM, in comparison to SSAs 50 – 52. The NO2 
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functionality is electron-withdrawing, increasing the acidity of the urea NHs, and the 
improved activity compared to SSAs 50 – 52 may be attributed to this. However, the NO2 
group is also more hydrophilic, reflected by its lower activity against E. coli, in comparison 
to SSA 32. The reduced activity against MRSA suggests that despite the increase in 
acidity of the central NHs, this wasn’t enough to combat the increased hydrophilicity of 
the phenyl ring, further solidifying the hypothesis that both hydrophobicity in the phenyl 
region and increased acidity in the central NH region are required for effective 
antimicrobial activity.  
SSA 54 had two CF3 groups on the phenyl ring, in the meta positions, which are more 
electron-withdrawing than the singular CF3 in SSA 32, and more hydrophobic. This 
significantly reduced activity against E. coli, decreasing growth by 5.97%, thereby failing 
the screening process. While SSA 54 performed better than SSAs 50 and 51, it had 
significantly lower activity than SSAs 52 and 53. Similarly, SSA 54 was more effective 
against MRSA, shown by its MIC50 value of 1.65 mM, than SSAs 50 and 51 (3.00 mM and 
2.18 mM, respectively) which had more electron-donating R groups at the phenyl ring, 
and was more effective than SSA 53 (2.59 mM), which had more hydrophilic groups. 
However, SSA 52, which was hydrophilic but neither electron-donating or withdrawing, 
exhibited higher efficacy than 54 against MRSA, as the MIC50 value for 52 was 0.98 mM, 
significantly lower than that of 54. This is further demonstrated by the significantly higher 
activity exhibited by SSA 32 (0.46 mM), whose singular CF3 was hydrophobic at the 
phenyl ring system and also electron-withdrawing, thereby increasing the acidity of the 
urea NHs, allowing stronger hydrogen bond complexation.  
A comparison using the thiourea counterparts of SSAs 50 – 54, (55 – 58), reveals 
improved activity when the thiourea functionality was present, with the exception of SSA 
56 against E. coli. SSA 56 had reduced activity against E. coli, with an MIC50 value of 
7.37 mM than SSAs 55 which produced an MIC50 value of 8.65 mM, consistent with the 
prior comparisons made between urea/thiourea-based molecules. Conversely, MRSA 
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activity was reversed, with SSA 56 producing a higher MIC50 value (2.24 mM) than SSA 
55 (1.96 mM). The improved activity exhibited by the thiourea counterpart may be 
attributed to the increased hydrophobicity of the thiourea in comparison to the urea 
functionality, and also the increased electronegativity of the sulphur in the thiourea, than 
the oxygen present in the urea. This is further demonstrated by the comparison between 
SSAs 51 and 55, which were the more electron-donating groups, in comparison to SSAs 
32 and 35.  SSA 51 had lower activity against E. coli than SSA 55, as SSA 51 failed the 
screening process but SSA 55 produced an MIC50 of 8.65 mM. Further, 55 produced a 
lower MIC50 value (1.96 mM) than 51 (2.18 mM), thus the presence of the thiourea may 
have ‘rescued’ the antimicrobial activity.  
These data provide evidence that maintaining hydrophobicity at the phenyl ring and whilst 
also using an electron-withdrawing group to ensure the amine group in the thio(urea) 
functionality remained acidic was essential in the activity of these molecules. A balance 
was required, however, as observed with SSAs 54 and 58, which though containing more 
hydrophobic R – groups at the phenyl ring, produced significantly lower antimicrobial 
activity, thus a singular CF3 functionality provided that balance whilst also maintaining the 
acidity of the urea NHs.  
3.5.7. Removal of the phenyl ring 
Having determined the role of the R – groups associated with the phenyl ring, the next 
step was to determine how the removal of the ring would impact the antimicrobial activity, 
giving rise to SSAs 71 – 76, which were compared to SSAs 32 and 35.  
A significant decrease in activity was observed with SSA 71, which increased both E. coli 
and MRSA growth by 0.05% and 2.00% respectively, failing the screening process. Its 
thiourea counterpart, SSA 74, while higher, produced an MIC50 of 3.07 mM against 
MRSA, which was close to that of SSA 35 (3.03 mM). Increasing the alkyl chain had 
improved activity against E. coli, as shown by the comparison of SSAs 32 – 34, and 
therefore, the alkyl chain was extended from n=1 in SSA 71 to n=2 in SSA 72 and n= 3 in 
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SSA 73. Unlike SSAs 32 – 34, SSA 72 exhibited better antimicrobial activity against both 
E. coli and MRSA than SSA 73 (n=3). The MIC50 values obtained for SSA 72 were 5.67 
mM against E. coli and 2.85 mM against MRSA. Whereas the MIC50 value of SSA 73 
against MRSA was 5.78, significantly higher than 72, and an MIC50 value could not be 
calculated against E. coli, as it was higher than the solubility of the compound under 
experimental conditions (Figure 41). Similarly, their thiourea counterparts exhibited better 
antimicrobial activity against MRSA when the alkyl chain was increased to n=2, with the 
lowest MIC50 within this subgroup of compounds being that of SSA 75 (2.78 mM), which 
was even lower than SSA 35. However, a comparison between SSAs 74 – 76 against E. 
coli revealed that SSA 74, which produced an MIC50 value of 6.03 mM, was the most 
effective SSA out of these three molecules, as SSA 75, increased E. coli growth by 1.75 
%, and SSA 76 produced an MIC50 of 6.91 mM.  
 
Figure 41. Growth curves of E. coli.  
Growth curves showing E. coli growth in the presence of SSA 73 at varying 
concentrations. An MIC50 value could not be obtained due to compound solubility under 
experimental conditions. 
Overall, the removal of the phenyl ring drastically reduced activity. This is demonstrated 
by the comparison between SSAs 32 which obtained MIC50 values of 3.85 mM against E. 
coli and 0.46 mM against MRSA, in comparison to SSA 71 which failed screening against 
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when structurally related compounds, only differing in the presence or absence of the 
phenyl ring, were compared.  SSA 33, which produced an MIC50 of 3.93 mM against E. 
coli and 0.98 mM against MRSA, was more effective than SSA 72, which produced MIC50 
values of 5.67 mM and 2.85 mM against E. coli and MRSA, respectively. Furthermore, 
SSA 37, which produced MIC50 values of 1.85 mM and 1.08 mM against E. coli and 
MRSA respectively, was more effective than SSA 76, which produced MIC50 values of 
6.91 mM and 8.99 mM against E. coli, respectively. These data provides evidence of the 
significance of the phenyl ring to the antimicrobial activity of the molecules, as molecules 
containing the phenyl ring exhibited greater antimicrobial activity than those without.   
3.5.8. Extension of the aromatic ring system 
Having established the importance of the phenyl ring to the antimicrobial activity, 
specifically for the urea-based molecules, we then sought to determine whether 
increasing the number of aromatic rings would improve activity, giving rise to SSAs 65 – 
70. 
Thiourea counterparts were not created for these molecules. By extending the aromatic 
ring system, we increased the propensity of our molecules to self-associate through the 
formation of pi-pi interactions. The addition of a singular aromatic ring (SSA 65) 
decreased activity against both E. coli and MRSA, with the MIC50 values increasing to 
4.30 mM and 2.96 mM, respectively, in comparison to those of SSA 32, which were 3.85 
mM against E. coli and 0.46 mM against MRSA. Whilst increasing this ring system 
further, forming SSA 66, decreased E. coli activity, MRSA activity remained the same, as 
seen with its MIC50 value of 0.46 mM. The carboxylate functionality present in SSA 61 
was previously shown to improve E. coli activity, so SSA 67 was created to determine 
whether this would improve activity against E. coli. However, this had the opposing effect, 
as SSA 67 failed the screening process against E. coli and its MIC50 value of 0.61 mM 
against MRSA was higher than that of SSAs 32 and SSA 66. Exchanging the electron-
rich anthracene group in SSA 66 to the electron-poor anthraquinone group present in 
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SSA 68 decreased antimicrobial efficacy against E. coli, as this molecule failed screening 
against E. coli, increasing growth by 2.49%, and produced a higher MIC50 value of 0.71 
against MRSA. Therefore, it was concluded that increasing the ring system decreased 
efficacy against E. coli, whereas MRSA activity was initially hindered by the addition of a 
singular ring, however, when this ring was further extended to form SSA 66, antimicrobial 
activity improved significantly, obtaining the same MIC50 value as SSA 32. Solution state 
studies conducted by Tyuleva et al., 2019  revealed stronger dimer formation due to 
increased acidity of the urea amine groups in SSA 68, compared to SSAs 66.66 Despite 
this, the replacement of the anthracene in SSA 66 to the anthraquinone group in SSA 68 
significantly reduced antimicrobial activity.  
The R – groups present in SSAs 69 and 70 are identical, however, the position of the 
benzothiazole ring system is different. SSA 69 has the benzothiazole group in the ortho 
position whereas SSA 70 has this group in the para position.  Similar to SSA 33, the 
crystal structure of SSA 69 revealed a greater propensity to form an intramolecular bond 
between the benzothiazole ring system and one of the urea NH groups, which may result 
in disrupted dimer formation due to reduced hydrogen bonding, compared to 70. The 
antimicrobial activity exhibited against MRSA provides evidence for this, as the MIC50 
value for SSA 70 was lower than that of 69. Conversely, with respect to E. coli activity, 
the MIC50 value for SSA 69 was lower than that of SSA 70, even though the percentage 
decrease was higher for SSA 70. Further analysis of the growth curves produced by SSA 
70 revealed variation in OD values in the presence of SSA 70 after 1000 minutes, which 
was not observed with other SSAs, even those that exhibited aggregation at the later 
stages of growth, such as SSA 34 (Figure 42). It was later discovered that SSA 70 
gelated in the presence of sodium salt solutions, in particular sodium chloride, which was 
present in the LB media used in these assays. It was therefore likely that SSA 70 was 
either forming a gel within the wells or similar aggregates, resulting in the variation in OD 
values obtained. The formation of these gel fibres within the wells prompted the 
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exploration of other methods for testing the antimicrobial efficacy for SSA 70, and any 






Figure 42. Comparative E. coli growth curves in the presence of SSAs 70 and SSA 
34. 
Growth curve depicting the variation of E. coli growth between wells on the same 96 well 
plate. (A) Variation of growth in the presence of SSA 70 at 3.3 mM in different wells on 
the same plate. (B) Variation of growth in the presence of SSA 34 at 3.3 mM in different 
wells on the same plate. Black dotted line – growth control; 5% EtOH added in place of 
compound. Green lines – growth curves of different wells, the darkest being the first well, 
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3.5.9. Antimicrobial gel plate testing 
The antimicrobial studies discussed within this section of the thesis were performed in 
collaboration with Jess Boles.155  
The gelation of SSA 70 in sodium salts prompted the use of gel-based antimicrobial 
testing to provide a comparison with the solution-based antimicrobial testing. To 
determine the activity of SSA 70 in its gelated form, agar well diffusion assays were 
conducted, as described in section 2.4.11 of the materials and methods. Briefly, LB agar 
was inoculated with either E. coli or MRSA and poured into sterile Petri dishes. Once set, 
wells were created using a sterile well cutter in the centre of the inoculated agar plate, 
and 50 µL of molten gel solution was pipetted into the well. Plates were incubated at 37°C 
for 18 hours and imaged using a scanner. This would ensure the gel was undisturbed and 
only the effects of the gel could be observed. To also determine whether any differences 
could be observed when the gel was placed directly on the surface of the gel, surface 
diffusion assays were conducted (Figure 43), as described in section 2.4.12 of the 





Figure 43. Comparison between the methods used in the antimicrobial gel assays. 
(A) Well diffusion assay: a well was created in the centre of the well, using a sterile cutter, 
and compound solutions were pipetted into the well, then allowed to set where applicable. 
(B) Surface diffusion assay: set gels were carefully placed in the centre of the inoculated 
agar plate. 
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Similar to the well diffusion assay, inoculated agar plates were created, however, instead 
of adding the gel solution to a cut well, we carefully placed a 50 µL aliquot of gel on the 
surface of the inoculated agar plate, then incubated the plates at 37°C for 18 hours and 
scanned the plates. Additionally, it was hypothesised that the SSA 70 gel could be used 
in combination with other antimicrobials, as previously shown by Ganewatta et al., who 
encapsulated ampicillin with their AMPs.149 Therefore, a co-formulated ampicillin gel was 
created by adding ampicillin sodium salt to SSA 70 at 5 mg/mL and conducting the well 
and surface diffusion assays on the resulting gel. The activity of ampicillin alone was as a 
comparison. Zones of inhibition were measured by Dr. George Williams (Table 10) and 
statistical analysis was conducted by me.  
Table 10: The zone of inhibition.  
The measured zones of inhibition by SSA 70, ampicillin, and the two in combination against 
E. coli and MRSA under these experimental conditions: a – surface diffusion, b – well 
diffusion.  
 
Zone of inhibition (mm) 
 
E. coli MRSA 
70 a 15 ± 2.65 15.67 ± 1.53 
Ampicillin and 70 a 59.33 ± 0.58 23.33 ± 1.53 
70 b 17.67 ± 4.16 13.67 ± 1.15 
Ampicillin and 70 b 53.33 ± 1.53 17.00 ± 1.00 
Ampicillin b 52.67 ± 2.89 15.33 ± 1.15 
While antimicrobial testing of the SSA 70 gel alone revealed the zones of inhibition 
measured using the surface diffusion method were generally numerically larger than 
those obtained using the well diffusion method, we needed to determine whether the 
values obtained were statistically significantly different. As such, paired-samples t-tests 
were performed to compare how different the two methods affected the zones of 
inhibitions created by the SSA 70 gel and the co-formulated ampicillin-70 gel against both 
bacteria.184–188 
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When the zones of inhibition created by SSA 70 gel alone were analysed, it was 
determined that there was not a statistically significant difference in the zones measured 
using the surface diffusion method (M = 15.00, SD = 2.65) and the well diffusion method 
(M = 17.67, SD = 4.16) against E. coli; t (2) = -1.835, p =.208. similarly, there was not a 
statistically significant difference when the zones created against MRSA using the 
surface diffusion method (M = 15.67, SD =1.53) and the well diffusion method (M =13.67, 
SD =1.15) were observed; t (2) =3.464, p =.074. These results suggest that the method 
selected had little effect on the zone of inhibition observed, and either method could be 
used when the SSA was tested alone. When co-formulated with ampicillin, however, a 
statistically significant difference in the zones of inhibitions measured was observed using 
the surface diffusion method (M =59.33, SD =.58) and the well diffusion method (M 
=53.33, SD =1.53) against E. coli; t (2) = 5.196, p =.035. Similarly, a significant difference 
was seen between the surface diffusion method (M =23.33, SD =1.53) and the well 
diffusion method (M = 17.00, SD =1.00) when tested against MRSA; t (2) =4.359, p 
=.049. The zones of inhibition measured using the surface diffusion method were 
statistically significantly larger than those measured using the well diffusion method. It 
was therefore determined that as the zones of inhibition using ampicillin were larger, the 
difference between the two methods was more clearly seen, and therefore antimicrobial 
analysis of compound gels would be carried out using the surface diffusion method as 
opposed to the well diffusion method.  
In order to determine how the efficacy of ampicillin was impacted by its coformulation with 
70 in a gel, a comparison was made between the zones of inhibition created in the 
presence of ampicillin alone and those created in the presence of the co-formulated 
ampicillin gel. To provide a thorough examination, a paired samples t-test was performed 
on these zones of inhibition measured.184–188  
While the co-formulated ampicillin gel produced zones of inhibition that were numerically 
larger than the ampicillin alone, there was not a statistically significant difference between 
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E. coli in the presence of ampicillin alone (M = 52.67, SD =2.89) and in the presence of 
the co-formulated ampicillin gel (M =53.33, SD =1.53); t (2) =-.277, p =.808. Similarly, 
there was not a statistically significant difference between MRSA in the presence of 
ampicillin alone (M =17.00, SD =1.00) and in the presence of the co-formulated ampicillin 
gel (M =15.33, SD =1.15); t (2) =1.890, p =.199. Therefore, little enhanced antimicrobial 
efficacy was observed with the co-formulated ampicillin gel, in comparison to the 
ampicillin alone. However, these data also revealed that co-formulating ampicillin in a gel 
with SSA 70 did not significantly hinder its activity, thereby providing another method of 
administering antimicrobials. Furthermore, using the structure-activity relationships 
detailed within this chapter to enhance the antimicrobial activity of SSA 70 and then co-
formulating this enhanced molecule with other antimicrobial compounds, could be 
effective in tackling antimicrobial resistance by reactivating molecules that have become 
less effective over time.  
3.5.10. Combinatory effects of aromatic compounds 
SSAs 66 – 68 were synthesised and had their physicochemical properties were 
determined by Stilyana N. Tyuleva and Lisa J. White, while the antimicrobial testing of 
these compounds was carried out by Stilyana N. Tyuleva and me.  
This sub-group of molecules allowed for the determination of the antimicrobial properties 
as independent species as well as in combination with one another, to ascertain the 
possibility of co-formulations with other molecules and enabling us to predict future 
interactions with other molecules. As such, 1:1 molar mixes of SSAs 66 – 68 were 
created (Figure 44A), then taken through the antimicrobial testing process in the same 
way as the singular compounds. As the antimicrobial screening results revealed a 100% 
decrease in MRSA growth, MIC50 values, and an additional screen at 0.375 mM were 
used for the comparison (Figure 44B).  
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SSA mix C had the highest MIC50 value of 0.75 mM, which was higher than those 
obtained for SSAs 67 (0.61 mM) and 68 (0.71 mM), suggesting antagonism between 
these two molecules. When observing the potential hydrogen bonding modes, it was 
A Mix A: SSAs 66 and 67 
 
 
Mix B: SSAs 66 and 68 
 
 






Figure 44. Antimicrobial studies conducted using 1:1 molar mixes of SSAs 66 – 68. 
(A) Heterogenous compound mixes used for this study and the hypothesised hydrogen 
binding modes predicted. (B) MRSA growth comparison at 3.75 mM and MIC50 values for 
homogeneous solutions of SSAs 66 (Red), 67 (blue), 68 (yellow), as well as 1:1 
heterogeneous mixes A (purple), B (orange) and C (green). Black = MRSA growth in the 



























Mix A 0.32 
Mix B 0.34  
Mix C 0.75 
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hypothesised that a differing hydrogen-bonding mode could be exhibited by SSA 67 and 
any compound mixtures it would create, due to the substituted carboxylate group (Figure 
44). The resulting complexes formed were hypothesised to be weaker, and thus lowering 
the antimicrobial efficacy of SSA 67 and the compound mix formed with SSA 68. Where 
SSA 66 was present, the MIC50 values were significantly reduced by almost half. SSA 67 
alone produced an MIC50 of 0.61 mM, however, in a 1:1 mix with SSA 66 this was 
reduced to 0.36 mM. Similarly, SSA 68 produced an MIC50 value of 0.71 mM alone, 
however, in a compound mix with 66 this was drastically reduced to 0.34 mM. Further, 
SSA 66 alone produced an MIC50 of 0.46 mM, however, this MIC50 value decreased when 
used in combination with SSA 67 (0.32). These data provide evidence for the use of 
these molecules, in particular, SSA 66 in combination therapies, as the combination of 
two molecules decreased the MIC50 values significantly. Further, as mentioned before, 
SSA 68 formed stronger hydrogen-bonded complexes, and should theoretically perform 
better than SSA 66. However, SSA 68 had the highest MIC50 value out of the 
independent SSAs and the second highest overall.  
3.6. Mode of Action Determination 
In an effort to discern the mode of action of these SSAs, several methods were utilised. 
Increasing the ring system of these molecules caused the compounds to be intrinsically 
fluorescent, and a number of fluorescence assays could then be employed to investigate 
the binding properties of these molecules. Therefore, fluorescence microscopy, using E. 
coli and MRSA, and fluorescence anisotropy, using the fluorescent molecules with 
liposomes, were conducted.   
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3.6.1. Fluorescence Microscopy 
While SSAs 65 – 70 were all fluorescent, the most amenable for imaging were SSAs 69 
and 70 (Figure 45).  
  
Figure 45. Structures of (A) SSA 69 and (B) SSA 70. 
Preliminary microscopy experiments consisted of adding SSAs 69 and 70 to E. coli cells 
at 0.6 mM and comparing the images obtained. In these preliminary experiments, SSA 70 
provided clearer images than SSA 69, and also appeared to exhibit stronger membrane 
binding, as all cells displayed membrane fluorescence in the presence of 70, which was 






Figure 46. Widefield fluorescence microscopy images.  
Comparative fluorescence of E. coli in the presence of SSA (A) 69 and (B) 70 at 0.6 mM. 
Scale = 10 µm. 
As such, all microscopy analysis was conducted using SSA 70, supplied in a 5 % EtOH 
solution. To visualise the localisation and morphology of bacteria in the presence of this 
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compound, E. coli and MRSA were grown to mid-log phase, as determined by their OD 
values, then incubated in the presence of SSA 70 at a final concentration of 0.6 mM for 
30 minutes before imaging. Once imaging samples had been taken, the cultures were 
then further incubated for 4 hours then imaged. To compare membrane binding and 
internalisation, control cultures in the absence of compound were grown alongside those 
with the compound and imaged at the same time points.  
The images presented in Figure 47 demonstrate the membrane fluorescence exhibited by 
MRSA and E. coli in the presence of SSA 70 after 30 minutes of incubation. SSA 70 
appeared to be evenly distributed around the E. coli membrane, with no internalisation 
visualised at this time point, whereas in, MRSA brighter regions were observed both 
around the membrane and within the cytoplasm, suggesting internalisation.  
A B 
  
Figure 47. Widefield fluorescence microscopy Images.  
Microscopy mages showing SSA 70 localization after 30 minutes of incubation with (A) E. 
coli cells and (B) MRSA cells. Scale = 10 µm.   
The images presented in Figure 48 show SSA 70 localisation after 4 hours of incubation 








Figure 48. Fluorescence Microscopy Images.  
Microscopy images showing SSA 70 localization after 4 hours of incubation with (A) E. 
coli cells and (B) MRSA cells. Scale = 10 µm 
4 hours after the initial addition of SSA 70, internalisation could be observed in all MRSA 
cells, with bright spots in the cytosol, and little discernible membrane binding was 
observed (Figures 48). However, for E. coli, while internalisation was observed, this was 
not the case for all cells, as shown in Figure 48. Where internalisation of SSA 70 in E. coli 
was observed, this was consistently non-uniform and similar to MRSA, there were more 
defined brighter regions, which suggested a secondary target within cells (Figure 49). 
A B 
Figure 49. Fluorescence 
Microscopy images. 
Images showing the 
internalisation of SSA 70 
at 0.6 mM in (A) E. coli 
and (B) MRSA after a 4-
hour incubation. Bright 
spots indicate a 
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To further characterise the comparative binding and internalisation of SSA 70 between E. 
coli and MRSA, a 1:1 heterogeneous culture of mid-log phase E. coli and MRSA was 
created, then SSA 70 at 0.6 mM was added. Images were taken 30 minutes, 1 hour, and 
then 4 hours after the initial addition of SSA 70. These images are presented in Figure 
50. 
Figure 50 shows SSA 70 being predominantly membrane-bound to E. coli after 30 
minutes, with few cells having internalised compound. A greater proportion of SSA 70 
was observed to be internalised in E. coli after 1 hour, however, the majority of cells 





Figure 50 – Fluorescence microscopy images of MRSA and E. coli. 
Bacteria in a 1:1 heterogeneous mix (A) 30 minutes (B) 1 hour and (C & D) 4 hours 
after the addition of SSA 70 at 0.6 mM. Scale = 10 µm  
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internalisation of SSA 70 was significantly more prevalent and rapid in MRSA than in E. 
coli; (Figure 50) cytoplasmic fluorescence of MRSA cells was observed from 30 minutes 
to 4 hours. Examination of the morphology of the cells in the 1:1 mix revealed abnormal 
fluorescent shapes present 4 hours after the addition of SSA 70, as shown in Figure 51. 
These compound-filled masses were hypothesised to be depolarised cells due to the 
activity of the compound, and so these images were compared to those of the 
homogenous bacterial cultures, shown in Figures 47 and 48.  
  
Figure 51. Fluorescence Microscopy Images of MRSA and E. coli in a 1:1 
heterogeneous mix.  
Images were captured 4 hours after the addition of SSA 70 at 0.6 mM. Large compound-
filled masses are highlighted in yellow. Scale bar = 10µM.  
A comparison between the transmitted images obtained of E. coli cells in the presence 
and absence of SSA 70 present revealed the vast majority of E. coli cells in the presence 
of 70 were similar to the untreated cells (Figure 52). However, where SSA 70 had 
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A  B  
  
Figure 52. Transmitted Light images of E. coli. 
Images comparing the morphology of E. coli in the (A) absence and (B) the presence of 
SSA 70 at 0.6 mM after a 4-hour incubation. Scale = 10µm. 
A more pronounced change in morphology was observed with MRSA cell after 4 hours of 
incubation with SSA 70 when the images in Figure 50 were compared to those in Figure 
48.  More irregular shapes and a loss of individual cell definition were observed which 
was not present in untreated cells, as shown in Figure 54.  
A B 
  
Figure 53. Transmitted Light Images of MRSA.  
Images showing the morphological changes of MRSA in the (A) absence and (B) 
presence of 70 at 0.6 mM. Scale = 10 µM. 
However, while these morphological changes occurred, changes in the sizes of the 
individual cells were not observed in any images obtained for MRSA. Therefore, it was 
hypothesised that these abnormal shapes may have been depolarised E. coli cells due to 
the action of SSA 70.  
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To further confirm these observations and better understand the extent of the lipid binding 
properties of SSA 70, a lipid binding microscopy assay was conducted, using FM4-64, a 
non-specific lipid binding molecule.  
SSA 70 and FM4-64 fluoresce at different wavelengths, allowing both molecules to be 
observed under the microscope independently of one another, using a 450 nm emission 
filter to observe SSA 70 fluorescence and a 605 nm filter to observe FM4-64 
fluorescence. Colocalization of these molecules would be consistent with lipid binding, 
which if absent, would suggest other targets on the membranes. E. coli and MRSA at 
mid-log phase were incubated in the presence of either 5 % EtOH alone, SSA 70 alone, 
FM4-64 alone, or the combination of 70 and FM4-64, as described in section 2.5.1 of the 
materials and methods. Samples were imaged at 30 minutes and 4 hours; then 
quantitative analysis was performed on the subsequent images to obtain average 
fluorescence intensities from between 30 and 100 cells in each experimental condition. 
Quantitative analysis was conducted by generating line scans across individual cells, 
then obtaining the fluorescence intensity profile of that line scan using Fiji (ImageJ), as 
shown in Figure 54.105,106,189 The background fluorescence from the intensity profiles was 
subtracted from the maximum fluorescence, which was then used as the final 
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A  B  
  
Figure 54. Quantitative microscopy image analysis.  
(A) line scans generated across the width of the cell, then intensity profiles of the line 
scans were then obtained using the “Plot profile” function in ImageJ.105,106 (B) Values 
used in fluorescence calculation: red line = background fluorescence, blue line = 
maximum fluorescence. 
After 30 minutes, FM4-64 fluorescence was seen to drop significantly, almost to 
background level, in the presence of SSA 70 (Figure 55). This was confirmed by the 
quantitative analysis, which revealed FM4-64 fluorescence for E. coli dropped by 80 % 
when 70 was present and by 86 % for MRSA (Figure 56). And while the fluorescence of 
70 in the presence of E. coli was lower with FM4-64 present, this was not as significant or 
as prominent as with FM4-64 (Figure 56). In contrast, the MRSA analysis at 30 minutes 
revealed SSA 70 fluorescence was higher in the presence of FM4-64, while FM4-64 
fluorescence decreased significantly (Figure 56). 
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Figure 55. Competitive binding microscopy assay.  
Fluorescence images of E. coli in the presence of (A) solvent alone (B) SSA 70 alone (C) 
FM4-64 alone and (D) a combination of FM4-64 and SSA 70. T = 30 minutes. 
Fluorescence images obtained using 450 and 605 nm filters to observe SSA 70 (blue) 
and FM4-64 (magenta) fluorescence, respectively. Scale = 10 µm. 
 A 
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 Figure 56. Quantitative Analysis of Fluorescence Microscopy Images.  
Graphs showing the average fluorescence intensity of between 30 and 100 cells: (A) 
E. coli after 30 minutes in the presence of solvent alone, SSA 70, FM4-64 and a 
combination of both 70 and FM4-64 and (B) MRSA after 30 minutes in the presence 
of SSA 70, FM4-64 and a combination of both 70 and FM4-64.  
After 4 hours, in E. coli cells with internalised SSA 70, FM4-64 fluorescence was detected 
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Figure 57. Combined Fluorescence Microscopy Images.  
Images showing SSA 70 fluorescence (blue) and FM4-64 fluorescence (magenta) and 
regions of co-localisation (white). Scale bar = 10 µm. 
Quantitative analysis, shown in Figure 58, reveals an increase in FM4-64 fluorescence of 
77% at 4 hours when compared to the fluorescence at 30 minutes. This was not 
observed with MRSA, however, as FM4-64 remained at background level in the presence 











Figure 58. Quantitative Analysis of Fluorescence Microscopy Images.  
Graphs showing the average fluorescence intensity of between 30 and 100 cells: (A) E. 
coli after 4 hours in the presence of solvent alone, SSA 70, FM4-64 and a combination of 
both 70 and FM4-64 and (B) MRSA after 4 hours in the presence of SSA 70, FM4-64 and 
a combination of both 70 and FM4-64. 
The large variation observed when SSA 70 was present after 4 hours was due to the 
brighter regions observed after its internalisation, as these bright regions were not 
uniform or present in every cell, in the case of E. coli. These data provide evidence to 
suggest SSA 70 and FM4-64 binding to the same region on the membrane. FM4-64 
binds non-specifically to lipids, and SSA 70 outcompeting FM4-64, confirmed that SSA 70 
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64 was only detected in E. coli in cells where the compound had internalised. FM4-64 
fluorescence within the cell was more likely due to compromised membrane integrity due 
to SSA 70, consequently allowing FM4-64 into the cytoplasm.   
3.6.2. Fluorescence Anisotropy and membrane binding 
After confirming membrane lipid binding, the next step was the investigation of the 
specific lipids these molecules were interacting with, as this would further verify their 
mode of action.  Consequently, fluorescence anisotropy assays were conducted using 
SSAs 69 and 70 as described in section 2.6.4 of the materials and methods. 
Fluorescence anisotropy is a measurement of the changing orientation of a fluorescent 
molecule in space through the use of fluorescence absorption and emission events. 
When a fluorophore is excited by polarised light, the emitted light is also polarised (Figure 
59).190  
 
Figure 59. Diagram showing the principles of fluorescence anisotropy.  
Free unbound ligands when excited with polarised light emit depolarised light due to 
faster rotational diffusion, whereas bound molecules emit polarised light due to slower 
rotational diffusion. Adapted from Cheow et al., 2014.191 
Anisotropy (r) measurements allow for the observation of the angular displacement of a 
fluorophore that occurs between the absorption and subsequent emission of polarised 
light. The extent of depolarised emission is reliant on the rotational diffusion of the 
145 
|Chapter 3: Investigating the structure activity of novel antimicrobial compounds      
 
molecule, which in turn is reliant on the shape and size of the molecule or the viscosity of 
the solvent.150,192,193  
Smaller molecules undergo more rapid rotation and therefore depolarise the polarised 
light to a greater extent. Conversely, larger molecules have a lower rotational diffusion 
rate, and therefore maintain polarisation to a greater extent.150,192,193 Changes in the 
shape and size of a fluorescent molecule result in changes in anisotropy, as the size of 
bound molecules is larger than the size of the free molecules in solution. Thus, 
fluorescence anisotropy measurements provide a way of monitoring binding events, as 
fluorescence anisotropy can detect the changes in mass between the free and bound 
states.150,192,193  
Fluorescent anisotropy experiments within this study were conducted by exciting 
fluorescent SSAs using polarized light, then measuring the extent of polarisation of the 
fluorescent molecule alone compared to that of the molecule in the presence of the 
liposomes.190 The final anisotropy values (r) represent the average polarisations of 
individual molecules in the solution.150,192,193 Typically, the fluorescent component is kept 
constant and the binding partner is titrated against it. It is equally correct to titrate the 
fluorescent component against a non-labelled binding partner.190,193–195  
Due to the intrinsic fluorescence of SSA 69 and 70, SSAs were titrated against non-
fluorescent liposomes, while liposomes were kept at a constant concentration. In 
anisotropy experiments where the fluorescent molecule concentration is maintained, any 
changes to anisotropy values will be a result of binding activities. The anisotropy values 
recorded within this system are a measure of the sum of individual anisotropies in 
solution; bound and unbound. Thus, an increase in fluorescent protein concentration 
would result in increasing anisotropy values due to the additional molecules, until a 
saturation point is reached. However, anisotropy values were seen to decrease with 
increasing SSA concentration (Figure 60A & 60B), and fluorescence intensity increased 
with increasing SSA, as expected (Figure 60C & 60D).  
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Figure 60. Fluorescence anisotropy and intensity measurements.  
Anisotropy measurements using (A) SSA 69 and (B) SSA 70 and corresponding intensity 
values of (C) SSA 69 and (D) SSA 70 in the absence and presence of POPC, POPG, E. 
coli total and E. coli polar lipids obtained from Avanti polar lipids. Data points are an 
average of 3 independent experiments, the standard deviation used as the error value.  
The SSAs have been shown to self-associate into larger aggregates, thus multiple 
interactions could be taking place within this experiment, not solely lipid binding. As such, 
any observations from this anisotropy experiment cannot determine absolute binding and 
can only suggest binding activities of these molecules. Furthermore, as it was 
hypothesised that multiple interactions could be occurring in the experiment, meaning 
multiple factors could impact the anisotropy results observed, disassociation constants 
could not be calculated. 
147 
|Chapter 3: Investigating the structure activity of novel antimicrobial compounds      
 
The anisotropy data suggests comparatively stronger binding of SSA 69 to E. coli total 
lipids; anisotropy values were significantly lower than those of the other lipids. Binding to 
E. coli polar lipids and POPG is also observed with SSA 69, however, this is to a lesser 
extent. Minimal binding was observed with POPC (Figure 60A), as the anisotropy values 
measured mirrored those of the SSA alone. Similarly, these data suggest SSA 70 binding 
strongly to E. coli total lipids, however stronger binding was observed with E. coli polar 
lipids compared to SSA 69. This was consistent with the microscopy images observed, as 
SSA 70 exhibited brighter membrane fluorescence indicating stronger binding to E. coli 
membranes than SSA 69 (Figure 46). similar to SSA 69, comparatively weaker binding to 
POPG was also observed, and minimal binding was observed with POPC (Figure 60B). 
In order to understand the binding observed, the profiles of the phospholipids present in 
the E. coli total and polar extracts were obtained from the Avanti Polar Lipids website196, 
shown in Table 11, and compared.  
Table 11. Phospholipid profiles.196  
Phospholipid profiles obtained from the Avanti website, for the E. coli total and polar lipid 
extracts used in the fluorescence anisotropy assay, a unspecified lipids. 
Phospholipid Profiles for E. coli lipid extracts 
Polar lipid extract PE (67.0%)  
PG (23.2%) 
CL (9.8%) 
Total lipid extract PE (57.5%) 
PG (15.1%)  
CL (9.8%) 
other a (17.6%) 
As binding was observed with PG for both molecules, it was determined that this would 
account for a portion of the binding observed with the E. coli polar and total liposomes. 
However, as both compounds bound to PG lipids to a lesser extent than E. coli total and 
polar, it was determined that binding to the other lipids present in these extracts may also 
have been taking place. The exception to this was SSA 69, which exhibited similar 
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binding to E. coli polar lipids and PG, suggesting PG present within the E. coli polar 
liposomes accounted for all the binding observed with 69.  
As PE and CL were present in both samples, this suggested binding to either one or both 
of these lipids in addition to PG. Furthermore, PE made up a larger proportion of the total 
and polar lipid extracts, and as tight binding was observed with liposomes created from 
these extracts, it was hypothesised that binding was occurring with PE lipids to some 
extent. SSA 69 exhibited tighter binding to total lipids than polar lipids, indicating the 
unspecified lipids in the total lipid extract may also influence binding to liposomes made 
from this extract, as they were not present in the polar lipid extract. These initial studies 
allow for the hypothesis of specific lipid binding by SSAs 69 and 70 to PG, PE, and CL 
lipids. Further analysis using the single lipids, particularly PE and CL lipids, would be 
required to further understand these lipid binding processes. Additionally, the use of 
fluorescent lipids would allow us to conduct this experiment more robustly, however, due 












Maintaining amphiphilicity through 
the use of specific functionalities 
and counter cations integral to the 
antimicrobial activity 
TEA cation present in SSA 41 disrupted 
hydrophilicity at the sulfonate region of the 
molecule, decreasing antimicrobial efficacy.  
The use of hydrophilic R-groups, such as the NH2 
and NO2 functionalities present in SSAs  50 and 53 
respectively, on the phenyl ring decreased 
antimicrobial activity.  
Comparatively hydrophobic cations were not 
soluble under experimental conditions, as seen 
with SSAs 43 and 44.  
The formation of self – associated 
structures, for example, dimers, 
was essential to antimicrobial 
activity 
Intramolecular bonds observed with SSAs 33 and 
69 disrupted dimerisation which led to reduced 
antimicrobial activity.  
SSA 61 had a comparatively higher association 
constant, suggesting the formation of higher order 
structures, and also exhibited greater activity 
against E. coli.  
The acidity of the thio(urea) 
amine groups contributed to 
effective antimicrobial activity 
Electron withdrawing R-groups associated to the 
phenyl ring, such as the CF3 present in SSAs 32, 
drastically improved activity, whereas those that 
were electron-donating such as the NH2 and MeO 
functionalities in SSAs 50 and 51, reduced 
antimicrobial activity.  
The coordination and 
hydrophilicity of the counter cation 
influenced the antimicrobial 
efficacy observed 
The TBA counter cation was less coordinating in 
comparison to the Na+, TMA, TEA, and TPA 
cations. 
SSAs with the TBA cation produced the highest 
efficacy against E. coli. 
Pyridinium counter cation present in SSAs 39 and 
48 produced the highest MRSA activity.  
SSA 41 which disrupted hydrophilicity, decreased 
antimicrobial activity.  
Multiple binding modes exhibited 
by the SSAs 
Growth stages and bacterial species impacted in 
different ways by SSAs, as shown by the growth 
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curves and types of inhibition observed.  
A decline in bacterial growth at the later stages of 
growth was only observed with E. coli and not with 
MRSA.  
Some functionalities that promoted E. coli activity 
(e.g., SSAs 34 and 61) were different from those 
that promoted MRSA activity, (e.g.  SSAs 32, 39, 
and 48). 
SSAs confirmed to bind to 
bacterial membrane lipids 
Bacterial membrane fluorescence was observed 
after incubation with SSAs 69 and 70.  
Drastic reduction in the fluorescence of FM4-64, a 
non-specific lipid binding molecule, in the presence 
of SSA 70 demonstrated lipid binding.  
Significantly differing fluorescence anisotropy 
values in the presence of different lipids suggested 
specific lipid binding. 
Secondary binding target once 
SSAs internalise 
Brighter regions observed in both E. coli and 
MRSA after SSA 70 internalisation, indicating 
compound accumulation at a specific region/target.  
SSA gel matrix allows for the 
diffusion of other antimicrobial 
molecules without hindering 
activity,  
The activity of ampicillin was not greatly hindered 
when co-formulated with the SSA 70 gel, as zones 
of inhibition measured with/without SSA 70 were 
not significantly different.  
Specific SSAs can be used in 
combination with other 
therapeutic agents with specific 
structures 
1:1 heterogenous mixes with SSA 66 produced 
drastically lower MIC50 values than those obtained 
for the independent SSA solutions.  
Antagonistic effects observed with SSAs 67 and 68 
indicated specific structures would need to be 
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Summary 
The data presented in this chapter provides evidence that the determination of structure-
activity relationships can be utilised in the development and optimisation of more potent 
therapeutics. It was also determined that more complex interactions were taking place, as 
SSAs 35 and 68 exhibited comparatively stronger hydrogen-bonded complex formation, 
however antimicrobial activity was weaker. Furthermore, the replacement of the TBA 
counter cation to a TEA counter cation produced varying results, as the thiourea-based 
molecule exhibited increased activity whereas the urea-based molecule exhibited a 
reduction in activity. The use of further computational analysis may allow for a more 
thorough investigation into these more complex interactions.  
The SSAs presented in this chapter were shown to bind to the bacterial membrane, 
through the use of microscopy using SSA 70, which outcompeted the lipid binding 
molecule FM4-64, suggesting lipid binding. The fluorescence anisotropy assay conducted 
on SSAs 69 and 70 suggested specific phospholipid binding to E. coli total and polar 
lipids, the predominant lipids present in these extracts being PG and PE. This suggested 
binding of SSAs 69 and 70 to PG, and CL lipids and to some extent PE lipids. Both CL 
and PG have a net negative charge, CL being more negative than PG.104 It is therefore 
hypothesised that the cationic component participates in electrostatic interactions with 
these lipids initially, then the lipophilic component on the anionic component can interact 
with the phospholipid tails. This may result in pore formation in the bacterial membranes 
leading to a loss in membrane integrity and resulting in cell death.  
In conclusion, the stepwise modifications to SSA 32 revealed how the geometry of the 
SSAs impacted self-associated structures, and the disruption of those structures resulted 
in a reduction of antimicrobial activity.  
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4.1. Introduction 
The optimisation of lead molecules is an essential step in antimicrobial drug design, and it 
is dependent on the nature of each molecule. QSAR data exploring the relationships 
between chemical structure and biological activity enable the design of new molecules 
that exhibit desired properties.142,197,198 Analyses of the structure-activity relationships and 
associated activities of molecules are often utilised to make stepwise structural 
modifications.142 These modifications can improve specific biological or physicochemical 
properties exhibited by the molecules, such as amphiphilicity, toxicity, potency, or 
solubility.198 Moreover, stepwise structural modifications allow for the determination of the 
impact that functional group placement has on desired activities, and for the removal of 
nonessential functional groups. Optimisation through the use of stepwise modification 
tends to be unidirectional; each molecular modification is tested, then the 
physicochemical properties are explored, thus refining any hypotheses previously 
made.142,143,198 Structural variation influences biological activity, binding selectivity, and 
affinity; thus, it is important for every modification made to a molecule to be thoroughly 
explored and understood to ensure these properties are not significantly reduced.142,198 
Furthermore, if molecules are to be used in combinatory therapies, it is vital to ensure 
that the modifications made are not antagonistic to the chosen complementary 
molecule.68,199 Experimental approaches to optimisation are typically used, however, they 
may be utilised for the prediction of future molecules through the use of computational 
methods.200 
4.1.1. Aim of studies 
These studies aim to utilise the structure-activity relationships presented in chapter 3 to 
produce more effective antimicrobial molecules and further understand the behaviour of 
these molecules by determining the physicochemical properties. Furthermore, the aims of 
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these studies are also utilise the gelation properties of SSA 70 to synthesise novel 
gelating SSAs and investigate the impact of salt solution on these properties.  
4.2. Molecular Design 
In designing the next generation of molecules, we sought to improve efficacy against 
gram-negative bacteria, modelled here by E. coli. Additionally, we sought to incorporate 
the gelation and fluorescent properties exhibited by SSA 70 to aid in visualisation and 
provide additional methods of administration. From the study of structure-activity 
relationships in Chapter 3, the key changes that improved E. coli activity were increasing 
the length of the alkyl chain between the sulfonate and the NH groups and the use of the 
carboxylate functional group. In order to adopt the fluorescent and gelation properties into 
the new molecules, a benzothiazole functional group was preferred. On the basis of these 
findings and requirements, we designed SSAs 82 - 85 (Figure 61).  
SSA 70 
 
SSA 83  
 







Figure 61. Structures of molecules discussed within this chapter.  
SSAs 70, 82 – 85 are next-generation molecules designed using the structure-
activity relationships established in chapter 3. 
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4.3. Physicochemical Studies 
Physicochemical analysis, first introduced in 1919 by Kurnakov, can be defined as a 
branch of chemistry concerned with the relationships between the composition of a 
molecule and its resulting properties.201–203 Knowledge of physicochemical properties is 
required in understanding the self-associative properties and biological interactions of the 
SSAs, which can then inform any further optimisation and molecule design.  
In this section, the methods used for determining the physicochemical properties of SSAs 
82 and 83 are described. These will enable a deeper understanding of their interactions 
with bacterial membranes and aid in the prediction of future molecules. The 
physicochemical properties of 84 and 85 were conducted separately from SSAs 82 and 
83 and are therefore not discussed in this section. 
4.3.1. Low level in silico modelling 
Electrostatic potential maps are computational models in three dimensional space that 
can be used to visualize the regions of electron excess and electron deficiency.204,205 
Negative electron potential values, which are red on electrostatic potential maps, 
correlate with concentrated electron density, and positive electron potential values, which 
are blue, correlate with low electron densities.204–206 Hunter (2004) utilised 
computationally derived electrostatic potential maps to produce Emin (minimum in 
electrostatic potential) and Emax (maximum in electrostatic potential) surface values which 
he proposed would correlate with those derived from experimental data.204  
Electrostatic potential maps can also be utilised to visualise hydrogen bonding sites and 
directionality in complexes and to predict the behaviour and subsequent interactions of 
complex molecules.206,207 An example of this is seen with the studies conducted by 
Sathyamurthy et al. (2007), who investigated hydrogen bonding using electrostatic 
potential maps and found that hydrogen bond strength and stability increases linearly with 
increasing electron density at the hydrogen bonding critical point.206 It has been 
hypothesised by Hiscock et al. (2018) that the increased acidity of the HBD groups within 
the anionic component of the SSAs increases the hydrogen bonded complex strength, 
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which may increase antimicrobial activity.154 Furthermore, through their studies, Emax 
values were shown to correlate with dimerisation constants, which suggested increased 
HBD acidity of SSAs would increase their propensity to form dimers. The data obtained in 
Chapter 3 suggests the involvement of multiple factors, including the strength of the 
complex formed, in the observed antimicrobial activity. 
Consequently, low-level theoretically derived electrostatic potential maps were generated 
for SSAs 82 and 83; described as low-level due to the simplicity of the method used. This 
would enable the prediction of favourable HBA and HBD sites and hydrogen bonding 
strengths in the resulting complexes formed. Drawing on research conducted by Hunter 
(2004), low-level electrostatic potential maps were generated using Spartan 16’ software 
to identify primary hydrogen bond donating and accepting sites in SSAs 82 and 83.204,208–
210 Emin and Emax values were calculated using semi-empirical PM6 methods after energy 
minimisation calculations and PM6 was used over AM1 in line with studies conducted by 
Stewart.208,209,211 Computational modelling and electrostatic potential maps were 
generated by Rebecca Ellaby, however, the interpretation was conducted by myself. The 
electrostatic potential map for SSA 82 is presented in Figure 62. 
 
Figure 62. Electrostatic potential map calculated for SSA 82.  
The Emax (-40.3394 kJ/mol) and Emin (-706.447 kJ/mol) correspond to the most 
positively and negatively charged points on the surface of the molecule, respectively. 
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The electrostatic potential map in Figure 62 can also support the evidence for the 
formation of intramolecular bond formation, as was previously reported with SSA 33. The 
cyclisation of the sulfonate group to the alkyl NH was observed with SSA 82, suggesting 
a preference for intramolecular hydrogen bonding. It was therefore hypothesised that the 
interactions and properties exhibited by SSA 33 would be comparable to those of SSA 
82. The electrostatic potential map for SSA 83 is presented in Figure 63. 
 
Figure 63. Electrostatic potential maps calculated for SSA 83.  
The Emax (-45.7281 kJ/mol) and Emin (-765.86 kJ/mol) correspond to the most positively 
and negatively charged points on the surface of the molecule, respectively. 
A planar structure was observed for SSA 83, which suggested the formation of the 
intramolecular hydrogen bond was no longer favourable. Furthermore, a higher Emax 
value was observed with SSA 83, suggesting higher acidity in comparison to SSA 82. 
Therefore, drawing on the work conducted by Hiscock et al. (2018), it was hypothesised 
SSA 83 would form complexes with comparatively stronger hydrogen bonds than those of 
SSA 83.154 The electrostatic potential maps and Emin/Emax values were compared to the 
subsequent experimental data. 
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4.3.2. Synthesis 
IR, 1H and 13C NMR spectroscopy and melting point experiments were conducted as 
described in sections 2.7.3, 2.7.6 and 2.7.7, respectively, in the materials and methods. 
1H and 13C NMR spectroscopy and synthesis were conducted by me; IR and melting 
points were obtained in collaboration with Jess Boles. 
For the synthesis of SSA 82, Tetrabutylammonium (TBA) hydroxide (1N) in methanol (4 
mL, 4 mM) was added to 2-aminoethane-1-sulfonic acid (0.25 g, 2.0 mM) and taken to 
dryness. Triphosgene (0.31 g, 1 mM) was added to a stirring solution of 4-(6-
methylbenzothiazol)aniline (0.50 g, 2 mM) in ethyl acetate (30 mL) and the mixture 
heated at reflux for 4 hours. The TBA salt was then dissolved in ethyl acetate (10 mL) 
and added to the reaction mixture and heated at reflux overnight, filtered and the solid 
washed with ethyl acetate (10 mL). Impurities were removed through precipitation in 
methanol with ethyl acetate, the solids filtered, and the filtrate taken to dryness to give the 
pure product as a pale-yellow solid in a 54.5 %, (0.69g, 1.09 mM). Melting point: >200°C; 
1H NMR (298K, 400 MHz, DMSO-d6): δ; 0.93 (t, J = 7.32 Hz, 12H), 1.32 (m, 8H), 1.56 (m, 
8H), 2.45 (s, 3H), 2.58 (t, J = 6.10 Hz, 2H), 3.16 (m, 8H), 3.39 (t, J = 6.4 Hz, 2H), 6.51 (t, 
J = 10.12 Hz, 1H), 7.32 (d, J = 10.12 Hz, 1H), 7.59 (d, J = 8.64 Hz, 2H), 7.89 (dd, J1 = 
8.72 Hz , J2 = 8.56 Hz, 4H), 9.30 (s, 1H); 13C{1H} NMR (100 MHz, 298K, DMSO-d6): δ; 
13.4 (CH3), 19.2 (CH2), 21.0 (CH3), 23.0 (CH2), 36.1 (CH2), 51.0 (CH2), 57.5 (CH2), 117.5 
(ArCH), 121.7 (ArCH), 121.9 (ArCH), 125.4 (ArC), 127.8 (ArCH), 134.3 (ArC), 134.6 
(ArC), 143.9 (ArC), 151.9 (ArC), 154.7 (ArC), 166.3 (C=O); IR (film): v (cm-1) = 2961 (NH 
stretch), 1685, 1179, 1163, 1037, 841;HRMS for the sulfonate-urea ion  (ESI): m/z: act: 
404.88 [M+H+CH3]-  cal: 390.45 [M]- 
For the synthesis of SSA 83, Tetrabutylammonium (TBA) hydroxide (1N) in methanol (4 
mL, 4.00 mM) was added to 3-aminopropane-1-sulfonic acid (0.28 g, 2.00 mM) and taken 
to dryness. Triphosgene (0.31 g, 1.00 mM) was added to a stirring solution of 4-(6-
methylbenzothiazol) aniline (0.50 g, 2 mM) in chloroform (30 mL) and the mixture heated 
at reflux for 4 hours. The TBA salt was then dissolved in chloroform (10 mL) and added to 
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the reaction mixture and heated at reflux overnight, filtered and the solid washed with 
chloroform (10 mL). Impurities were removed by precipitation in methanol with 
chloroform, the solids filtered, and the filtrate taken to dryness to give the pure product as 
a pale-yellow solid in a 58 %, (0.753g, 1.16 mM). Melting point: >200°C; 1H NMR (298K, 
400 MHz, DMSO-d6): δ: 0.91 (t, J = 7.44 Hz, 12H), 1.28 (m, 8H), 1.53 (m, 8H), 1.80 (m, 
2H), 2.43 (s, 3H), 2.57 (t, J = 7.64, 2H), 3.16 (t, J = 6.04 Hz, 10H), 6.74 (t, J = 5.60 Hz, 
1H), 7.30 (d, J = 8.24 Hz, 1H), 7.62 (d, J = 8.84 Hz, 2H), 7.87 (dd, J1 = 8.80 Hz , J2 = 9.88 
Hz, 4H), 9.12 (s, 1H); 13C{1H} NMR (100 MHz, 298K, DMSO-d6): δ; 13.5 (CH3), 19.2 
(CH2), 21.0 (CH3), 23.0 (CH2), 26.1 (CH2), 38.2 (CH2), 49.1 (CH2), 57.5 (CH2), 117.5 
(ArCH), 121.6 (ArCH), 121.9 (ArCH), 125.3 (ArC), 127.7 (ArCH), 127.8 (ArCH),  134.2 
(ArC), 134.6 (ArC), 143.9 (ArC), 151.9 (ArC), 154.9 (ArC), 166.3 (C=O); IR (film): v (cm-1) 
= 2963 (NH stretch), 1701, 1173, 1036, 847; HRMS for the sulfonate-urea ion (ESI): m/z: 
act: 404.88 [M]- cal: 404.07 [M]- 
4.3.3. Single-crystal x-ray diffraction 
Single crystal X-ray diffraction is a non-destructive analytical technique that can provide 
information on the binding modes of molecules in the solid state. This technique was 
utilised to investigate the self-associative properties of SSAs 82 and 83 in the solid state. 
Crystals were obtained from a slow evaporation process, as described in section 2.7.9 of 
the materials and methods and the crystallography data discussed within this section was 
obtained and refined by Dr. J Hiscock. The crystal structure of SSA 82 is presented in 
Figure 64. 
Contrary to the electrostatic potential maps, an intramolecular bond was not observed 
forming between the alkyl chain NH and the sulfonate functionality of SSA 82. The crystal 
structure for SSA 82 revealed dimerisation through the formation of four intermolecular 
bonds between the urea NH groups of one molecule and the sulfonate of the other 
molecule. This revealed a limitation of single molecule computational modeling methods 
undertaken. Previously published crystal structures of SSAs exhibiting this dimerisation 
by Hiscock et al., (2018) resulted in the hypothesis that SSA 82 is more likely to behave 
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more like SSA 32 than SSA 33, as the dimers observed with SSA 82 were more similar to 





Figure 64. Single-crystal X-ray structures of SSA 82. 
(A) Ball and stick representation of single crystals produced by SSA 82 illustrating the 
intermolecular hydrogen bond formation. TBA cation omitted for clarity. (B) Ellipsoid 
diagram of the crystal’s unit cell. red = oxygen, yellow = sulphur, blue = nitrogen, white 
= hydrogen, grey = carbon. 
The single-crystal structure of SSA 83 also reveals the formation of dimers, however 
secondary hydrogen bonds to water molecules were also observed, which acted as HBD 
bridges between dimers (Figure 65).   
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Figure 65. Single-crystal X-ray structures of SSA 83. 
(A) Ball and stick representation of single crystals produced by SSA 83 illustrating the 
intermolecular hydrogen bond formation. TBA cation omitted for clarity; (B) Ellipsoid 
diagram of the crystal’s unit cell; red = oxygen, yellow = sulphur, blue = nitrogen, white 
= hydrogen, grey = carbon. 
It was hypothesised that while SSA 83 formed larger complexes, these would be 
comparatively weaker in comparison to those of SSA 82, as the interactions with the 
competitive solvent interactions were not overcome. 
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The amino-sulfonate dimer had an interior dimerisation angle of 180.0° and was therefore 
planar in nature. Hydrogen bond angles were found to be 173.4 – 148.8 for SSA 82 and 
ranged between 154.6 – 173.5° for SSA 83. Furthermore, hydrogen bond lengths from 
donor to acceptor (D – A) for SSA 82 were 2.839 and 2.995 Å, whereas for SSA 83 these 
ranged between 2.8719 – 2.9591 Å. The hydrogen bond distances and angles are 
reported in Table 12. 
Table 12. Hydrogen bond angles and distances involved in hydrogen bonded self-
association.  
Hydrogen bond angles and distances calculated from single-crystal x-ray structures from 
Figures 64 and 65.  










N2 O4 2.839 (4) 173.44 (7) 
N3 O4 2.995 (4) 148.8 (2) 
83 
N1 O2 2.9478 (17) 154.64 (9) 
N2 O1 2.9591 (17) 156.20 (9) 
O5 O3 2.8719 (18) 173.45 (9) 
O5 N3 2.9280 (19) 167.14 (10) 
4.3.4. Gas-phase mass spectrometry 
ESI-MS is a ‘soft’ analytical technique used for the identification and quantification of 
analytes using the mass-to-charge ratio (m/z) of ions generated from a sample. 
Generally, no fragmentation occurs upon ionization and the molecules retain minimal 
amounts of residual energy, thus this procedure can be utilised for the observation of 
non-covalent interactions which can be preserved in the gas phase. Consequently, ESI-
MS experiments were conducted using SSAs 82 and 83 to determine whether the 
dimerisation or self-association observed in the solid state could also be observed in the 
gas phase. ESI-MS experiments were conducted by Rebecca Ellaby, however, the 
analysis of spectra obtained was conducted by me. The mass charge ratio prevents the 
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differentiation of monomeric [M]- and the dimeric [M+M]2- species, however, dimeric 
[M+M+H]- could be distinguished from monomeric species. CH3 fragments are common 
impurities within the mass spectrometer used for these experiments. 
ESI-MS spectra showed the presence of an SSA 82 anionic monomer [M+H+CH3]- with 






Figure 66. High-resolution ESI spectra of SSA 82 
Spectra showing (A) the monomeric [M+H+CH3]- species, highlighted in blue, and (B) 
the dimeric [M+M+H]- species, highlighted in red.  
However, dimeric [M+M+H]- were not observed on ESI-MS spectra of SSA 83, only the 
monomeric [M]- species with an m/z of 404.8818 were observed (Figure 67).  
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Figure 67. High-resolution ESI spectrum of SSA 83 
Spectrum showing (A) monomeric [M]- species, highlighted in purple; (B) dimeric 
[M+M+H]- species were not observed in the gas phase.  
These data suggests the presence of self-associated SSA 82 dimers in the gas phase but 
not of SSA 83, despite dimeric species of its analogues SSA 34 and 70 being observed in 
the gas phase.153 It is worth noting that gas phase experiments can be subject to 
experimental conditions, and therefore, solution state studies were employed to further 
investigate the intermolecular interactions. 
4.3.5. Solution state studies 
Self-associating molecules dissolved in solvents containing HBD/HBA groups are subject 
to competing solvent-solute interactions, which must be overcome for self-associated 
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complex formation. Solution state studies allow for the analysis of these interactions and 
the events leading up to aggregate formation. Furthermore, solution-state studies allow 
for the observation of molecular interactions in an environment representative of 
physiological conditions. As such, dynamic light scattering, surface tension, and zeta 
potential measurements as well as 1H NMR DOSY, q1HNMR, and 1H NMR dilution 
studies and were utilised to observe the behaviour of SSAs 82 and 83 in different solvent 
environments. 
4.3.5.1. Dynamic Light Scattering (DLS) 
The specific properties of molecules in solution can be observed through the use of light 
scattering measurements.212 This versatile technique can be utilised to observe a variety 
of particles and characterise their diffusion behaviour in different scientific disciplines.213–
215 Brownian motion, established by Einstein in 1905, is the random motion of particles in 
solution as a result of collision with surrounding solvent molecules.216,217 Sir George 
Stokes in 1845 suggested that the radius and viscosity of solvent are proportional to the 
friction exerted by a moving particle.218 Einstein utilised this discovery and developed 
what is now known as the Einstein-stokes equation (Equation 1), through which we can 
calculate the hydrodynamic diameter (dH) of a particle.218,219 




Equation 4. The Stokes-Einstein equation.  
dH – hydrodynamic diameter, kB – Boltzmann’s constant, T= thermodynamic temperature, 
η = dynamic viscosity, and D = translational diffusion constant. 
Larger molecules tend to diffuse more slowly and therefore overall motion is minimal, 
whereas smaller particles do not adopt specific positions as they are able to diffuse 
faster. Therefore, monitoring the movement of particles in solution provides information 
on the size of the macromolecules in a given solution.212 In DLS, particles encounter 
monochromatic light, which is then scattered due to the Brownian motion of the particles, 
and the scattered light signal is then appropriately detected.212 The dH calculated is based 
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on the assumption that the particles in solution are spherical, and therefore can only 
provide an indicative size of the aggregate.  
As the SSAs have been previously shown to aggregate, DLS was utilised in these studies 
to investigate the size of the aggregates, if any, created by SSAs 82 and 83.153,155,156 
Refractive index of these novel SSAs are yet to be explored, and therefore the number 
and volume distributions could not be obtained in these experiments. The polydispersity 
index (PDI) of particles in solution is reported instead, which will provide information 
concerning the width of the particle size distribution, where the number of particles at that 
size are weighted by size. Higher PDI values correspond to a wider range of aggregate 
sizes in solution.  
DLS experiments were carried out on SSAs as described in section 2.7.4 of the materials 
and methods, in solutions of EtOH:H2O (1:19). Samples underwent an annealing process 
whereby the SSA solutions were heated to 40°C then cooled to 25°C, thereby allowing 
any aggregates formed to achieve their thermodynamic minimum. As particle motion is 
dependent on temperature and accurate knowledge of the temperature is essential in 
DLS experiments, all experiments were conducted at 25°C.212,220 Table 13 provides a 
summary of the peak maxima (nm) and the PDI (%) of SSAs 82 and 83 in a solution of 
EtOH:H2O, (1:19) at 0.56 mM and 5.56 mM.   
Table 13. DLS Data.  
Peak maxima (nm) and PDI (%) obtained from an average intensity particle size 
distribution of SSAs 82 and 83 obtained at 0.56 mM and 5.56 mM in an EtOH: H2O (1:19) 
system by DLS.  
DLS Data 
 Conc (mM) Peak Maxima (nm) PDI (%) 
82 
5.56 119.75 ± 5.30 24.44 ± 1.15 
0.56 108.41 ± 2.07 25.08 ± 0.78 
83 
5.56 410.80 ± 8.98 23.17 ± 0.91 
0.56 212.35 ± 9.52 27.90 ± 0.92 
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A broad range of aggregate sizes from ~ 1 nm to > 1000 nm were observed with SSA 82 
at 5.56 mM, with a PDI of 24.44%. Smaller aggregates observed between 1 – 10 nm 
could be attributed to lower order structure formation, such as monomer, dimer, or trimer 
formation (Figure 68). These were classified as class 1 aggregates. 
 
Figure 68. Average intensity particle size distribution.  
Low order (green) and intermediate (blue) aggregates are highlighted. Aggregates > 1000 
nm were above the limit of the experiment. The standard error of the mean (s.e.m) used 
as error values. 
The solution predominantly contained aggregates of between 50 – 400 nm, the peak 
maxima being 119.75 nm. These aggregates were defined as intermediate class 2 
aggregates. Aggregates observed below 1 nm were below the size limit of the 
experimental method, as particles of that size are too small to scatter sufficient light to be 
detected. Furthermore, aggregates > 1000 nm exceeded the limitations of the instrument 
and may be attributed to the combination of smaller structures.  
Class 2 aggregates of SSA 82 persisted at 0.56 nm, with a peak maxima of 108.41 nm, 
suggesting the stability of these higher order complexes was not disrupted by competitive 
solvent interactions. Low-order structures (class 1) were also observed, as aggregates 
between 1-10 nm were recorded (Figure 69).  
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Figure 69. Average intensity particle size distribution.  
Low order (green) and intermediate (blue) aggregates are highlighted. Aggregates > 1000 
nm were above the limit of the experiment. The standard error of the mean (s.e.m) used 
as error values. 
Comparatively larger aggerates with a peak maxima of 410 nm were observed in the 
solution of SSA 83 at 5.56 mM, which were defined as class 3 aggregates (Figure 70). 
 
Figure 70. Average intensity particle size distribution.  
Higher order aggregates are highlighted in purple. Aggregates > 1000 nm were above 
the limit of the experiment. The standard error of the mean (s.e.m) used as error 
values. 
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Lower order structures were not detected, which may suggest their presence at 
concentrations too low to be detected by DLS. Furthermore, the absence of multiple 
peaks suggested a comparatively more homogenous solution of SSA 83 aggregates in 
comparison to SSA 82 which had two definitive peaks. Unlike SSA 82, these higher order 
structures exhibited by SSA 83 at 5.56 mM did not persist at 0.56 mM. Instead, class 2 
aggregates with a peak maxima of 212.35 nm were observed (Figure 71). 
This suggested that while the stability of the aggregates may be disrupted by solvent 
interactions, higher order complex formation was still preferable. Furthermore, the 
formation of comparatively larger aggregates even at 0.56 mM suggests more stable 
complexation, in comparison to SSA 82. While aggregates > 1000 nm were recorded, as 
described before, these were above the limitations of the experiments and may be 
attributed to the amalgamation of smaller structures. 
 
Figure 71. Average intensity particle size distribution.  
Class 2 aggregates are highlighted in blue. Aggregates > 1000 nm were above the limit 
of the experiment. The standard error of the mean (s.e.m) used as error values. 
4.3.5.2. Surface tension and CMC 
As previously described, the critical micelle concentration (CMC) can be determined 
through multiple surface tension measurements of a serially diluted solution.13 At lower 
concentrations, surface tension drops significantly, and as concentration increases, the 
surface tension continues to decrease due to the increased accumulation of molecules at 
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the water-air interface. When the surface is saturated with molecules, the surface tension 
no longer decreases, and the addition of more compound results in the formation of 
extended aggregates in solution. The concentration at which this occurs is the CMC.13 
The CMC of an antimicrobial molecule is hypothesised to be linked to antimicrobial 
activity.156 It was therefore essential to determine the CMCs of SSAs 82 and 83, in order 
to further define its relationship to the antimicrobial activity. Due to COVID restrictions, 
CMC experiments were conducted as stated in section 2.7.10 of the materials and 
methods by Kira Hilton, however, data analysis and CMC calculations were conducted by 
me. The CMC values and surface tension (σ) at CMC are reported in Table 14. 
Table 14. Critical micelle concentrations.  
CMCs (mM) of SSAs 82 and 83 and surface tension (σ) at the CMC. 
Critical Micelle Concentration 
 CMC 
(mM) 
σ at CMC 
(mN/m) 
82 1.92 56.24 
83 14.77 45.16 
The CMC obtained for SSA 82 (1.92 mM) was considerably lower than that of SSA 83 
(14.77 mM). It was hypothesised previously that SSA 82 would produce a higher CMC 
value due to the hypothesised intramolecular hydrogen bond forming between the NH 
groups and the sulfonate, as was observed with its single ring analogue SSA 2. However, 
the increase from n=2 (SSA 82) to n=3 (SSA 83) significantly increased CMC. Lower 
CMC values were hypothesised to improve antimicrobial efficacy; thus, it could be 
hypothesised that SSA 82 would be more active in comparison to SSA 83, despite the 
opposite being observed with their single ring analogues SSAs 32 and 33, respectively.  
4.3.5.3. 1H DOSY NMR 
Proton DOSY NMR can differentiate the NMR signals from a mixture of molecules based 
on their translational diffusion. DOSY experiments conducted by Hiscock et al., 2018 
were able to show the formation of hydrogen bonded dimers in DMSO and also 
170 
|Chapter 4: The characterisation and optimisation of novel antimicrobial compounds        
demonstrated the hydrogen bonding mode could be manipulated through the addition of 
competitive HBA/HBD species.154 Consequently, to investigate the aggregate formation 
observed in the DLS studies, a series of DOSY 1H NMR studies were conducted at 55.56 
mM in a DMSO-d6 0.5% H2O solution. The translational diffusion constants obtained were 
applied to Stokes-Einstein equation, thereby allowing for the determination of the dH. 
DOSY experiments for SSA 83 were conducted by Kira Hilton due to COVID restrictions, 
however DOSY experiments for SSA 82 and data analysis for both molecules were 
conducted by me. The dH calculated for SSAs 82 and 83 are reported in Table 15. 
Table 15. Calculated dH.  
The dH (nm) calculated for the anionic and cationic components of SSAs 82 and 83 in a 
DMSO-d6 0.5% H2O solution. 





82 1.54 1.25 
83 1.77 1.28 
The diffusion rate of the anionic component of SSA 82 (highlighted in blue in Figure 72) 
was different to that of the TBA counter-cation (red), which was also consistent with SSA 
83 (provided in the supplementary information). This confirmed previous findings of the 
TBA cation not being strongly coordinated to the anionic component. The dH of anionic 
components measured were 1.54 nm (SSA 82) and 1.77 nm (SSA 83), which suggested 
the presence of lower-order species (monomers or dimers) as opposed to higher order 
species in the DMSO-d6 0.5% H2O solution. However, the solution being predominantly 
composed of lower-order species supported the hypothesis that the larger aggregates 
(>100 nm) were combinations of lower-order complexes. 
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Figure 72. 1H NMR DOSY.  
Example 1H DOSY NMR of SSA 82 at 55.56 mM in a DMSO-d6 0.5% H2O solution, 
conducted at 298.15 K. Anionic component highlighted in blue, counter cation (TBA) 
highlighted in red; dH of the anionic component. 
4.3.5.4. Quantitative NMR 
Quantitative NMR studies are typically used to determine the concentrations and purity of 
low molecular weight molecules, such as the SSAs, through the use of an internal 
standard.221,222 Within this study, q1HNMR was utilised to confirm the presence of lower 
and higher order species observed in the DLS and 1H DOSY NMR studies. Higher order 
species adopt solid-like properties, resulting in them becoming ‘NMR-silent’.153 The 
magnitude of the peak on an NMR spectrum is proportional to the nuclei present. 
Therefore, a comparative integration of the SSAs to a known internal standard allows for 
the percentage of compound apparently ‘lost’ – due to the formation of higher order 
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complexes – of SSAs to be calculated. Initially, q1HNMR experiments were carried out on 
SSAs 82 and 83 in DMSO-d6 0.5% H2O solutions at 111.12 mM, using DCM (5 µL, 0.08 
mM) as an internal standard due to its miscibility with DMSO and as the peaks for DCM 
could be differentiated from those of the SSAs. Relaxation rate was increased to 60s to 
ensure that the complete signal intensity was recorded. Complex formation at low 
concentrations could not be detected using this technique as this would fall below the 
detection limit of the NMR. The spectra obtained from these experiments are reported in 
Figure 73A and 73B.  
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Figure 73. 1HNMR spectra of (A) SSA 82 and (B) SSA 83 with a delay of 60 s. 
Quantitative 1HNMR experiments were conducted in DMSO-d6 0.5% H2O solutions at 
111.12 mM, using DCM (5 µL, 0.08 mM) as an internal standard. 
While no apparent ‘loss’ of compound was observed for both SSAs in the DMSO-d6 0.5% 
H2O solution, DLS experiments had previously shown the presence of higher order 
species in DMSO solutions. This suggested the larger aggregates detected in the DLS 
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experiments (>100 nm) may have been present at too low concentrations or may have 
been tumbling too slowly to be resolved by q1HNMR studies. Furthermore, this also 
suggests that the larger complexes observed were combinations of lower-order 
complexes. Following this, similar q1HNMR experiments were conducted on SSAs 82 and 
83 in solutions of EtOH:D2O (1:19) at 5.56 mM, similar to the DLS conditions, with EtOH 
(25 µL) acting as the internal standard. The spectra obtained from those experiments are 
reported in Figures 74A and 74B, and the percentage ‘loss’ is reported in Table 16. 
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Figure 74. 1HNMR spectra of (A) SSA 82 and (B) SSA 83 with a delay of 60 s.  
Quantitative 1HNMR experiments were conducted in EtOH:D2O (1:19) solutions at 5.56 
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Table 16. Summary of the apparent percentage ‘loss’.  
Percentage ‘loss’ (%) values for the anionic and cationic components of SSAs 82 and 83 
in EtOH:D2O (1:19) solutions at 5.56 mM and in DMSO-d6 0.5% H2O solutions at 111.12 
mM obtained from 1HNMR experiments. 
Percentage ‘loss’ (%) 
 EtOH:D2O (1:19) DMSO-d6 0.5% H2O 
Anionic Cationic  Anionic Cationic  
82 45 59 0 0 
83 36 41 0 0 
Comparative integration against EtOH revealed a 45% ‘loss’ of the SSA 82 anion and a 
36% ‘loss’ of the SSA 83 anion. Furthermore, a 59% ‘loss’ of the SSA 82 cation and a 
41% ‘loss’ of the SSA 83 cation was observed, revealing the percentage of cation 
involved in aggregate formation. As mentioned previously, this apparent loss is attributed 
to the formation of higher-order complexes, as they can exhibit solid-like properties and 
are no longer observable by NMR, thus becoming signal silent. As these conditions mirror 
those of the DLS study in EtOH, this supports the observation of larger aggregates by 
both SSA 82 and SSA 83. Strikingly, SSA 83 exhibiting a lower percentage ‘loss’, which 
suggested the incorporation of fewer molecules into the aggregate structures. The DLS 
studies conducted on SSA 83 revealed larger complex formation in comparison to SSA 
82. However, quantitative data obtained using these 1H NMR studies suggest that this 
could be attributed to fewer larger complexes being formed by SSA 83 and multiple 
smaller complexes being formed in solutions of SSA 82.   
4.3.5.5. Zeta potential 
Zeta potential experiments are used to define the stability of particles in solution, using 
well established guidelines.223 Typically, a measurement more positive than + 30 mV and 
more negative than – 30 mV is considered stable. Liposomes, for example, are deemed 
stable when values fall between the range of – 10 mV and – 40 mV. Thus, zeta potential 
measurements were utilised to provide an indication of the stability of the higher order 
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aggregates formed by SSAs 82 and 83. Zeta potential measurements were conducted as 
described in section 2.7.5 of the materials and methods, however briefly, solutions of 
SSA 82 and 83 (5.56 mM) in EtOH:H2O (1:19) underwent an annealing process, similar to 
that of the DLS process, ensuring they had achieved their thermodynamic minimum. 
Following this, 10 consecutive zeta potential measurements were obtained, the average 
of values of which are reported in Table 17. 
Table 17. Summary zeta potential measurements.  
The final zeta potential value reported is an average of 10 consecutive experiments 
conducted with SSAs 82 and 83 and the standard error of the mean (s.e.m) used as the 
error value. Experiments were conducted in EtOH:H2O (1:19) at 25°C. 
Zeta Potential Summary 
 Zeta Potential 
(mV) 
82 -30.22 ± 0.0025 
83 -55.76 ± 0.0001 
SSA 82 was observed forming stable aggregates, shown by the zeta potential value of -
30.22 mV. Contrastingly, zeta potential experiments revealed the aggregates formed by 
SSA 83 were unstable, as shown by the zeta potential value of - 55.76 mV. An analysis of 
DLS studies supports these observations, as when the concentration of SSA 83 was 
decreased, the size of the resultant aggregates significantly decreased. This further 
solidifies the hypothesis that the aggregates formed by SSA 83 could be disrupted by the 
competing solvent environment, thus reducing the stability of these aggregates. 
4.3.5.6. 1H NMR Dilution studies 
To quantify the strength of hydrogen-bonded complexes, a series of 1H NMR dilution 
studies were carried out. Solutions of SSAs 82 and 52 were prepared in DMSO-d6 0.5% 
H2O at 112 mM, then serial dilutions were prepared from the same sample, obtaining a 
1HNMR spectra with each dilution. The downfield shift with increasing concentration of 
the HBD N-H resonances was measured and plotted against the concentration (Figure 
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75), then the data was fitted to two self-associative isotherms using BindFit v0.5224; the 
cooperative equal K (CoEK) model and the dimerisation / equal K (EK) model.225 The 
CoEK model assumes the first self-associative event is different from successive 
interactions, whereas the EK model assumes all self-associative events occurring are 
equal.154,224,225 Data fitted to both models allow for the derivation of self-association 
constants, which can be used to compare the strength of self-associative structures. 
 
Figure 75. Downfield Chemical Shift Graph.  
(A) SSA 82 was serially diluted, and the downfield chemical shift of the urea NH 
resonances with increasing concentration was recorded and plotted.224,225 
A summary of the self-association constants calculated for SSAs 82 and 83 are reported 
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Table 18. Summary Self-association constants.  
Self-association constants (M-1) for SSAs 82 and 83 in a solution of DMSO-d6 0.5% H2O 
at 298 K, derived using the EK and CoEK binding models; Ke – aggregation constant, Kdim 
– association constant and ρ: cooperativity factor.154,225,226 
Self-association constants 
 EK (M-1) CoEK 
 Ke Kdim Ke (M-1) Kdim (M-1) ρ 
82 1.83e-3 ± 2.31e-3 9.16e-4 ± 1.16e-3 -3.43 ± 4.10 -1.72 ± 2.05 0.75 ± 1.77 
83 12.55 ± 2.04 6.28 ± 1.02 27.07 ± 2.27 13.54 ± 1.14 0.4 ± 11.09 
A comparison of the errors produced by the EK and CoEK binding models reveals a 
preference to the dimerisation EK binding isotherm (Kdim), as such these association 
constants are used in the comparison. The association constants for both SSAs 82 and 
83 were relatively low, with Kdim values < 15 M-1. Additionally, the Kdim value of SSA 82 
(Kdim = 9.16e-4 M-1) was significantly lower than that of SSA 83 (Kdim = 6.28 M-1). From 
these data, it can be concluded that the low-order structures formed are most like dimers, 
as the dimerisation EK binding isotherm was preferred, and SSA 83 has a greater 
propensity to dimerise and a higher binding strength in comparison to SSA 82.   
4.4. Antimicrobial studies 
Following the physicochemical analysis, antimicrobial analyses were conducted using 
SSAs 82 – 85. It was previously hypothesised that SSA 82 would possess higher 
antimicrobial efficacy, due to the higher stability exhibited by complexes, in comparison to 
SSA 83, and SSA 84 would improve E. coli activity due to the carboxylate functionality.  
4.4.5.1. Analysis of Growth dynamics and kinetics 
To examine the antimicrobial efficacy of SSAs 82 – 85, antimicrobial screening 
(described in sections 2.4.3 and 2.4.6 of the materials and methods) was conducted on 
E. coli DH10β and MRSA USA300. OD values were utilised to calculate the growth rate 
of the exponential phase, as described by Fattah et al., (2018) Stensjøen et al. (2015), 
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and the percentage change in growth (section in 2.4.9 materials and methods).114,115 
Similar to previous antimicrobial studies, SSAs that decreased bacterial growth by > 10% 
were deemed to have passed the antimicrobial screening and taken forward for MIC 
determination. The type of inhibition exhibited by the SSAs was determined qualitatively 
using the growth curves and categories previously described in Chapter 3. Screening 
results are summarised in Table 19. 
Table 19: Growth parameters.  
Average growth rates (k, mins), type of inhibition observed, and the percentage change in 
growth (%) of MRSA and E. coli in the presence of SSAs 82 - 85.  a - growth rate 
assumed to be zero due to lack of growth; p – passed the screening process (defined by a 
reduction in growth of > 10%); controls – growth rates of bacteria in the absence of 
compounds 
Calculation of growth parameters 
 
k (mins.) Type of inhibition Percentage change (%)  
E. coli MRSA E. coli MRSA E. coli MRSA 
82 247.66 ± 5.60 a Partial/delayed Complete 48.66 p 92.25 p 
83 475.3 ± 193.55 a Partial Complete 70.02 p 98.86 p 
84 435.44 ± 60.97 a Partial Complete 86.42 p 97.97 p 
85 233.61 ± 28.71 a Partial Complete 45.74 p 101.73 p 
Controls, k (mins): E. coli = 78.57 ± 7.61, MRSA = 65.10 ± 1.12 
All SSAs exhibited complete inhibition of MRSA, as no growth was detected throughout 
the growth period. An examination of MRSA growth curves produced by SSA 84 revealed 
OD values below those of the growth curve towards the end of the growth period, and a 
minimal increase in OD values was observed between 0 – 200 minutes. SSA 84 was 
observed to be unstable over time, which may be the cause of these observations, 
however, the growth curve produced in the presence of SSA 84 was not significantly 
different from the growth curves with the other SSAs (Figure 76).  
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Figure 76. Example growth 
curves of MRSA 
demonstrating complete 
inhibition. 
MRSA growth in the presence 
of SSAs 82 – 85 at 3.3 mM 
compared to the 5% EtOH 
growth control. 
Although complete inhibition was observed, SSA 84 could not be taken forward for MIC50 
calculations due to its instability over time.  
While differences exist between the MRSA percentage decrease values for SSA 82, 83, 
and 85, an examination of the growth curves revealed a minimal difference in growth 
effects (Figure 76). Furthermore, growth rates could not be calculated for SSAs 82 – 85 
using the MRSA data, as no exponential phase was observed. As such, the following 
comparisons discuss the activity against E. coli only.  
The data presented in Table 19 reveals higher activity by SSA 84 in comparison to all the 
molecules tested in this series of compounds. SSA 84 decreased growth by 86.42% and 
the growth rate of E. coli in the presence of this SSA was one of the slowest growth rates 
recorded for E. coli. The second most effective SSA in this series of molecules was SSA 
83, which decreased growth by 70.02%. While the growth rate produced by SSA 83 was 
numerically higher than SSA 84, the errors associated with this growth rate value suggest 
no significant difference between the two values. Contrary to the earlier hypothesis, SSA 
82 exhibited lower activity in comparison to SSA 83, as it decreased bacterial growth by 
48.66% and a faster growth rate (247.66 minutes) was observed in the presence of this 
compound. This suggested a lower impact on E. coli growth in comparison to SSA 83. 
The delayed inhibition observed with SSA 34 was not observed with SSA 83, instead, 
partial inhibition was observed, as shown in Figure 77.  
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Figure 77. Example growth curves of E. coli demonstrating partial/delayed and 
partial inhibition of SSAs 82 and 83, respectively.  
E. coli growth in the presence of SSAs 82 and 83 at 3.3 mM compared to the 5% EtOH 
growth control. 
Furthermore, while delayed inhibition was exhibited in the presence of SSA 82, this was 
more gradual in comparison to SSA 33. This suggested differing impacts or interactions 
to the membrane in comparison to SSAs 33 and 34. The weakest activity in this group of 
SSAs was SSA 85, its only difference to SSA 70 being the removal of the CH3 attached to 
the ring system (Figure 78).  
 
 
Figure 78. Comparison between the structures of SSAs (A) 70 and (B) 85.  
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Initial comparisons suggest a higher activity by SSA 85 in comparison to SSA 70, as SSA 
70 reduced E. coli growth by 27.12%, whereas SSA 85 decreased growth by 45.74%. 
However, further comparisons can be made through the use of MIC50 calculations. 
4.3.1.1. MIC50 determination 
As previously described, MIC50 values represent the concentration at which 50% of 
isolates in a test bacterial population are inhibited by an antimicrobial molecule.167,168 
Following the screening, MIC50 values were determined for SSAs that inhibited growth by 
> 10%, as defined by the screening parameters (sections 2.4.4, 2.4.7, and 2.4.8 of the 
materials and methods). MIC50 values are reported in Table 20, along with the MIC50 
values for SSAs 34, 61, and 70 from the previous study. 
Table 20: MIC50 values obtained for SSAs 82 – 85.  
MIC50 values (mM) were calculated for SSAs that passed the screening. Most effective 
SSAs from prior studies are included to provide comparisons. a – unable to calculate MIC 
due to compound instability, b – unable to MIC50 due to crystallisation of compound, * - 




MIC50 (mM)  
E. coli MRSA 
82 2.16* 1.20 
83 1.16* 0.59 
84 a a 
85 3.38* 1.14 
34 1.48* b 
61 1.25 1.14 
70 5.00* 0.93 
The data presented in Table 20 reveals a higher efficacy of SSAs 82 and 83 against E. 
coli in comparison to SSA 70. The MIC50 value obtained for SSA 82 (2.16 mM) was 
significantly lower than that of SSA 70 (5.00 mM). Similarly, SSA 83 produced an MIC50 
value of 1.16 mM, which was not only lower than that of SSA 70, but the lowest MIC50 
182 
|Chapter 4: The characterisation and optimisation of novel antimicrobial compounds        
obtained against E. coli for all the molecules tested so far. The previously lowest MIC50 
values against E. coli were 1.25 mM (SSA 61) and 1.48 mM (SSA 34), as shown in Table 
20. While it was predicted the MIC50 for SSA 84 would be lower than those obtained for 
SSAs 82 and 83, its instability over time prevented MIC50 analysis. While SSA 85 
exhibited improved E. coli activity in comparison to SSA 70, it produced a higher MIC50 
value (3.38 mM) in comparison to SSAs 82 and 83 and was, therefore, less effective. 
Thus, improved E. coli activity may be achieved through further optimisation to improve 
the stability of SSA 84 and through the use of the extended alkyl chain (n=3) in SSA 83. 
A comparison of the MIC50 values obtained against MRSA reveals a differing trend in 
activity. SSA 83 produced the lowest MIC50 value (0.59 mM) in this series of molecules. 
Furthermore, the incorporation of the benzothiazole ring system provided additional 
stability to SSA 83 in comparison to SSA 34, as the crystallisation observed with SSA 34 
that prevented accurate antimicrobial analysis was not observed with SSA 83. This could 
be utilised in improving SSA stability. SSA 82, however, was far less effective against 
MRSA in comparison to SSA 70, as their MIC50 values were 1.20 mM and 0.93 mM, 
respectively. This was consistent with earlier observations, as SSA 70 was more effective 
against MRSA than SSA 34, the single ring analogue to SSA 82. The MIC50 value 
obtained for SSA 85 was 1.14 mM, which was higher than those of SSAs 83 and 70, but 
lower than that of SSA 82. It can therefore be concluded that the CH3 associated with the 
aromatic ring contributed to the antimicrobial activity observed against MRSA and its 
removal, as seen in SSA 85, decreased antimicrobial efficacy. 
While the MIC50 value obtained for SSA 61 against MRSA was low in comparison to other 
SSAs tested, it was not the most effective within the first set of SSAs. Furthermore, other 
functionalities were observed to improve MRSA activity more than the carboxylate group 
present in SSA 61. It was therefore hypothesised that while improved MRSA activity 
would be observed with SSA 84, it would still not be as active as SSAs 36 and 39, which 
obtained the lowest MIC50 values (0.25 mM and 0.35 mM respectively).  
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4.4. Gel Characterisation 
Supramolecular gel formation is another self-assembly process that results in the 
formation of a soft solid-like material. Similar to the aggregates formed in solution, 
supramolecular gels are formed through reversible non-covalent interactions between 
molecules, which result in a network of fibres. Three main categories are typically used to 
characterise supramolecular gels, depending on the solution present. Organogels are 
gels that utilise non-polar and polar organic solvents, and ionogels are gels that utilise 
ionic liquids.227–232  
The third type of gel is a hydrogel, which are the gels formed by the SSAs in this study. 
Supramolecular hydrogels are self-assembling polymeric networks of molecules that 
contain solvents predominantly made up of water.232,233 Hydrogels are preferable 
particularly in drug design, due to their high biocompatibility and flexibility.232,234,235 
Furthermore, their reversible nature allows hydrogels to respond to external stimuli, such 
as pH, salt content, and temperature, therefore allowing their properties to be easily 
manipulated. However, hydrogels are diverse in structure, and their dynamic nature and 
the properties of the monomeric units endows them with unique properties.155,233,235  
Characterisation of supramolecular gels provides information about the SSA-solvent 
interactions, enabling better manipulation and further optimisation of desired 
properties.232,234 As such, the gels formed by SSAs 82 and 83 were characterised as 
described below. Due to COVID restrictions, the inversion tests were conducted by Lisa 
White, and rheometry experiments were conducted by Kira Hilton, however, data 
analysis, antimicrobial analysis, and microscopy studies were conducted by me. The gel 
characterisation of SSA 85 was conducted as part of a separate study and is therefore 
not reported below. 
4.4.2. Inversion test and MGC 
SSA 70 has been previously shown to gelate in the presence of various salt solutions. As 
such, six salt solutions were selected from the study conducted by Hiscock et al. (2020) 
to elucidate the impact of different salt solutions in an aqueous environment on gel fibre 
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formation.155 Gelated materials were formed by dissolving SSA 82 and 83 (5 mg) in the 
appropriate sodium salt solutions (1 mL, 0.505 M), then heating these solutions at ~40°C 
and allowing them to cool to 25°C. The presence of a stable gel was determined by 
reproducible n=3 inversion tests, in which the vials containing the SSA gels were 
upturned and the gel was characterised by the resistance to flow.236  Inversion tests were 
utilised in the determination of the minimum gelation concentration (MGC), defined as the 
lowest gelator concentration required to form a stable gel. If the gel was able to retain its 
shape post inversion, then the MGC was determined. However, if the gel was not able to 
retain its shape, then the MGC was determined to be > 5 mg/mL and a further analysis 
was not conducted using inversion tests as gel processes could not be confirmed using 
MGC. A detailed description of this method is provided in in section 2.7.11 of the 
materials and methods. The minimum gelation concentrations of SSAs 82 and 83 are 
reported in Table 21. 
Table 21: Minimum gelation concentrations obtained from inversion tests.  
Minimum gelation Concentration (mg/mL) 
 
SSA 82 SSA 83 
NaCl > 5 > 5 
KCl > 5 > 5 
Na2SO4 > 5 > 5 
NaH2PO4 > 5 > 5 
NaNO3 > 5 > 5 
NaOBz > 5 > 5 
The inversion test revealed the gels formed by SSAs 82 and 83 were not stable, as they 
were not able to retain their shape when inverted in any of the sodium salt solutions. 
While the MGCs for SSAs 82 and 83 were all determined to be above 5 mg/mL, the 
effects of the different sodium salts on the observed gel strength can be compared.  
NaCl and KCl differ in the anion-cation coordination; Na+ is more strongly coordinating in 
comparison to K+. SSA 70 was previously reported to form comparatively stronger gels 
when the salt solution used contained a weakly coordinating cation, as this enabled gel 
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formation. A similar trend is observed with SSA 82, as gels were able to retain their 
shape more effectively with KCl present in comparison to NaCl (Figure 79A & 79B)  
A B C D 
    
Figure 79. Results from the inversion tests.  
Experiments conducted using SSA 82 (5 mg/mL) in (A) NaCl and (B) KCl and SSA 83 
(5 mg/mL) in (C) NaCl and (D) KCl. Salt concentrations = 0.505 M, experiments 
conducted at 25°C. 
This would support the hypothesis presented by Hiscock et al. (2020); that strong ion pair 
effects disrupt self-association events, leading to the instability of the gel structure. 
Conversely, the SSA 83 gels were able to retain their shape more effectively when NaCl 
was present, in comparison to KCl (Figure 79C & 79D). The strong ion-pair effects did not 
negatively impact the strength of the gel, suggesting differing gel fibre formation 
processes in comparison to SSA 82. The inversion test results using SSA 82 gelated in 
NaNO3 revealed more effective shape retention in comparison to NaCl (Figure 80).  
 
Figure 80. Results from the inversion tests. 
Experiments conducted using SSA 82 (5 mg/mL) and NaNO3 (0.505 
M). Experiments were conducted at 25°C. 
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A significantly weaker gel was observed with SSA 82 in NaH2PO4, as the resulting gel 
was unable to hold its shape (Figure 81A), in comparison to SSA 83 which was able to 





Figure 81. Results from the 
inversion tests.  
Experiments conducted using (A) 
SSA 82 (5 mg/mL) and (B) SSA 83 (5 
mg/mL) in NaH2PO4 (0.505 M). 
Experiments were conducted at 25°C. 
The weakest gels were observed when SSAs were dissolved in NaOBz, as SSAs 82 and 
83 were unable to retain their shape. Despite the resulting SSA 83 gel appearing more 
viscous in comparison to SSA 82, both gels exhibited more liquid-like behaviour in 






Figure 82. Results from the 
inversion tests.  
Experiments conducted using (A) 
SSA 82 (5 mg/mL) and (B) SSA 
83 (5 mg/mL) in NaOBz (0.505 M). 
Experiments were conducted at 
25°C. 
Minimal differences were observed between SSA 82 gels in NaCl and Na2SO4 (Figure 
83A), and also between SSA 83 gels in NaCl, NaNO3, and Na2SO4 (Figure 83B & 83C). 
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Figure 83. Results from the inversion tests.  
(A) SSA 82 in Na2SO4 SSA (B) 83 in NaNO3, (C) SSA 83 in Na2SO4. Experiments were 
conducted at 25°C using SSAs at 5 mg/mL and salt solutions (1 mL) at 0.505 M.  
4.4.3. Rheology 
Information about the mechanical properties, structure, and assembling dynamics of a 
supramolecular gel can be determined using rheology.155,237–241 In this technique, gelated 
materials are subjected to tensile and compressive stresses, and their deformation and 
flow behaviour are observed.237–239  
The flow and deformation behaviour can be quantified by the elastic properties storage 
(G’) and loss moduli (G’’). The storage modulus is a measure of the energy stored during 
a strain cycle, whereas the loss modulus is a measure of the energy lost.237–239 The 
dissipation factor (tan δ) is expressed by the ratio G’’/G’, which can assess the 
dominance of solid-like or liquid-like behaviour. When tan δ > 1 (G’’ > G’), the material 
displays viscous liquid properties, and when tan δ < 1, (G’’ < G’), the material displays 
more solid-like properties.237–239 
Typically, these properties are independent of applied stress and behave as elastic 
materials (G’’ > G’) up to the yield point, where the material’s behaviour is no longer 
linear. 155,238,239 At the yield point, G’ decreases along with the structural strength of the 
material, down to a critical point known as the gel-sol transition point.238 A graphical 
representation of these regions is presented in Figure 84. 
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Figure 84. Graphical representation of the amplitude sweep experiments.  
Graph showing the linear viscoelastic region (LVER), yield point, and the critical/flow 
point (gel-sol transition). 
Amplitude sweep experiments are typically used as an initial evaluation of the stress 
dependence of G’ and G’’ and the linear viscoelastic region (LVER) can be 
established.234,238,239 The LVER region is defined as the region where the material can 
undergo experimental procedures without a loss of structural integrity.155,238 Below this 
point, the material is more solid-like and above this, the material is more fluid.238,239  
Therefore, amplitude sweeps were conducted using SSA 82 and 83 gels in the six salt 
solutions tested in the inversion tests to determine their viscoelastic properties. In all of 
the salt solutions tested, gel-sol transition points were not observed when rheology 
experiments were conducted, as shown in Figure 85A. Furthermore, a gel-sol transition 
point was observed with SSA 82 in a solution of Na2SO4, the storage modulus was lower 




















































Figure 85. Example graph of amplitude sweep experiments conducted on SSA 82 
(5 mg/mL) in (A) NaNO3 and (B) in Na2SO4.  
Data points are an average of 3 results, using the standard deviation as the error value; 
salt solutions at 0.505 M; experiments conducted at 25°C. 1 = 100%. 
This indicated that the gel exhibited more fluid properties at the start of the experiment, 
and the transition into a solid material was likely induced by mechanical stress, in addition 
to the presence of the salt (Figure 85). The absence of a gel-sol transition point and fluid 
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SSA 82, thus further analysis using rheometry was not possible, as this is a requirement 
of this technique. Amplitude sweep experiments were also conducted on SSA 83 in NaCl, 
which had previously exhibited the most effective shape retention from the inversion tests 
(Figure 86). 
 
Figure 86. Example graph of amplitude sweep experiments conducted on SSA 83 
(5 mg/mL) in NaCl.  
Data points are an average of 3 results, using the standard deviation as the error value; 
salt solutions at 0.505 M; experiments conducted at 25°C. 1 = 100%. 
However, due to the absence of a gel-sol transition point, amplitude sweep experiments 
were not conducted with SSA 83 in the presence of the other salts.  
4.5. Microscopy studies 
Scanning electron microscopy (SEM) is a microscopic technique that utilises a narrow 
electron beam to produce high-resolution images.242,243 Typically, SEM is utilised in the 
examination of hydrogel microstructure, however, hydrogels must be dehydrated for this 
technique, bringing the fibres formed out of their native environment.234,244 Furthermore, 
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produce artifacts in the final images observed.234,244 Consequently, as SSAs 82, 83, and 
85 were intrinsically fluorescent, widefield fluorescence microscopy was utilised to 
observe the gelation properties of SSAs 82, 83, and 85 in the six salt solutions tested 
previously. While this microscopic technique produces comparatively lower resolution 
images, the native fibre can be observed within the solvent environment without 
destruction of the gel. 
Gel microscopy was carried out by first creating a chamber using a microscope slide and 
a coverslip, which were secured on three ends. Gel solutions were then prepared by 
dissolving SSAs (5 mg) in the appropriate sodium salt solution (1 mL) and heated to 
~40°C. Molten gel solutions were then pipetted into the chamber and allowed to form on 
the microscope to enable imaging of the initial stages of gel formation. Further details of 
this method are provided in section 2.5.4 of the materials and methods.  
4.5.1. Gel fibre characterisation 
It was discovered that the time taken for gelated materials to form differed significantly, 
thus images were taken at differing time points depending on each gel solution. The time 
taken for the final gel structure to form – defined by no further changes occurring to the 
structure observed – was recorded and used in the comparison.  
The microscopy images obtained using SSAs 82, 83, and 85 also revealed significantly 
varied gel fibre formation with differing salt solutions of the same SSA. Consequently, 
categories were created to characterise the gel fibres observed. Gel fibres were classified 
into the following categories; straight or curled; crosslinked or independent; short or long; 
densely packed, medium packing density or loosely packed; uniformly arranged or 
stochastically arranged; unidirectional fibres or multidirectional fibres.  
To define gel fibre packing density, three categories were created. Gel fibres that close 
together with very little solvent was visible were classified as being densely packed 
(Figure 87A).  
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Figure 87. Example images used to define packing density of gel fibres.  
(A) densely packed gel fibres; SSA 83 (5 mg) in an NaNO3 solution (1 mL, 0.505 M), 
(B) medium packing density; SSA 82 (5 mg) in an NaCl solution (1 mL, 0.505 M) (C) 
loosely packed gel fibres; SSA 85 (5 mg) in an NaNO3 solution (1 mL, 0.505 M). Scale 
= 15 µm. 
Medium packing density was defined by gel fibres with larger amounts of solvent visible, 
but the fibres were held close together due to cross-linking (Figure 87B). Gel fibres with 
large amounts of visible solvent regions and easily discernible individual strands or 
independent strands that were not held together were defined as loosely packed (Figure 
87C). Gel fibres were measured in order to determine whether they were long or short, 
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and all other categories were quantitatively determined. This provided a way to observe 
patterns between the salt solution present and the gel strand formed.  
During the imaging process, some gels were observed to have large amounts of sol 
surrounding the resulting gel, which was not incorporated into the matrix. This resulted in 
gel movement on the microscope slide, thus, resulting gels were further categorised as 
either stationary or motile, depending on whether any movement was observed by 
microscopy. 
4.5.2. Measurement of gel fibres 
To measure gel fibre length, gel images were opened in ImageJ and the scale was set. 
Following this, the ‘unsharp mask’ filter (σ = 2.0) was applied to the images to create a 
sharper image, thus defining the gel fibres, as shown in Figure 88.106,245 
A  B 
  
Figure 88. Example fluorescence microscopy images showing gel strand 
sharpening using the ‘unsharp mask’ filter.  
(A) original, unedited image of gel strands (B) image with ‘unsharp mask’ filter. Scale = 15 
µm. 
The ‘difference of gaussian’ filter (DoG) is often used to define edges in a sample, 
removing background noise. The DoG filter was applied to the defined images (σ1 = 1, σ2 
= 5), further enhancing the edges of the gel fibres and allowing specific layers of gel 
fibres to be observed.245 This would enable fibre length measurement with less noise, as 
shown in Figure 89.   
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A  B 
  
Figure 89. Example widefield fluorescence microscopy images showing further gel 
strand definition using the ‘difference of gaussians’ filter.  
(A) the original, unedited image of gel strands (B) the image with ‘difference of gaussians’ 
filter, used in the final length determination. Scale = 15 µm. 
The length of approximately 40 gel fibres from each condition (from multiple images) was 
measured using the segmented line tool and the measure length feature. The start and 
end points of gel fibres were determined in multiple ways. Firstly, if nodes (bright regions 
that appeared to be strand initiation sites) were present, these were determined to be the 
start of the strand. The strand was then followed along until it either branched to form 
multiple strands, it tapered off, or reached another node. These were determined to be 
the end points. Where nodes were not present, gel strands were measured either 
between tapered edges or from a tapered edge to the region where the strand branched 
to form multiple strands. Where the start and end points could not be determined, lengths 
were not measured. A full report of the averages of the lengths measured is reported in 
the appendix. Gel fibres were then classified as short if they were ≤ 20 µm in length and 
categorised as long if they were > 20 µm in length. Some gel fibres could not be 
measured as their length extended beyond the microscope camera's field of view; thus, a 
start and end point could not be accurately determined, and they could not be measured. 
These strands were classified as long fibres. A summary of the gel fibre formation is 
presented in Tables 22 and 23.  
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4.5.3. Microscopy summary Tables 
Table 22. Gel fibres summary Table.  
Approximate time taken for final gel formation of SSAs 82, 83 and 85 – defined by no 
further changes being observed in the gel structure – and the motility of the resulting gel. 
Motility is defined as either stationary or motile.  Salt concentration = 0.505 M. 
Approximately 50 µL of each sample was heated to ~ 40°C before being allowed to cool 
to ~18°C on the microscope stage. n/a = no gel fibre formation. 
 Gel Sample Summary 
  Time for gel fibre 
formation at 5 mg / mL 
Mobility of gel fibres 
within the sol 
82 KCl ~ 1 hour Stationary 
Na2SO4 < 1 minute Stationary 
NaCl ~ 30 minutes Stationary 
NaH2PO4 n/a n/a 
NaNO3 ~ 30 minutes Motile 
NaOBz < 30 minutes  Stationary 
83 KCl ~ 1 hour Stationary  
Na2SO4 ~ 2 hours Motile 
NaCl ~ 30 minutes Stationary 
NaH2PO4 n/a n/a 
NaNO3 ~ 30 minutes Stationary  
NaOBz ~ 5 hours  Motile 
85 KCl < 1 minute Stationary 
Na2SO4 ~ 30 minutes Motile 
NaCl < 1 minute Stationary 
NaH2PO4 ~ 2 hours  Motile  
NaNO3 ~ 2 hours Motile 
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Table 23. Gel fibres summary Table.  
Observed gel fibres formed by SSAs 82, 83, and 85 in various salt solutions. Strand 
formation of the final gel was defined by the following properties: straight (ST), curled 
(CL), crosslinked (LK), independent (IN), short (SH), long (LG), densely packed (DP), 
medium packing density (MP), loosely packed (LP), uniform arrangement (UF), stochastic 
arrangement (SC), unidirectional strands (UD), multidirectional strands (MD). a = larger 
than field of view, b = unable to discern individual fibres. 
   Morphology of gel fibres 
  ST CL LK IN SH LG DP MP LP UF SC UD MD 
82 
NaCl              
KCl              
NaH2PO4              
Na2SO4              
NaNO3      a        
*NaOBz      b        
83 
NaCl              
KCl              
NaH2PO4              
Na2SO4              
NaNO3      b        
NaOBz      a        
85 
NaCl              
KCl              
NaH2PO4      b        
Na2SO4      a        
NaNO3              
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4.5.4. The fibre formation of SSAs 82, 83, and 85 gels 
The most common features of the gel fibres formed were multidirectional fibres and 
cross-linking between strands. Gel strand initiation and cross-linking appeared to start at 
bright regions of aggregated compound (nodes) and for the majority of gel fibres, strands 
formed in multiple directions between nodes. An example of this is seen with SSA 82 in 
NaCl (Figure 90) 
A B 
  
Figure 90. Widefield fluorescence microscopy. 
Microscopy images showing the morphology gel strands formed by SSA 82 (5 mg/mL) 
in a NaCl solution (0.505 M).  (A) early gel formation (B) after 30 minutes, when no 
further changes to the gel structure were observed. Scale = 15 µm. 
During early gel formation (Figure 90A) cross-linking between nodes was observed, and 
the final gel structure observed (Figure 90B) was comprised of short, cross-linked fibres, 
with strands going in multiple directions from these nodes. As crosslinking between fibres 
was common in the majority of gel structures observed, it was hypothesised this was an 
integral feature in the gel strand formation process for this group of molecules. There 
were a couple of exceptions to this, however; SSA 82 in a NaNO3 solution and SSA 82 in 
a KCl solution. 
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The strands in the gel formed by SSA 82 in a NaNO3 solution appeared to develop 
independently, with no evidence of cross-linking between strands during early gel 
formation and 30 minutes later when the final gel structures had formed (Figure 91). 
A B 
  
Figure 91. Widefield fluorescence microscopy. 
Microscopy images showing the morphology gel strands formed by SSA 82 (5 mg/mL) in 
a NaNO3 solution (0.505 M). (A) early gel formation (B) after 30 minutes, when no further 
changes to the gel structure were observed. Scale = 15 µm. 
Additionally. while long, multidirectional strands were observed during early gel formation 
(Figure 91A), after 30 minutes, these strands had self-associated into compact regions of 
uniformly arranged, unidirectional fibres (Figure 91B). Strikingly, during early gel 
formation, gel fibres were straight, however, the final gel structure exhibited curled 
strands. However, the resulting gel was surrounded by large amounts of sol, causing the 
gel to be motile and fragile, and therefore the lack of cross-linked fibres may have 
reduced the stability of the resulting gel.  
SSA 82 in a KCl solution produced fibres that were also unidirectional. However, unlike 
those observed in the NaNO3 solution, strands remained straight, and cross-linking was 
observed from nodes (Figure 92). While the gel took longer to form, the gel matrix 
appeared to incorporate more sol, as there was no movement observed by microscopy. 
Thus, it was hypothesised that the cross-linking improved gel stability. 
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Figure 92. Widefield fluorescence microscopy. 
Microscopy image showing the morphology gel 
strands formed by SSA 82 (5 mg/mL) in a KCL 
solution (0.505 M). Scale = 15 µm. 
Table 23 reveals a greater propensity for short strands to form uniform structures. 
Examples of this are seen with SSA 83 in KCl (Figure 93A), and SSA 82 in Na2SO4 
(Figure 93B), whose short strands were arranged in a uniform, geometric pattern, cross-
linking between nodes. 
A B 
  
Figure 93. Widefield fluorescence microscopy. 
Microscopy images showing the morphology gel strands formed by (A) SSA 83 in KCl 
and (B) SSA 82 in Na2SO4. SSAs at 5 mg/mL and salt solutions as 0.505 M. Scale = 15 
µm. 
Increasing the length of strands increased the greater propensity for curled fibres and 
also for stochastic arrangements. In Figure 93, the strands observed in KCl were shorter 
than those in Na2SO4, and curled fibres were observed randomly distributed in the gel 
with Na2SO4. Further evidence of this is provided in the images of SSA 85 in NaNO3 
(Figure 94). 
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Figure 94. Widefield fluorescence microscopy. 
Microscopy image showing the morphology gel 
strands formed by SSA 85 (5 mg/mL) in NaNO3 
(0.505 M). Scale = 15 µm. 
These fibres were longer than those of SSA 82 in KCl and Na2SO4 and were also curled 
with no uniform arrangement of fibres. Exceptions to this were SSAs 82 in NaNO3 (Figure 
91), which produced long, curled fibres that were uniformly arranged, and SSA 83 in 
Na2SO4 (Figure 95), which both produced comparatively shorter, straight fibres in a 
uniform arrangement.  
 
Figure 95. Widefield fluorescence microscopy. 
Microscopy image showing the morphology gel 
strands formed by SSA 83 (5 mg/mL) in Na2SO4 
(0.505 M). Scale = 15 µm. 
This suggests the formation of curled fibres is reliant on the length of the strands, and the 
formation of curled fibres increases the likelihood of stochastically arranged fibres. 
NaNO3 molecules likely trigger the uniform arrangement of SSA 82, as this was the only 
solution where long curled fibres were uniformly arranged.  
SSA 82 had a high propensity to produce straight fibres in the salt solutions tested. 
Where curled fibres were present, they tended to make up a smaller proportion of the 
final gel structure, which was the case in Na2SO4 (Figure 96). 
201 
|Chapter 4: The characterisation and optimisation of novel antimicrobial compounds        
 
Figure 96. Widefield fluorescence microscopy. 
Microscopy image showing the morphology gel 
strands formed by SSA 82 (5 mg/mL) in Na2SO4 
(0.505 M). Scale = 15 µm. 
While fibres were predominantly short and straight fibres in a geometric arrangement, 
there were a few long curled fibres randomly distributed around the geometric matrix. 
These curled fibres made up a smaller proportion of the gel fibres observed. SSA 82 in 
Na2SO4 also provided evidence of a lack of homogeneity in these gels, as multiple types 
of fibres were observed in the same gel. This may lead to reduced stability, as was seen 
during the inversion tests and rheometry. Conversely, SSA 83 had a higher propensity to 
form curled fibres in the salt solutions tested. An example of this is seen with SSA 83 in a 
NaCl solution (Figure 97).  
 
Figure 97. widefield fluorescence microscopy. 
Microscopy image showing the morphology gel 
strands formed by SSA 83 (5 mg/mL) in NaCl (0.505 
M). Scale = 15 µm. 
Despite producing long curled fibres, the gel produced by SSA 83 in NaCl was able to 
retain its shape just as effectively as SSA 82 in NaCl. This revealed another factor 
influencing stable gel formation: the packing density of gel fibres. It was hypothesised that 
closer packing of gel fibres resulted in more stable gel formation.  Further evidence of this 
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was seen with the comparison between images obtained of SSAs 82 and 83 in NaOBz 
(Figure 98).  




Figure 98. widefield fluorescence microscopy images. 
Microscopy images showing the morphology gel strands formed by SSA 82 in NaOBz; 
(A) early gel fibre formation, (B) after 30 minutes when no further changes occurred to 
the gel and SSA 83 in NaOBz; (A) early gel fibre formation, (B) after 5 hours when no 
further changes occurred to the gel. SSAs at 5 mg/mL and salt solutions as 0.505 M; 
scale = 15 µm. 
Early gel fibre formation of SSA 82 revealed curled fibre formation (Figure 98A) which 
then aggregated together to form densely packed regions and sparsely packed regions 
(Figure 98B). Similarly, SSA 83 exhibited long, curled strands initially (Figure 98C), which 
then packed together to form a densely packed gel surrounded by sol (Figure 98D). 
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During the inversion test, both gels were significantly less stable in comparison to the 
other salt solutions, as neither could retain their shape. However, the SSA 83 gel 
appeared to be more viscous in comparison to SSA 82 gel, which suggested greater 
stability. The SSA 82 gel observed by microscopy consisted of densely packed regions of 
curled fibres and parsley packed regions of curled fibres (Figure 98B). The SSAs 83 gel, 
however, consisted of densely packed curled fibres surrounded by sol, resulting in high 
motility (Figure 98D). The increased viscosity observed by SSA 83 may be attributed to 
the gel fibres being more densely packed together in comparison to SSA 82, where the 
aggregates separated regions of fibres. Furthermore, although SSA 83 in NaNO3 
appeared to form a mix of curled and straight fibres initially (Figure 99A), the strands 
aggregated together resulting in a densely packed gel, which may have contributed to the 
comparative gel stability exhibited in the inversion test (Figure 99B). 
 A B 
  
Figure 99. Widefield fluorescence microscopy. 
Microscopy images showing the morphology gel strands formed by SSA 83 (5 mg/mL) in 
NaNO3 (0.505 M). Scale = 15 µm. 
The concentration of SSA 85 was reduced to 2.5 mg/mL, in an effort to slow the gelation 
process enough to visualize each step, and its gelation process in NaH2PO4 was 
observed. Initially, small aggregates were observed moving in the sol (Figure 100A), 
which were then observed to precipitate (Figure 100B). As more SSA precipitated from 
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Figure 100. Widefield fluorescence microscopy. 
Microscopy images showing the gel formation process of SSA 85 (2.5 mg/mL) in 
NaH2PO4 (0.505 M); (A) initial aggregate formation, (B) aggregate precipitation; (C) the 
initial morphology of large regions of aggregated compound formed by SSA 85 (2.5 
mg/mL) in NaH2PO4 (0.505 M), (D) as time progressed, more compound was recruited 
into these structures. Scale = 15 µm. 
Long, curled gel fibres started forming around the aggregated structures formed by SSA 
85 (Figure 101 A), which were then elongated at nodes. As the number of gel fibres 
increased and the fibres continued to elongate, the aggregated structures became less 
visible. The resultant gel was made up of a mass of long, curled fibres surrounded by sol 
(Figure 101B). 
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A B 
  
Figure 101. Widefield fluorescence microscopy. 
Microscopy image showing the gel formation process of SSA 85 (2.5 mg/mL) in 
NaH2PO4 (0.505 M); (A) gel strands formed around precipitated compound and 
appeared to elongate at nodes; (B) the resultant gel formed, made up of long curled 
fibres. Aggregated structures were no longer visible. Scale = 15 µm. 
The large regions of precipitated compound in Figure 100D were also observed when 
SSA 82 was in NaH2PO4 (Figure 102).  
 
Figure 102. Widefield fluorescence microscopy. 
Microscopy image showing the large regions of 
precipitated compound formed by SSA 82 in 
NaH2PO4. Scale = 15 µm. 
However, unlike SSA 85, no gel fibres formed after 5 hours, despite observing gelation 
during the inversion test. Similarly, SSA 52 was observed in the inversion test to be 
forming gels, however, even after 5 hours, no gel strands or large structures were 
observed on the microscope. The experimental conditions may have elongated gelation 
time, which may have resulted in the fibres not forming in the time scale of these 
experiments, especially considering the instability shown by the SSA 82 gel during the 
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inversion test. A similar gelation process was also observed by SSA 85 in Na2SO4. Initial 
aggregate formation showed the initial stages of gel formation (Figure 103A), followed by 
large regions of aggregated compound (Figure 103B). Gel strands then formed around 
the aggregated structures (Figure 103C), and as the length of the gel strands increased, 
the aggregated structures became less visible until the final gel – made up of a mass of 
long, stochastic fibres surrounded by sol – was formed (Figure 103D).  
A B Figure 103. Widefield 
fluorescence microscopy. 
Microscopy image showing 
the gel formation process of 
SSA 85 (5 mg/mL) in Na2SO4 
(0.505 M); (A) initial 
aggregate formation; (B) 
followed by the formation of 
large regions of precipitated 
compound; (C) gel strands 
then formed around 
precipitated compound 
structures; (D) the resultant 
gel was made up of long, 
stochastically arranged fibres 





Gel strand initiation from the precipitated compound regions was also observed with SSA 
85 in Na2SO4, providing further evidence of their role as gel fibre initiation sites (Figure 
104). 
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Figure 104. Widefield fluorescence microscopy. 
Microscopy image of SSA 85 (5 mg/mL) in Na2SO4 highlighting gel strand initiation 
from aggregated compound regions with enlarged ROI in. Scale = 15 µm. 
While different salt solutions were observed to produce different fibres, these data may 
provide insight into the gel formation processes for the gels that resulted in long, curled, 
stochastic fibres, which was the case for all SSA 85 gels. Further, the formation of the 
precipitated compound structures by SSA 82 in NaH2PO4 suggests a similar gel formation 
process to SSA 85 in NaH2PO4 and SSA 85 in Na2SO4. 
The microscopy data presented demonstrates how different salt solutions can impact gel 
fibre morphology and formation processes, and thereby impacting the stability and 
properties of the resultant gels. For example, in salts that triggered the formation of 
longer strands, such as NaNO3, reduced stability and increased motility was observed by 
the gels. Whereas salts that triggered shorter stand formation, such as KCl, tended to 
result in uniform arrangements that were thought to improve gel stability. Furthermore, 
salt solutions that allowed gel strands to pack closer together, such as Na2SO4and 
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NaNO3 also exhibited more stable gels in comparison to those that did not, such as 
NaOBz. 
A distinct feature of these gels was the formation of a gel mass surrounded by a large sol 
environment, which often resulted in motile gels that were difficult to image. This was 
more clearly seen with SSA 83 in NaOBz or SSA 82 in NaNO3. Motile gels were often 
fragile and would easily break down. This was attributed to large amounts of the sol not 
being incorporated into the final gel structure, resulting in a comparatively weaker gel, as 
was observed with SSA 85 in NaH2PO4. This may have contributed to the unstable gel 
formation by all the gels formed, as the MGCs determined were all > 5 mg/mL. This also 
suggested the sol needed to be heavily incorporated into the gel matrix to create a more 
stable gel, as opposed to surrounding the gel. An additional factor influencing gel 
formation was the time taken for gels to form. NaOBz tended to trigger slower gel 
formation in SSAs 83 and 85 as the final gel structures were only observed after 5 hours. 
The resulting gel for SSA 83 displayed more liquid-like behaviour in the inversion test. 
Whereas gelation in NaCl was fairly rapid, by 30 minutes all final gel structures were 
observed, and SSA 82 and 83 in NaCl were more stable during the inversion test, in 
comparison to NaOBz.  
While SSA 82, 83, and 85 were less stable gels in comparison to SSA 70, we sought to 
determine how this would impact the antimicrobial activity when gelated. 
4.5.4. Antimicrobial Studies 
To determine the activities of SSAs 82, 83, and 85 in their gelated form, surface diffusion 
assays were performed, as described in section 2.4.12 of the materials and methods. 
After an 18-hour incubation at 37°C, SSA 82, 83, and 85 gels were found to dissolve into 
the agar plate, making it difficult to define the area of gel placement. However, reduced 
antimicrobial activity of SSAs 82, 83, and 85 was observed with E. coli, as no zones of 
inhibition or gel placement were observed (Figure 105). 
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Figure 105. E. coli surface diffusion assay.  
Agar plates showing reduced E. coli activity by SSAs (A) 82, (B) 83, (C) 85 in 
comparison to SSA (D) 70. 
This was surprising as in solution, SSAs 82, 83, and 85 had improved antimicrobial 
activity in comparison to SSA 70, against E. coli, as shown by their lower MIC50 values.  
Greater activity was observed against MRSA by SSA 82 and 83 gels. Despite the 
difficulty in defining the area of gel placement, zones of inhibition were still calculable for 
MRSA gel plate, as the zone of inhibition includes the area of gel placement. Zones of 
inhibition for SSAs 82, 83, and 85 were measured in ImageJ, as described in section 
2.4.13 of the materials and methods, to ensure more accurate measurement as gel 
regions could not be defined. Furthermore, zones created by SSA 70 were measured 
again in ImageJ to provide an accurate comparison, as previously zones were measured 
manually.106,246 The results are summarised in Table 24. 
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Table 24. Zones on inhibition measured using ImageJ.106,246  
The zones of inhibition (mm) were measured for SSAs 70, 82, 83, and 85 against MRSA 
using the surface diffusion assay; n=3 for all groups. Standard deviation (SD) is used as 
the error value. 
Zones of inhibition 
 
Diameter (mm) 
70 10.59 ± 0.99 
82 14.67 ± 1.66 
83 19.15 ± 1.88 
85 n/a 
As seen in Table 24, the zone of inhibition measured by SSA 70 (M = 10.59 mm) in 
comparison to those of SSA 82 (M = 14.67 mm) and SSA 83 (M = 19.15 mm). A zone of 
inhibition was not observed for SSA 85, thus had considerably lower activity in 
comparison to SSAs 82 and 83, consistent with the MIC50 values obtained. While SSA 83 
produced a numerically larger zone than SSA 82, to determine whether this difference 
was statistically significant, a between-groups ANOVA was conducted using the values 
for SSAs 70, 82 and 83.247,248  
The between-groups one-way ANOVA is a statistical test used to determine whether any 
statistically significant differences exist between the means of three or more independent 
groups.184 The one-way ANOVA uses F-tests to determine whether the differences 
observed between group means is larger than the variability observed within groups. A 
larger ratio, demonstrated by a high F-value, is indicative of high variability between 
group means, relative to the variation observed within each group. 184 In determining 
statistical significance, F-values must be used in combination with p values, as p values 
determine the significance or importance of F-values. Typically, p values ≤ .05, are 
considered significant whereas p values > .05 are considered not significant. 184  
Prior to conducting the ANOVA, the assumption of homogeneity of variances was tested 
and satisfied based on Levene’s F test. The one-way between-groups ANOVA revealed a 
statistically significant effect; F(2, 33) = 90.60, p = .000, η2 = .846. Therefore, the 
211 
|Chapter 4: The characterisation and optimisation of novel antimicrobial compounds        
calculated zones of inhibition means in the presence of each SSA were not equal to each 
other. While the one-way between-groups ANOVA can assess whether statistically 
significant differences exist between the means calculated, it does not provide 
information about where those differences lie. A posthoc test can be utilised to identify 
the means that are statistically significantly different from each other. Consequently, three 
Fisher’s LSD posthoc tests were conducted to elucidate the nature of the 
differences.184,247,248 A visual representation of the results is presented in Figure 106, 
however, the full analysis is provided in the appendix.  
 
Figure 106. Means plot reporting the zones of inhibition for SSAs 70, 82 and 83 
used in determining statical significance. 
 Fisher’s LSD posthoc test (p-values): SSA 70 & SSA 82; p = .000, SSA 70 & SSA 83; p 
= .000, and SSA 82 and SSA 83; p = .000. n= 3 for all groups. 
The difference observed between zones measured with the SSA 70 and the SSA 82 gel 
was determined to be statistically significant, t (33) = -6.41, p =.000. Similarly, the 
differences observed between the SSA 70 gel and the SSA 83 gel were statistically 
significant; t(33) = -13.46, p = .000, as were the differences observed between SSA 82 
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gel and the SSA 83; t(33) = -7.04, p = .000. It can therefore be concluded that SSAs 82 
and 83 were both more effective antimicrobials against MRSA in their gelated form, as 
they produced statistically significantly larger zones of inhibition in comparison to SSA 70. 
Furthermore, SSA 83 was the most effective, as the gel made using this SSA produced 
the largest zones of inhibition which were statistically significantly higher than those of 
SSA 70 and 82.  
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4.6. Summary 
Statement Evidence 
SSAs 82 and 83 formed higher order 
complexes in EtOH:D2O (1:19) 
~ 50 – 500 nm aggregates observed by 
DLS.  
A 45% loss of SSA 82 and a 36% loss of 
SSA 83 in EtOH:D2O (1:19).  
SSA 83 formed larger complexes in 
comparison to SSA 82 
Comparatively larger aggerates with a 
peak maxima of 410 nm were observed in 
the solution of SSA 83 at 5.56 mM.  
The complexes formed by SSA 82 were 
comparatively more stable as those of 
SSA 83 may be dependent on or be 
disrupted by solvent interactions 
Peak maxima at 0.56 mM decreased to 
212.35 nm for SSA 83, whereas the peak 
maxima of SSA 82 did not significantly 
drop in the DLS experiments.  
Zeta potential for SSA was -30.22 mV, 
which was within the stable range for SSA 
82, whereas the zeta potential for SSA 83 
was - 55.76, which was not. 
Instability of the gels observed in the 
inversion test may have been a result of a 
lack of homogeneity and large amounts of 
sol not being incorporated into the gel 
matrix 
Gel-sol transition points were not 
observed in the majority of rheology 
experiments, suggesting more fluid 
behaviour. 
Multiple types of fibres were observed in 
the same gel.  
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A number of gels appeared to be 
surrounded by large amounts of sol, 
resulting in gel motility and fragility, for 
example, SSA 85 in NaH2PO4.  
Gels were more stable when gel fibres 
were densely packed  
salt solutions that allowed gel strands to 
pack closer together, such as Na2SO4 
exhibited more stable gels in comparison 
to those that did not, such as NaOBz.  
Longer strands had a greater propensity 
to curl, which reduced gel stability 
An increase in the length of strands 
increased the propensity for curled fibres 
and also for stochastic arrangements, 
which may have contributed to instability  
Cross-linking was an integral feature in 
the gel strand formation processes. 
Cross-linked fibres were observed in the 
majority of gel structures.  
Lack of cross-linked fibres may have 
contributed to the reduced stability of the 
SSA 82 gel in the NaNO3solution.  
SSAs 82, 83, and 85 exhibited reduced E. 
coli activity when gelated 
Discernible zones of inhibition were not 
observed with E. coli.  
SSAs 82 and 83 exhibited improved E. 
coli activity in solution 
SSAs 82 and 83 produced higher MIC50 
values in comparison to SSA 70 against 
E. coli.  
Improved E. coli activity may be achieved 
through the use of the extended alkyl 
SSA 83 produced the lowest MIC50 value 
against E. coli (1.16 mM).  
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chain (n=3) in SSA 83 and through further 
optimisation of SSA 84 to improve 
stability. 
SSA 84 decreased E. coli growth by 
86.42%, which was the highest 
percentage observed with E. coli.  
SSA 83 was the most effective against 
MRSA in this group of molecules 
SSA 83 produced the lowest MIC50 value 
(0.59 mM) against MRSA.  
SSA 83 produced the largest zones of 
inhibition which were statistically 
significantly higher than those of SSA 70 
and 82. 
The CH3 associated with the aromatic ring 
contributed to the antimicrobial activity of 
SSA 70 against MRSA, and its removal 
(SSA 85) decreased antimicrobial activity 
against MRSA. 
The MIC50 obtained for SSA 85 against 
MRSA was 1.14 mM, which was higher 
than that of SSA 70.  
A zone of inhibition was not observed for 
SSA 85 against MRSA.  
Summary  
The data presented within this chapter presents evidence for the optimisation of 
antimicrobial molecules through the use of stepwise modifications. The structure-activity 
relationships obtained in Chapter 3 were utilised to produce SSAs 82 – 85. While the 
gelation properties were comparatively weaker than those of SSA 70, SSAs 82 and 83 
exhibited improved antimicrobial efficacy against MRSA.155 Furthermore, SSA 83 was 
created in order to improve E. coli activity. While the activity of SSA 83 decreased when 
gelated, its activity in solution significantly increased in comparison to SSA 83.155 This 
provided further evidence for the hypothesis that increasing the alkyl chain could improve 
E. coli activity.  
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The physicochemical analysis conducted on SSA 82 and 83 provided insight into the 
behaviour of these molecules and allowed for the refinement of prior hypotheses. For 
example, the cyclisation predicted through the computational models was not observed in 
experimental data, highlighting a limitation of the computational approaches and a 
requirement for further improvement to these methods. Additionally, lower CMCs have 
been previously hypothesised to correlate with higher antimicrobial activity, however SSA 
83 produced a higher CMC (14.77 mM) but exhibited higher antimicrobial efficacy in 
comparison to SSA 82 (CMC = 1.92 mM). This information can be utilised to further 
understand and optimise these molecules, and form more accurate hypotheses.  
The microscopy data revealed characteristic features of resulting gels for each molecule, 
however the salt solution present could drastically alter the gelation process and 
properties of the resulting gel. A deeper investigation into the interactions between the sol 
components and the gelators is required in order to further understand the gelation 
processes of these SSAs. This will allow for the manipulation of gels so that they exhibit 
desired properties, which can then be utilised in a wide range of applications. 
In conclusion, stepwise optimisation of the most effective SSAs presented in Chapter 3 
resulted in the formation of SSAs that exhibited the desired improved antimicrobial 
efficacy. Further, the physicochemical and gelation analysis conducted on SSAs 82 – 85 
provided an insight into the properties of these molecules, allowing for future optimisation 
and manipulation of desired properties. 
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membrane-related proteins 
5.1. Introduction 
Membranes contain a variety of lipids, to separate the internal contents of cells from the 
external environment, and define the functionally distinct compartments within the cell.249 
Many essential cell processes are reliant on membrane interactions with specific proteins, 
including cell-cell communication, endo/exocytosis, and regulation of the cytoskeleton. 
Furthermore, membrane lipids are also thought to regulate functional activity and induce 
oligomerisation of many proteins.118 Many of these interactions are not yet fully 
understood. Membrane-binding proteins tend to be soluble and unstructured when 
cytosolic, however, upon interactions with membrane lipids, they undergo structural 
changes that are integral to their physiological function.249 Characterisation of the lipid-
protein interactions, and related conformational changes, is necessary for the 
determination of protein function. Further, a detailed investigation of specific interactions 
and protein function is imperative as misfolding or misregulation of these proteins can 
result in impaired binding and disease states.249 An example of this can be observed with 
alpha synuclein.  
Alpha synuclein (α-syn) is an aggregation-prone protein that is predominantly expressed 
in neuronal cells, preferentially found to localise to presynaptic terminals.250,251 While the 
precise cellular function is unknown, α-syn is thought to regulate vesicle turnover at 
synaptic termini and thereby negatively control neurotransmitter release.55,100 Aggregation 
of α-syn has been linked to a group of neurodegenerative diseases called 
synucleopathies, such as Parkinson’s disease.98,100,250–252 When cytosolic, α-syn is largely 
unstructured, however, upon interactions with certain lipid surfaces α-syn has been seen 
to adopt an alpha-helical structure.98,100,250–252 
Eukaryotic cells possess up to six different amino-alpha-transferase complexes, called 
NAT A-F which conjugate acetyl groups onto the amino terminals of proteins. This 
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process is known as Nt-acetylation and has many implications on protein structure, 
function, and stability.98,100 As mentioned previously, post-translational modifications, 
such as acetylation, are utilised in protein activity regulation. In the case of alpha-
Synuclein, Nt-acetylation is thought to stabilise alpha-helical structure formation and 
modulate its subsequent membrane interactions.98,100  
Thus, a detailed investigation into the specific lipid interactions and the impact Nt-
acetylation on these activities will provide clarity on α-syn function and may allow for the 
prevention or treatment of disease states.  
5.1.1. Aim of studies 
We sought to determine the impact of Nt-acetylation on the membrane binding properties 
of α-Syn, to ascertain an understanding of its physiological function and regulation.   
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5.2. Recombinant protein synthesis and purification 
Amino-terminal (Nt) acetylation of alpha synuclein is thought to regulate the stability of its 
alpha-helical structure, oligomerisation, and subsequent membrane interactions.98 While 
Nt- acetylation occurs in bacteria, this is infrequent due to their lack of the NAT 
complexes required for acetylation. Researchers tend to use eukaryotic expression 
systems or post-purification acetylation reactions to generate acetylated recombinant 
proteins, which tend to be expensive and time consuming.98 Consequently, Johnson et al. 
2010 developed a novel method of creating Nt-acetylated recombinant proteins in 
bacterial expression systems, which were used in the production of acetylated proteins 
within this project.98,253  
In an effort to understand the membrane binding capabilities of α-syn, we generated a 
plasmid coding for the first 38 amino acids from the N-terminus, which encompassed the 
hypothesised membrane binding domain. The resulting protein was also called the 
vesicle nucleating protein (VNp). VNp was tagged with the fluorescent protein, 
mNeonGreen (mNg), as well as 6 x histidine residues, to facilitate affinity chromatography 
purification using nickel resin.254 We also produced the full length alpha synuclein protein, 
which contained a histidine tag and a mCerulean tag (mCer3).255 The resulting proteins 
were termed either acetylated or unacetylated α-syn-mCer3, depending on the presence 
of amino-terminal modification.  
Wild type α-syn-mCer3 and VNp-mNg proteins were expressed using BL21 DE3 
competent cells co-expressing the fission yeast pNatB complex with a chloramphenicol 
selection marker, resulted in the production of Nt-acetylated isoforms. Successful protein 
expression and purification were verified using SDS PAGE and mass spectroscopy. After 
purification of the acetylated VNp-mNg protein, a clear strong band was present on the 
SDS PAGE gel between 85 – 100 kDa, which persisted throughout purification processes 
(Figure 107A). This band was hypothesised to be a result of VNp-mNg oligomerisation, 
which would create larger protein complexes and result in the higher band observed on 
the SDS PAGE gel. This was further investigated using western blot analysis, conducted 
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by Dr. Tara Eastwood, to confirm whether the second band was indeed oligomeric VNp-
mNg. The western blot profile conducted on both acetylated and unacetylated VNp-mNg 
confirmed multiple α-syn species present when the protein was acetylated (Figure 107B) 





Figure 107. SDS PAGE gel showing the expression and purification of VNp-mNg.  
(A) SDS-PAGE gel showing the expression and purification of unacetylated VNp-mNg: 
(i) pre induction, (ii) post induction, (iii) pre purification, (iv) post-purification, and 
acetylated VNp-mNg: (v) pre induction, (vi) post-induction, (vii) pre-purification, (viii) 
post purification. (B) Anti-His western blot of (i) unacetylated VNp-mNg and (ii) 
acetylated VNp-mNg. L = protein molecular weight marker, * - hypothesised oligomer 
formation band, ** - protein at ~ 32.3 kDa. 
In contrast, only one band was detected for unacetylated VNp-mNg, consistent with the 
SDS PAGE gel. This suggested acetylation involvement in oligomerisation of VNp-mNg. 
acetylated and unacetylated α-syn-mCer3 were also expressed and purified (Figure 
108A), and oligomer formation may also have been taking place with the acetylated 
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Figure 108. SDS PAGE gel showing the expression and purification α-syn-mCer3.  
(A) expression of α-syn-mCer3: (i) pre-induction unacetylated α-syn, (ii) post-induction 
unacetylated α-syn-mCer3, (iii) pre-induction acetylated α-syn-mCer3, (iv) post-
induction acetylated α-syn-mCer3. (B) Purified protein. (i) unacetylated α-syn-mCer3 
(ii) acetylated α-syn-mCer3. L = protein molecular weight markers; * - protein at ~ 42.6 
kDa, ** - oligomer formation.  
5.3. Fluorescence anisotropy 
It was important to select an appropriate membrane binding assay that would allow the 
observation of specific lipid interactions. As such, liposomes were created using the 
following lipids, as described in section 2.6.1 of the materials and methods: POPA, 
POPC, POPG, and E. coli total and polar lipids. Further, a 1:3 molar ratio was made up 
using POPG: DPPE lipids respectively, which will be called PG: PE from this point 
forward. 
The fusion of mNeongreen and mCerulean reporter proteins to VNp-mNg and α-syn-
mCer3 respectively allowed fluorescence-based assays to be employed. An example of 
this is fluorescence anisotropy, which was utilised for an initial examination of the specific 
lipid interactions.  
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As described previously, fluorescence anisotropy is a measure of the changing 
orientation of a fluorescent molecule in space through the use of fluorescence absorption 
and emission events. Changes in the shape and size of a fluorescent molecule result in 
changes in anisotropy, as the size of bound molecules is larger than the size of the free 
molecules in solution. Thus, fluorescence anisotropy measurements provide a way of 
monitoring binding events, as fluorescence anisotropy can detect the changes in mass 
between the free and bound states.150,192,193190 Determining and varying the concentration 
of proteins was more easily achievable in comparison to liposomes. Therefore, anisotropy 
experiments were conducted using a constant liposome concentration (1 mM) and 
varying fluorescent protein concentrations, as described in section 2.6.3 of the materials 
and methods.  
The anisotropy values are a measure of the sum of individual anisotropies in solution, 
bound and unbound, and an increase in fluorescent protein concentration will result in a 
higher number of molecules in solution and therefore increased anisotropy 
values.150,192,193 As such, anisotropy values of unbound protein were obtained and 
subtracted from anisotropy values with lipid present. This would remove the anisotropy 
values that were solely due to increased protein concentration and differences observed 
would be a result of binding activities (Figure 109). GraphPad Prism 9 software was used 
for subsequent data analysis.  
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Figure 109. Background 
anisotropy curve.  
Anisotropy values of unbound 
unacetylated and acetylated α-
syn-mCer3 were subtracted from 
anisotropy values in the 
presence of liposomes to 
determine binding activities. 
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The graphs presented below represent the change in anisotropy when the liposomes 
were present compared to the anisotropy of the protein alone. As the protein 
concentration increased, the signal became more saturated, and the differences in 
anisotropy between the protein alone and liposome-protein solutions became less 
distinguishable. Thus, the anisotropy values at higher concentrations were similar to 
those of the protein alone differences were predominantly observed at lower 
concentrations. 
The largest change was observed when unacetylated α-syn-mCer3 was in the presence 
of POPA. Anisotropy values started off significantly higher at low concentrations in 
comparison to the protein alone (Figure 110).  



























Figure 110. Unacetylated α-syn-mCer3 change in anisotropy curves.  
Graph showing the change in anisotropy of unacetylated α-syn-mCer3 in the presence of 
POPA, POPC, E. coli polar and E. coli total lipids. Data points recorded are an average of 
three independent experiments and error bars represent the standard error of the mean 
(s.e.m). 
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The decrease observed with increasing protein concentration was far more gradual in 
comparison to POPC and E. coli total and polar lipids, which suggested a higher affinity 
to POPA in comparison to the other lipids. When POPC was present, two distinct phases 
were observed: a sudden initial decrease was observed, followed by a slower, more 
gradual decrease. Similarly, when E. coli total and E. coli polar lipids were present, an 
initial faster decrease in anisotropy was observed. However, the second more gradual 
phase occurred more rapidly in comparison to when POPC and POPA were present. This 
data suggests a lower affinity of unacetylated α-syn-mCer3 to POPC than with POPA, 
and a lower affinity to E. coli total and polar lipids than with POPC and POPA. 
Additionally, the presence of two phases may suggest multiple binding events occurring, 
however further investigation would be required to determine a definitive reason for these 
two phases. Similarly, α-syn-mCer3 in the presence of POPA produced significantly 




























Figure 111. Acetylated α-syn-mCer3 anisotropy binding curves. 
Graph showing the change in anisotropy of acetylated α-syn-mCer3 in the presence of 
POPA and POPC. Data points recorded are an average of three independent 
experiments and error bars represent the standard error of the mean (s.e.m). 
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Further, while initially there were higher anisotropy values were observed at lower 
concentrations in the presence of POPC, at concentrations above 100 ug/mL they were 
the same as the protein alone. This could suggest weaker interactions in comparison to 
those observed when POPA was present, as the anisotropy did not change to the same 
extent as when POPA was present, similar to the unacetylated protein.  
Anisotropy values were seen to decrease below those of the protein controls in the 
presence of some liposomes, which resulted in a negative change in anisotropy. This was 
observed when acetylated α-Syn was in the presence of POPG, E. coli total and E. coli 




















































Figure 112. Acetylated α-syn-mCer3 anisotropy binding curves. 
Graph showing the change in anisotropy of acetylated α-syn-mCer3 in the presence of 
(A) POPG and (B) E. coli total and E. coli polar lipids. Data points recorded are an 
average of three independent experiments and error bars represent the standard error of 
the mean (s.e.m). 
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For all three lipids, an initial decrease was observed at lower concentrations of protein, 
which was below that of the protein alone. Anisotropy values then followed a similar 
pattern as the other lipids after this initial decrease. This was also observed when both 


























Figure 113. Acetylated α-syn-mCer3 Anisotropy binding curves.  
Graph showing anisotropy curves of acetylated and unacetylated α-syn-mCer3 alone 
and in the presence of a 1:1 PG:PE mix. Data points recorded are an average of 3 
independent experiments and error bars represent the standard error of the mean. 
While initially, increased anisotropy values were observed, as the concentration 
increased, the anisotropy values decreased below those of the proteins alone. This was 
further observed when unacetylated α-Syn was added to POPG. However, in this case a 
significant decrease in anisotropy was observed at lower concentrations of protein, which 
then increased rapidly with increasing concentration of protein and then gradually 
decreased. (Figure 114). 
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Figure 114. Anisotropy binding curves. 
The change in anisotropy observed when unacetylated α-syn-mCer3 was added to 
POPG. Data points recorded are an average of 3 independent experiments and error 
bars represent the standard error of the mean.  
The deceasing anisotropy values could indicate a change in the shape of either the 
proteins or the lipids upon interacting with one another. As previously mentioned, α-syn-
mCer3 has been observed adopting an α-helical structure when interacting with anionic 
phospholipids, such as PG and CL, both of which are also present in the E. coli total and 
polar lipid mixes. Therefore, it was hypothesised that the decrease in anisotropy values 
may be attributed to an initial conformational change in the presence of POPG, polar, and 
total lipids. The subsequent increase observed with some of lipids, such as was seen with 
unacetylated α-Syn and POPG, may suggest secondary binding activities. However, 
further investigation would be required to clarify these observations. 
A comparison of Figures 110 – 114 revealed reduced changed in anisotropy when 
acetylated α-syn-mCer3 was present in comparison to unacetylated α-Syn. This may 
suggest reduced binding activities when acetylated α-syn-mCer3 was present, which 
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The binding activities of acetylated and unacetylated VNp-mNg were next investigated 
using fluorescence anisotropy experiments in the presence of POPC, POPG, and E. coli 
total and polar lipids. Comparisons of unacetylated VNp-mNg in the presence of either 
POPG or POPC revealed a higher affinity for POPG in comparison to POPC, as a 
significantly larger increase in anisotropy was observed with POPG than with POPC 





Figure 115. VNp-mNg anisotropy binding curves  
Graph showing the change in anisotropy of (A) unacetylated and (B) acetylated VNp-
mNg in the presence of POPC and POPG. Data points recorded are an average of 3 
independent experiments and error bars represent the standard error of the mean 
(s.e.m). 
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Examination of the binding curves supports this, as anisotropy values were seen to 
drastically increase at lower protein concentrations when POPG was present. While an 
increase in anisotropy was observed with POPC, this was less than the increase 
observed in the presence of POPG. Similarly, acetylated VNp-mNg appeared to have a 
higher affinity for POPG than POPC, as significantly larger increases in anisotropy were 
observed (Figure 115B). A comparison of Figures 115A and 115B would suggest 
unacetylated VNp-mNg had a lower affinity for POPC in comparison to acetylated VNp-
mNg. However, a larger variation in acetylated VNp-mNg anisotropy values was 
observed and therefore overall affinity for POPC may be similar for both proteins.  
Aisotropy values that were lower than the protein alone were also observed with both 
VNp-mNg proteins in the presence of E. coli total lipids and when unacetylated VNp-mNg 
was in the presence of E. coli polar lipids (Figure 116). When unacetylated VNp-mNg was 
added to either E. coli polar or total lipids, anisotropy values at lower concentrations were 
seen to decrease below those of the protein alone with increasing protein concentration. 
Similarly, when acetylated VNp-mNg was added to E. coli polar lipids, an initial increase 
was observed, which was then followed by a decrease below the anisotropy values of the 
protein alone. As before, this was hypothesised to be either due to an initial 
conformational change in the protein, a change in shape or breakdown of the liposomes 
or a lack of binding. The binding activities observed with E. coli total and polar lipids 
between the α-Syn -mCer3 and VNp-mNg proteins appeared to differ, especially in the 
case of the unacetylated isoforms. This prompted the utilization of other binding assays to 
further characterise any interactions observed. Furthermore, while comparative affinities 
can be obtained by anisotropy, further analysis into the individual interactions was 

























































Figure 116. Anisotropy binding curves. 
The change in anisotropy was observed for (A) unacetylated VNp-mNg and (B) 
acetylated VNp-mNg in the presence of E. coli total and polar lipids. Data points recorded 
are an average of 3 independent experiments and error bars represent the standard error 
of the mean (s.e.m). 
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5.4. Melting temperature 
Following the anisotropy results, we sought to verify the binding activities exhibited by α-
syn-mCer3 and further define the specific lipid interactions of α-syn. We, therefore, 
adapted the methodology presented by Hattori et al., 2012 and Nji et al., 2018 to perform 
thermal shift assays on acetylated and unacetylated α-syn-mCer3.27,118 Thermal shift 
assays involve heating a fluorescently tagged protein at a range of temperatures in the 
presence and absence of liposomes, then comparing thermal denaturation to determine 
whether binding activities are taking place. The thermal shift assay is described in section 
2.6.5 of the materials and methods. Briefly, mNeongreen and mCerulean fused proteins 
were incubated in the presence or absence of liposomes and with the non-ionic detergent 
octyl-Beta-D-glucoside (β-OG), as heat-induced aggregates precipitate with this 
detergent. Protein samples were then heated over a range of different temperatures and 
any resulting aggregates were sedimented by centrifugation. The fluorescence intensity 
of the supernatant was then recorded using a plate reader. As temperature increases, 
protein denaturation increases thereby decreasing the fluorescence intensity of the 
fluorescent tag. By plotting the fluorescence intensity against temperature, an apparent 
melting temperature (Tm) can be calculated. Increased thermostability of protein in the 
presence of lipid compared to the absence of lipid would indicate binding, thus a higher 
Tm would be observed.27,118  
In order to determine whether the melting temperatures were statistically significantly 
different from one another, a between-groups ANOVA was performed. As the Levene's F 
test revealed that the homogeneity of variance assumption was not met, shown by p-
values less than .05, Welch's F test was utilised. A series of Games-Howell multiple 
comparisons were performed to verify where the differences were if any. A full analysis is 
provided in the supplementary information. Initially, unacetylated and acetylated α-syn-
mCer3 were heated at temperatures between 4°C and 100°C, then average fluorescence 
values were normalised and fitted to a sigmoidal curve and the Tm was calculated, as 
shown in Figure 117A.  
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Figure 117.  Melting curves of unacetylated α-syn-mCer3 alone. 
(A) Initial melting curve used to determine the final temperature range. (B) final graph 
showing the temperature range used in melting temperature calculations. Average 
fluorescence values plotted are an average of three independent experiments. 
From these initial melting curves, the optimal temperature range for analysis of the α-Syn 
-mCer3 proteins was determined to be between 60°C and 100°C. Following this, protein 
samples in the presence and absence of liposomes were heated at temperatures within 
that range and the individual melting temperatures were calculated, as demonstrated in 
Figure 117B. The final Tm values are reported in Table 26; each Tm reported uses 
average fluorescence intensity values from three independent experiments (mean ± SD). 
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The p-values obtained from the Games-Howell multiple comparisons post hoc test are 
recorded in Table 27.  
Table 25. Thermal shift assay.  
Melting temperatures calculated for unacetylated and acetylated α-Syn-mCer3 alone and 
in the presence of CL (cardiolipin), POPA, a 1:3 mix of PG:PE respectively, and E. coli 
total and polar lipids.  a – unable to calculate a melting temperature. Standard deviation 
(SD) is used as the error value. 









79.18 ± 0.48 77.86 ± 0.84 
CL a a 
POPA 82.16 ± 0.36* 82.48 ± 0.27* 
PG:PE Mix a a 
Polar lipids 79.46 ± 0.68** 77.59 ± 0.94** 
Total lipids 81.75 ± 0.16* 81.80 ± 0.58* 
*p <.05, **p >.05 in comparison to the respective protein alone  
Table 26. Statistical analysis summary Table.  
Summary of the Games-Howell posthoc test conducted on the melting temperatures of α-
Syn-mCer3; p-values reported are a comparison to the protein alone. a – unable to 
calculate a melting temperature. 
Games-Howell multiple comparisons posthoc summary 
 Unacetylated α-Syn-mCer3 Acetylated α-Syn-mCer3 
CL a a 
POPA .000 .000 
PC:PE Mix a a 
Polar lipids .966 .998 
Total lipids .000 .000 
Both unacetylated and acetylated α-syn-mCer3 exhibited improved thermostability in the 
presence of POPA and Total lipids. Unacetylated α-syn-mCer3 produced significantly 
higher melting temperatures of 82.16°C and 81.75°C in the presence of POPA and Total 
lipids. Similarly, acetylated α-syn-mCer3 produced higher melting temperatures of 
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82.48°C and 81.80°C respectively, which again were statistically significantly different to 
the protein alone (p = .000 and p = .000 respectively). This improved thermostability 
suggested binding to these lipids. Strikingly, both acetylated and unacetylated α-syn-
mCer3 in the presence of CL and the PC:PE mix appeared to exhibit significantly 
improved thermostability that minimal melting was observed in the presence of these 
lipids, thus no melting temperature could be calculated (Figure 118).  
 
Figure 118. Thermal shift melting curves.  
Melting curves were obtained for unacetylated α-syn-mCer3 alone and in the presence of 
Cardiolipin (CL) and a 1:3 PG:PE molar mix. Data points are an average of three 
independent experiments and standard deviation (SD) is used as the error value. 
These results suggested stronger interactions with CL and the PC:PE mix in comparison 
to the other lipids, and binding activities with these lipids significantly improved 
thermostability, so much that no melting was observed (Figure 118).   
Melting temperatures obtained in the presence of E. coli polar lipids were not statistically 
significantly different for both unacetylated (M = 79.46°C, SD = 0.68, p = .966) and 
acetylated (M = 77.59°C, SD = 0.94, p = .998) α-syn-mCer3 to those obtained for the 
proteins alone.  
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A comparison between the acetylated and unacetylated proteins revealed no difference in 
the binding activities, as both proteins exhibited binding to CL, POPA, PG:PE, and Total 
lipids, and no binding to polar lipids. However, the Tm value obtained for acetylated α-
syn-mCer3 alone (M = 77.86°C, SD = 0.84) was lower than the Tm of unacetylated α-syn-
mCer3 (M = 79.18°C, SD =0.48), which was found to be statistically significant (p = .020). 
Thus, acetylated α-syn-mCer3 appeared to be less stable in comparison to unacetylated 
α-syn-mCer3.  
To further characterise and confirm binding, unacetylated and acetylated VNp-mNg were 
used in thermal shift assays. Similar to the α-syn-mCer3, the optimal temperature range 
was determined by heating protein samples at temperatures between 4°C and 100°C and 
plotting the fluorescence values against the temperature. The melting temperature range 
used was 55 - 80°C, which was expected as the VNp-mNg proteins were smaller in 
comparison to α-syn-mCer3 proteins. We also sought to investigate binding with other 
lipids, in particular, the PG:PE liposomes, to make further comparisons with the 
anisotropy data. Average fluorescence values from three independent experiments were 
used to calculate the Tm which is reported in Table 28 and a summary from the multiple 
comparisons posthoc test using the Games-Howell procedure is reported in Table 29. 
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Table 27. Thermal shift assay.  
Melting temperatures calculated for acetylated and unacetylated VNp-mNg alone and in 
the presence of CL (cardiolipin), POPA, POPC, POPG, a 1:3 mix of PG:PE respectively, 
and E. coli total and polar lipids. Standard deviation (SD) is used as the error value. 




None 65.43 ± 0.31 65.22 ± 0.43 
CL 65.4 ± 0.30** 65.03 ± 0.14** 
POPA 64.94 ± 0.18** 63.92 ± 0.61* 
POPC 65.02 ± 0.29** 64.57 ± 0.33* 
PC:PE Mix 66.84 ± 0.37* 65.68 ± 0.06** 
POPG 65.2 ± 0.17** 64.44 ± 0.42* 
Polar lipids 66.85 ± 0.11* 66.11 ± 0.25* 
Total lipids 64.99 ± 0.60** 65.69 ± 0.57** 
*p <.05, **p >.05 in comparison to the respective protein alone 
Table 28. Statistical analysis summary Table  
Summary of the Games-Howell Posthoc test conducted on the melting temperatures of 
VNp-mNg; p-values reported are a comparison to the protein alone; a – unable to 
calculate a melting temperature. 




CL 1.000 .991 
POPA .057 .007 
POPC .300 .112 
PC:PE Mix .000 .261 
POPG .822 .064 
Polar lipids .000 .007 
Total lipids .814 .802 
Strikingly, the strong binding exhibited by unacetylated α-syn-mCer3 to CL was not 
observed with unacetylated VNp-mNg. In fact, the Tm value obtained for unacetylated 
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VNp-mNg in the presence of CL was not significantly different from the protein alone (p = 
1.000). Similarly, the melting temperature obtained for acetylated VNp-mNg alone was 
not statistically significant to the Tm values obtained in the presence of CL and the 
PC:PE mix. While a less prominent effect was observed with unacetylated VNp-mNg in 
the presence of the PC:PE mix, the melting temperature was obtained was significantly 
higher than that of the protein alone (p = .000). Improved thermostability was observed 
with both acetylated and unacetylated VNp-mNg in the presence of polar lipids, as the 
melting temperature values (66.11°C and 66.85°C respectively) were statistically 
significantly higher than those of the proteins alone (65.22°C and 65.43°C respectively). 
The melting temperatures obtained for acetylated VNp-mNg in the presence of POPA, 
POPC, and POPG (63.92°C, 64.57°C, and 64.44°C respectively) were lower than the 
melting temperature of the protein alone (65.22°C). While numerically higher, the melting 
temperatures obtained with POPC and POPG were not statistically significantly different 
from that of the protein alone. The posthoc tests conducted using values of the protein 
alone and in the presence of POPA revealed that this lower temperature was statistically 
significant (p = .007).  
It was hypothesised that lipid interactions may be induced by dimerisation of α-syn-
mCer3, and VNp-mNg protein solutions may contain a mix of monomers and oligomers, 
resulting in less prominent binding being observed. As such, leucine zipper proteins were 
utilised. Leucine zippers are alpha helical protein-protein interaction domains consisting 
of amphipathic helices that dimerise in parallel and a series of leucine residues spaced 
seven residues apart.256–259 Fusing proteins to leucine zippers provides a means of 
achieving guaranteed dimerisation of desired proteins in solution. Therefore, thermal shift 
assays were conducted using leucine zipper fused VNp-mNg.257,259 This would allow us to 
determine whether dimerisation improved the binding activities of VNp-mNg observed. 
Acetylated and unacetylated isoforms were expressed and purified by Dr. Tara Eastwood 
and subsequent thermal shift assays were conducted by myself. Tabulated Tm values 
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presented in Table 30 are an average calculated from three independent experiments 
and three technical repeats (mean ± SD).  
Table 29. Thermal shift assay. 
Melting temperatures calculated for leucine zipper fused acetylated and unacetylated 
VNp-mNg alone and in the presence of CL (cardiolipin), E. coli polar, and total lipids. 
Standard deviation (SD) is used as the error value. 





None 63.42 ± 1.72 63.67 ± 1.81 
CL 62.87 ± 0.21** 63.31 ± 0.29** 
Polar lipids 64.06 ± 0.31** 64.39 ± 0.22** 
Total lipids 63.75 ± 0.91** 64.42 ± 0.19** 
*p <.05, **p >.05 in comparison to the respective protein alone 
 
The multiple comparisons posthoc test using the Games-Howell procedure revealed that 
while the melting temperatures varied numerically, they did not vary statistically. This 
suggests a lack of lipid binding; however, this would be unusual as binding was observed 
with the full-length protein so that would be expected to translate when observing this 
membrane binding domain’s interactions. If any lipid interactions were taking place, they 
did not impact the thermostability of both acetylated and unacetylated Leucine zipper 
fused-VNp-mNg enough to observe any differences in this assay. Furthermore, this 
suggests the involvement of other domains in lipid interactions within α-syn, as α-syn-
mCer3 exhibited binding.  
5.5. Myosin 1  
Often model organisms are utilised in order to understand biological processes further, as 
a lot of these organisms contain homologs of bacterial genes and proteins and allow for 
the examination of these processes that are difficult to observe in humans.260 One of 
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these model organisms is the nematode Caenorhabditis elegans (C. elegans), often used 
as a simple model organism as they possess homologs of a majority of human genes. In 
particular, C. elegans encode at least 10 unconventional myosins, including the hum-1 
gene, which encodes a C. elegan Myosin 1 homolog. Class 1 myosins are single headed 
motor proteins involved in a variety of membrane related functions, however, their 
specific lipid interactions are not fully characterised.78,81,82,261 C. elegan myosin presents a 
typical class I structure, in that it contains an actin binding motor domain at the amino 
terminal, followed by a neck region and then finally a positively charged tail region, the 
focus of this study.262 Within the tail region is a positively charged polybasic tail homology 
domain (TH1) which contains a pleckstrin homology domain, whose affinity to anionic 
membrane lipids has been documented in literature, however, regulation of these 
interactions is not well understood.82 Phosphorylation, a mechanism employed to regulate 
protein function, is thought to be integral to Myosin 1 function. Potential phosphorylation 
sites have been identified within the TH1 domain and these are thought to be involved in 
regulating lipid interactions.86 And while the TH1 domain has been suggested to cause 
Myosin 1 membrane binding, when phosphorylated and unphosphorylated, its specificity 
and affinity are yet to be fully characterised.  
5.5.2. Aim of studies 
Therefore, as the mechanisms behind lipid binding of myosin 1, in particular, the role of 
the TH1 domain is not well defined, we also sought to understand the specific lipid 
binding activities and the impact of phosphorylation on these binding activities.   
5.5.3. Protein expression  
In an effort to understand the membrane binding affinities of the TH1 domain in Myosin 1 
and the role of phosphorylation in regulating these interactions, a recombinant wild type 
protein and also a phosphorylation mimic were generated from the C. elegans hum-1 
TH1 domain. The phospho-mimic was created by replacing a serine residue (S734) with 
aspartic acid.  After a variety of expression conditions and competent cell strains were 
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tested, it was determined that the use of BL21 PlysS DE3 competent cells significantly 
improved expression (Figure 119).  
 
 
Figure 119. SDS PAGE expression gel. 
Samples from wild type Hum-1 TH1 expression (i) pre-
induction and (ii) post-induction in BL21 PlysS. L = 
protein molecular weight marker * - protein size ~ 23 
kDa. 
PlysS plasmids tend to be used for the expression of toxic genes, as they co-express a 
T7 polymerase inhibitor which reduces the background expression levels of target 
genes.263 Ordinarily, expression of toxic genes in BL21 DE3 competent cells results in the 
selectivity of cells that do not produce the toxic gene, leading to varied, low, or a 
complete lack of protein expression, as was observed.263 This led us to hypothesise that 
the Hum-1 TH1 protein may be toxic to the cells, leading to the complete lack of protein, 
and the use of the plysS plasmid allowed us to overcome this. Reduction of the IPTG 
concentration to 20 µg/ml and the induction temperature to 25°C further improved 
expression, further solidifying the hypothesis. 
5.6. Hum-1 TH1 Purification and Refolding 
The presence of hydrophobic residues within the PH domain of the TH1 protein reduced 
the solubility of the protein.83 Purification under native conditions revealed a lack of 
binding to the nickel resin and the protein that was obtained in the final elutions 
precipitated out of solution (Figure 120A). As such, proteins were purified under 
denaturing conditions, through the use of urea which reversibly denatures and solubilises 
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through the use of a linear urea gradient.264,265 Proteins were successfully purified using 
denatured purification (Figure 120B), however during the dialysis process, the proteins 
were once again observed to precipitated fairly rapidly.  
A B 
       
Figure 120. SDS PAGE purification gels.  
(A) Native purification of Hum-1 TH1 S74D mutant: (i) pre-purification samples, (ii) 
post-purification elutions. (B) Denaturing purification of Hum-1 TH1 S734D: (i) pre-
purification samples, (ii) post-purification elutions. L = protein molecular weight marker 
* - protein size ~ 23 kDa. 
The use of chromatographic procedures, such as sephadex columns, has been 
previously used for the removal of molecules with small molecular weights, such as 
urea.266,267  Sephadex is a gel filtration resin that allows the migration of larger molecules, 
such as proteins, but retains smaller molecules, such as urea, thereby separating them. 
Desalting was carried out as described in section 2.3.17 of the materials and methods, 
however briefly, protein post-purification samples were loaded onto a pre-calibrated 
Sephadex column and 1 mL elutions were taken from the column. Typically, urea would 
be eluted from the column between elutions 4 – 7, whereas the protein should elute in the 
first and second fractions. The use of the desalting column allowed for faster urea 
removal, in the hope that precipitation would not occur. Both the WT and S734 Hum-1 
TH1 proteins were collected in the first 2 fractions (Figure 121), and no protein was 
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Figure 121. SDS PAGE desalting gels.  
Elutions from the Sephadex desalting column of WT 
Hum-1 TH1 protein. Protein was observed in the 
urea fractions only. L = protein molecular weight 
marker * - protein size ~ 23 kDa. 
Although the urea removal appeared to be successful (Figure 121), and proteins 
remained solubilised after the buffer exchange, initial co-sedimentation experiments 
conducted using revealed that the solubility observed with these proteins was short-lived, 
as proteins not only sedimented without lipid present but precipitated rapidly (Figure 122), 
which suggested impaired protein re-folding.  
           
Figure 122. SDS PAGE of co-sedimentation 
experiments.  
SDS-PAGE gel of pellet samples from initial 
co-sedimentation experiments: (i) S734D 
mutant alone, (ii) S734D mutant with PE lipid, 
(iii) Blank, (iv) WT protein and PE lipid, (v) WT 
protein alone. L = protein molecular weight 
marker; * - protein size ~ 23 kDa. 
Consequently, the Hum-1 TH1 proteins were fused with reporter protein mNeonGreen 
resulting in a protein ~51 kDa in size. This drastically improved solubility, and though 
overall protein yield was reduced due to the protein sedimentation pre-purification, 
successful purification under native conditions was achieved with the solubilised protein 
(Figure 123).  
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Figure 123. Hum-1 TH1-mNg SDS PAGE gels.  
(A) WT Hum-1 TH1-mNg expression; (i) pre induction; (ii) post induction samples and 
S734D Hum-1 TH1 expression (iii) pre induction and (iv) post induction samples. (B) 
purified WT Hum-1 TH1-mNg. L = protein molecular weight marker; * - protein size ~ 
51 kDa. 
5.7. Hum-1 TH1 lipid binding 
PIP strip arrays are nitrocellulose membranes with phospholipids noncovalently attached 
to the surface, which allow the lipid binding specificity of proteins to be observed even 
with low protein concentrations.112,268 As the overall protein expression was low, these 
provided an opportunity to observe any differences in the lipid binding properties between 
the wild type TH1 and the S734D mutant. PIP strip analysis was conducted as described 
in section 2.3.19 of the materials and methods, Briefly, proteins were incubated with PIP 
strips, allowing the proteins to bind to the phospholipids, then unbound protein was 
washed off and western blot procedures were used for detecting bound protein, which 
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1. Lysophosphatidic acid  
2. Lysophosphatidylcholine  
3. Phosphatidylinositol (PtdIns) 
4. PtdIns (3)P 
5. PtdIns (4)P 
6. PtdIns (5)P 
7. Phosphatidylethanolamine 
8. Phosphatidylcholine 
9. Sphingosine 1-phosphate 
10. PtdIns (3,4) P2 
11. PtdIns (3,5) P2 
12. PtdIns (4,5) P2 
13. PtdIns (3,4,5) P3 







Figure 124. PIP Strip binding assay.  
(A) Pip strip layout.112,268 (B) PIP Strip conducted using WT Hum-1 TH1-mNg (C) PIP 
Strip conducted using Hum-1 TH1 S734D-mNg.  
Similar binding was observed with both WT TH1 and the S734D mutant to PtdIns(3)P, 
PtdIns(4)P, and PtdIns(5)P. Interactions with these lipids by both Hum-1 isoforms 
suggested that phosphorylation did not impact binding to these lipids under these 
experimental conditions. While both proteins bound to PtdIns(3,5)P2 and PtdIns(4,5)P2, 
TH1 S734 exhibited stronger binding both lipids, indicated by the stronger detection. 
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observed WT TH1. Furthermore, there appeared to be weak binding of S734D TH1 to 
PtdIns(3,4,5)P3. Stronger phosphatidic acid binding was observed with S734D TH1, 
which suggested phosphorylation-based regulation to this specific lipid, thus may impact 
specific processes within the cell.  
Following these results, we sought to use liposomes to further characterise binding to 
these lipids, and confirm the results observed with the PIP strip experiments. 
Sedimentation assays had previously been shown to be ineffective with the TH1 proteins, 
as the proteins readily sedimented regardless of the presence of liposomes. Therefore, 
co-sedimentation assays under a density gradient were conducted, using the 
fluorescence of mNeonGreen to detect the presence of the protein and the addition of 
FM4-64 after centrifugation to detect the presence of the liposomes. Due to time 
constraints, only the WT TH1 was used in the following assay, thus only a confirmation of 
the binding observed in the above PIP strip could be conducted and a comparison could 
not be obtained using this assay. Co-sedimentation assays were carried out as described 
in section 2.6.2 of the materials and methods, briefly WT TH1 mNeongreen protein the 
presence and absence of liposomes underwent sucrose density centrifugation, with two 
repeats of each condition. Following this, three fractions were obtained (top, middle, and 
bottom) and the protein fluorescence in each fraction was determined by the 
mNeongreen fluorescence values obtained using a fluorescence detecting plate reader. 
FM4-64 was then added to each fraction, allowed to mix, and bind, then FM4-64 
fluorescence was used to detect the presence of liposomes in each fraction. The average 
fluorescence intensity was calculated using the values from each repeat and a graphical 
representation of the fluorescence values is shown in Figure 125. 
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Figure 125. Average fluorescence intensity values obtained from the density 
gradient co-sedimentation assay.  
PC – phosphatidylcholine, PG – phosphatidylglycerol, PA – phosphatidic acid, W – WT 
Hum-1 TH1, (1) – fraction 1, (2) – fraction 2, (3) – fraction 3. n = 2 for all groups. 
Standard deviation (SD) was used as the error value.  
A series of multiple comparisons were performed using Games-Howell’s posthoc test in 
order to determine whether the fluorescence values were equal to each other. A detailed 
description of the statistical analysis performed is provided in the supplementary 
information, however, a summary of relevant comparisons is reported in tables - below. 
 An initial comparison between the fractions obtained for the negative control (protein with 
no lipid present) reveals no statistically significant difference in the FM4-64 and 
mNeongreen fluorescence values (Table 31). This suggested an even distribution of 
protein between fractions for the controls, and no significant difference in FM4-64 
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Table 30. Summary of statistical analysis for the negative controls.  
Summary Table using p-values obtained from the Games-Howell multiple comparisons 
posthoc test conducted from the on FM4-64 and mNg fluorescence values obtained for 
each fraction of WT Hum-1 TH1 protein alone; p-values reported. mNg – mNeongreen 
fluorescence, (1) – fraction 1, (2) – fraction 2, (3) – fraction 3.  














FM4-64 (1) - 1.000 .987    
FM4-64 (2) 1.000 - .701    
mNg (1)    - .448 .314 
mNg (2)    .448 - .785 
p > .05 – no statistically significant difference, p < .05 – statistically significant difference. 
As shown in Table 32 below, any differences in FM4-64 fluorescence values obtained in 
the presence of PC between fractions 1 and 2 (p = .999), 1 and 3 (p = .731), and 2 and 3 
(p = 1.000) were not statistically significantly different from one another. This indicated an 
even distribution of lipid. 
Table 31. Statistical analysis comparing mean FM4-64 fluorescence values. 
Summary Table using p-values obtained from the Games-Howell’s multiple comparisons 
posthoc test conducted on FM4-64 fluorescence values obtained for each fraction of WT 
Hum-1 TH1 protein in the presence of PC (phosphatidylcholine), n = 2 for each group. (1) 
– fraction 1, (2) – fraction 2, (3) – fraction 3; p-values reported. 
Games-Howell’s Posthoc Test Summary 
  PC (1) PC (2) PC (3) 
PC (1)  - .999 .731 
PC (2) .999  - 1.000 
p > .05 – no statistically significant difference 
p < .05 – statistically significant difference. 
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However, the protein was observed predominantly in the second and third fractions. The 
mNeongreen fluorescence values obtained from the first fraction (Table 33) were 
statistically significantly lower than those of fraction 3 (p = .023), whereas no statistically 
significant difference was observed with fraction 2 in comparison to fractions 1 (p = .337) 
and 3 (p= .561).  
Table 32.  Statistical analysis comparing mean mNg fluorescence values. 
Summary Table using p-values obtained from the Games-Howell’s multiple comparisons 
posthoc test conducted on mNg fluorescence values obtained for each fraction of WT 
Hum-1 TH1 protein in the presence of PC (phosphatidylcholine), n = 2 for each group. (1) 
– fraction 1, (2) – fraction 2, (3) – fraction 3. 
Games-Howell’s Posthoc Test Summary 
  PC (1) PC (2) PC (3) 
PC (1) - .337 .023 
PC (2) .337 - .561 
p < .05 – statistically significant difference. 
p > .05 – no statistically significant difference 
This suggested an increasing protein concentration from factions 1 – 3. Furthermore, as 
the lipid remained evenly dispersed but the protein sedimented, this indicated low binding 
to PC lipids, consistent with the PIP strip results. 
Conversely, both PG lipids and WT TH1 were predominantly located in the third fraction 
together. The FM4-64 fluorescence intensity values obtained in the third fractions were 
found to be statistically significantly higher than those of fractions 1 (p = .000) and fraction 
2 (p= .000) (Table 34). This suggested sedimentation of PG lipids, as the sedimentation 
of PG lipids was not observed with PC lipids. When mNeongreen fluorescence values 
were compared (Table 35), lower fluorescence values were obtained for fraction 1, which 
was found to be statistically significantly different from fraction 2 (p = .045) and fraction 3 
(p = .047).  
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Table 33. Statistical analysis comparing mean FM4-64 fluorescence values. 
Summary Table of the Games-Howell’s multiple comparisons posthoc test conducted on 
FM4-64 fluorescence values obtained for each fraction of WT Hum-1 TH1 protein in the 
presence of PG (phosphatidylglycerol), n = 2 for each group. (1) – fraction 1, (2) – fraction 
2, (3) – fraction 3. 
Games-Howell’s Posthoc Test Summary  
PG (1) PG (2) PG (3) 
PG (1) - .143 .000 
PG (2) .143 - .000 
p < .05 – statistically significant difference. 
p > .05 – no statistically significant difference 
 
Table 34. Statistical analysis comparing mean mNg fluorescence values. 
Summary Table using p-values obtained from the Games-Howell’s multiple comparison 
posthoc test conducted on mNeongreen fluorescence values obtained for each fraction of 
WT Hum-1 TH1 protein in the presence of PG (phosphatidylglycerol), n = 2 for each 
group. (1) – fraction 1, (2) – fraction 2, (3) – fraction 3. 
Games-Howell’s Posthoc Test Summary  
PG (1) PG (2) PG (3) 
PG (1) - .045 .047 
PG (2) .045 - .131 
p < .05 – statistically significant difference. 
p > .05 – no statistically significant difference 
However, while fluorescence values obtained for fraction 3 were higher than those of 
fraction 2, no statistical difference was observed between them (p = .131) This suggested 
predominant distribution of protein in fractions 2 and 3, which also indicated protein 
sedimentation. As lipid and protein appeared to sediment together, this suggested 
binding of PG lipids to WT Hum1 TH1. 
The FM4-64 fluorescence values obtained in the presence of PA lipids suggested 
predominant localisation in fraction 3. The multiple comparisons posthoc test revealed no 
250 
|Chapter 5: Exploring the lipid binding properties of membrane-related proteins 
 
statistically significant difference when compared to fraction 1 (p = .334) and fraction 2 (p 
= .343), as seen in Table 36.  
Table 35.  Statistical analysis comparing mean FM4-64 fluorescence values.  
Summary Table using p-values obtained from the Games-Howell’s multiple comparisons 
posthoc test conducted on FM4-64 fluorescence values obtained for each fraction of WT 
Hum-1 TH1 protein in the presence of PA (phosphatidic acid), n = 2 for each group. (1) – 
fraction 1, (2) – fraction 2, (3) – fraction 3. 
Games-Howell’s Posthoc Test Summary  
PA (1) PA (2) PA (3) 
PA (1) - .029 .334 
PA (2) .029 - .343 
p < .05 – statistically significant difference. 
p > .05 – no statistically significant difference 
This is more likely due to the large variation observed; thus no solid conclusion can be 
made from this value. An increase in FM4-64 fluorescence values obtained in fraction 2, 
which was found to be statistically significantly different from those of fraction 1 (p = 
.029). This suggested the lipid was most likely located in fractions 2 and 3. When 
mNeongreen fluorescence values were examined, no statistically significant difference 
was observed between the fluorescence values obtained (Table 37), despite higher 
fluorescence values being obtained in fractions 2 and 3.  
Table 36.  Statistical analysis comparing mean mNg fluorescence values. 
Summary Table using p-values obtained from the Games-Howell’s multiple comparisons 
posthoc test conducted on mNg fluorescence values obtained for each fraction of WT 
Hum-1 TH1 protein in the presence of PA (phosphatidic acid), n = 2 for each group. (1) – 
fraction 1, (2) – fraction 2, (3) – fraction 3. 
Games-Howell’s Posthoc Test Summary  
PA (1) PA (2) PA (3) 
PA (1) - .111 .062 
PA (2) .111 - .076 
p < .05 – statistically significant difference. 
p > .05 – no statistically significant difference 
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Therefore, no solid conclusion could be made from these data, as these results from the 
multiple comparisons posthoc test were most likely a result of the large variation 
observed. An additional repeat may reduce the variation observed with these data. 
A comparison of the PIP strip results and the density gradient co-sedimentation assay 
highlights the need for multiple lipid binding assays to gain a clearer picture of the protein 
binding properties. While the results with PC lipids were consistent in that minimal binding 
was observed in both assays, notably, while PG is not present on the PIP strip. However, 
a comparison could be made with the other anionic lipids present on the PIP strip, which 
were PI, PtdIns(4)P, PtdIns(4,5)P2, and PtdIns(3,4,5)P3, PS. These lipids contain 1, 3, 5, 
7, and 1 net negative charges, respectively. From the PIP strip results, out of the anionic 
lipids, stronger binding of S734D, as suggested by the darker spots, was observed with 
PtdIns(4,5)P2, which carried a net negative charge of -5. Phosphatidic acid (PA) carries a 
net negative charge of -2, and stronger binding was observed with S compared to the 
wild type. However, despite carrying a negative charge of -7, PtdIns(3,4,5)P3 showed less 
binding in comparison to the other lipids, indicating lipid binding was not solely due to 
charge interactions. This was further observed with the binding of PtdIns(3,4)P2, 
PtdIns(3)P, PtdIns(4)P, and PtdIns(5)P exhibited by both wild type and S734 TH1, 
despite holding weaker negative charges. Thus, while the density gradient co-
sedimentation assay provided additional lipid binding information, further binding 
experiments would need to be carried out in order to confirm the binding properties of 
Hum-1 TH1.  
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Oligomerisation was observed 
with acetylated α-syn-mCer3 but 
not unacetylated α-syn-mCer3. 
Two clear strong bands were observed for 
both acetylated VNp-mNg and α-syn-mCer3; 
one at the expected protein size and another 
at ~85-100 kDa on both SDS PAGE gels and 
western blots.  
A single band at the expected protein size 
was observed with unacetylated isoforms. 
Unacetylated α-syn-mCer3 
exhibited higher lipid binding 
affinities than acetylated α-syn-
mCer3, therefore acetylation 
may reduce lipid interactions. 
Larger increases in anisotropy were 
observed with unacetylated α-syn-mCer3 in 
comparison to the acetylated isoform.  
Decreasing anisotropy values were observed 
predominantly with acetylated α-syn-mCer3. 
Unacetylated α-syn-mCer3 
exhibited higher lipid binding 
affinities to E. coli polar lipids 
than E. coli total lipids, which 
suggests binding PE and PG 
lipids. 
A larger increase in anisotropy were 
observed in the presence of polar lipids, 
which contained a higher PE and PG content 
than total lipids. 
Highest affinity observed with 
POPA with both α-syn-mCer3 
isoforms 
Significantly larger increases in anisotropy 
were observed with POPA 
The presence of CL, POPA, 
PG:PE, and E. coli total lipids 
improved the thermostability of 
both unacetylated and 
acetylated α-syn-mCer3. 
Larger thermal shifts were observed when 
these lipids were present in comparison to 
the other lipids and the proteins alone. 
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Reduced binding activities were 
observed with both VNp-mNg 
isoforms. 
The majority of melting temperatures 
calculated were not statistically significant to 
the protein alone. 
Unacetylated VNp-mNg 
interacted with PG:PE 
liposomes. 
Improved thermostability observed with the 
presence of PG:PE liposomes. 
Interactions between leucine 
zipper fused VNp-mNg proteins 
and liposomes did not impact 
the thermostability of the 
proteins. 
Melting temperatures obtained with leucine 
zipper fused VNp-mNg isoforms were not 
statistically significant whether lipid was 
present or absent. 
Other domains may be involved 
in specific lipid interactions. 
Overall reduced lipid interactions observed 
with VNp-mNg proteins when compared to 
the α-syn-mCer3. 
Dimerisation through the use of leucine 
zipper fused VNp-mNg isoforms did not 
improve lipid binding. 
Suggested PA and PG binding 
of WT TH1 
PG and PA lipids sedimented with the protein 
whereas PC lipids were generally evenly 
spread out.  
Increased fluorescence was also observed in 
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Summary 
The anisotropy results suggest a higher affinity of α-syn-mCer3 to POPA liposomes, 
which was further solidified by the improved thermostability of both proteins whilst the 
lipid was present. While it was hypothesised that α-syn-mCer3 interactions with PG:PE 
liposomes were either minimal or unstable through the anisotropy results, the thermal 
shift assay revealed stronger binding in comparison to the other liposomes. The negative 
anisotropy results suggest a change in the shape of the protein or liposomes, which is 
known to occur with alpha synuclein upon interactions with liposomes. This may explain 
sudden changes in anisotropy observed with PG:PE liposomes and with total and polar 
liposomes. The thermostability of the VNp-mNg proteins was not greatly impacted by any 
interactions that may have been taking place. Conversely, the anisotropy data revealed 
lipid interactions, thus highlighting the need for multiple binding assays in defining the 
specific lipid interactions. 
Through these studies, we were able to observe the impact of post-translational 
modifications on specific lipid interactions. A comparison between the acetylated and 
unacetylated proteins revealed reduced binding, making it possible to gain insight into the 
regulatory role of acetylation. The anisotropy results revealed lower lipid affinities with 
acetylated α-syn-mCer3 in comparison to unacetylated α-syn-mCer3, which suggests 
acetylation reducing lipid interactions. Furthermore, oligomerisation was observed with 
acetylated proteins but not with the unacetylated isoforms, which suggests a role in 
protein folding and conformation. A comparison of WT and S734D Hum 1 TH1 revealed 
phosphorylation increasing binding to specific lipids, in particular PA, which indicates a 
phosphorylation-based regulation. Further investigation, which was not possible due to 
COVID, would be required in order to further characterise these lipid interactions. 
Nonetheless, the data presented within this chapter aids in the understanding of post-
translational regulation. 
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6.1. The development of multifunctional SSAs to tackle antimicrobial 
resistance 
The studies described in chapter 3 sought to explore the relationship between the 
structure of an antimicrobial molecule and the bacterial activity exhibited, through 
stepwise molecular changes to SSA 32 and subsequent antimicrobial testing. In chapter 
4, these structure-activity relationships were then utilised for the creation of second-
generation SSAs that exhibited improved E. coli activity. While several functional groups 
were observed to improve activity, it is worth noting that simply incorporating these 
groups in molecules did not always improve activity. An example of this is observed with 
the TEA counter cation, which exhibited reduced activity when paired with a urea anion, 
but improved activity when paired with a thiourea anion. Thus, how the different functional 
groups interacted with one another, and the resulting structures observed also influenced 
the antimicrobial activity. Furthermore, improved antimicrobial activity may also be 
achieved by incorporating other functional groups that can achieve similar interactions.  
As described previously, lipid interactions can occur through binding to the head group, 
the acyl chains, or both.104 Thus, the improved activity observed with more amphiphilic 
molecules may be due to those SSAs having a higher likelihood to interact with both polar 
head groups and hydrophobic tails.  
Overall, SSAs exhibited improved activity against MRSA in comparison to E. coli, the 
predominant cause of this most likely being the additional outer membrane present in E. 
coli. However, a comparison of the lipid composition may provide further insight into the 
higher activity exhibited against MRSA. The predominant lipids present in E. coli 
membranes are PE (~75%) and anionic lipids PG and CL (~20%), whereas MRSA 
predominantly contains PG (~50%), DAG (~ 20%), and other PG derivatives 
(~38%).70,163,269,270 As the SSAs were observed interacting with membrane lipids through 
the FM4-64 competitive binding assay, and PG lipids are the most abundant MRSA 
membrane lipid, it is hypothesised that SSAs were interacting with PG lipids.  
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CL lipids are also present in MRSA membranes, however their relative proportion 
changes depending on growth stages. During the exponential phase, CL lipids make up ~ 
1% of MRSA membranes, however as cells enter stationary phase this is estimated to 
increase six-fold.70,269 Similarly, as E. coli cells enter stationary phase, PG lipids are 
converted to CL lipids resulting in a lower PG content and increased CL content. Some 
SSAs, such as SSA 34, were characterised as producing delayed inhibition against E. 
coli, as a reduction in growth was not observed until the stationary phase.70,271 Thus, 
interactions with both CL and PG lipids may produce the delayed inhibition exhibited by 
SSAs against E. coli as well as complete inhibition of MRSA. The anisotropy experiments 
provided further evidence of PG and CL binding, as SSAs 69 and 70 were both observed 
interacting with PG lipids and with E. coli total and polar lipids. The E. coli total and polar 
lipid extracts also contained PG lipids (15% and 23% respectively) and CL lipids (10% for 
both).196 Thus, SSAs were hypothesised to interact with PG predominantly and CL to a 
lesser extent. 
Targeting bacterial membranes is by no means simple, due to the diversity of lipid 
compositions, firstly between bacterial species and also between growth phases. 
However, if successful, membrane targeting can provide a way to target specific bacteria 
with high accuracy whilst also reducing mammalian toxicity. While the propensity to 
develop resistance is lower for membrane binding antimicrobials, bacteria may be able to 
redistribute membrane lipids as a mechanism of resistance. Thus, combination therapies 
become attractive options, as resistance is less likely to occur with multiple targets.148 
When SSA 66 was present in 1:1 heterogeneous mixtures with other SSAs, drastically 
lower MIC50 values were obtained against MRSA. Conversely, an antagonistic effect was 
exhibited when SSAs 67 and 68 were in a 1:1 heterogeneous mix. These data highlight 
the importance of investigating the intermolecular interactions between these molecules 
which can assist in the design of synergistic antimicrobial molecules. 
The use of hydrogels can be an attractive option in antimicrobial drug design as they can 
be manipulated to exhibit desired properties and they tend to have high 
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biocompatibility.272,273 Hydrogels can also be utilised for a wide range of applications, 
such as their use as drug delivery vehicles, as surface coatings for implants and wound 
dressings.273,274 An example of their use in antimicrobial research is seen with the studies 
conducted by Zhou et al., 2011, who developed antimicrobial hydrogels that exhibited low 
toxicity and high bactericidal activity. Supramolecular hydrogels can also be utilised in 
combination therapies, as shown by Marchesan et al., 2013 who described a hydrogel 
that actively incorporated the antibiotic ciprofloxacin into its matrix and exhibited activity 
against S. aureus, E. coli, and a clinical strain of K. pneumoniae.275 Similarly, ampicillin 
was incorporated into the gel matrix formed by SSA 70, and the activity of ampicillin was 
not significantly reduced. Optimisation of the structure of SSA 70 may not only produce 
an effective drug delivery vehicle, but also a hydrogel that exhibits antimicrobial activity of 
its own, rendering it a better candidate for combination therapies.  
The structure-activity relationships studies conducted were successfully utilised to 
develop second-generation SSAs 83 and 84, which exhibited improved E. coli activity in 
solution. Furthermore, the physicochemical analysis of the second generation SSAs 82 – 
85 provided further insight into the activities exhibited within the first generation of SSAs. 
For example, functional groups that promoted dimer formation within the first generation 
of molecules exhibited improved activity, such as the carboxylate functionality in SSA 61. 
Additionally, disruption of these self-association processes resulted in reduced activity, as 
was observed with SSA 33. However, in the second generation of molecules, SSA 83 
exhibited weaker dimer formation, in comparison to SSA 82, but improved antimicrobial 
activity. Therefore, improved antimicrobial activity was not solely due to dimerisation. It is 
uncertain whether SSAs interact with membrane lipids as dimers or as monomers. An 
investigation to determine this could provide information about the role of dimerisation in 
lipid interactions of SSAs, and their consequent antimicrobial activity. 
The use of fluorescence microscopy enabled the visualisation of the gel fibre formation 
processes of SSAs 82, 83, and 85 in different salt solutions. The geometry of the anionic 
component was previously reported to influence gel formation by Hiscock et al., 2020. 
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Within these studies, the salt solution present was shown to impact gel fibre formation 
and the properties of the resulting gel due to the interactions between the SSAs and salt 
molecules. 
Key observations included NaOBz promoting the formation of gels that exhibited fluid-like 
properties which may have been a result of its benzene ring and larger size in 
comparison to the other salts, which may have prevented closer packing of gel fibres. 
Additionally, two main types of gel stand formation were observed. One involved the 
formation of precipitated compound structures where long, curled fibre formation was 
initiated, which resulted in more fluid gels. The other involved the formation of SSA nodes 
followed by gel strand formation and cross-linking between nodes, which tended to 
produce straighter fibres and resulted in more rigid gels.  
SSAs 82, 83, and 85 exhibited less stable gels overall, in comparison to the gels formed 
by SSA 70 as previously reported by Hiscock et al., 2020. This may be attributed to the 
sol not being fully incorporated into the gel matrix and the presence of multiple types of 
fibres in some gels, both of which were not observed in the stable gels reported by 
Hiscock et al., 2020.155 The data obtained in these studies could not provide a specific 
reason for these observations, and a detailed investigation into the interactions between 
salt solutions and SSAs and also the influence of the anion geometry would be required 
to further understand. 
6.2. Investigating the role of post-translational modifications on lipid 
interactions. 
Post-translational modifications have been previously shown to be vital in the regulation 
of protein function, including protein-membrane interactions.276 The studies conducted in 
Chapter 5 sought to investigate the role of post-translational modifications on lipid 
interactions, specifically Nt-acetylation and phosphorylation.  
Oligomerisation was observed with acetylated α-Syn and VNp, but not with unacetylated 
α-Syn or VNp, which suggested a role in protein folding and conformation. Furthermore, 
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aggregated α-Syn  has been observed in Lewy bodies, which are intracellular inclusions 
predominantly composed of α-Syn ; a pathological hallmark of Parkinson’s disease 
(PD).277 Therefore, this may also suggest impaired acetylation of α-Syn  may have a role 
in the formation of Lewy bodies, and consequently the pathogenesis of PD. 
α-Syn oligomers have been observed to disrupt a variety of membranes in PD, which has 
not been observed with native α-Syn in non-disease states. Further, the lipid composition 
of cell membranes and their physical properties have been shown to influence α-Syn 
membrane affinities. Thus, investigating the lipid interactions of α-Syn may provide further 
information concerning its physiological function and the role of the lipid interactions in 
PD pathogenesis. These studies also allowed for the exploration into the specific lipid 
interactions of acetylated and unacetylated α-Syn and VNp proteins to ascertain their 
physiological functions as well as the role of acetylation. Both acetylated and 
unacetylated α-Syn proteins exhibited higher binding affinities to POPA lipid in the 
anisotropy and thermal shift assays. POPA is an important signalling lipid that has been 
observed to recruit or activate specific proteins particularly in the central nervous 
system.278,279 Therefore, the interactions observed with PA lipids suggest α-Syn  may be 
one of the proteins recruited by POPA. This does not specify function but may provide 
insight into α-Syn localisation. Significantly higher thermostability was exhibited by both 
acetylated and unacetylated α-Syn -mCer3 proteins in the presence of CL and PG: PE 
liposomes. CL lipid is estimated to constitute ~10-20% of mitochondrial membrane 
phospholipids and is involved in processes such as energy conversion and respiration.280–
282 The research conducted by Shen et al., 2014, Devi et al., 2008, and Camilleri et al., 
2013 provides evidence to suggest α-Syn  interacts directly with the mitochondria, and 
more specifically with CL lipids.280,283–285 It has thus been hypothesised that these 
interactions with CL may aid in the targeting of α-Syn  oligomers to the mitochondria, 
resulting in membrane disruption of neuronal mitochondrial membranes.280,281 Therefore, 
the strong interactions observed by both acetylated and unacetylated α-Syn  with CL 
liposomes in the thermal shift assay provide further evidence to support these 
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hypotheses. Similarly, PE lipids in the central nervous system are particularly abundant in 
the inner mitochondrial membrane and play vital roles in membrane fusion events and 
interestingly in assisting membrane protein folding.286,287 A reduction in PE consequently 
reduces membrane protein folding, resulting in the accumulation of toxic unfolded 
proteins. 286,287 Furthermore, a reduction in PE lipids has been observed in PD patients in 
studies conducted by Riekkinen et al., 1975 and Hattingen et al., 2009.288,289 Thus, the 
strong interactions with PE lipids observed in thermal shift studies by α-Syn -mCer3 
suggest PE involvement in α-Syn  folding and its reduction may result in the accumulation 
of α-Syn  that is observed in PD.  
The increased interactions by unacetylated α-Syn to E. coli polar lipids in comparison to 
E. coli total lipids provides further evidence of PE binding, as the E. coli polar lipid extract 
contains a higher PE content. In addition to this, in the anisotropy experiments, a 
decrease in anisotropy values was observed when acetylated α-Syn -mCer3 was in the 
presence of POPG liposomes, which was then followed by an increase in anisotropy 
values. α-Syn  has been observed adopting an alpha-helical conformation when in the 
presence of anionic lipids, which could explain these observations.100,290 Lastly, 
unacetylated α-Syn -mCer3 exhibited increased lipid binding activities in comparison to 
acetylated α-Syn -mCer3. Acetylation of α-Syn  has been reported in literature to 
modulate its lipid interactions by changing its affinity for specific lipids, thus, the data 
obtained suggests Nt-acetylation regulates α-Syn  interactions by reducing its lipid 
interactions.291,292  
Despite the VNp containing the proposed membrane binding domain, reduced binding 
activities were observed with VNp proteins in the thermal shift experiments and 
anisotropy experiments, in comparison to α-Syn -mCer3. This may suggest the 
involvement of other domains within α-Syn for lipid interactions that were not present in 
VNp. For example, the C-terminus of α-Syn  has previously been reported to increase 
lipid binding of α-Syn  through calcium binding.293–295 Thus, its absence in the VNp protein 
may have resulted in reduced lipid interactions. 
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Phosphorylation of myosin-1 has previously been shown to regulate cellular localisation 
and ATPase activities.296 However, the role of phosphorylation in the regulation of lipid 
interactions is not well known. In these studies, myosin 1 was not only observed to 
interact predominantly with anionic lipids, but phosphorylation was observed to increase 
binding to specific lipids, in particular PA. Thus, the data obtained in these studies 
suggests the lipid interactions may be positively regulated by phosphorylation. However, 
an extensive analysis of the individual interactions is required to confirm these 
observations, which could not be conducted due to COVID.   
6.3. Conclusion 
Biological membranes are dynamic and complex structures that provide cells with 
protection, define the cell compartments, control cell interactions, and perform vital 
cellular processes. The analysis of specific lipid interactions can provide vital information 
into complex membrane interactions, especially those that are not well characterised. 
These studies sought to investigate the lipid interactions of membrane-related proteins 
through the use of a variety of binding assays. Furthermore, these studies were able to 
show how information about specific lipid interactions can provide valuable information 
about the function, localisation, and regulation of proteins. Lastly, these studies enabled 
the optimisation of membrane binding antimicrobial compounds, which can then be used 
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Screening growth curves 
Escherichia coli (E. coli) 
 
Figure S126 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 32, 35, 37, 46, 55, 56, 66, 69, 70 and 77. 
 
Figure S127 - E. coli DH10B growth curves created from an average of 6 absorbance 
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Figure S128 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 34 and 42.  
  
Figure S129 - E. coli DH10B growth curves created from an average of 6 absorbance 
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Figure S130 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 40 and 41.  
 
Figure S131 - E. coli DH10B growth curves created from an average of 6 absorbance 
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Figure S132 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 50, 67, 78, 75 and 51.  
 
Figure S133 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 60, 64 and 71. MIC not calculated for compound 33 






































Figure S134 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 72, 73, 74 and 76.    
 
Figure S135 - E. coli DH10B growth curves created from an average of 6 absorbance 






































Figure S136 - E. coli DH10B growth curves created from an average of 6 absorbance 
readings in the presence of SSA 68.  
 
Figure S137 - E. coli DH10B growth curves created from an average of 6 absorbance 


































5% EtOH SSA 61
302 
 
USA 300 Methicillin-resistant Staphylococcus aureus (MRSA) 
 
Figure S138 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 32, 35, 36, 46, 54, 55, 56, 69 and 70.   
 
Figure S139 - MRSA growth curves created from an average of 6 absorbance 
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Figure S140 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 34 and 42.  
 
Figure S141 - MRSA growth curves created from an average of 6 absorbance 




































Figure S142 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 40 and 41. 














Figure S143 - MRSA growth curves created from an average of 6 absorbance 



















Figure S144 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 52, 53, 57, 58, 68 and 77. 
 
Figure S145 - MRSA growth curves created from an average of 6 absorbance 
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Figure S146 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 60 and 71.  
 
Figure S147 - MRSA growth curves created from an average of 6 absorbance 



































Figure S148 - MRSA growth curves created from an average of 6 absorbance 
readings in the presence of SSAs 66, 67 and 68. Screening conducted at 3.75 mM as 




















5% ETOH SSA 66 SSA 67 SSA 68
308 
 
Antimicrobial gel plates 
  
 
Figure S149 – Surface diffusion assay using the SSA 70 (5 mg/mL) gel on MRSA 




Figure S150 – Surface diffusion assay using the SSA 70 (5 mg/mL) gel on E. coli 





Figure S151 – Well diffusion assay using the SSA 70 (5 mg/mL) gel on MRSA 




   
 
Figure S152 – Well diffusion assay using the SSA 70 (5 mg/mL) gel on E. coli 




Figure S153 – Well diffusion assay using the Ampicillin (5 mg/mL) on MRSA 
inoculated agar plates.  
 






Figure S154 – Well diffusion assay using Ampicillin (5 mg/mL) gel on E. coli 




Figure S155 – Surface diffusion assay using the co-formulated SSA 70 and ampicillin 





Figure S156 – Well diffusion assay using the co-formulated SSA 70 and ampicillin gel 







Figure S157 – Surface diffusion assay using the co-formulated SSA 70 and ampicillin 






Figure S158 – Well diffusion assay using the co-formulated SSA 70 and ampicillin gel 





Quantitative Microscopy Analysis 
Table S37. Fluorescence intensities (FI) of E. coli at T=30 min and T= 4 hours under various 
conditions. Cells ntotal = total number of cells analyzed for that condition. DAPI (450 nm) and 
mCherry (605 nm) filters used. 
 
Peak Wavelength examined 





Peak Wavelength examined 





450 nm 605 nm 450 nm 605 nm 
Solvent 
alone 
21.15 ± 1.59 4.28 ± 0.74 54 22.68 ± 1.96 4.46 ± 0.48 
72 
SSA 70 104.35 ± 
10.86 
5.41 ± 0.43 69 
264.58 ± 
35.65 
5.55 ± 4.02 
74 
FM 4-64 
22.23 ± 0.91 
32.66 ± 
11.68 
















Table S38. Fluorescence intensities (FI) of MRSA at T=30 min and T= 4 hours under various 
conditions. Cells ntotal = total number of cells analyzed for that condition. DAPI (450 nm) and 









Peak Wavelength examined 





450 nm 605 nm 450 nm 605 nm 
Solvent 
Alone 
22.46 ± 3.20 6.95 ± 1.87 73 23.38 ± 0.11 5.66 ± 0.57 78 
SSA 70 133.98 ± 
16.90 
4.28 ± 1.91 69 
297.77 ± 
87.37 
4.65 ± 2.95 66 
FM 4-64 26.81 ± 1.04 53.24 ± 8.35 32 27 ± 1.36 22.05 ± 2.52 64 




7.20 ± 3.02 86 
268.05 ± 
45.99 





E. coli at 30 minutes 
 
Figure S159 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
30 minutes. Transmitted image used to locate cells on fluorescence image. Scale bar 
= 10 µM. 
  
Figure S160 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
30 minutes. Transmitted image used to locate cells on fluorescence image. Scale bar 
























Figure S161 – E. coli transmitted image and fluorescence image at 450 nm images 
used in fluorescence intensity calculations in the absence of both SSA 70 and FM4-
64 at T = 30 minutes. Transmitted image used to locate cells on fluorescence image 
at 450 nm. Scale bar = 10 µM. 
 
Figure S162 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
30 minutes. Transmitted image used to locate cells on fluorescence image. Scale bar 





















Figure S163 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
30 minutes. Transmitted image used to locate cells on Fluorescence image at 450 
nm. Scale bar = 10 µM. 
 
Figure S164 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
30 minutes. Transmitted image used to locate cells on fluorescence image. Scale bar 






















Figure S165 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 
Scale bar = 10 µM. 
 
Figure S166 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 



















Figure S167 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 
Scale bar = 10 µM. 
 
Figure S168 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 





























Figure S169 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 
Scale bar = 10 µM. 
 
Figure S170 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 30 minutes. 




































Figure S171 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 30 minutes. 
Scale bar = 10 µM. 
 
Figure S172 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 30 minutes. 


























Figure S173 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 30 minutes. 















Figure S174 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 30 minutes. 
Fluorescence image at 605 nm used to locate cells on fluorescence image at 450 nm. 























Figure S175 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 30 minutes. 
Fluorescence image at 605 nm used to locate cells on fluorescence image at 450 nm. 
























Figure S176 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Scale bar = 10 µM. 
 
Figure S177 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Fluorescence image at 450 nm and transmitted image used to locate 






















Figure S178 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Scale bar = 10 µM. 
 
Figure S179 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Fluorescence image at 450 nm and transmitted image used to locate 



























Figure S180 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Scale bar = 10 µM. 
 
Figure S181 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
30 minutes. Fluorescence image at 450 nm and transmitted image used to locate 



























E. coli at 4 hours 
 
Figure S182 – E. coli transmitted image and fluorescence image at 450 used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
4 hrs. Transmitted image used to locate cells on fluorescence image. Scale bar = 
10µM. 
 
Figure S183 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 

























Figure S184 – E. coli transmitted image and Fluorescence image at 450 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
4 hrs. Transmitted image used to locate cells on fluorescence image. Scale bar = 
10µM. 
 
Figure S185 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 

































Figure S186 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 
4 hrs. Transmitted image used to locate cells on fluorescent image. Scale bar = 
10µM. 
 
Figure S187 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 



























Figure S188 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 4 hours. Scale 
bar = 10µM.  
 
Figure S189 – Z-slice image used in combination with above figure to obtain more 
accurate fluorescence intensity calculations. Fluorescence image at 450 nm of E. coli 














Figure S190 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 4 hours. Scale 













Figure S191 – Different z-slices used in combination with figure above to obtain more 
accurate fluorescence calculations. Fluorescence images at 450 nm of E. coli in the 






Figure S192 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 at T = 4 hours. Scale 













Figure S193 – Different z-slices used in combination to obtain more accurate 
fluorescence calculations. Fluorescence image at 450 nm of E. coli in the presence of 






Figure S194 – (Above) E. coli transmitted image and fluorescence image at 605 nm 
used in fluorescence intensity calculations in the presence of SSA 70 at T = 4 hours. 
(Below) fluorescent images at 450 used in combination with transmitted images to 









































Figure S195 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 4 hours. Scale 
bar = 10µM. 
 
Figure S196 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 4 hours. Scale 






















Figure S197 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 at T = 4 hours. Scale 
















Figure S198 – (Above) E. coli transmitted image and fluorescence image at 450 nm 
used in fluorescence intensity calculations in the presence of FM4-64 at T = 4 hours. 
(Below) Fluorescence image at 605 nm used to locate cells on fluorescence image at 












Figure S199 – (Above) E. coli transmitted image and fluorescence image at 450 nm 
used in fluorescence intensity calculations in the presence of FM4-64 at T = 4 hours. 
(Below) Fluorescence image at 605 nm used to locate cells on fluorescence image at 






























Figure S200 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Scale bar = 10µM.  
 
Figure S201 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Fluorescence image at 450nm (Figure S658) and transmitted image used in 
combination with the fluorescence image at 605 nm to locate cells on fluorescence 




























Figure S202 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Scale bar = 10µM. 
 
Figure S203 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Fluorescence image at 450 nm (Figure S684) and transmitted images used 


























Figure S204 – E. coli transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Scale bar = 10µM. 
 
Figure S205 – E. coli transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 
4 hours. Figure S710 and transmitted images used in combination with fluorescence 






























MRSA at 30 minutes 
 
Figure S206 – MRSA transmitted image and fluorescence image at 450nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S207 – MRSA transmitted image and fluorescence image at 605nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 30 

















































Figure S208 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S209 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 30 























Figure S210 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 30 minutes. Scale 
bar = 10µM 
 
Figure S211 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 30 minutes. Scale 


















Figure S212 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 30 minutes. Scale 
bar = 10µM 
 
Figure S213 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 30 minutes. Scale 




















Figure S214 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 30 minutes. 
Fluorescence image at 450 nm used to locate cells on fluorescence image at 605 nm. Scale 








































Figure S215 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 30 minutes. Scale 
bar = 10µM 
 
Figure S216 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 30 minutes. Scale 






















Figure S217 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 30 minutes. Scale 
bar = 10µM 
 
Figure S218 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 



























Figure S219 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S220 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 

























Figure S221 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S222 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 






















Figure S223 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S224 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 
























Figure S225 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 30 
minutes. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
MRSA at 4 hours 
 
Figure S226 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 4 hours. 
























Figure S227 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 4 hours. 
Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S228 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 4 hours. 


































Figure S229 – MRSA transmitted image and fluorescence image at 450nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 4 hours. 
Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S230 – MRSA transmitted image and fluorescence image at 450nm used in 
fluorescence intensity calculations in the absence of both SSA 70 and FM4-64 at T = 4 hours. 









































Figure S231 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 4 hours. Scale bar = 
10µM 
 
Figure S232 – MRSA transmitted image and fluorescence image at 450 nm used in 



























Figure S233 – MRSA transmitted image and fluorescence image at 450 nm used in 















Figure S234 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of SSA 70 only at T = 4 hours. 
Fluorescence image taken 450 nm used to locate cells on fluorescence image 605 nm. Scale 






































Figure S235 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 4 hours. Scale bar = 
10µM 
 
Figure S236 – MRSA transmitted image and fluorescence image at 605 nm used in 


















Figure S237 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 4 hours. Scale bar = 
10µM 
 
Figure S238 – MRSA transmitted image and fluorescence image at 605 nm used in 

























Figure S239 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of FM4-64 only at T = 4 hours. 
Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S240 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 4 







































Figure S241 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 only at T = 4 
hours. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S242 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 4 


















Figure S243 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 only at T = 4 
hours. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S244 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 4 






























Figure S245 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 only at T = 4 
hours. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
 
Figure S246 – MRSA transmitted image and fluorescence image at 450 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 at T = 4 































Figure S247 – MRSA transmitted image and fluorescence image at 605 nm used in 
fluorescence intensity calculations in the presence of both SSA 70 and FM4-64 only at T = 4 
hours. Transmitted image used to locate cells on fluorescence image. Scale bar = 10µM 
Antimicrobial plates statistics 
Ampicillin vs ampicillin co-formulated gel 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 EAmpalone_well 52.6667 3 2.88675 1.66667 
EAmp70gel_well 53.3333 3 1.52753 .88192 
Pair 2 MAmpalone_well 17.0000 3 1.00000 .57735 
MAmp70gel_well 15.3333 3 1.15470 .66667 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 EAmpalone_well & 
EAmp70gel_well 
3 -.756 .454 
Pair 2 MAmpalone_well & 
MAmp70gel_well 

















Paired Samples Test 
 
Paired Differences 





Interval of the 
Difference 
Lower 
Pair 1 EAmpalone_well – 
Eamp70gel_well 
-.66667 4.16333 2.40370 -11.00896 
Pair 2 MAmpalone_well – 
Mamp70gel_well 
1.66667 1.52753 .88192 -2.12792 
 




t df Sig. (2-tailed) 
95% 
Confidence 
Interval of the 
Difference 
Upper 
Pair 1 EAmpalone_well - 
EAmp70gel_well 
9.67562 -.277 2 .808 
Pair 2 MAmpalone_well - 
MAmp70gel_well 
5.46125 1.890 2 .199 
 
Surface vs Well 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 E.coli_Surface 15.0000 3 2.64575 1.52753 
E.coli_Well 17.6667 3 4.16333 2.40370 
Pair 2 MRSA_Surface 15.6667 3 1.52753 .88192 
MRSA_Well 13.6667 3 1.15470 .66667 
Pair 3 AmpE_Surface 59.3333 3 .57735 .33333 
AmpE_Well 53.3333 3 1.52753 .88192 
Pair 4 AmpM_Surface 23.3333 3 1.52753 .88192 
AmpM_Well 17.0000 3 1.00000 .57735 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 E.coli_Surface & E.coli_Well 3 .817 .391 
Pair 2 MRSA_Surface & MRSA_Well 3 .756 .454 
Pair 3 AmpE_Surface & AmpE_Well 3 -.756 .454 
366 
 
Pair 4 AmpM_Surface & AmpM_Well 3 -.982 .121 
 
Paired Samples Test 
 
Paired Differences 





Interval of the 
Difference 
Lower 
Pair 1 E.coli_Surface - 
E.coli_Well 
-2.66667 2.51661 1.45297 -8.91828 
Pair 2 MRSA_Surface - 
MRSA_Well 
2.00000 1.00000 .57735 -.48414 
Pair 3 AmpE_Surface - 
AmpE_Well 
6.00000 2.00000 1.15470 1.03172 
Pair 4 AmpM_Surface - 
AmpM_Well 
6.33333 2.51661 1.45297 .08172 
 




t df Sig. (2-tailed) 
95% 
Confidence 
Interval of the 
Difference 
Upper 
Pair 1 E.coli_Surface - 
E.coli_Well 
3.58494 -1.835 2 .208 
Pair 2 MRSA_Surface - 
MRSA_Well 
4.48414 3.464 2 .074 
Pair 3 AmpE_Surface - 
AmpE_Well 
10.96828 5.196 2 .035 
Pair 4 AmpM_Surface - 
AmpM_Well 





Physicochemical studies conducted on second generation SSAs 
 
Hydrogen 






(D•••A) (Å)  
Hydrogen 
bond angle (D-
H•••A) (°)  
N2  O4  2.839(4)  173.44(7)  
N3  O4  2.995(4)  148.8(2)  
 
Figure S248 – Hydrogen bond distances and angles observed for 3, calculated from 
the single-crystal X-ray structure shown of SSA 82. 
Information for Figure 64: 
Single crystal X-ray structure of SSA 82: red = oxygen; yellow = sulfur; blue = 
nitrogen; white = hydrogen; grey = carbon. CCDC 2023004, C33H52N4O4S2 (M = 
632.90): monoclinic, space group P 2/n, a = 16.4865(13) Å, b = 10.4507(7) Å, c = 
20.0106(17) Å, α = 90°, β = 94.596(7)°, γ = 90°, V = 3436.7(4) Å3, Z = 4, T = 100(1) 
K, CuK\α = 1.5418 Å, Dcalc = 1.223 g/cm3, 22331 reflections measured (7.238 ≤ 2Θ 
≤ 133.202), 6083 unique (Rint = 0.1112, Rsigma = 0.1299) which were used in all 









(D•••A) (Å)  
Hydrogen 
bond angle 
(D-H•••A) (°)  
N1  O2  2.9478 (17)  154.64 (9)  
N2  O1  2.9591 (17)  156.20 (9)  
O5  O3  2.8719 (18)  173.45 (9)  
O5  N3  2.9280 (19)  167.14 (10)  
Figure S249 – Hydrogen bond distances and angles observed for 3, calculated from 
the single crystal X-ray structure shown of SSA 83. 
Information for Figure 65: 
Single crystal X-ray structure of 83: red = oxygen; yellow = sulfur; blue = nitrogen; 
white = hydrogen; grey = carbon. CCDC 2033371, C34H56N4O5S2 (M = 664.94): 
triclinic, space group P -1, a = 9.2701(2) Å, b = 9.2791(3) Å, c = 21.7492(7) Å, α = 
91.169(3)°, β = 96.234(2)°, γ = 103.561(2)°, V = 1805.87(9) Å3, Z = 2, T = 100(1) K, 
CuK\α = 1.5418 Å, Dcalc = 1.223 g/cm3, 12423 reflections measured (8.184 ≤ 2Θ ≤ 
143.716), 6885 unique (Rint = 0.0271, Rsigma = 0.0402) which were used in all 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S250 – 1H NMR of SSA 82 in DMSO-d6 conducted at 298.15 K. 
Sep2220KH NA-2 Full.010.001.1r.esp
Chemical Shift (ppm)








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S251 –1H NMR of SSA 83 in DMSO-d6 conducted at 298.15 K. 
Acquisition Time (sec) 2.3809 Date 23 Sep 2020 03:44:16 Date Stamp 23 Sep 2020 03:44:16
File Name E:\NYA NMR\Sep2220KH NA-2 Full\11\PDATA\1\1r Frequency (MHz) 100.52 Nucleus 13C Number of Transients 512
Origin spect Original Points Count 59522 Owner nmrsu Points Count 131072 Pulse Sequence zgpg30
Receiver Gain 2050.00 SW(cyclical) (Hz) 25000.00 Solvent DMSO-d6 Spectrum Offset (Hz) 11007.8467 Spectrum Type STANDARD
Sweep Width (Hz) 24999.81 Temperature (degree C) 25.000
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/
Sep2220KH NA-2 Full.011.001.1r.esp
Chemical Shift (ppm)
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No. (ppm) (Hz) Height
1 13.45 1352.4 0.7016
2 19.18 1927.8 0.2945
3 21.00 2110.7 0.0913
4 23.04 2316.0 0.3446
No. (ppm) (Hz) Height
5 26.07 2620.4 0.0751
6 38.21 3840.7 0.0549
7 49.10 4935.5 0.0687
8 57.51 5781.0 0.1512
No. (ppm) (Hz) Height
9 117.49 11810.4 0.1076
10 121.64 12228.3 0.0714
11 121.89 12252.9 0.0725
12 125.29 12595.2 0.0675
No. (ppm) (Hz) Height
13 127.75 12841.7 0.1286
14 127.83 12849.9 0.0648
15 134.24 13494.9 0.0776
16 134.63 13533.5 0.0712
 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S253 – 13C NMR of SSA 83 in DMSO-d6 conducted at 298.15 K. 






Figure S254 – 1H DOSY NMR spectrum of SSA 82 (55.56 mM) in DMSO-d6 at 298 K 
and a table reporting the diffusion constants calculated for each peak used to 







Figure S255 – 1H NMR spectrum of SSA 83 (55.56 mM) in DMSO-d6 at 298 K and a 
table reporting the diffusion constants calculated for each peak used to determine the 




Figure S256 –1H NMR stack plot of SSA 82 in DMSO-d6 0.5 % H2O solution. 
Samples were prepared in series with an aliquot of the most concentrated solution 
undergoing serial dilution. 
 
Figure S257 –1H NMR stack plot OF SSA 83 in DMSO-d6 0.5 % H2O solution. 
Samples were prepared in series with an aliquot of the most concentrated solution 
undergoing serial dilution. 
 
Figure S258 – Graph illustrating the 1H NMR down-field change in chemical shift of 
urea NH resonances with increasing concentration of SSA 82 in DMSO-d6 0.5 % H2O 









































Figure S259 – Graph illustrating the 1H NMR down-field change in chemical shift of 
urea NH resonances with increasing concentration of SSA 83 in DMSO-d6 0.5 % H2O 







Figure S260 – Correlation function data for 10 DLS runs of SSA 82 (0.56 mM) in an 
EtOH:H2O (1:19) solution at 298 K. 
 
Figure S261 – Correlation function data for 10 DLS runs of SSA 82 (5.56 mM) in an 




Figure S262 – Correlation function data for 10 DLS runs of SSA 83 (0.56 mM) in an 
EtOH:H2O (1:19) solution at 298 K. 
 
Figure S263 – Correlation function data for 10 DLS runs of SSA 83 (5.56 mM) in an 
EtOH:H2O (1:19) solution at 298 K. 










y = 1.4293ln(x) + 45.305
R² = 0.9531





















Figure S264 – Calculation of CMC (28.95 mM) for SSA 82 in an EtOH: H2O 1:19 
















y = 11.947ln(x) + 12.801
R² = 0.8677





















Figure S265 – Calculation of CMC (28.95 mM) for SSA 83 in an EtOH: H2O 1:19 
mixture using surface tension measurements. 
Gelation studies 
 
Figure S266 – Results of the amplitude sweep experiments. For SSA 82 in the 




Figure S267 – Results of the amplitude sweep experiments. For SSA 82 in the 
presence of KCl (0.505 M). 
 
Figure S268 – Results of the amplitude sweep experiments. For SSA 82 in the 




Figure S269 – Results of the amplitude sweep experiments. For SSA 82 in the 
presence of Na2SO4 (0.505 M). Sol to gel transition likely caused by experimental 
conditions. 
 
Figure S270 – Results of the amplitude sweep experiments. For SSA 82 in the 





Figure S271 – Results of the amplitude sweep experiments. For SSA 82 in the 
presence of NaCl (0.505 M) 
   
 
Figure S272 – SSA 82(5 mg/mL) inversion test in the presence of NaCl (0.505 M). 
380 
 
   
Figure S273 – SSA 82(5 mg/mL) inversion test in the presence of KCl (0.505 M). 
   
Figure S274 – SSA 82(5 mg/mL) inversion test in the presence of NaH2PO4 (0.505 
M). 
   
Figure S275 – SSA 82(5 mg/mL) inversion test in the presence of Na2SO4 (0.505 M). 
381 
 
   
Figure S276 – SSA 82(5 mg/mL) inversion test in the presence of NaNO3 (0.505 M). 
   
Figure S277 – SSA 82(5 mg/mL) inversion test in the presence of NaOBz (0.505 M). 
   
Figure S278 – SSA 83 (5 mg/mL) inversion test in the presence of NaCl (0.505 M). 
382 
 
   
Figure S279 – SSA 83 (5 mg/mL) inversion test in the presence of KCl (0.505 M). 
   
Figure S280 – SSA 83 (5 mg/mL) inversion test in the presence of NaH2PO4 (0.505 
M). 
   




   
 
Figure S282 – SSA 83 (5 mg/mL) inversion test in the presence of NaNO3 (0.505 M). 
   
 
Figure S283 – SSA 83 (5 mg/mL) inversion test in the presence of NaOBz (0.505 M). 
Antimicrobial gel plates: second generation SSAs 
 
  
Figure S284 – Surface diffusion assay using the SSA 82 (5 mg/mL) gel on E. coli 






Figure S285 – Surface diffusion assay using the SSA 82 (5 mg/mL) gel on MRSA 





Figure S286 – Surface diffusion assay using the SSA 83 (5 mg/mL) gel on E. coli 





Figure S287 – Surface diffusion assay using the SSA 83 (5 mg/mL) gel on MRSA 







Figure S288 – Surface diffusion assay using the SSA 85 (5 mg/mL) gel on MRSA 




Figure S289 – Surface diffusion assay using the SSA 85 (5 mg/mL) gel on E. coli 
inoculated agar plates.  
Lengths of gel fibres used to determine long and short strands 
Table 39. a = larger than field of view, b = unable to discern individual fibres, c = no gel 
fibres observed 
 
length of fibres (µm)  
82 83 85 
NaCl 19.27 ± 7.43 34.47 ± 13.60 37.83 ± 15.81 
KCl 18.98 ± 7.64 9.00 ± 1.52 25.84 ± 13.29 
NaNO3 a b 51.17 ± 28.07 
Na2SO4 19.59 ± 12.38 23.79 ± 9.51 a 
NaH2PO4 c c b 





Gel fluorescence microscopy images 
  
  
Figure S290. Fluorescence microscopy images showing the gel formation process of 





Figure S291 - Fluorescence microscopy images showing the gel formation process of 
compound 85 (5 mg/ mL) in NaCl (0.505 mM). Majority of strands formed were long, 
curled, and resultant gel was made up of layers of densely packed curled fibres and 






Figure S292 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in NaCl (0.505 mM). Long straight strands form initially 
which then branch off at bright spots (nodes), and pack closer together. The resultant 





Figure S293 – Fluorescence microscopy images showing the gel formation process of 
compound 83 (5 mg/ mL) in NaCl (0.505 mM). Long strands formed and curled as 
they elongated, multiple strands branched off at bright spots (nodes). Gel fibres then 







Figure S294 – Fluorescence microscopy images showing the gel formation process of 
compound 85 (5 mg/ mL) in KCl (0.505 mM). Branching strands, gel made up of long, 






Figure S295 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in KCl (0.505 mM). Long unidirectional strands that were 







Figure S296 – Fluorescence microscopy images showing the gel formation process of 
compound 83 (5 mg/ mL) in KCl (0.505 mM). Regions of short straight fibres formed 
between regions of compound that hadn’t formed strands yet. These regions of 
compound that hadn’t formed strands yet became smaller over time, connecting the 






Figure S297 – Fluorescence microscopy images showing the gel formation process of 
compound 85 (5 mg/ mL) in NaH2PO4 (0.505 mM). However, at 5mg/mL, aggregates 
formed, and the structures formed quickly. Then, small, fragile gel clumps formed 
which easily broke up and the resulting structures were indiscernible. Due to 






Figure S298 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in NaH2PO4 (0.505 mM). Small aggregates formed and the 






Figure S299 – Fluorescence microscopy images showing the gel formation process of 





Figure S300 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in Na2SO4 (0.505 mM). Majority of strands were short 







Figure S301 – Fluorescence microscopy images showing the gel formation process of 
compound 83 (5 mg/ mL) in Na2SO4 (0.505 mM). The long, curled strands from earlier 





Figure S302 – Fluorescence microscopy images showing the gel formation process of 
compound 85 (5 mg/ mL) in NaNO3 (0.505 mM). Compound aggregates formed then 
fibres, potentially using the aggregates to elongate. Resulting gel was made up of 







Figure S303 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in NaNO3 (0.505 mM). The final gel was made up of regions 
of densely packed gel fibres and regions of solvent. The resulting gel also ‘floated’ 







Figure S304 – Fluorescence microscopy images showing the gel formation process of 
compound 83 (5 mg/ mL) in NaNO3 (0.505 mM). Initial aggregates, then short straight 
strands formed. The strands got longer, and as they were elongated, they began to 
curl into themselves. Aggregated together in an almost cross-hatched manner and 





Figure S305 – Fluorescence microscopy images showing the gel formation process of 
compound 85 (5 mg/ mL) in NaOBz (0.505 mM). Strands formed quickly from bright 






Figure S306 – Fluorescence microscopy images showing the gel formation process of 
compound 82 (5 mg/ mL) in NaOBz (0.505 mM). The resulting gel had regions of long 





Figure S307 – Fluorescence microscopy images showing the gel formation process of 
compound 83 (5 mg/ mL) in NaOBz (0.505 mM). Initially long curled fibres formed, 
branching off at bright spots. The resulting gel was made up of regions of densely 





Zones of inhibition 
Descriptives 
Zones   





95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
70 12 10.5911 .98802 .28522 9.9633 11.2188 
82 12 14.6700 1.66212 .47981 13.6139 15.7261 
83 12 19.1475 1.88131 .54309 17.9522 20.3428 
Total 36 14.8029 3.85320 .64220 13.4991 16.1066 
Descriptives 
Zones 
 Minimum Maximum  
70 8.76 12.15  
82 10.60 16.77  
83 15.92 21.83  
Total 8.76 21.83  
Tests of Homogeneity of Variances 
 
Levene 
Statistic df1 df2 Sig. 
Zones Based on Mean 2.249 2 33 .121 
Based on Median 1.665 2 33 .205 
Based on Median and 
with adjusted df 
1.665 2 27.851 .207 
Based on trimmed 
mean 
2.218 2 33 .125 
ANOVA 





Square F Sig. 
Between 
Groups 
439.591 2 219.796 90.599 .000 
Within Groups 80.059 33 2.426   
Total 519.651 35    









Zones Eta-squared .846 .719 .891 
Epsilon-squared .837 .702 .885 
Omega-squared Fixed-
effect 
.833 .696 .882 
Omega-squared 
Random-effect 
.713 .534 .789 
a. Eta-squared and Epsilon-squared are estimated based on the fixed-
effect model. 
 
Robust Tests of Equality of Means 
Zones   
 Statistica df1 df2 Sig. 
Welch 102.354 2 20.195 .000 
Brown-
Forsythe 
90.599 2 27.600 .000 




70 82 83 








Error t df 
Zones Assume equal 
variances 
1 -8.5564 .63588 -13.456 33 
Does not assume equal 
variances 
1 -8.5564 .61343 -13.949 16.639 
 
Contrast Tests 
  Contrast Sig. (2-tailed) 
Zones Assume equal variances 1 .000 
Does not assume equal variances 1 .000 
 










Zones Cohen's d 1 1.55758 -5.493 -7.024 -3.938 
Hedges' 
correction 
1 1.59413 -5.367 -6.863 -3.848 
406 
 
a. The denominator used in estimating the effect sizes. Cohen's d uses the pooled 
standard deviation for all the groups. Hedges' uses pooled standard deviation for all the 
groups, plus a correction factor. 
 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   Zones   















70 82 -4.07892* .63588 .000 -5.3726 
83 -8.55642* .63588 .000 -9.8501 
82 70 4.07892* .63588 .000 2.7852 
83 -4.47750* .63588 .000 -5.7712 
83 70 8.55642* .63588 .000 7.2627 
82 4.47750* .63588 .000 3.1838 
 
Multiple Comparisons 
Dependent Variable:   Zones   
LSD   
(I) Compound (J) Compound 
95% Confidence Interval 
Upper Bound 
70 82 -2.7852 
83 -7.2627 
82 70 5.3726 
83 -3.1838 
83 70 9.8501 
82 5.7712 





Tm_WT   





95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
Unace Alone 9 79.1822 .47715 .15905 78.8155 79.5490 
Unace PA 9 82.1611 .35744 .11915 81.8864 82.4359 
Unace Polar 9 79.4600 .67797 .22599 78.9389 79.9811 
Unace Total 9 81.7511 .15957 .05319 81.6285 81.8738 
407 
 
Ace Alone 9 77.8567 .83911 .27970 77.2117 78.5017 
Ace PA 9 82.4811 .26895 .08965 82.2744 82.6878 
Ace Polar 9 77.5878 .93888 .31296 76.8661 78.3095 
Ace Total 9 81.8044 .57544 .19181 81.3621 82.2468 
Total 72 80.2856 1.96254 .23129 79.8244 80.7467 
Descriptives 
Tm_WT   
 Minimum Maximum  
Unace Alone 78.51 79.60  
Unace PA 81.82 82.63  
Unace Polar 78.65 80.26  
Unace Total 81.55 81.93  
Ace Alone 76.67 78.70  
Ace PA 82.17 82.80  
Ace Polar 76.38 78.80  
Ace Total 81.05 82.32  
Total 76.38 82.80  
Tests of Homogeneity of Variances 
 
Levene 
Statistic df1 df2 Sig. 
Tm_WT Based on Mean 6.023 7 64 .000 
Based on Median 2.436 7 64 .028 
Based on Median and 
with adjusted df 
2.436 7 40.268 .035 
Based on trimmed 
mean 









Square F Sig. 
Between Groups 250.825 7 35.832 101.307 .000 
Within Groups 22.637 64 .354   
Total 273.462 71    







Tm_WT Eta-squared .917 .865 .932 
Epsilon-squared .908 .850 .925 
Omega-squared Fixed-
effect 





.582 .444 .635 
a. Eta-squared and Epsilon-squared are estimated based on the fixed-
effect model. 
Robust Tests of Equality of Means 
Tm_WT   
 Statistica df1 df2 Sig. 
Welch 98.261 7 26.486 .000 
Brown-
Forsythe 
101.307 7 38.407 .000 
a. Asymptotically F distributed. 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   Tm_WT   
Games-Howell   













Unace PA -2.97889* .19873 .000 -3.6742 -2.2836 
Unace Polar -.27778 .27635 .966 -1.2492 .6936 
Unace Total -2.56889* .16771 .000 -3.2011 -1.9367 
Ace Alone 1.32556* .32176 .020 .1721 2.4790 
Ace PA -3.29889* .18258 .000 -3.9540 -2.6438 
Ace Polar 1.59444* .35106 .011 .3214 2.8675 
Ace Total -2.62222* .24918 .000 -3.4889 -1.7556 
Unace PA Unace 
Alone 
2.97889* .19873 .000 2.2836 3.6742 
Unace Polar 2.70111* .25548 .000 1.7782 3.6241 
Unace Total .41000 .13048 .114 -.0694 .8894 
Ace Alone 4.30444* .30402 .000 3.1823 5.4266 
Ace PA -.32000 .14911 .432 -.8415 .2015 
Ace Polar 4.57333* .33487 .000 3.3244 5.8223 
Ace Total .35667 .22580 .754 -.4458 1.1592 
Unace Polar Unace 
Alone 
.27778 .27635 .966 -.6936 1.2492 
Unace PA -2.70111* .25548 .000 -3.6241 -1.7782 
Unace Total -2.29111* .23217 .000 -3.1856 -1.3966 
Ace Alone 1.60333* .35959 .008 .3510 2.8556 
Ace PA -3.02111* .24312 .000 -3.9245 -2.1177 
Ace Polar 1.87222* .38603 .004 .5180 3.2264 
Ace Total -2.34444* .29642 .000 -3.3743 -1.3146 
Unace Total Unace 
Alone 
2.56889* .16771 .000 1.9367 3.2011 
Unace PA -.41000 .13048 .114 -.8894 .0694 
Unace Polar 2.29111* .23217 .000 1.3966 3.1856 
409 
 
Ace Alone 3.89444* .28471 .000 2.7880 5.0009 
Ace PA -.73000* .10424 .000 -1.1021 -.3579 
Ace Polar 4.16333* .31745 .000 2.9254 5.4012 
Ace Total -.05333 .19905 1.000 -.8135 .7068 
Ace Alone Unace 
Alone 
-1.32556* .32176 .020 -2.4790 -.1721 
Unace PA -4.30444* .30402 .000 -5.4266 -3.1823 
Unace Polar -1.60333* .35959 .008 -2.8556 -.3510 
Unace Total -3.89444* .28471 .000 -5.0009 -2.7880 
Ace PA -4.62444* .29372 .000 -5.7353 -3.5136 
Ace Polar .26889 .41973 .998 -1.1867 1.7245 
Ace Total -3.94778* .33915 .000 -5.1425 -2.7531 
Ace PA Unace 
Alone 
3.29889* .18258 .000 2.6438 3.9540 
Unace PA .32000 .14911 .432 -.2015 .8415 
Unace Polar 3.02111* .24312 .000 2.1177 3.9245 
Unace Total .73000* .10424 .000 .3579 1.1021 
Ace Alone 4.62444* .29372 .000 3.5136 5.7353 
Ace Polar 4.89333* .32555 .000 3.6526 6.1341 
Ace Total .67667 .21173 .103 -.0977 1.4510 
Ace Polar Unace 
Alone 
-1.59444* .35106 .011 -2.8675 -.3214 
Unace PA -4.57333* .33487 .000 -5.8223 -3.3244 
Unace Polar -1.87222* .38603 .004 -3.2264 -.5180 
Unace Total -4.16333* .31745 .000 -5.4012 -2.9254 
Ace Alone -.26889 .41973 .998 -1.7245 1.1867 
Ace PA -4.89333* .32555 .000 -6.1341 -3.6526 
Ace Total -4.21667* .36706 .000 -5.5229 -2.9105 
Ace Total Unace 
Alone 
2.62222* .24918 .000 1.7556 3.4889 
Unace PA -.35667 .22580 .754 -1.1592 .4458 
Unace Polar 2.34444* .29642 .000 1.3146 3.3743 
Unace Total .05333 .19905 1.000 -.7068 .8135 
Ace Alone 3.94778* .33915 .000 2.7531 5.1425 
Ace PA -.67667 .21173 .103 -1.4510 .0977 
Ace Polar 4.21667* .36706 .000 2.9105 5.5229 
*. The mean difference is significant at the 0.05 level. 
VNp ANOVA 
Descriptives 
Tm_VNP   





95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
Unace Alone 9 65.4289 .31106 .10369 65.1898 65.6680 
Unace CL 9 65.4033 .29551 .09850 65.1762 65.6305 
Unace PA 9 64.9389 .18435 .06145 64.7972 65.0806 
410 
 
Unace PC 9 65.0156 .28893 .09631 64.7935 65.2376 
Unace 
PC:PE 
9 66.8378 .37077 .12359 66.5528 67.1228 
Unace PG 9 65.2011 .16811 .05604 65.0719 65.3303 
Unace Polar 9 66.8489 .11084 .03695 66.7637 66.9341 
Unace Total 9 64.9889 .60142 .20047 64.5266 65.4512 
Ace Alone 9 65.2167 .42965 .14322 64.8864 65.5469 
Ace CL 9 65.0322 .14060 .04687 64.9241 65.1403 
Ace PA 9 63.9222 .60710 .20237 63.4556 64.3889 
Ace PC 9 64.5744 .32600 .10867 64.3239 64.8250 
Ace PC:PE 9 65.6789 .05968 .01989 65.6330 65.7248 
Ace PG 9 64.4378 .42496 .14165 64.1111 64.7644 
Ace Polar 9 66.1056 .24511 .08170 65.9171 66.2940 
Ace Total 9 65.6867 .56591 .18864 65.2517 66.1217 




 Minimum Maximum  
Unace Alone 65.09 65.81  
Unace CL 65.08 65.78  
Unace PA 64.69 65.12  
Unace PC 64.79 65.40  
Unace PC:PE 66.47 67.32  
Unace PG 64.99 65.38  
Unace Polar 66.75 67.00  
Unace Total 64.18 65.47  
Ace Alone 64.93 65.96  
Ace CL 64.85 65.17  
Ace PA 63.11 64.42  
Ace PC 64.29 65.05  
Ace PC:PE 65.61 65.75  
Ace PG 63.95 64.94  
Ace Polar 65.85 66.42  
Ace Total 65.15 66.31  
Total 63.11 67.32  
Tests of Homogeneity of Variances 
 
Levene 
Statistic df1 df2 Sig. 
Tm_VNP Based on Mean 11.757 15 128 .000 
Based on Median 1.745 15 128 .050 
Based on Median and 
with adjusted df 
1.745 15 56.717 .068 
Based on trimmed 
mean 









Square F Sig. 
Between 
Groups 
83.529 15 5.569 42.733 .000 
Within Groups 16.680 128 .130   
Total 100.209 143    
 






Tm_VNP Eta-squared .834 .759 .851 
Epsilon-squared .814 .731 .834 
Omega-squared Fixed-
effect 
.813 .730 .833 
Omega-squared 
Random-effect 
.225 .153 .250 
a. Eta-squared and Epsilon-squared are estimated based on the fixed-
effect model. 
Robust Tests of Equality of Means 
Tm_VNP   
 Statistica df1 df2 Sig. 
Welch 103.939 15 47.599 .000 
Brown-
Forsythe 
42.733 15 70.087 .000 
a. Asymptotically F distributed. 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   Tm_VNP   
Games-Howell   











Unace Alone Unace CL .02556 .14302 1.000 -.5473 .5984 
Unace PA .49000 .12053 .057 -.0096 .9896 
Unace PC .41333 .14152 .300 -.1537 .9804 
Unace 
PC:PE 
-1.40889* .16132 .000 -2.0577 -.7600 
Unace PG .22778 .11786 .822 -.2659 .7215 
Unace Polar -1.42000* .11007 .000 -1.9021 -.9379 
Unace Total .44000 .22570 .814 -.5102 1.3902 
Ace Alone .21222 .17681 .995 -.5062 .9306 
412 
 
Ace CL .39667 .11379 .155 -.0898 .8831 
Ace PA 1.50667* .22738 .001 .5484 2.4650 
Ace PC .85444* .15020 .002 .2529 1.4560 
Ace PC:PE -.25000 .10558 .600 -.7308 .2308 
Ace PG .99111* .17555 .003 .2785 1.7037 
Ace Polar -.67667* .13201 .007 -1.2096 -.1438 
Ace Total -.25778 .21525 .994 -1.1577 .6421 
Unace CL Unace Alone -.02556 .14302 1.000 -.5984 .5473 
Unace PA .46444 .11610 .061 -.0141 .9430 
Unace PC .38778 .13776 .347 -.1638 .9394 
Unace 
PC:PE 
-1.43444* .15804 .000 -2.0720 -.7969 
Unace PG .20222 .11333 .884 -.2697 .6741 
Unace Polar -1.44556* .10520 .000 -1.9041 -.9870 
Unace Total .41444 .22337 .854 -.5315 1.3603 
Ace Alone .18667 .17382 .998 -.5228 .8962 
Ace CL .37111 .10908 .172 -.0925 .8347 
Ace PA 1.48111* .22507 .002 .5270 2.4352 
Ace PC .82889* .14667 .002 .2408 1.4169 
Ace PC:PE -.27556 .10049 .422 -.7322 .1811 
Ace PG .96556* .17254 .004 .2620 1.6691 
Ace Polar -.70222* .12798 .004 -1.2172 -.1872 
Ace Total -.28333 .21281 .985 -1.1782 .6116 
Unace PA Unace Alone -.49000 .12053 .057 -.9896 .0096 
Unace CL -.46444 .11610 .061 -.9430 .0141 
Unace PC -.07667 .11424 1.000 -.5465 .3931 
Unace 
PC:PE 
-1.89889* .13802 .000 -2.4826 -1.3152 
Unace PG -.26222 .08316 .213 -.5956 .0712 
Unace Polar -1.91000* .07170 .000 -2.2067 -1.6133 
Unace Total -.05000 .20968 1.000 -.9802 .8802 
Ace Alone -.27778 .15584 .880 -.9478 .3922 
Ace CL -.09333 .07728 .994 -.4060 .2194 
Ace PA 1.01667* .21149 .031 .0778 1.9555 
Ace PC .36444 .12484 .318 -.1558 .8847 
Ace PC:PE -.74000* .06459 .000 -1.0253 -.4547 
Ace PG .50111 .15441 .218 -.1619 1.1642 
Ace Polar -1.16667* .10223 .000 -1.5808 -.7526 
Ace Total -.74778 .19839 .118 -1.6236 .1280 
Unace PC Unace Alone -.41333 .14152 .300 -.9804 .1537 
Unace CL -.38778 .13776 .347 -.9394 .1638 
Unace PA .07667 .11424 1.000 -.3931 .5465 
Unace 
PC:PE 
-1.82222* .15668 .000 -2.4552 -1.1892 
Unace PG -.18556 .11142 .924 -.6484 .2773 
Unace Polar -1.83333* .10315 .000 -2.2820 -1.3847 
Unace Total .02667 .22241 1.000 -.9176 .9709 
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Ace Alone -.20111 .17259 .996 -.9071 .5049 
Ace CL -.01667 .10711 1.000 -.4707 .4374 
Ace PA 1.09333* .22411 .020 .1408 2.0459 
Ace PC .44111 .14520 .253 -.1415 1.0237 
Ace PC:PE -.66333* .09834 .004 -1.1098 -.2169 
Ace PG .57778 .17129 .160 -.1222 1.2777 
Ace Polar -1.09000* .12630 .000 -1.5977 -.5823 
Ace Total -.67111 .21180 .233 -1.5641 .2219 
Unace 
PC:PE 
Unace Alone 1.40889* .16132 .000 .7600 2.0577 
Unace CL 1.43444* .15804 .000 .7969 2.0720 
Unace PA 1.89889* .13802 .000 1.3152 2.4826 
Unace PC 1.82222* .15668 .000 1.1892 2.4552 
Unace PG 1.63667* .13570 .000 1.0568 2.2166 
Unace Polar -.01111 .12899 1.000 -.5844 .5622 
Unace Total 1.84889* .23551 .000 .8769 2.8209 
Ace Alone 1.62111* .18917 .000 .8613 2.3809 
Ace CL 1.80556* .13218 .000 1.2300 2.3811 
Ace PA 2.91556* .23712 .000 1.9359 3.8952 
Ace PC 2.26333* .16457 .000 1.6028 2.9238 
Ace PC:PE 1.15889* .12518 .000 .5856 1.7321 
Ace PG 2.40000* .18799 .000 1.6453 3.1547 
Ace Polar .73222* .14815 .012 .1252 1.3393 
Ace Total 1.15111* .22552 .009 .2262 2.0760 
Unace PG Unace Alone -.22778 .11786 .822 -.7215 .2659 
Unace CL -.20222 .11333 .884 -.6741 .2697 
Unace PA .26222 .08316 .213 -.0712 .5956 
Unace PC .18556 .11142 .924 -.2773 .6484 
Unace 
PC:PE 
-1.63667* .13570 .000 -2.2166 -1.0568 
Unace Polar -1.64778* .06712 .000 -1.9229 -1.3727 
Unace Total .21222 .20816 .998 -.7174 1.1418 
Ace Alone -.01556 .15379 1.000 -.6831 .6520 
Ace CL .16889 .07305 .622 -.1250 .4628 
Ace PA 1.27889* .20998 .007 .3406 2.2172 
Ace PC .62667* .12227 .012 .1118 1.1416 
Ace PC:PE -.47778* .05946 .001 -.7383 -.2172 
Ace PG .76333* .15234 .020 .1028 1.4238 
Ace Polar -.90444* .09907 .000 -1.3089 -.4999 
Ace Total -.48556 .19678 .547 -1.3606 .3894 
Unace Polar Unace Alone 1.42000* .11007 .000 .9379 1.9021 
Unace CL 1.44556* .10520 .000 .9870 1.9041 
Unace PA 1.91000* .07170 .000 1.6133 2.2067 
Unace PC 1.83333* .10315 .000 1.3847 2.2820 
Unace 
PC:PE 
.01111 .12899 1.000 -.5622 .5844 
Unace PG 1.64778* .06712 .000 1.3727 1.9229 
Unace Total 1.86000* .20385 .000 .9304 2.7896 
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Ace Alone 1.63222* .14791 .000 .9683 2.2961 
Ace CL 1.81667* .05968 .000 1.5758 2.0576 
Ace PA 2.92667* .20571 .000 1.9883 3.8650 
Ace PC 2.27444* .11478 .000 1.7696 2.7793 
Ace PC:PE 1.17000* .04196 .000 .9942 1.3458 
Ace PG 2.41111* .14639 .000 1.7544 3.0678 
Ace Polar .74333* .08967 .000 .3600 1.1266 
Ace Total 1.16222* .19222 .009 .2876 2.0368 
Unace Total Unace Alone -.44000 .22570 .814 -1.3902 .5102 
Unace CL -.41444 .22337 .854 -1.3603 .5315 
Unace PA .05000 .20968 1.000 -.8802 .9802 
Unace PC -.02667 .22241 1.000 -.9709 .9176 
Unace 
PC:PE 
-1.84889* .23551 .000 -2.8209 -.8769 
Unace PG -.21222 .20816 .998 -1.1418 .7174 
Unace Polar -1.86000* .20385 .000 -2.7896 -.9304 
Ace Alone -.22778 .24638 1.000 -1.2300 .7744 
Ace CL -.04333 .20588 1.000 -.9726 .8859 
Ace PA 1.06667 .28485 .079 -.0738 2.2071 
Ace PC .41444 .22803 .871 -.5404 1.3693 
Ace PC:PE -.69000 .20146 .203 -1.6207 .2407 
Ace PG .55111 .24547 .661 -.4484 1.5506 
Ace Polar -1.11667* .21648 .016 -2.0525 -.1809 
Ace Total -.69778 .27527 .493 -1.8005 .4049 
Ace Alone Unace Alone -.21222 .17681 .995 -.9306 .5062 
Unace CL -.18667 .17382 .998 -.8962 .5228 
Unace PA .27778 .15584 .880 -.3922 .9478 
Unace PC .20111 .17259 .996 -.5049 .9071 
Unace 
PC:PE 
-1.62111* .18917 .000 -2.3809 -.8613 
Unace PG .01556 .15379 1.000 -.6520 .6831 
Unace Polar -1.63222* .14791 .000 -2.2961 -.9683 
Unace Total .22778 .24638 1.000 -.7744 1.2300 
Ace CL .18444 .15069 .991 -.4805 .8494 
Ace PA 1.29444* .24792 .007 .2852 2.3037 
Ace PC .64222 .17978 .112 -.0855 1.3699 
Ace PC:PE -.46222 .14459 .261 -1.1267 .2023 
Ace PG .77889 .20144 .064 -.0276 1.5854 
Ace Polar -.88889* .16488 .007 -1.5753 -.2025 
Ace Total -.47000 .23684 .802 -1.4286 .4886 
Ace CL Unace Alone -.39667 .11379 .155 -.8831 .0898 
Unace CL -.37111 .10908 .172 -.8347 .0925 
Unace PA .09333 .07728 .994 -.2194 .4060 
Unace PC .01667 .10711 1.000 -.4374 .4707 
Unace 
PC:PE 
-1.80556* .13218 .000 -2.3811 -1.2300 
Unace PG -.16889 .07305 .622 -.4628 .1250 
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Unace Polar -1.81667* .05968 .000 -2.0576 -1.5758 
Unace Total .04333 .20588 1.000 -.8859 .9726 
Ace Alone -.18444 .15069 .991 -.8494 .4805 
Ace PA 1.11000* .20772 .018 .1719 2.0481 
Ace PC .45778 .11834 .092 -.0507 .9663 
Ace PC:PE -.64667* .05091 .000 -.8658 -.4275 
Ace PG .59444 .14921 .088 -.0634 1.2523 
Ace Polar -1.07333* .09419 .000 -1.4652 -.6815 
Ace Total -.65444 .19437 .206 -1.5289 .2200 
Ace PA Unace Alone -1.50667* .22738 .001 -2.4650 -.5484 
Unace CL -1.48111* .22507 .002 -2.4352 -.5270 
Unace PA -1.01667* .21149 .031 -1.9555 -.0778 
Unace PC -1.09333* .22411 .020 -2.0459 -.1408 
Unace 
PC:PE 
-2.91556* .23712 .000 -3.8952 -1.9359 
Unace PG -1.27889* .20998 .007 -2.2172 -.3406 
Unace Polar -2.92667* .20571 .000 -3.8650 -1.9883 
Unace Total -1.06667 .28485 .079 -2.2071 .0738 
Ace Alone -1.29444* .24792 .007 -2.3037 -.2852 
Ace CL -1.11000* .20772 .018 -2.0481 -.1719 
Ace PC -.65222 .22970 .354 -1.6151 .3106 
Ace PC:PE -1.75667* .20334 .001 -2.6962 -.8171 
Ace PG -.51556 .24702 .749 -1.5222 .4911 
Ace Polar -2.18333* .21824 .000 -3.1276 -1.2390 
Ace Total -1.76444* .27665 .001 -2.8729 -.6560 
Ace PC Unace Alone -.85444* .15020 .002 -1.4560 -.2529 
Unace CL -.82889* .14667 .002 -1.4169 -.2408 
Unace PA -.36444 .12484 .318 -.8847 .1558 
Unace PC -.44111 .14520 .253 -1.0237 .1415 
Unace 
PC:PE 
-2.26333* .16457 .000 -2.9238 -1.6028 
Unace PG -.62667* .12227 .012 -1.1416 -.1118 
Unace Polar -2.27444* .11478 .000 -2.7793 -1.7696 
Unace Total -.41444 .22803 .871 -1.3693 .5404 
Ace Alone -.64222 .17978 .112 -1.3699 .0855 
Ace CL -.45778 .11834 .092 -.9663 .0507 
Ace PA .65222 .22970 .354 -.3106 1.6151 
Ace PC:PE -1.10444* .11047 .000 -1.6083 -.6006 
Ace PG .13667 .17853 1.000 -.5854 .8587 
Ace Polar -1.53111* .13596 .000 -2.0818 -.9804 
Ace Total -1.11222* .21770 .011 -2.0175 -.2070 
Ace PC:PE Unace Alone .25000 .10558 .600 -.2308 .7308 
Unace CL .27556 .10049 .422 -.1811 .7322 
Unace PA .74000* .06459 .000 .4547 1.0253 
Unace PC .66333* .09834 .004 .2169 1.1098 
Unace 
PC:PE 
-1.15889* .12518 .000 -1.7321 -.5856 
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Unace PG .47778* .05946 .001 .2172 .7383 
Unace Polar -1.17000* .04196 .000 -1.3458 -.9942 
Unace Total .69000 .20146 .203 -.2407 1.6207 
Ace Alone .46222 .14459 .261 -.2023 1.1267 
Ace CL .64667* .05091 .000 .4275 .8658 
Ace PA 1.75667* .20334 .001 .8171 2.6962 
Ace PC 1.10444* .11047 .000 .6006 1.6083 
Ace PG 1.24111* .14304 .001 .5839 1.8984 
Ace Polar -.42667* .08409 .025 -.8054 -.0479 
Ace Total -.00778 .18968 1.000 -.8835 .8679 
Ace PG Unace Alone -.99111* .17555 .003 -1.7037 -.2785 
Unace CL -.96556* .17254 .004 -1.6691 -.2620 
Unace PA -.50111 .15441 .218 -1.1642 .1619 
Unace PC -.57778 .17129 .160 -1.2777 .1222 
Unace 
PC:PE 
-2.40000* .18799 .000 -3.1547 -1.6453 
Unace PG -.76333* .15234 .020 -1.4238 -.1028 
Unace Polar -2.41111* .14639 .000 -3.0678 -1.7544 
Unace Total -.55111 .24547 .661 -1.5506 .4484 
Ace Alone -.77889 .20144 .064 -1.5854 .0276 
Ace CL -.59444 .14921 .088 -1.2523 .0634 
Ace PA .51556 .24702 .749 -.4911 1.5222 
Ace PC -.13667 .17853 1.000 -.8587 .5854 
Ace PC:PE -1.24111* .14304 .001 -1.8984 -.5839 
Ace Polar -1.66778* .16353 .000 -2.3477 -.9879 
Ace Total -1.24889* .23590 .006 -2.2045 -.2933 
Ace Polar Unace Alone .67667* .13201 .007 .1438 1.2096 
Unace CL .70222* .12798 .004 .1872 1.2172 
Unace PA 1.16667* .10223 .000 .7526 1.5808 
Unace PC 1.09000* .12630 .000 .5823 1.5977 
Unace 
PC:PE 
-.73222* .14815 .012 -1.3393 -.1252 
Unace PG .90444* .09907 .000 .4999 1.3089 
Unace Polar -.74333* .08967 .000 -1.1266 -.3600 
Unace Total 1.11667* .21648 .016 .1809 2.0525 
Ace Alone .88889* .16488 .007 .2025 1.5753 
Ace CL 1.07333* .09419 .000 .6815 1.4652 
Ace PA 2.18333* .21824 .000 1.2390 3.1276 
Ace PC 1.53111* .13596 .000 .9804 2.0818 
Ace PC:PE .42667* .08409 .025 .0479 .8054 
Ace PG 1.66778* .16353 .000 .9879 2.3477 
Ace Total .41889 .20557 .769 -.4640 1.3018 
Ace Total Unace Alone .25778 .21525 .994 -.6421 1.1577 
Unace CL .28333 .21281 .985 -.6116 1.1782 
Unace PA .74778 .19839 .118 -.1280 1.6236 





-1.15111* .22552 .009 -2.0760 -.2262 
Unace PG .48556 .19678 .547 -.3894 1.3606 
Unace Polar -1.16222* .19222 .009 -2.0368 -.2876 
Unace Total .69778 .27527 .493 -.4049 1.8005 
Ace Alone .47000 .23684 .802 -.4886 1.4286 
Ace CL .65444 .19437 .206 -.2200 1.5289 
Ace PA 1.76444* .27665 .001 .6560 2.8729 
Ace PC 1.11222* .21770 .011 .2070 2.0175 
Ace PC:PE .00778 .18968 1.000 -.8679 .8835 
Ace PG 1.24889* .23590 .006 .2933 2.2045 
Ace Polar -.41889 .20557 .769 -1.3018 .4640 
*. The mean difference is significant at the 0.05 level. 
Lz ANOVA 
Descriptives 
Tm_Lz   





95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
Unace 
Alone 
9 63.4167 1.72327 .57442 62.0920 64.7413 
Unace CL 9 62.8733 .21154 .07051 62.7107 63.0359 
Unace Polar 9 64.0600 .30777 .10259 63.8234 64.2966 
Unace Total 9 63.7544 .90856 .30285 63.0561 64.4528 
Ace Alone 9 63.6700 1.81424 .60475 62.2755 65.0645 
Ace CL 9 63.3078 .29154 .09718 63.0837 63.5319 
Ace Polar 9 64.3856 .22260 .07420 64.2144 64.5567 
Ace Total 9 64.4178 .18687 .06229 64.2741 64.5614 
Total 72 63.7357 1.04408 .12305 63.4903 63.9810 
 
Descriptives 
Tm_Lz   
 Minimum Maximum  
Unace Alone 61.11 64.64  
Unace CL 62.57 63.08  
Unace Polar 63.66 64.75  
Unace Total 62.17 64.41  
Ace Alone 61.25 65.05  
Ace CL 62.70 63.54  
Ace Polar 64.03 64.60  
Ace Total 64.17 64.75  





Tests of Homogeneity of Variances 
 
Levene 
Statistic df1 df2 Sig. 
Tm_Lz Based on Mean 25.739 7 64 .000 
Based on Median 2.622 7 64 .019 
Based on Median and 
with adjusted df 
2.622 7 20.318 .042 
Based on trimmed 
mean 
21.161 7 64 .000 
 
ANOVA 





Square F Sig. 
Between 
Groups 
18.234 7 2.605 2.818 .013 
Within Groups 59.164 64 .924   
Total 77.398 71    
 







Tm_Lz Eta-squared .236 .013 .330 
Epsilon-squared .152 -.095 .257 
Omega-squared Fixed-
effect 
.150 -.093 .255 
Omega-squared 
Random-effect 
.025 -.012 .047 
a. Eta-squared and Epsilon-squared are estimated based on the fixed-
effect model. 
b. Negative but less biased estimates are retained, not rounded to zero. 
Robust Tests of Equality of Means 
Tm_Lz   
 Statistica df1 df2 Sig. 
Welch 45.176 7 27.020 .000 
Brown-
Forsythe 
2.818 7 21.495 .030 
a. Asymptotically F distributed. 
 
 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   Tm_Lz   
419 
 

















Unace Alone Unace CL .54333 .57873 .972 -1.7289 2.8155 
Unace Polar -.64333 .58351 .940 -2.9155 1.6289 
Unace Total -.33778 .64937 .999 -2.6837 2.0081 
Ace Alone -.25333 .83407 1.000 -3.1420 2.6354 
Ace CL .10889 .58258 1.000 -2.1632 2.3810 
Ace Polar -.96889 .57920 .703 -3.2410 1.3033 
Ace Total -1.00111 .57779 .672 -3.2734 1.2712 
Unace CL Unace Alone -.54333 .57873 .972 -2.8155 1.7289 
Unace Polar -1.18667* .12449 .000 -1.6251 -.7482 
Unace Total -.88111 .31095 .199 -2.0798 .3176 
Ace Alone -.79667 .60884 .874 -3.1889 1.5955 
Ace CL -.43444* .12007 .041 -.8555 -.0134 
Ace Polar -1.51222* .10236 .000 -1.8667 -1.1577 
Ace Total -1.54444* .09409 .000 -1.8708 -1.2180 
Unace Polar Unace Alone .64333 .58351 .940 -1.6289 2.9155 
Unace CL 1.18667* .12449 .000 .7482 1.6251 
Unace Total .30556 .31976 .971 -.8987 1.5098 
Ace Alone .39000 .61339 .997 -2.0021 2.7821 
Ace CL .75222* .14131 .001 .2628 1.2417 
Ace Polar -.32556 .12661 .241 -.7697 .1186 
Ace Total -.35778 .12002 .132 -.7853 .0697 
Unace Total Unace Alone .33778 .64937 .999 -2.0081 2.6837 
Unace CL .88111 .31095 .199 -.3176 2.0798 
Unace Polar -.30556 .31976 .971 -1.5098 .8987 
Ace Alone .08444 .67634 1.000 -2.3719 2.5407 
Ace CL .44667 .31806 .836 -.7561 1.6495 
Ace Polar -.63111 .31181 .516 -1.8301 .5679 
Ace Total -.66333 .30919 .456 -1.8615 .5349 
Ace Alone Unace Alone .25333 .83407 1.000 -2.6354 3.1420 
Unace CL .79667 .60884 .874 -1.5955 3.1889 
Unace Polar -.39000 .61339 .997 -2.7821 2.0021 
Unace Total -.08444 .67634 1.000 -2.5407 2.3719 
Ace CL .36222 .61250 .998 -2.0298 2.7543 
Ace Polar -.71556 .60928 .920 -3.1077 1.6766 
Ace Total -.74778 .60794 .902 -3.1401 1.6445 
Ace CL Unace Alone -.10889 .58258 1.000 -2.3810 2.1632 
Unace CL .43444* .12007 .041 .0134 .8555 
Unace Polar -.75222* .14131 .001 -1.2417 -.2628 
Unace Total -.44667 .31806 .836 -1.6495 .7561 
Ace Alone -.36222 .61250 .998 -2.7543 2.0298 
Ace Polar -1.07778* .12227 .000 -1.5050 -.6505 
Ace Total -1.11000* .11543 .000 -1.5190 -.7010 
420 
 
Ace Polar Unace Alone .96889 .57920 .703 -1.3033 3.2410 
Unace CL 1.51222* .10236 .000 1.1577 1.8667 
Unace Polar .32556 .12661 .241 -.1186 .7697 
Unace Total .63111 .31181 .516 -.5679 1.8301 
Ace Alone .71556 .60928 .920 -1.6766 3.1077 
Ace CL 1.07778* .12227 .000 .6505 1.5050 
Ace Total -.03222 .09688 1.000 -.3690 .3045 
Ace Total Unace Alone 1.00111 .57779 .672 -1.2712 3.2734 
Unace CL 1.54444* .09409 .000 1.2180 1.8708 
Unace Polar .35778 .12002 .132 -.0697 .7853 
Unace Total .66333 .30919 .456 -.5349 1.8615 
Ace Alone .74778 .60794 .902 -1.6445 3.1401 
Ace CL 1.11000* .11543 .000 .7010 1.5190 
Ace Polar .03222 .09688 1.000 -.3045 .3690 
*. The mean difference is significant at the 0.05 level. 
Hum1 Fluorescence 
Descriptives 
Fluorescence_Intensity   
 N Mean 
Std. 






mNg PC 1 6 7488.1667 4277.40793 1746.24447 2999.3023 
mNg PC 2 6 39631.0000 22389.61007 9140.52004 16134.5452 
mNg PC 3 6 75662.5000 23362.65825 9537.76529 51144.8938 
mNg PG 1 6 5764.8333 5490.94008 2241.66690 2.4451 
mNg PG 2 6 22881.6667 6606.99174 2697.29308 15948.0541 
mNg PG 3 6 81110.3333 30405.62610 12413.0448
8 
49201.5856 
mNg PA 1 6 1095.5000 399.20008 162.97275 676.5652 
mNg PA 2 6 8969.0000 3918.88556 1599.87833 4856.3818 





mNg Alone 1 6 6230.5000 1284.85373 524.53934 4882.1287 
mNg Alone 2 6 17214.6667 8591.58583 3507.50023 8198.3503 
mNg Alone 3 6 39540.6667 22790.72443 9304.27429 15623.2682 
FM4-64 PC 1 6 21363.3333 1181.64016 482.40258 20123.2780 
FM4-64 PC 2 6 29483.0000 17843.53749 7284.59367 10757.3558 
FM4-64 PC 3 6 39699.5000 18963.71123 7741.90269 19798.3056 
FM4-64 PG 1 6 714.0000 127.41272 52.01602 580.2886 
FM4-64 PG 2 6 2438.1667 920.35307 375.73257 1472.3154 
FM4-64 PG 3 6 222371.666
7 
2900.83337 1184.26027 219327.4287 
FM4-64 PA 1 6 847.5000 118.25185 48.27612 723.4023 
FM4-64 PA 2 6 1584.5000 278.08110 113.52614 1292.6718 
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FM4-64 PA 3 6 76251.0000 52757.76360 21538.2668
0 
20885.1226 
FM4-64 WT 1 6 2914.6667 2291.29052 935.41544 510.1047 
FM4-64 WT 2 6 2606.8333 684.82565 279.57890 1888.1529 
FM4-64 WT 3 6 4912.6667 2211.57841 902.87311 2591.7575 
FM4-64 
Background 
6 21363.3333 1181.64016 482.40258 20123.2780 
Total 150 35365.7200 55153.15465 4503.23622 26467.2659 
 
Descriptives 
Fluorescence_Intensity   
 
95% Confidence 
Interval for Mean 
Minimum 
Maximu
m Upper Bound 
mNg PC 1 11977.0310 3410.00 11586.0
0 
mNg PC 2 63127.4548 18862.00 60439.0
0 
mNg PC 3 100180.1062 51086.00 98220.0
0 
mNg PG 1 11527.2216 719.00 11044.0
0 
mNg PG 2 29815.2793 16592.00 29692.0
0 
mNg PG 3 113019.0810 53586.00 124956.
00 
mNg PA 1 1514.4348 716.00 1503.00 
mNg PA 2 13081.6182 5319.00 13116.0
0 
mNg PA 3 219361.0492 88573.00 259933.
00 
mNg Alone 1 7578.8713 5009.00 7626.00 
mNg Alone 2 26230.9830 9236.00 26016.0
0 
mNg Alone 3 63458.0651 17478.00 63201.0
0 
FM4-64 PC 1 22603.3886 20161.00 23178.0
0 
FM4-64 PC 2 48208.6442 13053.00 46350.0
0 
FM4-64 PC 3 59600.6944 21624.00 59501.0
0 
FM4-64 PG 1 847.7114 580.00 842.00 
FM4-64 PG 2 3404.0180 1502.00 3384.00 
FM4-64 PG 3 225415.9046 218369.00 226359.
00 
FM4-64 PA 1 971.5977 729.00 1010.00 
422 
 
FM4-64 PA 2 1876.3282 1285.00 1918.00 
FM4-64 PA 3 131616.8774 27109.00 152203.
00 
FM4-64 WT 1 5319.2286 1343.00 7208.00 
FM4-64 WT 2 3325.5138 1928.00 3345.00 
FM4-64 WT 3 7233.5759 2808.00 7008.00 
FM4-64 Background 22603.3886 20161.00 23178.0
0 
Total 44264.1741 580.00 259933.
00 
Tests of Homogeneity of Variances 
 Levene Statistic df1 df2 
Fluorescence_Intensi
ty 
Based on Mean 17.532 24 125 
Based on Median 9.192 24 125 
Based on Median and with 
adjusted df 
9.192 24 8.367 
Based on trimmed mean 16.216 24 125 
 
Tests of Homogeneity of Variances 
 Sig. 
Fluorescence_Intensity Based on Mean .000 
Based on Median .000 
Based on Median and with adjusted df .001 
Based on trimmed mean .000 
ANOVA 
Fluorescence_Intensity   
 
Sum of 














   









Eta-squared .887 .824 .892 
Epsilon-squared .865 .790 .872 
Omega-squared Fixed-
effect 
.864 .789 .871 
Omega-squared 
Random-effect 
.209 .135 .219 
423 
 
a. Eta-squared and Epsilon-squared are estimated based on the fixed-effect model. 
Robust Tests of Equality of Means 
Fluorescence_Intensity   
 Statistica df1 df2 Sig. 
Welch 1209.079 24 44.514 .000 
Brown-
Forsythe 
40.728 24 19.833 .000 
a. Asymptotically F distributed. 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:   Fluorescence_Intensity   





Difference (I-J) Std. Error Sig. 





mNg PC 1 mNg PC 2 -32142.83333 9305.83023 .337 -86790.5401 22504.8734 
mNg PC 3 -68174.33333* 9696.30530 .023 -
125256.2718 
-11092.3949 
mNg PG 1 1723.33333 2841.55596 1.000 -12009.3020 15455.9687 
mNg PG 2 -15393.50000 3213.21642 .061 -31339.5571 552.5571 
mNg PG 3 -73622.16667 12535.27235 .053 -
148293.0075 
1048.6742 
mNg PA 1 6392.66667 1753.83291 .296 -4159.5948 16944.9281 
mNg PA 2 -1480.83333 2368.32861 1.000 -12779.3312 9817.6645 







1257.66667 1823.32424 1.000 -9028.0562 11543.3896 
mNg Alone 
2 
-9726.50000 3918.15360 .683 -30122.6627 10669.6627 
mNg Alone 
3 
-32052.50000 9466.72540 .356 -87703.7836 23598.7836 
FM4-64 PC 
1 
-13875.16667* 1811.65173 .012 -24193.9096 -3556.4237 
FM4-64 PC 
2 
-21994.83333 7490.97288 .500 -65258.0524 21268.3858 
FM4-64 PC 
3 
-32211.33333 7936.39887 .202 -78281.0424 13858.3758 
FM4-64 PG 
1 
6774.16667 1747.01901 .249 -3814.3339 17362.6672 
FM4-64 PG 
2 
















5903.66667 1749.93084 .367 -4669.0978 16476.4311 
FM4-64 PA 
3 





4573.50000 1981.00273 .763 -5598.4644 14745.4644 
FM4-64 WT 
2 
4881.33333 1768.48357 .571 -5599.7017 15362.3684 
FM4-64 WT 
3 
2575.50000 1965.84577 .996 -7585.7763 12736.7763 
FM4-64 
Background 
-13875.16667* 1811.65173 .012 -24193.9096 -3556.4237 
mNg PC 2 mNg PC 1 32142.83333 9305.83023 .337 -22504.8734 86790.5401 
mNg PC 3 -36031.50000 13210.52888 .561 -98963.5767 26900.5767 
mNg PG 1 33866.16667 9411.38550 .294 -20377.6492 88109.9825 
mNg PG 2 16749.33333 9530.18869 .940 -37127.2128 70625.8795 
mNg PG 3 -41479.33333 15415.34267 .582 -
116499.5766 
33540.9099 
mNg PA 1 38535.50000 9141.97280 .192 -16903.0701 93974.0701 
mNg PA 2 30662.00000 9279.47828 .381 -24098.8600 85422.8600 







33400.50000 9155.55831 .297 -21964.2555 88765.2555 
mNg Alone 
2 
22416.33333 9790.38632 .766 -30935.0996 75767.7663 
mNg Alone 
3 
90.33333 13042.95314 1.000 -62020.4354 62201.1021 
FM4-64 PC 
1 
18267.66667 9153.24089 .867 -37109.5692 73644.9026 
FM4-64 PC 
2 
10148.00000 11688.21678 1.000 -46198.0439 66494.0439 
FM4-64 PC 
3 
-68.50000 11978.57102 1.000 -57490.5404 57353.5404 
FM4-64 PG 
1 
38917.00000 9140.66804 .186 -16528.7422 94362.7422 
FM4-64 PG 
2 











38783.50000 9140.64752 .188 -16662.3551 94229.3551 
FM4-64 PA 
2 
38046.50000 9141.22501 .200 -17396.1788 93489.1788 
FM4-64 PA 
3 










37024.16667 9144.79474 .218 -18398.9414 92447.2748 
FM4-64 WT 
3 
34718.33333 9185.00334 .266 -20491.7639 89928.4306 
FM4-64 
Background 
18267.66667 9153.24089 .867 -37109.5692 73644.9026 
mNg PC 3 mNg PC 1 68174.33333* 9696.30530 .023 11092.3949 125256.2718 
mNg PC 2 36031.50000 13210.52888 .561 -26900.5767 98963.5767 
mNg PG 1 69897.66667* 9797.65468 .019 13215.9021 126579.4312 
mNg PG 2 52780.83333 9911.82913 .067 -3528.9822 109090.6488 
mNg PG 3 -5447.83333 15654.15759 1.000 -81221.9843 70326.3176 
mNg PA 1 74567.00000* 9539.15756 .017 16718.4012 132415.5988 
mNg PA 2 66693.50000* 9671.01739 .026 9500.6706 123886.3294 





69432.00000* 9552.17820 .023 11654.2210 127209.7790 
mNg Alone 
2 
58447.83333* 10162.25982 .040 2698.3241 114197.3426 
mNg Alone 
3 
36121.83333 13324.35690 .569 -27333.6920 99577.3587 
FM4-64 PC 
1 
54299.16667 9549.95702 .064 -3490.5956 112088.9289 
FM4-64 PC 
2 
46179.50000 12001.42791 .169 -11955.4397 104314.4397 
FM4-64 PC 
3 
35963.00000 12284.38130 .467 -23147.1681 95073.1681 
FM4-64 PG 
1 
74948.50000* 9537.90713 .017 17093.0271 132803.9729 
FM4-64 PG 
2 










74815.00000* 9537.88747 .017 16959.4189 132670.5811 
FM4-64 PA 
2 
74078.00000* 9538.44091 .018 16225.4631 131930.5369 
FM4-64 PA 
3 





72747.83333* 9583.52591 .018 15134.9489 130360.7178 
FM4-64 WT 
2 
73055.66667* 9541.86204 .019 15221.8917 130889.4416 
FM4-64 WT 
3 
70749.83333* 9580.40430 .021 13120.8791 128378.7875 
FM4-64 
Background 
54299.16667 9549.95702 .064 -3490.5956 112088.9289 
mNg PG 1 mNg PC 1 -1723.33333 2841.55596 1.000 -15455.9687 12009.3020 
426 
 
mNg PC 2 -33866.16667 9411.38550 .294 -88109.9825 20377.6492 
mNg PC 3 -69897.66667* 9797.65468 .019 -
126579.4312 
-13215.9021 
mNg PG 2 -17116.83333* 3507.20123 .045 -33956.0390 -277.6277 
mNg PG 3 -75345.50000* 12613.83184 .047 -
149659.4170 
-1031.5830 
mNg PA 1 4669.33333 2247.58328 .840 -8896.7032 18235.3699 
mNg PA 2 -3204.16667 2754.02999 .999 -16665.0671 10256.7338 







-465.66667 2302.21893 1.000 -13789.5352 12858.2018 
mNg Alone 
2 
-11449.83333 4162.64679 .555 -32152.5386 9252.8719 
mNg Alone 
3 
-33775.83333 9570.50628 .312 -89024.6241 21472.9574 
FM4-64 PC 
1 
-15598.50000* 2292.98555 .025 -28957.0395 -2239.9605 
FM4-64 PC 
2 
-23718.16667 7621.70424 .431 -66585.5149 19149.1816 
FM4-64 PC 
3 
-33934.66667 8059.90867 .169 -79600.7612 11731.4279 
FM4-64 PG 
1 
5050.83333 2242.27031 .775 -8543.8432 18645.5099 
FM4-64 PG 
2 











4917.33333 2242.18667 .797 -8677.8019 18512.4686 
FM4-64 PA 
2 
4180.33333 2244.53975 .907 -9401.9903 17762.6570 
FM4-64 PA 
3 





2850.16667 2429.00649 .999 -10203.2663 15903.5997 
FM4-64 WT 
2 
3158.00000 2259.03405 .988 -10349.5601 16665.5601 
FM4-64 WT 
3 
852.16667 2416.66099 1.000 -12213.0775 13917.4108 
FM4-64 
Background 
-15598.50000* 2292.98555 .025 -28957.0395 -2239.9605 
mNg PG 2 mNg PC 1 15393.50000 3213.21642 .061 -552.5571 31339.5571 
mNg PC 2 -16749.33333 9530.18869 .940 -70625.8795 37127.2128 
mNg PC 3 -52780.83333 9911.82913 .067 -
109090.6488 
3528.9822 
mNg PG 1 17116.83333* 3507.20123 .045 277.6277 33956.0390 
427 
 
mNg PG 3 -58228.66667 12702.71912 .131 -
132179.1800 
15721.8466 
mNg PA 1 21786.16667* 2702.21207 .015 5451.0619 38121.2714 
mNg PA 2 13912.66667 3136.08046 .097 -1890.2503 29715.5837 







16651.16667* 2747.82305 .043 532.3735 32769.9598 
mNg Alone 
2 
5667.00000 4424.69748 .998 -15748.6859 27082.6859 
mNg Alone 
3 
-16659.00000 9687.35826 .948 -71538.3055 38220.3055 
FM4-64 PC 
1 
1518.33333 2740.09164 1.000 -14633.3172 17669.9838 
FM4-64 PC 
2 
-6601.33333 7767.92733 1.000 -49170.6533 35967.9866 
FM4-64 PC 
3 
-16817.83333 8198.31978 .858 -62158.8771 28523.2104 
FM4-64 PG 
1 
22167.66667* 2697.79459 .014 5808.5955 38526.7379 
FM4-64 PG 
2 











22034.16667* 2697.72507 .014 5674.7138 38393.6195 
FM4-64 PA 
2 
21297.16667* 2699.68112 .016 4948.3994 37645.9339 
FM4-64 PA 
3 





19967.00000* 2854.88914 .016 4167.3723 35766.6277 
FM4-64 WT 
2 
20274.83333* 2711.74378 .020 3989.5515 36560.1152 
FM4-64 WT 
3 
17969.00000* 2844.39270 .027 2148.1285 33789.8715 
FM4-64 
Background 
1518.33333 2740.09164 1.000 -14633.3172 17669.9838 
mNg PG 3 mNg PC 1 73622.16667 12535.27235 .053 -1048.6742 148293.0075 
mNg PC 2 41479.33333 15415.34267 .582 -33540.9099 116499.5766 
mNg PC 3 5447.83333 15654.15759 1.000 -70326.3176 81221.9843 
mNg PG 1 75345.50000* 12613.83184 .047 1031.5830 149659.4170 
mNg PG 2 58228.66667 12702.71912 .131 -15721.8466 132179.1800 
mNg PA 1 80014.83333* 12414.11468 .039 4722.9672 155306.6995 
mNg PA 2 72141.33333 12515.72186 .058 -2623.7852 146906.4519 







74879.83333 12424.12269 .051 -357.3344 150117.0011 
mNg Alone 
2 
63895.66667 12899.07907 .090 -9391.7740 137183.1073 
mNg Alone 
3 
41569.66667 15513.00110 .587 -33750.9695 116890.3028 
FM4-64 PC 
1 
59747.00000 12422.41504 .122 -15499.4563 134993.4563 
FM4-64 PC 
2 
51627.33333 14392.67133 .248 -21038.5589 124293.2256 
FM4-64 PC 
3 
41410.83333 14629.44771 .519 -31653.8879 114475.5546 
FM4-64 PG 
1 
80396.33333* 12413.15386 .038 5099.1827 155693.4840 
FM4-64 PG 
2 










80262.83333* 12413.13875 .038 4965.5995 155560.0671 
FM4-64 PA 
2 
79525.83333* 12413.56400 .040 4230.9392 154820.7275 
FM4-64 PA 
3 





78195.66667* 12448.24024 .042 3087.7420 153303.5913 
FM4-64 WT 
2 
78503.50000* 12416.19295 .042 3223.0445 153783.9555 
FM4-64 WT 
3 
76197.66667* 12445.83717 .047 1077.0259 151318.3074 
FM4-64 
Background 
59747.00000 12422.41504 .122 -15499.4563 134993.4563 
mNg PA 1 mNg PC 1 -6392.66667 1753.83291 .296 -16944.9281 4159.5948 
mNg PC 2 -38535.50000 9141.97280 .192 -93974.0701 16903.0701 
mNg PC 3 -74567.00000* 9539.15756 .017 -
132415.5988 
-16718.4012 
mNg PG 1 -4669.33333 2247.58328 .840 -18235.3699 8896.7032 
mNg PG 2 -21786.16667* 2702.21207 .015 -38121.2714 -5451.0619 
mNg PG 3 -80014.83333* 12414.11468 .039 -
155306.6995 
-4722.9672 
mNg PA 2 -7873.50000 1608.15757 .111 -17534.4775 1787.4775 







-5135.00000* 549.27373 .004 -8220.5788 -2049.4212 
mNg Alone 
2 





-38445.16667 9305.70149 .205 -94877.2132 17986.8799 
FM4-64 PC 
1 
-20267.83333* 509.18794 .000 -23096.3486 -17439.3180 
FM4-64 PC 
2 
-28387.50000 7286.41648 .246 -72565.9601 15790.9601 
FM4-64 PC 
3 
-38604.00000 7743.61785 .107 -85557.0942 8349.0942 
FM4-64 PG 
1 
381.50000 171.07245 .789 -576.1743 1339.1743 
FM4-64 PG 
2 











248.00000 169.97264 .985 -712.4607 1208.4607 
FM4-64 PA 
2 
-489.00000 198.61596 .694 -1463.2393 485.2393 
FM4-64 PA 
3 





-1819.16667 949.50627 .894 -7423.8115 3785.4782 
FM4-64 WT 
2 
-1511.33333 323.61162 .076 -3147.1861 124.5194 
FM4-64 WT 
3 
-3817.16667 917.46387 .190 -9222.5100 1588.1767 
FM4-64 
Background 
-20267.83333* 509.18794 .000 -23096.3486 -17439.3180 
mNg PA 2 mNg PC 1 1480.83333 2368.32861 1.000 -9817.6645 12779.3312 
mNg PC 2 -30662.00000 9279.47828 .381 -85422.8600 24098.8600 
mNg PC 3 -66693.50000* 9671.01739 .026 -
123886.3294 
-9500.6706 
mNg PG 1 3204.16667 2754.02999 .999 -10256.7338 16665.0671 
mNg PG 2 -13912.66667 3136.08046 .097 -29715.5837 1890.2503 
mNg PG 3 -72141.33333 12515.72186 .058 -
146906.4519 
2623.7852 
mNg PA 1 7873.50000 1608.15757 .111 -1787.4775 17534.4775 







2738.50000 1683.67223 .966 -6653.0321 12130.0321 
mNg Alone 
2 
-8245.66667 3855.14831 .830 -28639.9420 12148.6087 
mNg Alone 
3 
-30571.66667 9440.82257 .401 -86335.1819 25191.8486 
FM4-64 PC 
1 





-20514.00000 7458.21129 .573 -63897.9365 22869.9365 
FM4-64 PC 
3 
-30730.50000 7905.48341 .235 -76919.8553 15458.8553 
FM4-64 PG 
1 
8255.00000 1600.72369 .094 -1445.2552 17955.2552 
FM4-64 PG 
2 











8121.50000 1600.60653 .100 -1579.3955 17822.3955 
FM4-64 PA 
2 
7384.50000 1603.90113 .141 -2298.6436 17067.6436 
FM4-64 PA 
3 





6054.33333 1853.27081 .346 -3308.7921 15417.4588 
FM4-64 WT 
2 
6362.16667 1624.12285 .233 -3223.0458 15947.3792 
FM4-64 WT 
3 
4056.33333 1837.06029 .807 -5285.4213 13398.0880 
FM4-64 
Background 
-12394.33333* 1671.02451 .013 -21816.5399 -2972.1268 
mNg PA 3 mNg PC 1 144515.83333 26261.15921 .073 -14117.3796 303149.0463 
mNg PC 2 112373.00000 27751.54446 .186 -41079.9831 265825.9831 
mNg PC 3 76341.50000 27884.90775 .572 -76873.9939 229556.9939 
mNg PG 1 146239.16667 26298.74871 .069 -12195.7008 304674.0341 
mNg PG 2 129122.33333 26341.49774 .111 -29091.9297 287336.5964 
mNg PG 3 70893.66667 28994.53046 .700 -81435.2238 223222.5571 
mNg PA 1 150908.50000 26203.54315 .062 -8036.7943 309853.7943 
mNg PA 2 143035.00000 26251.83277 .076 -15648.0645 301718.0645 
mNg Alone 
1 
145773.50000 26208.28599 .071 -13145.7317 304692.7317 
mNg Alone 
2 
134789.33333 26436.74850 .094 -22952.0084 292530.6750 
mNg Alone 
3 
112463.33333 27805.91004 .186 -40889.0459 265815.7126 
FM4-64 PC 
1 
130640.66667 26207.47652 .107 -28283.0085 289564.3418 
FM4-64 PC 
2 
122521.00000 27196.77220 .133 -32278.6791 277320.6791 
FM4-64 PC 
3 
112304.50000 27322.81410 .184 -42135.4396 266744.4396 
FM4-64 PG 
1 
151290.00000 26203.08797 .061 -7657.7992 310237.7992 
FM4-64 PG 
2 










151156.50000 26203.08081 .061 -7791.3386 310104.3386 
FM4-64 PA 
2 
150419.50000 26203.28226 .062 -8527.2299 309366.2299 
FM4-64 PA 
3 
75753.00000 33918.96298 .803 -87264.2805 238770.2805 
FM4-64 WT 
1 
149089.33333 26219.72760 .065 -9767.3018 307945.9684 
FM4-64 WT 
2 
149397.16667 26204.52781 .064 -9542.7113 308337.0446 
FM4-64 WT 
3 
147091.33333 26218.58679 .068 -11771.5256 305954.1922 
FM4-64 
Background 
130640.66667 26207.47652 .107 -28283.0085 289564.3418 
mNg Alone 
1 
mNg PC 1 -1257.66667 1823.32424 1.000 -11543.3896 9028.0562 
mNg PC 2 -33400.50000 9155.55831 .297 -88765.2555 21964.2555 
mNg PC 3 -69432.00000* 9552.17820 .023 -
127209.7790 
-11654.2210 
mNg PG 1 465.66667 2302.21893 1.000 -12858.2018 13789.5352 
mNg PG 2 -16651.16667* 2747.82305 .043 -32769.9598 -532.3735 
mNg PG 3 -74879.83333 12424.12269 .051 -
150117.0011 
357.3344 
mNg PA 1 5135.00000* 549.27373 .004 2049.4212 8220.5788 
mNg PA 2 -2738.50000 1683.67223 .966 -12130.0321 6653.0321 







-10984.16667 3546.50523 .448 -32062.4937 10094.1603 
mNg Alone 
3 
-33310.16667 9319.04832 .314 -89669.6629 23049.3295 
FM4-64 PC 
1 
-15132.83333* 712.63859 .000 -18532.0485 -11733.6182 
FM4-64 PC 
2 
-23252.50000 7303.45442 .423 -67339.0701 20834.0701 
FM4-64 PC 
3 
-33469.00000 7759.65197 .176 -80335.4166 13397.4166 
FM4-64 PG 
1 
5516.50000* 527.11212 .004 2348.3074 8684.6926 
FM4-64 PG 
2 











5383.00000* 526.75621 .005 2212.9734 8553.0266 
FM4-64 PA 
2 










3315.83333 1072.44746 .413 -2144.1722 8775.8388 
FM4-64 WT 
2 
3623.66667* 594.39539 .019 568.7332 6678.6002 
FM4-64 WT 
3 
1317.83333 1044.18454 .998 -3963.7448 6599.4115 
FM4-64 
Background 
-15132.83333* 712.63859 .000 -18532.0485 -11733.6182 
mNg Alone 
2 
mNg PC 1 9726.50000 3918.15360 .683 -10669.6627 30122.6627 
mNg PC 2 -22416.33333 9790.38632 .766 -75767.7663 30935.0996 
mNg PC 3 -58447.83333* 10162.25982 .040 -
114197.3426 
-2698.3241 
mNg PG 1 11449.83333 4162.64679 .555 -9252.8719 32152.5386 
mNg PG 2 -5667.00000 4424.69748 .998 -27082.6859 15748.6859 
mNg PG 3 -63895.66667 12899.07907 .090 -
137183.1073 
9391.7740 
mNg PA 1 16119.16667 3511.28437 .143 -5136.7246 37375.0579 
mNg PA 2 8245.66667 3855.14831 .830 -12148.6087 28639.9420 







10984.16667 3546.50523 .448 -10094.1603 32062.4937 
mNg Alone 
3 
-22326.00000 9943.44397 .785 -76664.7539 32012.7539 
FM4-64 PC 
1 
-4148.66667 3540.51834 .998 -25255.3456 16958.0122 
FM4-64 PC 
2 
-12268.33333 8085.03945 .983 -54617.5252 30080.8586 
FM4-64 PC 
3 
-22484.83333 8499.38910 .610 -67502.8398 22533.1732 
FM4-64 PG 
1 
16500.66667 3507.88590 .132 -4773.7709 37775.1043 
FM4-64 PG 
2 











16367.16667 3507.83244 .136 -4907.5648 37641.8981 
FM4-64 PA 
2 
15630.16667 3509.33698 .159 -5636.3206 36896.6539 
FM4-64 PA 
3 





14300.00000 3630.09089 .218 -6453.2866 35053.2866 
FM4-64 WT 
2 





12302.00000 3621.84175 .346 -8477.8771 33081.8771 
FM4-64 
Background 
-4148.66667 3540.51834 .998 -25255.3456 16958.0122 
mNg Alone 
3 
mNg PC 1 32052.50000 9466.72540 .356 -23598.7836 87703.7836 
mNg PC 2 -90.33333 13042.95314 1.000 -62201.1021 62020.4354 
mNg PC 3 -36121.83333 13324.35690 .569 -99577.3587 27333.6920 
mNg PG 1 33775.83333 9570.50628 .312 -21472.9574 89024.6241 
mNg PG 2 16659.00000 9687.35826 .948 -38220.3055 71538.3055 
mNg PG 3 -41569.66667 15513.00110 .587 -
116890.3028 
33750.9695 
mNg PA 1 38445.16667 9305.70149 .205 -17986.8799 94877.2132 
mNg PA 2 30571.66667 9440.82257 .401 -25191.8486 86335.1819 







33310.16667 9319.04832 .314 -23049.3295 89669.6629 
mNg Alone 
2 
22326.00000 9943.44397 .785 -32012.7539 76664.7539 
FM4-64 PC 
1 
18177.33333 9316.77156 .881 -38194.4336 74549.1002 
FM4-64 PC 
2 
10057.66667 11816.71803 1.000 -47017.5710 67132.9043 
FM4-64 PC 
3 
-158.83333 12103.99014 1.000 -58267.8966 57950.2300 
FM4-64 PG 
1 
38826.66667 9304.41969 .198 -17612.4261 95265.7594 
FM4-64 PG 
2 











38693.16667 9304.39953 .200 -17746.0370 95132.3703 
FM4-64 PA 
2 
37956.16667 9304.96686 .213 -18479.9165 94392.2499 
FM4-64 PA 
3 





36626.00000 9351.17758 .239 -19564.8808 92816.8808 
FM4-64 WT 
2 
36933.83333 9308.47380 .232 -19483.0208 93350.6875 
FM4-64 WT 
3 
34628.00000 9347.97839 .282 -21579.2936 90835.2936 
FM4-64 
Background 
18177.33333 9316.77156 .881 -38194.4336 74549.1002 
FM4-64 PC 
1 
mNg PC 1 13875.16667* 1811.65173 .012 3556.4237 24193.9096 
mNg PC 2 -18267.66667 9153.24089 .867 -73644.9026 37109.5692 
434 
 
mNg PC 3 -54299.16667 9549.95702 .064 -
112088.9289 
3490.5956 
mNg PG 1 15598.50000* 2292.98555 .025 2239.9605 28957.0395 
mNg PG 2 -1518.33333 2740.09164 1.000 -17669.9838 14633.3172 
mNg PG 3 -59747.00000 12422.41504 .122 -
134993.4563 
15499.4563 
mNg PA 1 20267.83333* 509.18794 .000 17439.3180 23096.3486 
mNg PA 2 12394.33333* 1671.02451 .013 2972.1268 21816.5399 







15132.83333* 712.63859 .000 11733.6182 18532.0485 
mNg Alone 
2 
4148.66667 3540.51834 .998 -16958.0122 25255.3456 
mNg Alone 
3 
-18177.33333 9316.77156 .881 -74549.1002 38194.4336 
FM4-64 PC 
2 
-8119.66667 7300.54911 .999 -52221.6882 35982.3549 
FM4-64 PC 
3 
-18336.16667 7756.91753 .731 -65217.1834 28544.8501 
FM4-64 PG 
1 
20649.33333* 485.19884 .000 17737.8361 23560.8305 
FM4-64 PG 
2 











20515.83333* 484.81216 .000 17602.3676 23429.2991 
FM4-64 PA 
2 
19778.83333* 495.58090 .000 16912.0955 22645.5711 
FM4-64 PA 
3 





18448.66667* 1052.48007 .000 13005.8744 23891.4589 
FM4-64 WT 
2 
18756.50000* 557.56310 .000 15935.0420 21577.9580 
FM4-64 WT 
3 
16450.66667* 1023.66600 .000 11191.8635 21709.4698 
FM4-64 
Background 
.00000 682.22026 1.000 -3248.4905 3248.4905 
FM4-64 PC 
2 
mNg PC 1 21994.83333 7490.97288 .500 -21268.3858 65258.0524 
mNg PC 2 -10148.00000 11688.21678 1.000 -66494.0439 46198.0439 
mNg PC 3 -46179.50000 12001.42791 .169 -
104314.4397 
11955.4397 
mNg PG 1 23718.16667 7621.70424 .431 -19149.1816 66585.5149 
mNg PG 2 6601.33333 7767.92733 1.000 -35967.9866 49170.6533 





mNg PA 1 28387.50000 7286.41648 .246 -15790.9601 72565.9601 
mNg PA 2 20514.00000 7458.21129 .573 -22869.9365 63897.9365 







23252.50000 7303.45442 .423 -20834.0701 67339.0701 
mNg Alone 
2 
12268.33333 8085.03945 .983 -30080.8586 54617.5252 
mNg Alone 
3 
-10057.66667 11816.71803 1.000 -67132.9043 47017.5710 
FM4-64 PC 
1 
8119.66667 7300.54911 .999 -35982.3549 52221.6882 
FM4-64 PC 
3 
-10216.50000 10630.25692 1.000 -60880.4886 40447.4886 
FM4-64 PG 
1 
28769.00000 7284.77938 .236 -15418.4526 72956.4526 
FM4-64 PG 
2 











28635.50000 7284.75364 .239 -15552.0942 72823.0942 
FM4-64 PA 
2 
27898.50000 7285.47824 .259 -16285.1103 72082.1103 
FM4-64 PA 
3 





26568.33333 7344.40651 .300 -17309.7293 70446.3960 
FM4-64 WT 
2 
26876.16667 7289.95675 .289 -17282.9454 71035.2787 
FM4-64 WT 
3 
24570.33333 7340.33275 .371 -19327.7069 68468.3736 
FM4-64 
Background 
8119.66667 7300.54911 .999 -35982.3549 52221.6882 
FM4-64 PC 
3 
mNg PC 1 32211.33333 7936.39887 .202 -13858.3758 78281.0424 
mNg PC 2 68.50000 11978.57102 1.000 -57353.5404 57490.5404 
mNg PC 3 -35963.00000 12284.38130 .467 -95073.1681 23147.1681 
mNg PG 1 33934.66667 8059.90867 .169 -11731.4279 79600.7612 
mNg PG 2 16817.83333 8198.31978 .858 -28523.2104 62158.8771 
mNg PG 3 -41410.83333 14629.44771 .519 -
114475.5546 
31653.8879 
mNg PA 1 38604.00000 7743.61785 .107 -8349.0942 85557.0942 
mNg PA 2 30730.50000 7905.48341 .235 -15458.8553 76919.8553 












22484.83333 8499.38910 .610 -22533.1732 67502.8398 
mNg Alone 
3 
158.83333 12103.99014 1.000 -57950.2300 58267.8966 
FM4-64 PC 
1 
18336.16667 7756.91753 .731 -28544.8501 65217.1834 
FM4-64 PC 
2 
10216.50000 10630.25692 1.000 -40447.4886 60880.4886 
FM4-64 PG 
1 
38985.50000 7742.07743 .103 -7976.0575 85947.0575 
FM4-64 PG 
2 











38852.00000 7742.05321 .104 -8109.6908 85813.6908 
FM4-64 PA 
2 
38115.00000 7742.73501 .112 -8842.9417 85072.9417 
FM4-64 PA 
3 





36784.83333 7798.20872 .127 -9883.4986 83453.1653 
FM4-64 WT 
2 
37092.66667 7746.94918 .124 -9842.2066 84027.5399 
FM4-64 WT 
3 
34786.83333 7794.37214 .154 -11900.5675 81474.2341 
FM4-64 
Background 
18336.16667 7756.91753 .731 -28544.8501 65217.1834 
FM4-64 PG 
1 
mNg PC 1 -6774.16667 1747.01901 .249 -17362.6672 3814.3339 
mNg PC 2 -38917.00000 9140.66804 .186 -94362.7422 16528.7422 
mNg PC 3 -74948.50000* 9537.90713 .017 -
132803.9729 
-17093.0271 
mNg PG 1 -5050.83333 2242.27031 .775 -18645.5099 8543.8432 
mNg PG 2 -22167.66667* 2697.79459 .014 -38526.7379 -5808.5955 
mNg PG 3 -80396.33333* 12413.15386 .038 -
155693.4840 
-5099.1827 
mNg PA 1 -381.50000 171.07245 .789 -1339.1743 576.1743 
mNg PA 2 -8255.00000 1600.72369 .094 -17955.2552 1445.2552 







-5516.50000* 527.11212 .004 -8684.6926 -2348.3074 
mNg Alone 
2 
-16500.66667 3507.88590 .132 -37775.1043 4773.7709 
mNg Alone 
3 
-38826.66667 9304.41969 .198 -95265.7594 17612.4261 
FM4-64 PC 
1 





-28769.00000 7284.77938 .236 -72956.4526 15418.4526 
FM4-64 PC 
3 
-38985.50000 7742.07743 .103 -85947.0575 7976.0575 
FM4-64 PG 
2 











-133.50000 70.96654 .930 -471.8830 204.8830 
FM4-64 PA 
2 
-870.50000* 124.87534 .011 -1530.5700 -210.4300 
FM4-64 PA 
3 





-2200.66667 936.86056 .737 -7867.0469 3465.7136 
FM4-64 WT 
2 
-1892.83333* 284.37656 .029 -3565.4232 -220.2434 
FM4-64 WT 
3 
-4198.66667 904.37023 .137 -9667.3680 1270.0347 
FM4-64 
Background 
-20649.33333* 485.19884 .000 -23560.8305 -17737.8361 
FM4-64 PG 
2 
mNg PC 1 -5050.00000 1786.20960 .543 -15456.2644 5356.2644 
mNg PC 2 -37192.83333 9148.23926 .215 -92597.1605 18211.4938 
mNg PC 3 -73224.33333* 9545.16326 .018 -
131040.0948 
-15408.5718 
mNg PG 1 -3326.66667 2272.93763 .982 -16768.9460 10115.6126 
mNg PG 2 -20443.50000* 2723.33710 .018 -36671.5631 -4215.4369 
mNg PG 3 -78672.16667* 12418.73013 .042 -
153938.7289 
-3405.6044 
mNg PA 1 1342.66667 409.55473 .360 -843.5073 3528.8406 
mNg PA 2 -6530.83333 1643.40671 .215 -16038.9511 2977.2844 







-3792.33333* 645.22591 .016 -6944.3684 -640.2982 
mNg Alone 
2 
-14776.50000 3527.56755 .192 -35947.0380 6394.0380 
mNg Alone 
3 
-37102.50000 9311.85776 .229 -93500.8972 19295.8972 
FM4-64 PC 
1 
-18925.16667* 611.46317 .000 -21880.2882 -15970.0452 
FM4-64 PC 
2 
-27044.83333 7294.27721 .284 -71180.5150 17090.8483 
FM4-64 PC 
3 
-37261.33333 7751.01491 .121 -84174.1202 9651.4536 
FM4-64 PG 
1 













1590.66667 378.82126 .189 -672.5054 3853.8387 
FM4-64 PA 
2 
853.66667 392.50878 .810 -1358.9681 3066.3014 
FM4-64 PA 
3 





-476.50000 1008.05605 1.000 -5928.8498 4975.8498 
FM4-64 WT 
2 
-168.66667 468.33676 1.000 -2444.7385 2107.4052 
FM4-64 WT 
3 
-2474.50000 977.93395 .662 -7732.3503 2783.3503 
FM4-64 
Background 
-18925.16667* 611.46317 .000 -21880.2882 -15970.0452 
FM4-64 PG 
3 
mNg PC 1 214883.50000* 2109.93889 .000 204491.2480 225275.7520 
mNg PC 2 182740.66667* 9216.91808 .000 127690.1750 237791.1583 
mNg PC 3 146709.16667* 9611.00615 .001 89234.4672 204183.8662 
mNg PG 1 216606.83333* 2535.25992 .000 203555.0596 229658.6070 
mNg PG 2 199490.00000* 2945.82117 .000 183799.2027 215180.7973 
mNg PG 3 141261.33333* 12469.40879 .003 66263.8958 216258.7709 
mNg PA 1 221276.16667* 1195.42147 .000 214149.8432 228402.4901 
mNg PA 2 213402.66667* 1990.49819 .000 203722.4254 223082.9080 
mNg PA 3 70367.66667 26229.78432 .603 -88434.2703 229169.6036 
mNg Alone 
1 
216141.16667* 1295.22735 .000 209252.9552 223029.3781 
mNg Alone 
2 
205157.00000* 3702.03055 .000 184590.6892 225723.3108 
mNg Alone 
3 
182831.00000* 9379.33859 .000 126781.0705 238880.9295 
FM4-64 PC 
1 
201008.33333* 1278.74338 .000 194108.1379 207908.5288 
FM4-64 PC 
2 
192888.66667* 7380.22882 .000 149179.2401 236598.0932 
FM4-64 PC 
3 
182672.16667* 7831.95567 .000 136165.6317 229178.7017 
FM4-64 PG 
1 
221657.66667* 1185.40206 .000 214480.1640 228835.1694 
FM4-64 PG 
2 
219933.50000* 1242.43605 .000 212972.8315 226894.1685 
FM4-64 PA 
1 
221524.16667* 1185.24384 .000 214345.8043 228702.5291 
FM4-64 PA 
2 
220787.16667* 1189.68927 .000 213632.3402 227941.9932 
FM4-64 PA 
3 





219457.00000* 1509.13035 .000 212174.9207 226739.0793 
FM4-64 WT 
2 
219764.83333* 1216.81418 .000 212727.9466 226801.7201 
FM4-64 WT 
3 
217459.00000* 1489.17837 .000 210243.8468 224674.1532 
FM4-64 
Background 
201008.33333* 1278.74338 .000 194108.1379 207908.5288 
FM4-64 PA 
1 
mNg PC 1 -6640.66667 1746.91166 .264 -17229.7546 3948.4213 
mNg PC 2 -38783.50000 9140.64752 .188 -94229.3551 16662.3551 
mNg PC 3 -74815.00000* 9537.88747 .017 -
132670.5811 
-16959.4189 
mNg PG 1 -4917.33333 2242.18667 .797 -18512.4686 8677.8019 
mNg PG 2 -22034.16667* 2697.72507 .014 -38393.6195 -5674.7138 
mNg PG 3 -80262.83333* 12413.13875 .038 -
155560.0671 
-4965.5995 
mNg PA 1 -248.00000 169.97264 .985 -1208.4607 712.4607 
mNg PA 2 -8121.50000 1600.60653 .100 -17822.3955 1579.3955 







-5383.00000* 526.75621 .005 -8553.0266 -2212.9734 
mNg Alone 
2 
-16367.16667 3507.83244 .136 -37641.8981 4907.5648 
mNg Alone 
3 
-38693.16667 9304.39953 .200 -95132.3703 17746.0370 
FM4-64 PC 
1 
-20515.83333* 484.81216 .000 -23429.2991 -17602.3676 
FM4-64 PC 
2 
-28635.50000 7284.75364 .239 -72823.0942 15552.0942 
FM4-64 PC 
3 
-38852.00000 7742.05321 .104 -85813.6908 8109.6908 
FM4-64 PG 
1 
133.50000 70.96654 .930 -204.8830 471.8830 
FM4-64 PG 
2 











-737.00000* 123.36437 .029 -1397.7970 -76.2030 
FM4-64 PA 
3 





-2067.16667 936.66036 .792 -7734.6263 3600.2930 
FM4-64 WT 
2 
-1759.33333* 283.71631 .041 -3434.7879 -83.8788 
FM4-64 WT 
3 





-20515.83333* 484.81216 .000 -23429.2991 -17602.3676 
FM4-64 PA 
2 
mNg PC 1 -5903.66667 1749.93084 .367 -16476.4311 4669.0978 
mNg PC 2 -38046.50000 9141.22501 .200 -93489.1788 17396.1788 
mNg PC 3 -74078.00000* 9538.44091 .018 -
131930.5369 
-16225.4631 
mNg PG 1 -4180.33333 2244.53975 .907 -17762.6570 9401.9903 
mNg PG 2 -21297.16667* 2699.68112 .016 -37645.9339 -4948.3994 
mNg PG 3 -79525.83333* 12413.56400 .040 -
154820.7275 
-4230.9392 
mNg PA 1 489.00000 198.61596 .694 -485.2393 1463.2393 
mNg PA 2 -7384.50000 1603.90113 .141 -17067.6436 2298.6436 







-4646.00000* 536.68399 .008 -7771.3059 -1520.6941 
mNg Alone 
2 
-15630.16667 3509.33698 .159 -36896.6539 5636.3206 
mNg Alone 
3 
-37956.16667 9304.96686 .213 -94392.2499 18479.9165 
FM4-64 PC 
1 
-19778.83333* 495.58090 .000 -22645.5711 -16912.0955 
FM4-64 PC 
2 
-27898.50000 7285.47824 .259 -72082.1103 16285.1103 
FM4-64 PC 
3 
-38115.00000 7742.73501 .112 -85072.9417 8842.9417 
FM4-64 PG 
1 
870.50000* 124.87534 .011 210.4300 1530.5700 
FM4-64 PG 
2 











737.00000* 123.36437 .029 76.2030 1397.7970 
FM4-64 PA 
3 





-1330.16667 942.27927 .987 -6968.5679 4308.2346 
FM4-64 WT 
2 
-1022.33333 301.74914 .329 -2651.4604 606.7937 
FM4-64 WT 
3 
-3328.16667 909.98243 .291 -8768.0262 2111.6929 
FM4-64 
Background 
-19778.83333* 495.58090 .000 -22645.5711 -16912.0955 
FM4-64 PA 
3 
mNg PC 1 68762.83333 21608.94043 .423 -61508.7109 199034.3776 
mNg PC 2 36620.00000 23397.56490 .977 -88752.2250 161992.2250 





mNg PG 1 70486.16667 21654.60706 .400 -59549.2778 200521.6112 
mNg PG 2 53369.33333 21706.50425 .693 -76406.5596 183145.2263 
mNg PG 3 -4859.33333 24859.21599 1.000 -
130784.1948 
121065.5281 
mNg PA 1 75155.50000 21538.88337 .337 -55492.6158 205803.6158 
mNg PA 2 67282.00000 21597.60513 .445 -63049.2841 197613.2841 





70020.50000 21544.65312 .404 -60595.9340 200636.9340 
mNg Alone 
2 
59036.33333 21821.99566 .593 -70194.4034 188267.0701 
mNg Alone 
3 
36710.33333 23462.02158 .977 -88617.8207 162038.4874 
FM4-64 PC 
1 
54887.66667 21543.66842 .657 -75734.1658 185509.4991 
FM4-64 PC 
2 
46768.00000 22736.80368 .855 -79513.8691 173049.8691 
FM4-64 PC 
3 
36551.50000 22887.41999 .971 -89444.5463 162547.5463 
FM4-64 PG 
1 
75537.00000 21538.32961 .332 -55114.1628 206188.1628 
FM4-64 PG 
2 










75403.50000 21538.32090 .334 -55247.7108 206054.7108 
FM4-64 PA 
2 
74666.50000 21538.56599 .343 -55983.3620 205316.3620 
FM4-64 WT 
1 
73336.33333 21558.56996 .359 -57204.1803 203876.8470 
FM4-64 WT 
2 
73644.16667 21540.08127 .355 -56997.3615 204285.6948 
FM4-64 WT 
3 
71338.33333 21557.18248 .386 -59209.7180 201886.3846 
FM4-64 
Background 
54887.66667 21543.66842 .657 -75734.1658 185509.4991 
FM4-64 WT 
1 
mNg PC 1 -4573.50000 1981.00273 .763 -14745.4644 5598.4644 
mNg PC 2 -36716.33333 9188.25928 .224 -91909.7695 18477.1029 
mNg PC 3 -72747.83333* 9583.52591 .018 -
130360.7178 
-15134.9489 
mNg PG 1 -2850.16667 2429.00649 .999 -15903.5997 10203.2663 
mNg PG 2 -19967.00000* 2854.88914 .016 -35766.6277 -4167.3723 
mNg PG 3 -78195.66667* 12448.24024 .042 -
153303.5913 
-3087.7420 
mNg PA 1 1819.16667 949.50627 .894 -3785.4782 7423.8115 
mNg PA 2 -6054.33333 1853.27081 .346 -15417.4588 3308.7921 
442 
 







-3315.83333 1072.44746 .413 -8775.8388 2144.1722 
mNg Alone 
2 
-14300.00000 3630.09089 .218 -35053.2866 6453.2866 
mNg Alone 
3 
-36626.00000 9351.17758 .239 -92816.8808 19564.8808 
FM4-64 PC 
1 
-18448.66667* 1052.48007 .000 -23891.4589 -13005.8744 
FM4-64 PC 
2 
-26568.33333 7344.40651 .300 -70446.3960 17309.7293 
FM4-64 PC 
3 
-36784.83333 7798.20872 .127 -83453.1653 9883.4986 
FM4-64 PG 
1 
2200.66667 936.86056 .737 -3465.7136 7867.0469 
FM4-64 PG 
2 











2067.16667 936.66036 .792 -3600.2930 7734.6263 
FM4-64 PA 
2 
1330.16667 942.27927 .987 -4308.2346 6968.5679 
FM4-64 PA 
3 





307.83333 976.30242 1.000 -5203.0178 5818.6845 
FM4-64 WT 
3 
-1998.00000 1300.06996 .987 -8190.3966 4194.3966 
FM4-64 
Background 
-18448.66667* 1052.48007 .000 -23891.4589 -13005.8744 
FM4-64 WT 
2 
mNg PC 1 -4881.33333 1768.48357 .571 -15362.3684 5599.7017 
mNg PC 2 -37024.16667 9144.79474 .218 -92447.2748 18398.9414 
mNg PC 3 -73055.66667* 9541.86204 .019 -
130889.4416 
-15221.8917 
mNg PG 1 -3158.00000 2259.03405 .988 -16665.5601 10349.5601 
mNg PG 2 -20274.83333* 2711.74378 .020 -36560.1152 -3989.5515 
mNg PG 3 -78503.50000* 12416.19295 .042 -
153783.9555 
-3223.0445 
mNg PA 1 1511.33333 323.61162 .076 -124.5194 3147.1861 
mNg PA 2 -6362.16667 1624.12285 .233 -15947.3792 3223.0458 







-3623.66667* 594.39539 .019 -6678.6002 -568.7332 
mNg Alone 
2 





-36933.83333 9308.47380 .232 -93350.6875 19483.0208 
FM4-64 PC 
1 
-18756.50000* 557.56310 .000 -21577.9580 -15935.0420 
FM4-64 PC 
2 
-26876.16667 7289.95675 .289 -71035.2787 17282.9454 
FM4-64 PC 
3 
-37092.66667 7746.94918 .124 -84027.5399 9842.2066 
FM4-64 PG 
1 
1892.83333* 284.37656 .029 220.2434 3565.4232 
FM4-64 PG 
2 











1759.33333* 283.71631 .041 83.8788 3434.7879 
FM4-64 PA 
2 
1022.33333 301.74914 .329 -606.7937 2651.4604 
FM4-64 PA 
3 





-307.83333 976.30242 1.000 -5818.6845 5203.0178 
FM4-64 WT 
3 
-2305.83333 945.16888 .701 -7617.6396 3005.9730 
FM4-64 
Background 
-18756.50000* 557.56310 .000 -21577.9580 -15935.0420 
FM4-64 WT 
3 
mNg PC 1 -2575.50000 1965.84577 .996 -12736.7763 7585.7763 
mNg PC 2 -34718.33333 9185.00334 .266 -89928.4306 20491.7639 
mNg PC 3 -70749.83333* 9580.40430 .021 -
128378.7875 
-13120.8791 
mNg PG 1 -852.16667 2416.66099 1.000 -13917.4108 12213.0775 
mNg PG 2 -17969.00000* 2844.39270 .027 -33789.8715 -2148.1285 
mNg PG 3 -76197.66667* 12445.83717 .047 -
151318.3074 
-1077.0259 
mNg PA 1 3817.16667 917.46387 .190 -1588.1767 9222.5100 
mNg PA 2 -4056.33333 1837.06029 .807 -13398.0880 5285.4213 







-1317.83333 1044.18454 .998 -6599.4115 3963.7448 
mNg Alone 
2 
-12302.00000 3621.84175 .346 -33081.8771 8477.8771 
mNg Alone 
3 
-34628.00000 9347.97839 .282 -90835.2936 21579.2936 
FM4-64 PC 
1 
-16450.66667* 1023.66600 .000 -21709.4698 -11191.8635 
FM4-64 PC 
2 





-34786.83333 7794.37214 .154 -81474.2341 11900.5675 
FM4-64 PG 
1 
4198.66667 904.37023 .137 -1270.0347 9667.3680 
FM4-64 PG 
2 











4065.16667 904.16283 .154 -1404.6512 9534.9846 
FM4-64 PA 
2 
3328.16667 909.98243 .291 -2111.6929 8768.0262 
FM4-64 PA 
3 





1998.00000 1300.06996 .987 -4194.3966 8190.3966 
FM4-64 WT 
2 
2305.83333 945.16888 .701 -3005.9730 7617.6396 
FM4-64 
Background 
-16450.66667* 1023.66600 .000 -21709.4698 -11191.8635 
FM4-64 
Background 
mNg PC 1 13875.16667* 1811.65173 .012 3556.4237 24193.9096 
mNg PC 2 -18267.66667 9153.24089 .867 -73644.9026 37109.5692 
mNg PC 3 -54299.16667 9549.95702 .064 -
112088.9289 
3490.5956 
mNg PG 1 15598.50000* 2292.98555 .025 2239.9605 28957.0395 
mNg PG 2 -1518.33333 2740.09164 1.000 -17669.9838 14633.3172 
mNg PG 3 -59747.00000 12422.41504 .122 -
134993.4563 
15499.4563 
mNg PA 1 20267.83333* 509.18794 .000 17439.3180 23096.3486 
mNg PA 2 12394.33333* 1671.02451 .013 2972.1268 21816.5399 







15132.83333* 712.63859 .000 11733.6182 18532.0485 
mNg Alone 
2 
4148.66667 3540.51834 .998 -16958.0122 25255.3456 
mNg Alone 
3 
-18177.33333 9316.77156 .881 -74549.1002 38194.4336 
FM4-64 PC 
1 
.00000 682.22026 1.000 -3248.4905 3248.4905 
FM4-64 PC 
2 
-8119.66667 7300.54911 .999 -52221.6882 35982.3549 
FM4-64 PC 
3 
-18336.16667 7756.91753 .731 -65217.1834 28544.8501 
FM4-64 PG 
1 
20649.33333* 485.19884 .000 17737.8361 23560.8305 
FM4-64 PG 
2 













20515.83333* 484.81216 .000 17602.3676 23429.2991 
FM4-64 PA 
2 
19778.83333* 495.58090 .000 16912.0955 22645.5711 
FM4-64 PA 
3 





18448.66667* 1052.48007 .000 13005.8744 23891.4589 
FM4-64 WT 
2 
18756.50000* 557.56310 .000 15935.0420 21577.9580 
FM4-64 WT 
3 
16450.66667* 1023.66600 .000 11191.8635 21709.4698 
*. The mean difference is significant at the 0.05 level. 
Means Plots 
 
 
 
 
 
 
